| Excerpt | Reference |
|---|
| "Type 2 diabetes mellitus is characterised by resistance of peripheral tissues to insulin and a relative deficiency of insulin secretion." | ( Bergman, RN; Kahn, CR; Krolewski, AS; Martin, BC; Soeldner, JS; Warram, JH, 1992) |
| "Given that NIDDM is reaching epidemic proportions in Oklahoma Indians and that most may be afflicted with retinopathy, frequent ophthalmological examinations are clearly indicated for this high-risk population." | ( Asal, NR; Bradford, RH; Kingsley, RM; Lee, ET; Lee, VS; Lu, M; Russell, D; Wilkinson, CP, 1992) |
| "Type 1 and type 2 diabetes mellitus are both characterized by increased cardiovascular mortality and morbidity." | ( Giberti, B; Micossi, P; Parlavecchia, M; Ruotolo, G; Zoppo, A, 1991) |
| "We conclude that NIDDM is characterized by a steady-state re-regulation of plasma glucose concentration at an elevated level in which islet dysfunction plays a necessary role." | ( Kahn, SE; Porte, D, 1991) |
| "Increased Nox in NIDDM is primarily into lactate." | ( Bulacan, F; Gumbiner, B; Henry, RR; Thorburn, AW; Wallace, P, 1990) |
| "NIDDM is associated with decreased chiro-inositol excretion and decreased chiro-inositol content in muscle." | ( Bogardus, C; Craig, J; Hansen, BC; Hill, CR; Kennington, AS; Larner, J; Ortmeyer, HK; Raz, I; Romero, G, 1990) |
| "Type 2 diabetes mellitus is associated with an exaggerated glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals which is independent of any effect of obesity." | ( Hayes, TM; Jones, IR; Luzio, S; Owens, DR; Williams, S, 1989) |
| "Therefore, NIDDM is characterized by reduced activation of a key step in the process of muscle glycogen repletion after a meal." | ( Beck-Nielsen, H; Kolterman, OG; Mandarino, LJ; Wright, KS, 1988) |
| "Eight adults with NIDDM are reported here who consumed at least 30 grams of guar gum for at least 16 weeks without any change in hematologic, hepatic, or renal function." | ( Cummings, CC; McIvor, ME; Mendeloff, AI, 1985) |
| "The dyslipidemia in NIDDM is characterized by abnormalities in composition and metabolism of very low density lipoproteins, low-density lipoproteins (LDL) and high-density lipoproteins (HDL)." | ( Garg, A; Grundy, SM, 1988) |
| "Once NIDDM is diagnosed in the older patient, the propensity for these patients to develop atherosclerotic vascular complications involving every organ system and the socioeconomic sequela of the disease make treatment prudent." | ( Coon, PJ; Goldberg, AP, 1987) |
| "NIDDM is characterized by decreased insulin secretory responses to glucose and to nonglucose stimuli, hyperglucagonemia, and decreased tissue sensitivity to insulin." | ( Beard, JC; Benedetti, TJ; Halter, JB; Johnston, CL; Porte, D; Ward, WK, 1985) |
| "NIDDM is also associated with defects in fatty acid metabolism, i." | ( Girard, J, 1995) |
| "NIDDM is characterized by insulin resistance which is complicated by impaired insulin secretion at the time of appearance of hyperglycaemia and clinical diabetes." | ( Aro, A; Virtanen, SM, 1994) |
| "Type 2 diabetes is characterized by resistance to insulin action of glucose metabolism and lipolysis." | ( Anyaoku, V; Coldham, N; Gelding, SV; Johnston, DG; Niththyananthan, R, 1995) |
| "Patients with Type 2 diabetes are at increased risk from macrovascular disease whether or not they are hyperlipidaemic." | ( Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW, 1995) |
| "Because NIDDM is often a more insulin-resistant state, it was hypothesized that SMLPL activity would be further increased by insulin/glucose in subjects who were obese and had NIDDM." | ( Eckel, RH; Froyd, KK; Jensen, DR; Yost, TJ, 1995) |
| "The incidence of Type 2 diabetes is considerably increased in subjects with two diabetic parents." | ( Girard, J, 1994) |
| "Type 2 diabetes is associated with abnormal lipoprotein levels and altered plasma concentrations of insulin, intact and 32, 33 split proinsulin." | ( Andres, C; Gelding, SV; Gray, IP; Johnston, DG; Niththyananthan, R; Richmond, W, 1994) |
| "Type 2 diabetes is characterized by abnormalities in both glucose and lipoprotein metabolism and genes involved in lipid metabolism are legitimate candidates for involvement in Type 2 diabetes." | ( Baker, WA; Hawrami, K; Hitman, GA; McCarthy, MI; Mohan, V; Nissinen, A; Riikonen, A; Tuomilehto, J; Tuomilehto-Wolf, E; Viswanathan, M, 1994) |
| "In the RW pedigree, MODY is associated with polymorphic DNA markers on chromosome 20q." | ( Bell, GI; Fajans, SS; Halter, JB; Herman, WH; Ortiz, FJ; Polonsky, KS; Smith, MJ; Sturis, J, 1994) |
| "Patients with NIDDM are unable to increase their glucose oxidation normally in response to insulin to meet the energy demands of the body." | ( Ferrannini, E; Groop, LC, 1993) |
| "NIDDM is a heterogeneous disorder, characterized by defects in insulin secretion as well as in insulin action." | ( Van Haeften, TW; Wolffenbuttel, BH, 1993) |
| "We conclude that NIDDM is polygenic and fasting hyperglycaemia and postprandial hyperglycaemia clearly have distinct genetic bases." | ( Fakhrai-Rad, H; Galli, J; Glaser, A; Jacob, HJ; Jiao, H; Lander, ES; Li, LS; Luthman, H; Ostenson, CG, 1996) |
| "We conclude that NIDDM is a life-long disease characterized by intraabdominal obesity and macrovascular events several years in advance of hyperglycemia, and that insulin resistance in skeletal muscle plays an important pathophysiological part and also may be used in prediction of the disease." | ( Beck-Nielsen, H; Henriksen, JE; Hother-Nielsen, O; Vaag, A, 1995) |
| "NIDDM is the result of concomitant defects in both insulin secretion and insulin action." | ( Crepaldi, G; Del Prato, S, 1995) |
| "We conclude that NIDDM is accompanied by low glycogen content in the muscle, and that some clinically normal monkeys have an alteration in insulin action on muscle GS, GP, and whole-body glucose disposal rates that may precede the development of hyperinsulinemia." | ( Bodkin, NL; Hansen, BC; Ortmeyer, HK; Varghese, SS, 1996) |
| "Actually NIDDM is not a single disorder but is rather a syndrome of diverse etiology and pathogenesis." | ( Galajda, P; Martinka, E; Mokán, M, 1996) |
| "ICA at diagnosis of NIDDM is a marker of more favorable cardiovascular risk profile 5 years after clinical diagnosis." | ( Ahmed, M; Fernlund, P; Gottsäter, A; Lilja, B; Sundkvist, G, 1996) |
| "NIDDM is associated with stiffer arteries and an increased incidence of macrovascular disease." | ( Gosling, RG; Hopkins, KD; Jones, RL; Lehmann, ED; Turay, RC, 1996) |
| "People with NIDDM are resistant to insulin." | ( Alzaid, A; Basu, A; Bettini, F; Caumo, A; Cobelli, C; Gelisio, A; Rizza, RA, 1997) |
| "NIDDM is even more common in the elderly and in minority population including Hispanic Americans, African Americans, Asian and Pacific Island Americans, and Native Americans." | ( Flórez, H, 1997) |
| "Type 2 diabetes is a slowly progressive disease, in which the gradual deterioration of glucose tolerance is associated with the progressive decrease in beta-cell function." | ( Bagriaçik, N; Cerasi, E; Glaser, B; Ilkova, H; Tunçkale, A, 1997) |
| "Type 2 diabetes is preceded by a long period of impaired glucose tolerance, a reversible metabolic state associated with increased prevalence of macrovascular complications." | ( Dagogo-Jack, S; Santiago, JV, 1997) |
| "Type 2 diabetes is increasing in prevalence and is predominantly managed in general practice." | ( Phillips, PJ; Popplewell, PY; Tallis, GA, 1997) |
| "We conclude that NIDDM is associated with an elevated acute-phase response, particularly in those with features of syndrome X." | ( Burt, D; Chusney, GD; Mattock, MB; Pickup, JC, 1997) |
| "NIDDM is associated with excessive rates of endogenous glucose production in both the postabsorptive and postprandial states." | ( Basu, A; Dinneen, SF; Nielsen, MF; Rizza, RA; Schwenk, WF; Wise, S, 1997) |
| "Type 2 diabetes is associated with elevated circulating IAPP; GLP-1stimulates IAPP secretion both in healthy human subjects and in type 2 diabetes; IAPP secretion correlates with insulin secretion only in healthy subjects and not in type 2 diabetes." | ( Ahrén, B; Gutniak, M, 1997) |
| "Low birthweight and Type 2 diabetes are common in India." | ( Barker, DJ; Cox, V; Fall, CH; Hales, CN; Kumaran, K; Osmond, C; Stein, CE, 1998) |
| "Type 2 diabetes is an important public health problem because of its high prevalence and morbidity rate which both are associated with a considerable social and human cost." | ( Scheen, AJ, 1998) |
| "Patients with NIDDM are characterized by excessive cardiovascular morbidity and mortality, and LVH, an independent risk factor for cardiac events, is often present in NIDDM patients." | ( Ali, S; Kastrup, J; Nielsen, FS; Parving, HH; Sato, A; Smidt, UM; Tarnow, L, 1998) |
| "Elevated UAER in NIDDM is closely associated with components of the metabolic syndrome and an increased risk of IHD and PVD." | ( Abuaisha, B; Boulton, AJ; Kumar, S; Malik, R, 1998) |
| "In conclusion, NIDDM+ is accompanied by a significant increase in plasma ET-1 levels." | ( Baldoncini, R; Bellini, C; Bravi, MC; Cassone-Faldetta, M; De Mattia, G; Ferri, C; Laurenti, O; Santucci, A, 1998) |
| "Type 2 diabetes is a complex metabolic disorder characterized by peripheral insulin resistance and impaired beta cell function." | ( Accili, D; Castle, AL; Ebina, Y; Hayashi, H; Kido, Y; Lauro, D; Zarnowski, MJ, 1998) |
| "The onset of Type 2 diabetes is insidious and is usually recognized only 5-12 years after hyperglycaemia develops." | ( Muggeo, M, 1998) |
| "Type 2 diabetes is characterized by 2 major defects: 1." | ( Girard, J, 1999) |
| "Type 2 diabetes is associated with disturbances in coagulation and fibrinolysis." | ( Beilin, LJ; Burke, V; Dunstan, DW; Mori, TA; Morton, AR; Puddey, IB; Stanton, KG, 1999) |
| "Type 2 diabetes is a heterogeneous disease in which both beta-cell dysfunction and insulin resistance are pathogenetic factors." | ( Binder, C; Dinesen, B; Hartling, SG; Houssa, P; Røder, ME; Sodoyez-Goffaux, F; Vestergaard, H, 1999) |
| "Type 2 diabetes is not an autoimmune disease but rather results from both insulin resistance and a nonautoimmune insulin secretory defect." | ( Brooks-Worrell, BM; Greenbaum, CJ; Juneja, R; Minokadeh, A; Palmer, JP, 1999) |
| "Type 2 diabetes is associated with a marked increase in the risk of coronary artery disease." | ( Haffner, SM, 1999) |
| "Type 2 diabetes is associated with an increased risk for cardiovascular disease." | ( Kuusisto, J; Laakso, M, 1999) |
| "Patients with type 2 diabetes are often obese and require large doses of insulin to achieve glycemic control." | ( Avilés-Santa, L; Raskin, P; Sinding, J, 1999) |
| "Type 2 diabetes mellitus is a dynamic disease whose natural history is characterized by a progressive aggravation leading to a progressively severe hyperglycaemia, which generally requires a more complex therapy as time progresses." | ( Lefèbvre, PJ; Paquot, N; Scheen, AJ, 1999) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action." | ( DeFronzo, RA, 1999) |
| "NIDDM is characterized by a decrease in insulin sensitivity of the liver, the muscles and adipocytes." | ( Gin, H; Rigalleau, V, 1999) |
| "Type 2 diabetes mellitus is one of the most common chronic metabolic diseases in man." | ( Ferreira, FM; Palmeira, CM; Santos, MS; Seiça, R, 1999) |
| "Most attention in type 2 diabetes care is currently focused on the deleterious effects of post-prandial hyperglycemia peaks on endothelium, as shown in vitro." | ( Home, P, 1999) |
| "Type 2 diabetes mellitus is a progressive disorder, and although oral monotherapy is often initially successful, it is associated with a high secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia." | ( Riddle, M, 2000) |
| "Type 2 diabetes mellitus is characterized by impaired glucose uptake." | ( Cheng, WY; Feng, HF; Hu, XJ; Peng, F; Zhang, ZH; Zhou, HQ, 2000) |
| "Obesity and Type 2 diabetes are now major public health issues in developed nations and have reached epidemic proportions in many developing nations, as well as disadvantaged groups in developed countries, e." | ( Boyko, EJ; Collier, GR; de Courten, M; Zimmet, P, 1999) |
| "Type 2 diabetes is a chronic metabolic derangement that results from defects in both insulin action and secretion." | ( Moller, DE; Zhang, BB, 2000) |
| "NIDDM is associated with multiple apoB metabolism abnormalities that are potentially atherogenic." | ( Duvillard, L; Florentin, E; Galland-Jos, C; Gambert, P; Pont, F; Vergès, B, 2000) |
| "Type 2 diabetes is associated with increased circulating concentrations of markers of the acute-phase response and interleukin-6 (IL-6)." | ( Burt, D; Chusney, GD; Pickup, JC; Thomas, SM, 2000) |
| "An early defect in Type 2 diabetes is the loss of acute insulin release after food intake, which causes prolonged elevation of postprandial glucose levels." | ( Ikenoue, T; Kondo, N, 2000) |
| "Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often associated with insulin resistance." | ( Lauritzen, T; Nattrass, M, 2000) |
| "Type 2 diabetes is characterised by a progressive deterioration of the prandial insulin response, in a situation of continuing insulin resistance." | ( Garber, AJ, 2000) |
| "Type 2 diabetes is a polygenic disease characterized by defects in both insulin secretion and insulin action." | ( Kahn, CR; Kulkarni, RN; Mauvais-Jarvis, F; Michael, MD; Virkamaki, A; Winnay, JN; Zisman, A, 2000) |
| "Type 2 diabetes is a cardiovascular risk factor." | ( Arnett, DK; Bella, JN; Devereux, RB; Hopkins, PN; Kitzman, DW; Liu, JE; Morgan, D; Oberman, A; Palmieri, V; Rao, DC; Schuck, MY, 2001) |
| "Type 2 diabetes is also associated with atherogenic dyslipidemias." | ( Garber, AJ, 2000) |
| "Type 2 diabetes mellitus is a growing problem not only in the United States but also across the world." | ( Henry, RR; Mudaliar, S, 2001) |
| "The development of type 2 diabetes is linked to insulin resistance coupled with a failure of pancreatic B-cells to compensate by adequate insulin secretion." | ( Kahn, CR; Mauvais-Jarvis, F, 2000) |
| "Type 2 diabetes mellitus is a complex heterogenous metabolic disorder in which peripheral insulin resistance and impaired insulin release are the main pathogenetic factors." | ( Landgraf, R, 2000) |
| "Type 2 diabetes is accompanied by a priming of PMNs, resulting in OS and increased self-necrosis." | ( Herskovits, AT; Kristal, B; Nasser, L; Sela, S; Shapiro, G; Shasha, SM; Shurtz-Swirski, R, 2001) |
| "Type 2 diabetes is characterized by increased acute phase serum proteins." | ( Ebeling, P; Koistinen, HA; Koivisto, VA; Teppo, AM, 2001) |
| "Type 2 diabetes mellitus is a common metabolic disorder that has become a major public health problem because of the long-term microvascular and macrovascular complications associated with it." | ( Kumar, S; Valsamakis, G, 2000) |
| "The GK rat model of type 2 diabetes is especially convenient to dissect the pathogenic mechanism necessary for the emergence of overt diabetes because all adult rats obtained in our department (GK/Par colony) to date have stable basal mild hyperglycemia and because overt diabetes is preceded by a period of normoglycemia, ranging from birth to weaning." | ( Bailbe, D; Gangnerau, MN; Giroix, MH; Marie, JC; Mithieux, G; Movassat, J; Plachot, C; Portha, B; Rajas, F; Serradas, P, 2001) |
| "Type 2 diabetes is a disorder that has numerous components, including insulin resistance, an insulin secretory defect, and an increase in hepatic glucose production." | ( Peters, AL, 2001) |
| "Type 2 diabetes mellitus is characterised by impaired insulin secretion, diminished peripheral insulin action and increased hepatic glucose production." | ( Huijberts, MS; Sels, JP; Wolffenbuttel, BH, 2001) |
| "We conclude that type 2 diabetes is associated with a generalized impairment in insulin suppression of lipolysis compared with equally obese ND individuals." | ( Basu, A; Basu, R; Jensen, MD; Rizza, RA; Shah, P; Vella, A, 2001) |
| "Type 2 diabetes is defined as a syndrome characterized by insulin deficiency, insulin resistance and increased hepatic glucose output." | ( Feinglos, MN; Luna, B, 2001) |
| "Type 2 diabetes is associated with elevated oxidative stress and declines in antioxidant defense." | ( Barbieri, M; Manzella, D; Paolisso, G; Ragno, E, 2001) |
| "Type 2 diabetes is characterized by two fundamental biological defects: a reduced glucose-dependent insulin secretion and an increased resistance to the action of insulin at the level of various target tissues." | ( Chamie, K; Perfetti, R, 2001) |
| "Type 2 diabetes mellitus is characterized by insulin deficiency but in particular by insulin resistance." | ( Rybka, J, 2001) |
| "Type 2 diabetes is understood to result most often from insulin resistance and insulin deficiency." | ( Drexler, AJ; Robertson, C, 2001) |
| "Type 2 diabetes is the most prevalent form of diabetes, accounting for approximately 90% of cases." | ( Kitabchi, AE; Umpierrez, GE, 2001) |
| "Type 2 diabetes is associated with obesity and improves with weight loss." | ( Greenway, F, 1999) |
| "Type 2 diabetes is increasingly common and can be difficult to control." | ( Lawrence, JM; Reckless, JP, 2001) |
| "Type 2 diabetes is characterized by peripheral tissue insulin resistance." | ( Anilkumar, KL; Marita, AR, 2001) |
| "The incidence of NIDDM is highest in economically developed nations, particularly the U." | ( McDonald, RB; Ruhe, RC, 2001) |
| "Type 2 diabetes is a syndrome that affects 5-10% of the adult population." | ( Bar-On, H; Kalman, R; Perez, R; Shafrir, E; Ziv, E, 2001) |
| "Type 2 diabetes is a classic example of a complex disorder." | ( Cox, NJ, 2001) |
| "The complexity of type 2 diabetes is related to factors such as genetic heterogeneity, interactions between genes, and the modulating role played by the environment." | ( Busch, CP; Hegele, RA, 2001) |
| "Although type 2 diabetes is recognized as an independent risk factor for cardiovascular disease and cardiovascular disease is associated with endothelial dysfunction, the influence of type 2 diabetes per se on the endothelial function is controversial." | ( Blauw, GJ; de Man, FH; Huisman, MV; Meinders, AE; van de Ree, MA; van der Vijver, JC, 2001) |
| "Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications." | ( Badimon, JJ; Crandall, JP; Fallon, JT; Fuster, V; Heflt, G; Herson, P; Lev, EI; Osende, JI; Rabito, P; Rauch, U; Rodriguez, OJ; Vidhun, R; Zaman, A, 2001) |
| "Type 2 diabetes is characterized by decreased secretion of insulin and insulin resistance." | ( Kuzuya, T, 2001) |
| "Type 2 diabetes is associated with multiple metabolic abnormalities including insulin resistance and the procoagulant state." | ( Flemmer, M; Scott, J, 2001) |
| "Type 2 diabetes mellitus is characterized by insulin-resistant glucose and lipid metabolism." | ( Davis, AO; Klein, S; McGill, JB; Racette, SB, 2002) |
| "Most Koreans with type 2 diabetes are insulin deficient and insulin resistant." | ( Choi, SB; Park, S, 2002) |
| "Type 2 diabetes is a chronic metabolic disorder that results from defects in both insulin and glucagon secretion as well as insulin action." | ( Alstrup, KK; Gregersen, S; Hermansen, K; Jeppesen, PB, 2002) |
| "Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population." | ( Cooper, BP; Fucetola, R; Haupt, DW; Melson, AK; Newcomer, JW; Schweiger, JA; Selke, G, 2002) |
| "The importance of type 2 diabetes is due to its high prevalence, the difficulties in achieving optimal glucose control (financial, time, quality of life) and the high frequency of chronic microvascular and macrovascular complications that add very significantly to the morbidity, mortality and overall cost of the disease." | ( Yale, JF, 2000) |
| "Type 2 diabetes is an increasing problem in children." | ( Matthews, DR; Wallace, TM, 2002) |
| "Obesity and type 2 diabetes are associated with insulin resistance, the mechanisms of which remain poorly understood." | ( Bastard, JP; Bruckert, E; Capeau, J; Grimaldi, A; Hainque, B; Jardel, C; Maachi, M; Robert, JJ; Van Nhieu, JT, 2002) |
| "Type 2 diabetes is associated with biochemical evidence of low-grade inflammation, and experimental studies have suggested that both insulin and glucose affect inflammatory responses." | ( Agwunobi, AO; Carlson, GL; Childs, C; Cooper, RG; Duxbury, H; Gibson, JM; Hopkins, SJ; Little, RA; Maycock, P; Soop, M, 2002) |
| "Type 2 diabetes is characterized by endothelial dysfunction, which may be caused by dyslipidemia." | ( de Koning, EJ; Gaillard, CA; Honing, ML; Rabelink, TJ; Stroes, ES; van Etten, RW, 2002) |
| "Type 2 diabetes is a recognized independent cardio-vascular risk factor, which adds to other known risk factors." | ( Valensi, P, 2002) |
| "Type 2 diabetes is responsible for various micro and macro-vascular complications, appearing early in the course of the disease." | ( Halimi, S, 2002) |
| "Type 2 diabetes is associated with an increased risk of cardiovascular disease." | ( Eskildsen, PC; Ihlemann, N; Stokholm, KH, 2002) |
| "Type 2 diabetes is known to be associated with a small body size at birth." | ( Barker, DJ; Eriksson, JG; Forsén, TJ; Laakso, M; Lindi, V; Osmond, C; Uusitupa, M, 2002) |
| "The development of type 2 diabetes is linked to insulin resistance coupled with a failure of pancreatic beta-cells to compensate by adequate insulin secretion." | ( Kahn, CR; Kulkarni, RN; Mauvais-Jarvis, F, 2002) |
| "People with type 2 diabetes are at elevated risk of stroke compared with those without diabetes." | ( Adler, AI; Holman, RR; Kothari, V; Manley, SE; Neil, HA; Stevens, RJ; Stratton, IM, 2002) |
| "Patients with type 2 diabetes are known to have abnormalities in their remnant metabolism and low density lipoprotein (LDL) subfraction pattern, with a preponderance of small dense LDL." | ( Akanuma, Y; Fujita, T; Ishibashi, S; Iwamoto, Y; Kawazu, S; Kuzuya, N; Morisaki, N; Saito, Y; Shiba, T; Shimano, H; Sone, H; Takahashi, A; Teramoto, T; Yamada, N; Yoshino, G, 2002) |
| "We conclude that type 2 diabetes is specifically associated with myocardial IR that is independent of and nonadditive with angiographic CAD and proportional to skeletal muscle and whole-body IR." | ( Betteridge, DJ; Camici, PG; Chareonthaitawee, P; Dutka, D; Ferrannini, E; Iozzo, P, 2002) |
| "Type 2 diabetes is associated with excessive cardiovascular morbidity and mortality." | ( Fuecker, K; Graessler, J; Hanefeld, M; Julius, U; Kopprasch, S; Kuhlisch, E; Kühne, H; Pietzsch, J; Temelkova-Kurktschiev, T, 2002) |
| "Type 2 diabetes is associated with insulin resistance in peripheral tissues, such as muscle and fat, impaired glucose-stimulated insulin secretion from pancreatic beta-cells and elevated hepatic gluconeogenesis." | ( Gottschalk, WK; Lenhard, JM, 2002) |
| "Type 2 diabetes is the leading cause of end-stage renal disease (ESRD) in most industrialized countries in Europe." | ( Brenner, B; Carides, GW; Gerth, WC; Hannedouche, T; Martinez-Castelao, A; Remuzzi, G; Shahinfar, S; Viberti, G, 2002) |
| "Type 2 diabetes is associated with accelerated atherosclerosis." | ( Diamant, M; Nieuwland, R; Pablo, RF; Radder, JK; Smit, JW; Sturk, A, 2002) |
| "Type 2 diabetes mellitus is a common disease whose complications have great costs, both in quality of life and expense of treatment." | ( Caro, J; Salas, M; Ward, A, 2002) |
| "Type 2 diabetes is generally perceived as a polygenic disorder, with disease development being influenced by both hereditary and environmental factors." | ( Schwanstecher, C; Schwanstecher, M, 2002) |
| "Type 2 diabetes mellitus is a social and civilization-related disease that leads to various micro- and macroangiopathic complications, including diabetic nephropathy." | ( Bartłomiejczyk, I; Kropiewnicka, HE; Paczek, L; Senatorski, G, 2002) |
| "Insulin therapy in type 2 diabetes is also accompanied by untoward weight gain." | ( Baron, AD; Kim, D; Weyer, C, 2002) |
| "Type 2 diabetes mellitus is associated with a heavy burden of suffering." | ( Donahue, K; Frame, P; Harris, R; Lohr, KN; Rathore, SS; Woolf, SH, 2003) |
| "Type 2 diabetes is a widespread disease where effective pharmacologic therapies can have a profound beneficial public health impact." | ( Kurukulasuriya, R; Link, JT; Madar, DJ; Pei, Z; Richards, SJ; Rohde, JJ; Souers, AJ; Szczepankiewicz, BG, 2003) |
| "Type 2 diabetes is a polygenic disorder characterized by multiple biochemical defects including transcriptional, translational, and posttranslational abnormalities." | ( Shi, Y; Sonenberg, N; Tan, SL; Taylor, SI, 2003) |
| "Type 2 diabetes mellitus is characterized by both insulin deficiency and insulin resistance." | ( Bokhari, SU; Duckworth, WC; Gopal, UM, 2003) |
| "Type 2 diabetes is characterised by peripheral insulin resistance and a relative deficiency in insulin production." | ( Törn, C, 2003) |
| "Type 2 diabetes is reaching epidemic proportions worldwide, fueled by the increasing prevalence of obesity as many populations adopt a western lifestyle." | ( Smith, SA; Tadayyon, M, 2003) |
| "Type 2 diabetes mellitus is frequently accompanied by hypercoagulability and hypofibrinolysis." | ( Brussaard, HE; Kluft, C; Krans, HM; Leuven, JA, 2002) |
| "Type 2 diabetes is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action." | ( Passaro, MD; Ratner, RE, 2001) |
| "Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity." | ( Cruickshank, JM, 2002) |
| "Type 2 diabetes mellitus is the commonest form of diabetes." | ( Ramachandran, A, 2002) |
| "Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements." | ( Basu, A; Kudva, YC; Zangeneh, F, 2003) |
| "Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality." | ( Scheen, AJ, 2003) |
| "Type 2 diabetes mellitus is characterised both by impaired release of insulin and by resistance to the action of insulin." | ( Pørksen, N, 2002) |
| "Type 2 diabetes is characterized by increased plasma triglyceride levels and a fourfold increase in ischemic heart disease, but the mechanism is unclear." | ( Aitman, TJ; Baglin, TP; Byrne, CD; Englyst, NA; Taube, JM, 2003) |
| "Type 2 diabetes is the most common metabolic disease." | ( Bouche, C; Goldfine, AB, 2003) |
| "Type 2 diabetes is a multiorgan disease that results from the combination of insulin resistance and a beta-cell secretory defect." | ( Wyne, KL, 2003) |
| "Type 2 diabetes is a chronic and progressive disease." | ( Allavoine, T; Howlett, H; Kuhn, T; Nicholson, G; Porte, F, 2003) |
| "Patients with type 2 diabetes are often treated with oral antidiabetic agents plus a basal insulin." | ( Fritsche, A; Häring, HU; Schweitzer, MA, 2003) |
| "Type 2 diabetes mellitus is characterised by insulin resistance as well as progressive pancreatic beta cell dysfunction." | ( Diamant, M; Heine, RJ, 2003) |
| "The prevalence of type 2 diabetes mellitus is increasing in children and adolescents worldwide, particularly among minority youth." | ( Homko, CJ; Reece, EA, 2003) |
| "Patients with type 2 diabetes mellitus are associated with insulin resistance and/or impaired insulin secretion." | ( Odawara, M, 2003) |
| "The prevalence of type 2 diabetes is increasing due to a combination of factors: increasing lifespan, sedentary lifestyle, excessive intake of high energy foods, increasing prevalence of overweight/obese people." | ( Lai, LC, 2002) |
| "Glycated insulin in type 2 diabetes is reduced in response to the insulin secretagogue nateglinide, resulting in preferential release of native insulin." | ( Bell, PM; Flatt, PR; Lindsay, JR; McKillop, AM; Mooney, MH; O'Harte, FP, 2003) |
| "Type 2 diabetes is characterised by insulin resistance in association with clustering of atherothrombotic risk factors (dysglycaemia, hyperinsulinaemia, hypertension, raised triglyceride, low HDL cholesterol and increased levels of plasminogen activator inhibitor-1 (PAI-1) and clotting factor VII)." | ( Grant, PJ, 2003) |
| "Type 2 diabetes is now a global epidemic, with the number of people affected worldwide predicted to more than double to 300 million by the year 2025." | ( Gadsby, R; Reusch, JE, 2003) |
| "Patients with type 2 diabetes mellitus are at an increased risk of atherosclerosis including peripheral arterial disease (PAD)." | ( Emoto, M; Kimoto, E; Koyama, H; Nishizawa, Y; Shinohara, K; Shoji, T; Tanaka, S; Yokoyama, H, 2003) |
| "Type 2 diabetes is an ever-growing problem worldwide." | ( Lewis, EJ; Lewis, JB, 2003) |
| "Type 2 diabetes is strongly associated with increased risk of cardiovascular disease." | ( Evans, M; Rees, A; Roberts, AW; Thomas, A, 2003) |
| "Type 2 diabetes is caused by reduced insulin secretion and insulin resistance in skeletal muscle and liver." | ( Beck-Nielsen, H; Henriksen, JE; Hother-Nielsen, O; Poulsen, MK, 2003) |
| "Patients with type 2 diabetes mellitus are at increased risk for postangioplasty restenosis, which results from excessive intimal hyperplasia." | ( Bruemmer, D; Law, RE, 2003) |
| "Type 2 diabetes is associated with chronic low-grade inflammation, but the underlying mechanism(s) is not well understood." | ( Betteridge, J; Bucala, R; Chow, WS; Tam, S; Tan, KC, 2004) |
| "Type 2 diabetes is a global concern, accounting for the vast majority of cases of diabetes." | ( Chi, EM; Lehr, KH; Shukla, UA, 2004) |
| "Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality." | ( Schernthaner, G, 2003) |
| "Type 2 diabetes is associated with increased plasma concentrations of coagulation and inflammation markers." | ( MacGillavry, MR; Meijers, JC; Reitsma, PH; Sommeijer, DW; Ten Cate, H; Van Zanten, AP, 2004) |
| "Type 2 diabetes is a common manifestation of hemochromatosis, a disease of iron overload." | ( Hu, FB; Jiang, R; Ma, J; Manson, JE; Meigs, JB; Rifai, N, 2004) |
| "The risk of type 2 diabetes mellitus is increased in people who have low birth weights and who subsequently become obese as adults." | ( Barker, DJ; Bhargava, SK; Biswas, SK; Fall, CH; Lakshmy, R; Osmond, C; Prabhakaran, D; Ramji, S; Reddy, KS; Sachdev, HS, 2004) |
| "The incidence of type 2 diabetes is increasing rapidly, but clinical maintenance of normoglycemia remains challenging." | ( Kansal, AR, 2004) |
| "Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion." | ( Abrahamson, MJ, 2004) |
| "Type 2 diabetes is caused by insulin resistance and beta-cell dysfunction." | ( Jia, D; Otani, M; Otsuki, M; Yamamoto, M, 2004) |
| "Type 2 diabetes mellitus is the most common serious metabolic condition in the world, and results from a subnormal response of tissues to insulin (insulin resistance) and a failure of the insulin-secreting beta cells to compensate." | ( Klover, PJ; Mooney, RA, 2004) |
| "Type 2 diabetes is characterized by high concentrations of glucose in the blood, which is caused by decreased secretion of insulin from the pancreas and decreased insulin action." | ( Bulotta, A; Di Mario, U; Nourparvar, A; Perfetti, R, 2004) |
| "Type 2 diabetes is an epidemic that is affecting an ever-increasing proportion of the US population." | ( Ford, ES; Gross, LS; Li, L; Liu, S, 2004) |
| "Type 2 diabetes is increasing globally and is a major cause of conditions such as cardiovascular disease, retinopathy and nephropathy." | ( Ruilope, LM, 2004) |
| "Type 2 diabetes is a growing world epidemic which is fuelled by the increased prevalence of obesity, together with changes in lifestyle and nutritional habits." | ( Lind, P, 2004) |
| "Type 2 diabetes mellitus is associated with impaired endothelial function and increased levels of TNF-alpha, IL-6 and sVCAM-1, especially in patients with DM and CAD." | ( Antoniades, C; Stefanadis, C; Tentolouris, C; Tountas, C; Tousoulis, D; Toutouza, M; Toutouzas, P; Tsioufis, C; Vasiliadou, C, 2004) |
| "Type 2 diabetes is a common disease associated with an increased risk of long-term complications, in particular cardiovascular disease." | ( Del Prato, S; Volpe, L, 2004) |
| "Type 2 diabetes is associated with significantly accelerated rates of macrovascular complications such as atherosclerosis." | ( Nadler, JL; Natarajan, R, 2004) |
| "Type 2 diabetes is a common chronic illness with many complications, entailing enormous expenditures health services." | ( Kitai, E; Nakar, S; Ram, R; Vinker, S, 2004) |
| "Obesity and type 2 diabetes are associated with nonalcoholic steatohepatitis (NASH), but an obese/diabetic animal model that mimics human NASH remains undefined." | ( Green, RM; Malladi, P; Melin-Aldana, H; Pan, X; Paul, R; Sahai, A; Whitington, PF, 2004) |
| "Type 2 diabetes mellitus is a condition characterized by impaired insulin secretion and resistance to insulin-mediated glucose uptake and utilization." | ( Bates, PC; Dietrich, K; Lübben, G; Seufert, J, 2004) |
| "Type 2 diabetes is associated with vascular dysfunction, accelerated atherosclerotic morbidity, and mortality." | ( Best, M; Eastwood, PR; Green, DJ; Halliwill, JR; O'Driscoll, G; Walsh, JH; Weisbrod, CJ, 2004) |
| "Type 1 and type 2 diabetes are both diseases of insulin insufficiency, although they develop by distinct pathways." | ( Burgess, S; Chen, G; Hohmeier, HE; Jensen, MV; Lu, D; Newgard, CB; Sherry, AD; Tran, VV, 2004) |
| "Type 2 diabetes is an important comorbid medical condition associated with schizophrenia." | ( Brown, CH; Dickerson, FB; Dixon, LB; Donner, TW; Fang, L; Goldberg, RW; Kreyenbuhl, JA; Marano, C; Messias, E; Postrado, L; Wohlheiter, K; Wolheiter, K, 2004) |
| "Type 2 diabetes is characterized by progressive beta-cell failure." | ( Mayfield, JA; White, RD, 2004) |
| "Nephropathy in type 2 diabetes is the single most common cause of end-stage renal disease (ESRD), but the decline in kidney function varies considerably between individuals, and determinants of renal function loss, early in the course of renal disease, have not been clearly identified." | ( Christensen, PK; Hovind, P; Parving, HH; Rossing, K; Rossing, P; Tarnow, L, 2004) |
| "Type 2 diabetes is a complex disorder with diminished insulin secretion and insulin action contributing to the hyperglycemia and wide range of metabolic defects that underlie the disease." | ( Bouché, C; Goldfine, AB; Kahn, CR; Serdy, S, 2004) |
| "Patients with type 2 diabetes are at high risk of cardiovascular disease." | ( Boyle, PJ, 2004) |
| "Type 2 diabetes is the leading cause of end-stage renal disease (ESRD)." | ( Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004) |
| "In patients whose type 2 diabetes is inadequately controlled with metformin monotherapy, the addition of rosiglitazone significantly improves glycemic control, insulin sensitivity and beta-cell function, compared with either drug alone." | ( Cox, SL, 2004) |
| "The management of type 2 diabetes mellitus is complicated by the presence of risk factors related to overweight and obesity, particularly visceral adiposity." | ( Berber, A; Campos-Franco, E; Fanghänel, G; Martínez-Rivas, L; Sánchez-Reyes, L; Yamamoto, J, 2004) |
| "Type 2 diabetes is associated with lower total testosterone (T) levels in cross-sectional studies." | ( Bandyopadhyay, A; Chaudhuri, A; Dandona, P; Dhindsa, S; Prabhakar, S; Sethi, M, 2004) |
| "Type 2 diabetes mellitus is associated with an augmented risk for cardiovascular disease." | ( Alcaraz Tafalla, MS; Carrillo Alcaraz, A; Illán Gómez, F; Pascual Díaz, M, 2004) |
| "Type 2 diabetes is a major manifestation of this syndrome, although increased risk for cardiovascular disease (CVD) often precedes the onset of frank clinical diabetes." | ( Csete, M; Doyle, J; Kimura, T; Kitano, H; Matsuoka, Y; Muramatsu, M; Oda, K, 2004) |
| "Type 2 diabetes mellitus is a growing epidemic." | ( Anderson, DC, 2005) |
| "Type 2 diabetes is characterized by hyperglycemia and hyperinsulinemia, features of insulin resistance." | ( Frost, SC; Hyun, CK; Kim, IY, 2004) |
| "Type 2 diabetes mellitus is a common problem in patients after solid organ transplantation." | ( Baldwin, D; Luther, P, 2004) |
| "Type 2 diabetes is caused by defective insulin secretion and impaired insulin action." | ( Eriksson, J; Hämäläinen, H; Ilanne-Parikka, P; Keinänen-Kiukaanniemi, S; Laakso, M; Laukkanen, O; Lindström, J; Pihlajamäki, J; Tuomilehto, J; Uusitupa, M; Valle, TT, 2004) |
| "Glycemia in type 2 diabetes is characterized by a nonsteady but stable diurnal cycle." | ( Pye, S; Radziuk, J, 2004) |
| "Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term." | ( Bailey, CJ; Krentz, AJ, 2005) |
| "Rates of type 2 diabetes mellitus are increasing worldwide at an explosive rate." | ( Leiter, LA; Lewanczuk, RZ, 2005) |
| "Type 2 diabetes is the most frequent cause of end-stage renal failure in many Western countries." | ( De Vriese, AS; Denner, L; Flyvbjerg, A; Lameire, NH; Schrijvers, BF; Tilton, RG; Van de Voorde, J, 2005) |
| "Type 2 diabetes is an important cause of morbidity and mortality." | ( Carey, IM; Cook, DG; DeWilde, S; Lusignan, S; Richards, N; Sismanidis, C, 2005) |
| "Prevalence of type 2 diabetes is increasing." | ( Carey, IM; Cook, DG; DeWilde, S; Lusignan, S; Richards, N; Sismanidis, C, 2005) |
| "Patients with type 2 diabetes mellitus are at high risk of cardiovascular disease." | ( Forst, T; Füllert, SD; Hohberg, C; Kann, P; Konrad, T; Langenfeld, MR; Lübben, G; Pfützner, A; Sachara, C, 2005) |
| "Manifestation of type 2 diabetes is determined by both environmental factors such as lack of physical exercise and overeating and a genetic predisposition." | ( Böttcher, Y; Kovacs, P; Stumvoll, M; Tönjes, A, 2005) |
| "Type 2 diabetes mellitus is a widespread disease, affecting millions of people globally." | ( Barbetti, F; Brunetti, A; Brunetti, L; Chiefari, E; Croce, CM; Fedele, M; Foti, D; Fusco, A; Iuliano, R; Manfioletti, G; Paonessa, F, 2005) |
| "Type 2 diabetes mellitus is a disease with a high incidence and prevalence in the world." | ( Arredondo, M; Leiva, E; Mujica, V; Orrego, R; Prieto, M, 2005) |
| "Type 2 diabetes is characterised by inappropriate regulation of hepatic glucose production, which is due, at least in part, to an imbalance in the bihormonal relationship between plasma levels of glucagon and insulin." | ( Michael, MD; Moyers, JS; Sloop, KW, 2005) |
| "Type 2 diabetes is the leading cause of end-stage renal failure in Australia's indigenous people." | ( Gill, JP; Shephard, MD, 2005) |
| "MODY is a group of six different forms of monogenic diabetes, characterized by insulin secretion defects in pancreatic beta-cells, supposed to be responsible for 2-5% of all cases of diabetes." | ( Giuffrida, FM; Reis, AF, 2005) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action." | ( Giorgino, F; Laviola, L; Leonardini, A, 2005) |
| "The hallmark of type 2 diabetes is insulin resistance and insufficient insulin secretion, and appropriate therapy should be selected for each patient." | ( Gorogawa, S; Hazama, Y; Kaneto, H; Kawamori, D; Matsuhisa, M; Ohtoshi, K; Yamasaki, Y; Yoshiuchi, K, 2005) |
| "Type 2 diabetes is at least 4 times more common among British South Asians than in the general population." | ( Ahmad, N; Douglas, M; Hallowell, N; Hanna, L; Lawton, J, 2006) |
| "Type 2 diabetes is associated with increased cardiovascular risk." | ( Forst, T; Konrad, T; Langenfeld, M; Lübben, G; Marx, N; Pfützner, A; Walcher, D, 2005) |
| "Type 2 diabetes is a disorder of hyperglycemia resulting from failure of beta cells to produce adequate insulin to accommodate an increased metabolic demand." | ( Creemers, JW; Flamez, D; Kaufman, RJ; Ribick, M; Scheuner, D; Schuit, FC; Song, B; Tsukamoto, K; Vander Mierde, D, 2005) |
| "Type 2 diabetes is characterised by reduced monocyte TIMP-1 mRNA levels, and a lower plasma MMP-9 to TIMP-1 protein ratio compared to controls, a pattern that would promote coronary plaque instability if reproduced within vascular plaque." | ( Baugh, M; Davies, I; Gavrilovic, J; Hughes, D; Sampson, M; Wall, S; Worley, J, 2006) |
| "However, common type 2 diabetes is likely to result from the contribution of many genes interacting with different environmental factors to produce wide variation in the clinical course of the disease." | ( Vozarova de Courten, B; Wolford, JK, 2004) |
| "Patients with Type 2 diabetes are at increased risk of liver damage." | ( Belcher, G; Schernthaner, G, 2005) |
| "We conclude that type 2 diabetes is associated with predominant left ventricular diastolic dysfunction." | ( Busch, AE; Huber, J; Linz, W; Rütten, H; Schäfer, S; Wihler, C, 2006) |
| "Type 2 diabetes is characterized by islet dysfunction resulting in hyperglycemia, which can then lead to further deterioration in islet function." | ( Andrikopoulos, S; Aston-Mourney, K; Cooper, ME; Dunlop, M; Favaloro, J; Forbes, JM; Kebede, M; Kooptiwut, S; Proietto, J; Thomas, MC; Tikellis, C; Visinoni, S; Zraika, S, 2005) |
| "Type 2 diabetes mellitus is increasing globally and is an established risk factor for the development of atherosclerotic vascular disease." | ( Channer, KS; Jones, TH; Kapoor, D; Malkin, CJ, 2005) |
| "NIDDM is characterized by progressive insulin resistance and the failure of insulin-producing pancreatic beta cells to compensate for this resistance." | ( Accili, D; Banks, AS; Hribal, ML; Kashiwada, M; Li, J; McKeag, L; Rothman, PB, 2005) |
| "Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke." | ( Betteridge, J; Birkeland, K; Charbonnel, B; Dormandy, JA; Eckland, DJ; Erdmann, E; Golay, A; Heine, RJ; Korányi, L; Laakso, M; Lefèbvre, PJ; Massi-Benedetti, M; Mokán, M; Moules, IK; Murray, GD; Norkus, A; Pirags, V; Podar, T; Scheen, A; Scherbaum, W; Schernthaner, G; Schmitz, O; Skene, AM; Skrha, J; Smith, U; Standl, E; Tan, MH; Taton, J; Wilcox, RG; Wilhelmsen, L, 2005) |
| "New onset type 2 diabetes is associated with a shift to the L phenotype." | ( Carlson, O; Doyle, ME; Egan, JM; Juhaszova, M; Michopoulos, S; Petraki, K; Theodorakis, MJ, 2006) |
| "Although type 2 diabetes is associated with a clustering of risk factors, the cause for an excess risk of cardiovascular disease remains unknown." | ( Laakso, M, 2002) |
| "IMT in people with Type 2 diabetes is independently and continuously related to urine albumin levels and to the duration of diabetes." | ( Celermajer, DS; Grieve, SM; Griffiths, K; Groshens, M; Keech, AC; Marwick, TH; Patel, A; Skilton, M; Watts, GF, 2005) |
| "Type 2 diabetes is increasingly viewed as a disease of insulin deficiency due not only to intrinsic pancreatic beta-cell dysfunction but also to reduction of beta-cell mass." | ( Masiello, P, 2006) |
| "Type 2 diabetes mellitus is a heterogeneous condition in which the clinical manifestation of hyperglycemia is a reflection of the impaired balance between insulin sensitivity and insulin secretion." | ( Arslanian, S; Bacha, F; Gungor, N; Hannon, T; Libman, I, 2005) |
| "Type 2 diabetes mellitus is a chronic disease with potentially devastating long-term complications." | ( Jacobson-Dickman, E; Levitsky, L, 2005) |
| "The prevalence of type 2 diabetes mellitus is rapidly increasing." | ( Dounis, V; Hansen, A; Malmberg, K; Rydén, L; Thrainsdottir, IS; Von Bibra, H, 2005) |
| "Type 2 diabetes is characterized by insulin resistance and progressive beta-cell failure." | ( Behar, V; Cerasi, E; Donath, MY; Fraenkel, M; Kaiser, N; Ktorza, A; Leibowitz, G; Magnan, C; Nesher, R, 2005) |
| "Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy." | ( Barter, P; Best, J; Colman, P; d'Emden, M; Davis, T; Drury, P; Ehnholm, C; Forder, P; Glasziou, P; Hunt, D; Keech, A; Kesäniemi, YA; Laakso, M; Pillai, A; Scott, R; Simes, RJ; Sullivan, D; Taskinen, MR; Whiting, M, 2005) |
| "Patients with type 2 diabetes are at high risk of developing cardiovascular complications." | ( Bachmann, C; Bardy, D; Beer, S; Feihl, F; Gaillard, RC; Golay, S; Ruiz, J; Waeber, B, 2005) |
| "Type 2 diabetes is associated with a high prevalence of dyslipidaemia and a high incidence of cardiovascular disease." | ( Howes, LG, 2006) |
| "Type 2 diabetes is associated with enhanced risk of adverse cardiovascular events following exposure to PM(2." | ( Dreher, KL; Kelly, SE; Proctor, SD; Russell, JC, 2006) |
| "Type 2 diabetes is characterized by hyperglycemia resulting from insulin resistance in the setting of inadequate beta-cell compensation." | ( Baggio, LL; Drucker, DJ, 2006) |
| "Women with Type 2 diabetes are not at higher risk of developing ASB than non-diabetic women." | ( Ishay, A; Lavi, I; Luboshitzky, R, 2006) |
| "The prevalence of type 2 diabetes mellitus is increasing rapidly in industrialized countries, and adrenal glucocorticoids may intensify this disease." | ( Born, J; Dodt, B; Fehm, HL; Oltmanns, KM; Peters, A; Raspe, HH; Schultes, B; Schweiger, U, 2006) |
| "Type 2 diabetes is recognised as a major cardiovascular risk factor, and future therapies must therefore address more than just blood glucose levels." | ( Lebovitz, H, 2006) |
| "Type 2 diabetes mellitus is a major cause of morbidity and mortality worldwide, and the prevalence is set to increase dramatically over the coming decades." | ( Petersen, KF; Shulman, GI, 2006) |
| "Patients with type 2 diabetes are prone to hypertension and persistent protein leakage from the kidney (microalbuminuria or macroalbuminuria)." | ( Barnett, A, 2006) |
| "Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide." | ( Brenner, BM; Chan, J; de Zeeuw, D; Kurokawa, K; Lash, JP; Ramjit, D; Remuzzi, G; Ribeiro, AB; Shahinfar, S; Zhang, Z, 2006) |
| "Type 2 diabetes is not only associated with hyperglycemia but also with disorders of lipid metabolism." | ( Agrawal, RP; Kochar, A; Kochar, DK; Pal, M; Sharma, P, 2006) |
| "Type 2 diabetes is a risk factor for nephrolithiasis in general and has been associated with uric acid stones in particular." | ( Adams-Huet, B; Cameron, MA; Maalouf, NM; Moe, OW; Sakhaee, K, 2006) |
| "Patients with type 2 diabetes are at high of cardiovascular events because they have abnormal lipid status compared to their non-diabetic counterparts." | ( Amayo, EO; Mwendwa, FW; Ogola, EN; Otieno, CF; Vaghela, V, 2005) |
| "Type 2 diabetes is a complex polygenic metabolic disorder of epidemic proportions." | ( Mziaut, H; Schwarz, PE; Solimena, M; Trajkovski, M, 2006) |
| "Type 2 diabetes mellitus is increasing to near epidemic proportions, with a reported 190 million patients worldwide." | ( Sawyer, TS; Spiller, HA, 2006) |
| "Individuals with Type 2 diabetes are at increased risk of stroke." | ( Buysschaert, M; Gala, JL; Hermans, MP, 2006) |
| "Type 2 diabetes is characterized by an incretin defect: while GIP does not stimulate insulin secretion, GLP-1 action is still preserved under supraphysiological concentrations." | ( Gallwitz, B, 2006) |
| "As NIDDM is increasing in prevalence in India, the above observations have ominous dimensions in terms of total burden of CAD in India." | ( Balachander, J; Rajappa, M; Sethuraman, KR; Sridhar, MG, 2006) |
| "Type 2 diabetes is up to four times more common in British South Asians than in the indigenous white population." | ( Baradaran, HR; Knill-Jones, RP; Rodgers, A; Wallia, S, 2006) |
| "Type 2 diabetes mellitus is a multigenic disease with evident genetic predisposition, and complex pathogenesis in which environmental and genetic factors interact." | ( Chang, YS; Fang, FD; He, AB; Liu, XJ, 2006) |
| "Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease." | ( Coca, A; Ekman, S; Girerd, X; Hua, T; Jamerson, K; Julius, S; Kjeldsen, SE; Larochelle, P; MacDonald, TM; Mancia, G; McInnes, GT; Schmieder, RE; Schork, MA; Stolt, P; Viskoper, R; Weber, MA; Widimský, J; Zanchetti, A, 2006) |
| "Type 2 diabetes is thought to develop as a result of progressive beta-cell dysfunction in the setting of insulin resistance, leading to increased risks of microvascular and macrovascular complications." | ( Kendall, DM; Kim, D; Maggs, D, 2006) |
| "Type 2 diabetes is a polygenic disease that can lead to severe complications in multiple tissues." | ( Kulkarni, RN; Neubauer, N, 2006) |
| "Type 2 diabetes is characterized by cellular and extracellular Mg depletion." | ( Barbagallo, M; Dominguez, LJ, 2007) |
| "When type 2 diabetes is managed with glucose-lowering monotherapy, glycemic control ultimately deteriorates due to the inability of the beta-cell to overcome insulin resistance." | ( Seufert, J, 2006) |
| "Type 2 diabetes is a complex metabolic disease with hyperglycemia as its recognizable hallmark." | ( Henke, BR; Sparks, SM, 2006) |
| "Type 2 diabetes mellitus is associated with abnormal MBF response to CPT, which can be significantly improved by euglycaemic control with glyburide and metformin." | ( Cadenas, J; Facta, AD; Hsueh, WA; Prior, JO; Quinones, MJ; Schelbert, HR; Schindler, TH, 2007) |
| "Type 2 diabetes mellitus is a cause of primary NAFLD." | ( Chung, CH; Leung, CH; Liu, SC; Wang, CH, 2006) |
| "Type 2 diabetes is now one of the most challenging health-care problems, and novel treatment strategies are required." | ( Bates, PC; Ristic, S, 2006) |
| "Type 1 and type 2 diabetes are characterised by a beta cell deficit." | ( Butler, AE; Butler, PC; Galasso, R; Meier, JJ; Rizza, RA, 2006) |
| "Type 2 diabetes is characterised by insulin resistance and progressive beta-cell dysfunction (which leads to hyperglycaemia), the risk of progressive worsening of glycaemic control and an increased risk of both macrovascular and microvascular complications." | ( Holcombe, JH; Kendall, DM; Stonehouse, AH, 2006) |
| "Insulin therapy in type 2 diabetes is initiated when glycemic control is inadequate despite the combination of antihyperglycemic drugs." | ( Ceponis, J; Varanauskaite, I; Varanauskiene, E, 2006) |
| "Guidelines for type 2 diabetes care in general practice are well known and accepted, but the implementation falls short." | ( Akkermans, RP; Braspenning, JC; de Grauw, WJ; Grol, RP; Harms, L; Lucas, AE; Meulepas, MA, 2007) |
| "Type 2 diabetes is one of the major risk factors for the development of CAD and subsequent MI." | ( Milutinović, A; Petrovic, D, 2006) |
| "Type 2 diabetes mellitus is usually preceded by impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG), which are often referred to as pre-diabetes." | ( Schwartz, S, 2006) |
| "Type 2 diabetes mellitus is the single most common cause of chronic kidney disease (CKD); however its real impact on renal anaemia has not been established." | ( Andreucci, M; Faga, T; Francesco, M; Fuiano, G; Li Vecchi, M; Mancuso, D; Provenzano, R; Sponton, A; Tozzo, C, 2007) |
| "Type 2 diabetes mellitus is the result of a combination of impaired insulin secretion with reduced insulin sensitivity of target tissues." | ( Bentley, E; Cheeseman, M; Connor, SC; Cox, RD; Griffin, JL; Haselden, JN; Hough, T; Maguire, ML; Nunez, D; Rubtsov, DV; Salek, RM; Sweatman, BC, 2007) |
| "Type 2 diabetes is preceded by a symptom-free period of impaired glucose tolerance (IGT)." | ( Hokamaki, J; Kawano, H; Miyamoto, S; Miyazaki, Y; Nagayoshi, Y; Nakamura, H; Ogawa, H; Yamabe, H; Yodoi, J; Yoshida, T, 2007) |
| "In addition, as type 2 diabetes is a progressive disease, it is still questionable whether the effect corresponds to a prevention effect or only to a postponing of the development of the disease." | ( Scheen, AJ, 2007) |
| "Maternal history of type 2 diabetes is independently associated with DN in type 1 diabetic patients." | ( Boissonnot, M; Bridoux, F; Duengler, F; Faure-Gerard, G; Guilhot, J; Hadjadj, S; Maréchaud, R; Mauco, G; Torremocha, F, 2007) |
| "Type 2 diabetes is characterized by reduced insulin secretion from the pancreas and overproduction of glucose by the liver." | ( Barucci, N; Burns, M; Buxton, JM; Clairmont, KB; Claus, TH; Livingston, JN; Ortiz, AA; Pan, CQ; Reynolds, JC; Roczniak, S; Whelan, JP; Yang, L, 2007) |
| "Most patients with type 2 diabetes mellitus are overweight or obese, and the relation between obesity, especially of the visceral compartment, and the risk for developing diabetes is well recognized." | ( Aronne, LJ; Lee, M, 2007) |
| "Type 2 diabetes mellitus is a strong predictor of cerebrovascular disease, yet few studies have assessed the incidence of stroke and the role of other risk factors in unselected type 2 diabetes mellitus populations." | ( Alegiani, SS; Avogaro, A; Ferrannini, E; Giorda, CB; Lombardo, F; Maggini, M; Mannucci, E; Raschetti, R; Turco, S; Velussi, M, 2007) |
| "Subjects with type 2 diabetes are at risk for vascular injury." | ( Goh, SK; Lim, SC; Morgenthaler, NG; Subramaniam, T; Sum, CF; Wu, YS, 2007) |
| "Type 2 diabetes is difficult to manage in patients with a long history of disease requiring insulin therapy." | ( Albrecht, D; Baron, MA; Chang, I; Dejager, S; Fonseca, V; Schweizer, A, 2007) |
| "Early-onset type 2 diabetes is associated with marked visceral obesity and extreme insulin resistance, but its pathogenesis and response to treatment are not completely understood." | ( Burns, N; Finucane, FM; Gasparro, D; Gastaldelli, A; Gilman, M; Hatunic, M; Mari, A; Murphy, M; Nolan, JJ, 2007) |
| "(1) Type 2 diabetes is rare in children." | ( , 2007) |
| "Obese type 2 diabetes is recently increasing in Korea, indicating a shift from insulin secretory defects to insulin resistance." | ( Cho, HK; Huh, KB; Kim, DJ; Lee, KW; Park, JW; Song, KE, 2007) |
| "Type 2 diabetes is a polygenic disorder with multiple genes located on different chromosomes contributing to its susceptibility." | ( Mohan, V; Radha, V, 2007) |
| "Type 2 diabetes is characterized by abnormal metabolism of glucose and fat, due in part to resistance to the actions of insulin in peripheral tissues." | ( Chakrabarti, R; Misra, P, 2007) |
| "Type 2 diabetes is a heterogeneous syndrome characterized by defective insulin secretion and/or insulin resistance." | ( Fukushima, M; Kuroe, A; Nakai, Y; Ohgushi, M; Ohya, M; Seino, Y; Taniguchi, A, 2007) |
| "Type 2 diabetes is characterized by increased acute phase serum proteins." | ( Ebeling, P; Heliövaara, MK; Herz, M; Leinonen, E; Teppo, AM, 2007) |
| "The prevalence of type 2 diabetes is increasing worldwide, and prevention of the disease is a key objective." | ( Vassanelli, C; Zanolla, L, 2007) |
| "Type 2 diabetes is often accompanied by abnormal blood lipid and lipoprotein levels, but most studies on the link between hyperlipidemia and diabetes have focused on free fatty acids (FFAs)." | ( Gunawardana, SC; Hao, M; Hasty, AH; Head, WS; Piston, DW, 2007) |
| "Type 2 diabetes is characterised by a gradual decline in glycaemic control and progression from oral glucose-lowering monotherapy to combination therapy and exogenous insulin therapy." | ( Hanefeld, M, 2007) |
| "Patients with type 2 diabetes are commonly overweight, which can contribute to poor cardiovascular outcomes." | ( Anderson, KM; Bakris, GL; Bangalore, S; Bell, DS; Fonseca, V; Holdbrook, FK; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "Most patients with type 2 diabetes are overweight or obese, overweight or obesity increases the risk of developing type 2 diabetes and obesity per se is strongly associated with multiple cardiometabolic risk factors." | ( Golay, A, 2008) |
| "Patients with type 2 diabetes mellitus are at increased risk for macrovascular disease complications." | ( McGuire, DK; Stancoven, A, 2007) |
| "Type 2 diabetes is a progressive disease characterized by insulin resistance and declining beta-cell function, often leading to a requirement for insulin therapy to maintain good glycemic control and prevent diabetes-associated complications." | ( Barnett, A, 2007) |
| "Type 2 diabetes is associated with an increased risk of cardiovascular disease (CVD)." | ( Betteridge, DJ, 2007) |
| "Type 2 diabetes is characterized by a relentless decline in pancreatic islet beta cell function and worsening hyperglycemia despite optimal medical treatment." | ( Harmon, JS; Robertson, R; Zhang, T; Zhou, H, 2007) |
| "Type 2 diabetes is characterised by a progressive decline in HbA1c control over time." | ( Baird, J; Campbell, IW; Chalmers, J; Franks, CI; Hunter, JE; Mariz, S; Martin, M; Robertson, SJ; Whately-Smith, CR, 2007) |
| "Type 2 diabetes is characterized by impaired pancreatic beta-cell function and decreased insulin sensitivity." | ( Ferrannini, E; Frayling, TM; Hattersley, AT; Ibrahim, IM; Mari, A; McCarthy, MI; Pascoe, L; Patel, SK; Tura, A; Walker, M; Weedon, MN; Zeggini, E, 2007) |
| "Type 2 diabetes is a chronic disease characterized by progressive worsening of glycaemic control as indicated by the United Kingdom Prospective Diabetes Study (UKPDS)." | ( Bianchi, C; Del Prato, S; Marchetti, P, 2007) |
| "Type 2 diabetes is the most common form of diabetes in humans." | ( Dotta, F; Lauro, D; Marchetti, P; Purrello, F, 2008) |
| "The presence of type 2 diabetes is associated with a lower risk of osteoporosis." | ( Afshinnia, F; Chacko, S; Zahedi, T, 2007) |
| "Type 2 diabetes is associated with reduced antioxidant defence." | ( Albanes, D; Kataja-Tuomola, M; Kontto, J; Männistö, S; Sundell, JR; Virtamo, J; Virtanen, MJ, 2008) |
| "Type 2 diabetes mellitus is twice as prevalent in African Americans and Hispanic Americans as in non-Hispanic whites." | ( Cobitz, AR; Davidson, JA; McMorn, SO; Waterhouse, BR, 2007) |
| "(1) When type 2 diabetes is inadequately controlled with oral antidiabetic therapy, one option is to add subcutaneous insulin injections (or to accept less stringent glycaemic control)." | ( , 2007) |
| "Type 2 diabetes is the most common cause of chronic renal failure worldwide." | ( Li, PK; Szeto, CC, 2008) |
| "Obesity and type 2 diabetes are the most prevalent metabolic diseases in the western world." | ( Febbraio, MA; Matthews, VB, 2008) |
| "Type 2 diabetes is a heterogeneous, polygenic disorder in which dysfunction in a number of important metabolic pathways appears to play roles." | ( Fujioka, K, 2007) |
| "Type 2 diabetes is manifested by progressive metabolic impairments in tissues such as skeletal muscle, adipose tissue and liver, such that these tissues become less responsive to insulin." | ( Bouzakri, K; Koistinen, HA; Zierath, JR, 2005) |
| "Type 2 diabetes is reaching epidemic proportions throughout the world, which has major health implications as such patients have considerably increased risk of coronary heart disease (CHD)." | ( Thomas, GN; Tomlinson, B, 2008) |
| "Type 2 diabetes is a progressive syndrome that evolves toward complete insulin deficiency during the patient's life." | ( Massi-Benedetti, M; Orsini-Federici, M, 2008) |
| "Type 2 diabetes mellitus is associated with elevated plasma triglyceride levels, low high-density lipoprotein cholesterol, and a high incidence of cardiovascular disease." | ( Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "Type 2 diabetes is associated with an increased risk of nephrolithiasis, specifically in the form of uric acid (UA) nephrolithiasis." | ( Daudon, M; Jungers, P, 2007) |
| "Type 2 diabetes is associated with microvascular complications." | ( Belmadani, S; Boulares, HA; Gonzalez-Villalobos, RA; Matrougui, K; Palen, DI, 2008) |
| "Type 2 diabetes mellitus is associated with progressive decreases in pancreatic beta-cell function." | ( Gutkin, SW; Nauck, MA; Van Gaal, LF, 2008) |
| "Type 2 diabetes is associated with an increased risk of endothelial dysfunction and microvascular complications with impaired autoregulation of tissue perfusion." | ( Immink, RV; Karemaker, JM; Kim, YS; Secher, NH; Stok, WJ; van Lieshout, JJ, 2008) |
| "Overt type 2 diabetes is usually preceded by a condition known as prediabetes, which is characterized by impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)." | ( Fonseca, VA, 2007) |
| "Type 2 diabetes is characterized partially by elevated fasting blood serum glucose and insulin concentrations and the percentage of hemoglobin as HbA1c." | ( Barre, DE; Griscti, O; Hafez, K; Mizier-Barre, KA, 2008) |
| "Type 2 diabetes mellitus is a common age-dependent disease." | ( Cheon, GJ; Cho, KA; Ha, MK; Jun, HS; Khil, LY; Lee, TS; Oh, YS; Park, SC; Ryu, SJ; Yoon, JW, 2008) |
| "The development of type 2 diabetes is accompanied by decreased immune function and the mechanisms are unclear." | ( Hao, J; Liu, J; Liu, Z; Long, J; Luo, C; Ren, J; Sharman, E; Shen, W; Tian, C, 2009) |
| "Type 2 diabetes mellitus is usually accompanied by concomitant disorders, such as dyslipidemia, hypertension and atherosclerosis." | ( Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Rizos, CV, 2008) |
| "Since type 2 diabetes is associated with chronic subclinical inflammation, we have determined whether serum EL concentration is increased in type 2 diabetes and investigated the effect of insulin on EL." | ( Huang, Y; Shiu, SW; Tan, KC; Wong, Y, 2008) |
| "Hypertension and type 2 diabetes are common co-morbidities." | ( Beck-Nielsen, H; Curtis, P; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; Pocock, SJ; Zambanini, A, 2008) |
| "Hypertension and Type 2 diabetes are co-morbid diseases that lead to the development of nephropathy." | ( Hammock, BD; Imig, JD; Kim, IH; Luria, A; Mitchell, BC; Newman, JW; Olearczyk, JJ; Quigley, JE; Yamamoto, T, 2009) |
| "Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive beta cell dysfunction as well as abnormalities in pancreatic alpha cell function and postprandial substrate delivery." | ( Kendall, D; Maggs, D; Okerson, T; Stonehouse, A, 2008) |
| "The prevalence of Type 2 diabetes is increasing dramatically as a result of the obesity epidemic, and poses a major health and socio-economic burden." | ( Cnop, M, 2008) |
| "Type 2 diabetes mellitus is associated with elevated level of oxidative stress, which is one of the most important factors responsible for the development of chronic complications of this disease." | ( Blasiak, J; Drzewoski, J; Kasznicki, J; Sliwinska, A, 2008) |
| "Patients with type 2 diabetes mellitus are at increased risk for the development of atherosclerosis." | ( Ayers, CR; Hedrick, CC; Mauldin, JP; McNamara, CA; Nagelin, MH; Skaflen, MD; Srinivasan, S; Wojcik, AJ, 2008) |
| "Type 2 diabetes is characterized by decreases in insulin secretion and insulin sensitivity." | ( Raskin, P, 2008) |
| "Type 2 diabetes is a common disorder with high risk of macrovascular and microvascular complications." | ( Brinton, EA, 2008) |
| "Type 2 diabetes is a heterogeneous disease with multiple causes revolving around beta cell dysfunction, insulin resistance and enhanced hepatic glucose output." | ( Amayo, AA; Huho, AN; Njagi, E; Omonge, EO; Otieno, CF, 2008) |
| "Type 2 diabetes is a heterogeneous disease where clinical judgement alone does not adequately tell the various aetiological types apart without additional laboratory testing of C-peptide levels and GAD antibody status." | ( Amayo, AA; Huho, AN; Njagi, E; Omonge, EO; Otieno, CF, 2008) |
| "Type 2 diabetes is a progressive disease." | ( Handelsman, Y, 2008) |
| "A review of Type 2 diabetes mellitus is presented." | ( Hall, MA, 2008) |
| "Periodontitis and type 2 diabetes are co-morbid conditions, both characterized by infectious susceptibility." | ( Bassim, CW; Becker, KL; DeNucci, DJ; Nylen, ES; Redman, RS, 2008) |
| "Type 2 diabetes mellitus is characterized by insulin resistance, impaired glucose-induced insulin secretion, and inappropriately elevated glucagon levels which eventually result in hyperglycemia." | ( Knop, FK; Vilsbøll, T, 2008) |
| "Type 2 diabetes is a major health problem in individuals with schizophrenia." | ( Dickerson, F; Leister, F; Origoni, A; Rubalcaba, E; Stallings, C; Sullens, A; Viscidi, R; Yang, S; Yolken, R, 2008) |
| "Type 2 diabetes is a situation at high cardiovascular risk, characterized by platelet hyperactivation, oxidative stress, elevated very-low density lipoprotein (VLDL) and low high-density lipoprotein concentrations." | ( Calzada, C; Charrière, S; Guichardant, M; Guillot, N; Ibrahim, S; Lagarde, M; Moulin, P; Ponsin, G; Pruneta-Deloche, V, 2009) |
| "Type 2 diabetes mellitus is a worldwide health problem." | ( Sriwijitkamol, A; Thongtang, N, 2008) |
| "Type 2 diabetes is an increasing problem in China, yet there is a paucity of data regarding the cost-effectiveness of pharmacological interventions in the Chinese setting." | ( Gibbs, M; Kotchie, RW; Nielsen, S; Palmer, JL; Scheijbeler, HW; Valentine, WJ; White, J, 2008) |
| "Type 2 diabetes mellitus is a complex disease characterized by beta-cell failure in the setting of insulin resistance." | ( Bernal-Mizrachi, E; Chang-Chen, KJ; Mullur, R, 2008) |
| "Type 2 diabetes is characterized by a combination of insulin resistance, dyslipidemia, and increased blood pressure." | ( Abe, M; Kikuchi, F; Matsumoto, K; Okada, K, 2008) |
| "New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia." | ( Bode, B; Garber, A; Garcia-Hernandez, PA; Hale, PM; Henry, R; Olvera-Alvarez, I; Ratner, R; Rodriguez-Pattzi, H; Zdravkovic, M, 2009) |
| "Type 2 diabetes mellitus is associated with an increased risk of cardiovascular diseases and accelerated atherosclerosis, which has been associated to hyperglycemia and chronic inflammation." | ( Bernard, EA; de Souza, LF; de Souza, MM; Jardim, FR; Sauter, IP, 2008) |
| "Type 2 diabetes is associated with many circulatory manifestations, including alteration in endothelial function and hypertension." | ( Aalkjaer, C; Brondum, E; Flyvbjerg, A; Kold-Petersen, H; Nilsson, H, 2008) |
| "Type 2 diabetes mellitus is a metabolic disease leading to microvascular and macrovascular complications including coronary artery disease and stroke." | ( Fonseca, VA; John-Kalarickal, J; Wani, JH, 2008) |
| "Once type 2 diabetes is diagnosed, the principles of its management are similar to those in younger patients, but with special considerations linked to the increased prevalence of co-morbidities and relative inability to tolerate the adverse effects of medication and hypoglycaemia." | ( Abbatecola, AM; Maggi, S; Paolisso, G, 2008) |
| "Type 2 diabetes mellitus is associated with a marked increase in the risk of coronary heart disease (CHD) or stroke (by a factor of two to three compared with non-diabetic patients), and cardiovascular disease (CVD) accounts for the majority of deaths among patients with diabetes." | ( Balasubramanian, R; Baliga, VP; Bolmall, C; Kathale, A; Nagraj, LM; Nayak, UP; Periyandavar, I; Sharma, A; Varadharajan, S, 2008) |
| "The prevalence of type 2 diabetes is rising at an alarming rate worldwide." | ( Karastergiou, K; Kaski, JC, 2008) |
| "Type 2 diabetes is a major health problem associated with excess mortality and morbidity." | ( Carvalho, C; Correia, S; Moreira, PI; Oliveira, CR; Santos, MS; Seiça, R, 2008) |
| "Type 2 diabetes is one of the most widespread and rapidly spreading diseases world-wide and has been subject of extensive research efforts." | ( Cedersund, G; Strålfors, P, 2009) |
| "Patients with type 2 diabetes are under high oxidative stress, and levels of hyperglycemia correlate strongly with levels of LDL oxidation." | ( Avitabile, T; Cammalleri, L; Malaguarnera, M; Motta, M; Vacante, M, 2009) |
| "Type 2 diabetes mellitus is an increasingly prevalent condition worldwide." | ( Feinglos, M; Green, J, 2008) |
| "Patients with type 2 diabetes are at considerable risk of excessive morbidity and mortality from cardiovascular disease (CVD)." | ( Park, D; Rohdewald, PJ; Watson, RR; Zibadi, S, 2008) |
| "Type 2 diabetes is associated with elevated inflammatory systemic cytokines but activin A serum levels were similar in slim probands, overweight controls and type 2 diabetic patients." | ( Aslanidis, C; Buechler, C; Filarsky, M; Neumeier, M; Schäffler, A; Schober, F; Schölmerich, J; Schramm, A; Sporrer, D; Stögbauer, F; Wanninger, J; Weber, M; Weigert, J; Wurm, S, 2009) |
| "Type 2 diabetes is becoming epidemic." | ( Morini, E; Prudente, S; Trischitta, V, 2009) |
| "Patients with type 2 diabetes are at increased risk of macro- and microvascular disease, and the presence of albuminuria and/or reduced kidney function further enhances macrovascular risk." | ( Armbrecht, J; Brenner, BM; Chaturvedi, N; de Zeeuw, D; Ghadanfar, M; Haffner, SM; McMurray, JJ; Parving, HH; Pfeffer, MA; Solomon, SD; Weissbach, N; Xiang, Z, 2009) |
| "Islet pathology in type 2 diabetes is characterized by beta-cell loss, islet amyloid derived from islet amyloid polypeptide (IAPP), and increased beta-cell apoptosis characterized by endoplasmic reticulum (ER) stress." | ( Butler, AE; Butler, PC; Daval, M; Gurlo, T; Matveyenko, AV, 2009) |
| "Both obesity and type 2 diabetes are associated with increased morbidity and mortality." | ( Hauptman, J; Jacob, S; Meier, MK; Rabbia, M, 2009) |
| "Type 2 diabetes mellitus is the leading cause of macrovascular diseases and related death." | ( Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karti, SS; Ukinc, K, 2009) |
| "Importantly, type 2 diabetes is associated with reduced insulin-stimulated glycogen synthase activation." | ( Jensen, J; Lai, YC, 2009) |
| "Type 2 diabetes is one of the fastest growing public health problems worldwide, resulting from both genetic factors and inadequate adaptation to environmental changes." | ( Amouyal, C; Andreelli, F; Devin-Leclerc, J; Foretz, M; Hebrard, S; Lantier, L; Mounier, R; Viollet, B, 2009) |
| "Type 2 diabetes is closely related to abdominal obesity and is generally associated with other cardiometabolic risk factors, resulting in a high incidence of cardiovascular complications." | ( Scheen, AJ, 2009) |
| "Type 2 diabetes is a complicated disease that is primarily characterized by insulin resistance and relative insulin deficiency mediated by numerous organs." | ( Chu, KY; Leung, PS, 2009) |
| "Type 2 diabetes is associated with insulin resistance, endothelial dysfunction and accelerated atherosclerotic diseases." | ( Cao, W; Liu, Z, 2009) |
| "Type 2 diabetes mellitus is a growing public health concern throughout the world." | ( Conway, JR; MacNair, D; Marble, RJ; Patasi, B, 2009) |
| "Type 2 diabetes is associated with higher fracture risk at a given bone mineral density." | ( Bauer, DC; Black, DM; Cummings, SR; Feingold, KR; Garnero, P; Harris, TB; Hillier, TA; Resnick, HE; Schwartz, AV; Sellmeyer, DE; Strotmeyer, ES; Tylavsky, FA, 2009) |
| "Overt type 2 diabetes is usually preceded by a condition known as prediabetes, which is characterized by impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)." | ( Fonseca, VA, 2008) |
| "Type 2 diabetes mellitus is a multifactorial metabolic disorder." | ( Fonseca, VA; John-Kalarickal, J; Surampudi, PN, 2009) |
| "Type 2 diabetes is characterized by hyperglycaemia, delayed gastric emptying and a blunted response of gut hormones during feeding that may modulate satiety." | ( Chevalier, S; Gougeon, R; Lamarche, M; Morais, JA; Mourad, C, 2009) |
| "Understanding type 2 diabetes is challenged by the diversity of patient phenotypes." | ( Klinke, DJ, 2009) |
| "Type 2 diabetes mellitus is a major and increasingly prevalent independent risk factor for cardiovascular morbidity and mortality worldwide." | ( Gore, MO; McGuire, DK, 2009) |
| "Type 2 diabetes is a common disorder with an increased risk of macrovascular complications." | ( Hobbs, FD; Taylor, C, 2009) |
| "Type 2 diabetes is treated in a stepwise manner, progressing from diet and physical activity to oral antidiabetic agents and insulin." | ( Clar, C; Royle, P; Waugh, N, 2009) |
| "Obesity and type 2 diabetes are related metabolic disorders of high prevalence." | ( Gao, J; He, J; Wada, T; Xie, W; Zhai, Y, 2009) |
| "Type 2 diabetes mellitus is a progressive disease characterized by persistent insulin resistance and a relentless decline in insulin secretion that is accelerated by chronic hyperglycemia." | ( Rosenstock, J, 2004) |
| "Type 2 diabetes is a complex disorder with a strong genetic background." | ( Liu, Y; Meng, Y; Xu, HY; Yang, HW; Zhang, J, 2009) |
| "Type 2 diabetes mellitus is associated with high mortality and morbidity, mainly due to coronary artery disease and atherosclerosis, although female gender is a protective factor in the development of, for example, atherosclerosis and hypertension." | ( Kamata, K; Kobayashi, T; Matsumoto, T; Taguchi, K; Takenouchi, Y, 2009) |
| "Type 2 diabetes is characterized by hyperglycemia resulting from insulin resistance in the setting of inadequate beta-cell compensation." | ( Legakis, I; Mantouridis, T, 2009) |
| "Type 2 diabetes mellitus is a complex metabolic disease that is caused by insulin resistance and beta-cell dysfunction." | ( Fritsche, A; Häring, HU; Machicao, F; Staiger, H, 2009) |
| "Patients with type 2 diabetes are known to have an increased risk for fracture compared with non-type 2 diabetic control subjects, despite having higher bone mineral density (BMD)." | ( Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M, 2009) |
| "Type 2 diabetes is associated with substantially increased cardiovascular mortality." | ( Maltezos, E; Papanas, N, 2009) |
| "Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology." | ( Berneis, K; Rini, GB; Rizvi, AA; Rizzo, M; Spinas, GA, 2009) |
| "Type 2 diabetes mellitus is a common, chronic and progressive metabolic disorder, which accounts for 90% of diabetes cases worldwide." | ( Casellini, CM; Fernández Landó, L, 2009) |
| "Type 2 diabetes is associated with a higher cardiovascular risk and there has been a growing interest in using dietary intervention to improve lipid profile and glucose control." | ( Biorklund, M; Cugnet-Anceau, C; Holm, J; Landin-Olsson, M; Laville, M; Le Coquil, E; Moulin, P; Nazare, JA; Onning, G; Sassolas, A; Sothier, M, 2010) |
| "Type 2 diabetes is a chronic metabolic disease that involves both environmental and genetic factors." | ( Kasif, S; Kohane, IS; Kong, SW; Lai, WR; Park, PJ; Tebaldi, T, 2009) |
| "Many patients with type 2 diabetes are obese (diabesity), and the two conditions together impose a particularly complex therapeutic challenge." | ( Bailey, CJ, 2009) |
| "Patients with type 2 diabetes are at an increased risk for both diabetes- and CV-related outcomes, and weight reduction is an important component of diabetes management." | ( Pi-Sunyer, FX, 2009) |
| "Type 2 diabetes is a progressive disease characterized by insulin resistance and impaired beta-cell function." | ( Vilsbøll, T, 2009) |
| "Type 2 diabetes is a very common worldwide disorder, with major consequences for patients, society, and health care services." | ( Barnett, AH; Palalau, AI; Piya, MK; Tahrani, AA, 2009) |
| "Type 2 diabetes is a progressive disease for which current treatments are often unsatisfactory with respect to achieving therapeutic goals and unwanted side effects." | ( Deacon, CF; Holst, JJ, 2010) |
| "* Patients with Type 2 diabetes are likely to have or to develop renal impairment, which affects the pharmacokinetics of some antidiabetic treatments." | ( Hindsberger, C; Jacobsen, LV; Robson, R; Zdravkovic, M, 2009) |
| "Type 2 diabetes mellitus is a disease characterized by persistent and progressive deterioration of glucose tolerance." | ( Del Prato, S, 2009) |
| "Obesity and type 2 diabetes are associated with renal dysfunction, which improves after Roux-en-Y gastric bypass (RYGB)." | ( Abumrad, NN; Feurer, ID; Ikizler, A; Isbell, JM; Kasim, NR; Marks, P; Saliba, J; Tamboli, RA, 2010) |
| "Exenatide use in type 2 diabetes is limited in routine clinical practice." | ( Bain, SC; Davies, J; Edavalath, M; Evans, D; Jenkins, L; Marshall-Richards, N; Natarajan, B; Price, DE; Stephens, JW, 2010) |
| "In fact, type 2 diabetes is often accompanied by abnormal blood lipid and lipoprotein levels, but most studies on the link between hyperlipidemia and pathogenesis of diabetes have focused on free fatty acids (FFAs), which were believed to enhance hyperglycemia- induced beta cell deterioration and insulin secretion impairment, while the impact of cholesterol in the pathogenesis of diabetes has not been reported." | ( Lin, Y; Peng, Y; Qian, L; Xu, L, 2010) |
| "People with type 2 diabetes are at increased risk of cognitive impairment but the mechanism is uncertain." | ( Deary, IJ; Fowkes, FG; Frier, BM; Labad, J; Lee, AJ; Mitchell, R; Price, JF; Reynolds, RM; Seckl, JR; Strachan, MW; Walker, BR, 2010) |
| "Once type 2 diabetes is diagnosed, the principles of its management are similar to those in younger patients, but with special considerations linked to the increased prevalence of comorbidities and relative inability to tolerate adverse effects of medication and hypoglycemia." | ( Abbatecola, AM; Paolisso, G, 2009) |
| "People with type 2 diabetes are at increased cardiovascular disease risk and thus are suitable to study associations of plasma cortisol with cardiovascular risk." | ( Braun, A; Fowkes, FG; Frier, BM; Labad, J; Lee, AJ; Price, JF; Reynolds, RM; Seckl, JR; Strachan, MW; Walker, BR, 2010) |
| "Indeed, type 2 diabetes is improved or even reversed soon after these operations and well before significant weight loss occurs." | ( Castagneto-Gissey, L; Mingrone, G, 2009) |
| "Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke." | ( Kawamori, R, 2010) |
| "Type 2 diabetes is a major global health problem." | ( Li, D; Liu, XX; Lun, YZ; Sun, WP; Zhou, SS; Zhou, YM, 2010) |
| "Type 2 diabetes is the most prevalent and serious metabolic disease all over the world, and its hallmarks are pancreatic beta-cell dysfunction and insulin resistance." | ( Kaneto, H; Katakami, N; Matsuhisa, M; Matsuoka, TA, 2010) |
| "Type 2 diabetes is a complex metabolic disorder with obesity being a major contributing factor in its development." | ( Bharadwaj, D; Chauhan, G; Dwivedi, OP; Ghosh, S; Mahajan, A; Tabassum, R; Tandon, N, 2010) |
| "Type 2 diabetes mellitus is associated with low high-density lipoprotein (HDL) cholesterol levels, which is an independent cardiovascular risk factor." | ( Schultheiss, HP; Spillmann, F; Tschöpe, C; Van Linthout, S, 2010) |
| "Type 2 diabetes mellitus is a chronic debilitating disease characterized by insulin resistance and progressive pancreatic dysfunction." | ( Henry, RR; Mudaliar, S, 2010) |
| "It is obvious that type 2 diabetes is closely correlated with a variety of underlying disorders of atherosclerosis." | ( Kawamori, R, 2010) |
| "Microalbuminuria in Type 2 diabetes is associated with arterial endothelial dysfunction, but the venous bed was never evaluated." | ( Bertoluci, MC; Irigoyen, MC; Moreno, H; Plentz, RD; Schaan, BD; Signori, LU; Silva, AM, 2010) |
| "Type 2 diabetes is associated with numerous long-term complications." | ( Alt, EU; Cramer, C; Dupin, CL; Freisinger, E; Izadpanah, R; Jones, RK; Newsome, ER; Slakey, DP, 2010) |
| "Type 2 diabetes is associated with excessively low urine pH, which increases the risk for uric acid nephrolithiasis." | ( Cameron, MA; Maalouf, NM; Moe, OW; Sakhaee, K, 2010) |
| "Patients with type 2 diabetes are reported to have a worse response to cancer chemotherapy, have more complications, and have a poorer prognosis than patients with cancer without diabetes." | ( Gallagher, EJ; LeRoith, D, 2010) |
| "The management of type 2 diabetes is designed to reduce disease-related complications and improve long-term outcomes." | ( Hollander, PA; Kushner, P, 2010) |
| "Type 2 diabetes mellitus is a complicated metabolic disease affecting millions of individuals worldwide." | ( Parkin, CG; Unger, J, 2010) |
| "Type 2 diabetes is characterized by impaired beta-cell secretory function, insulin resistance, reduced high-density lipoprotein (HDL) levels, and increased cardiovascular risk." | ( Appavoo, M; Barter, PJ; Fryirs, MA; Heather, AK; Rye, KA; Tabet, F; Tuch, BE, 2010) |
| "The increase in type 2 diabetes mellitus is associated to cardiovascular morbidity and mortality." | ( Ghiadoni, L, 2010) |
| "Type 2 diabetes is a very common worldwide disorder." | ( Abel, T; Fehér, J, 2010) |
| "Individuals with type 2 diabetes are more likely than non-diabetic subjects to experience silent or manifest episodes of myocardial ischaemia as the first presentation of coronary artery disease." | ( De Caterina, R; Madonna, R; Sourij, H; Wascher, T, 2010) |
| "Type 2 diabetes mellitus is associated with increased risk of malignancy (mainly cancer of the pancreas, breast, colon, endometrium and bladder)." | ( Maltezos, E; Mikhailidis, DP; Papanas, N, 2010) |
| "Type 2 diabetes is a metabolic disease, which frequency increases substantially with age." | ( Kedziora, J; Kedziora-Kornatowska, K; Kupczyk, D; Rybka, J, 2010) |
| "Type 2 diabetes is in essence a vascular disease and is frequently associated with hypertension, macrovascular events, and microvascular complications." | ( Cao, W; Ko, SH; Liu, Z, 2010) |
| "Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells." | ( Bailey, CJ; Flatt, PR; Green, BD, 2010) |
| "Type 2 diabetes is associated with increased expression of IAPP." | ( Chan, JC; Fan, R; Gu, X; Li, X; Xu, G, 2010) |
| "Type 2 diabetes is associated with an increased risk for developing fatty liver disease, which results in an increased incidence of diabetic nephropathy." | ( Gaikwad, AB; Gupta, J; Tikoo, K, 2010) |
| "Type 2 diabetes is an increasingly prevalent disease resulting from various complex combinations of defects in insulin secretion and insulin action." | ( Scheen, AJ, 2010) |
| "Type 2 diabetes is characterized by progressive β-cell dysfunction." | ( Cho, DH; Chung, DJ; Chung, JO; Chung, MY, 2010) |
| "Patients with type 2 diabetes mellitus are characterized by increased incidence of cardiovascular events and enhanced thromboxane-dependent platelet activation." | ( Davì, G; Mucci, L; Santilli, F, 2011) |
| "Patients with type 2 diabetes are at an increased risk for disease and treatment related complications after the initial approach of oral mono/dual antidiabetic therapy has failed." | ( Binz, C; Bramlage, P; Deeg, E; Gitt, AK; Krekler, M; Plate, T; Tschöpe, D, 2010) |
| "Type 2 diabetes is associated with a higher risk of cancer, which appears more obvious since the reduction of cardiovascular mortality." | ( Beck, E; Scheen, AJ, 2010) |
| "Type 2 diabetes is associated with glycocalyx perturbation and increased vascular permeability, which are partially restored following sulodexide administration." | ( Broekhuizen, LN; Holleman, F; Lemkes, BA; Meuwese, MC; Mooij, HL; Nieuwdorp, M; Schlingemann, RO; Stroes, ES; Verberne, H; Vink, H, 2010) |
| "The prevalence of Type 2 diabetes is increasing in rural areas of India, where there is also often a lack of health infrastructure." | ( Chakraborty, C; Kumar, BD; Mitra, A; Mukherjee, S; Thakur, G, 2009) |
| "The prevalence of type 2 diabetes is increasing dramatically throughout the world." | ( Hanaoka, K; Kawaguchi, M; Kojima, H; Minegishi, I; Nagano, T; Okabe, T; Terai, T, 2010) |
| "Type 2 diabetes is caused by relative deficiency of insulin secretion and is associated with dysregulation of glucagon secretion during the late stage of diabetes development." | ( Gustavsson, N; Han, W; Lao, Y; Radda, GK; Seah, T; Südhof, TC, 2011) |
| "As Type 2 diabetes is characterized by subclinical inflammation, and arachidonic acid and metabolites thereof are produced during states of inflammation, it is possible that pancreatic β-cells use arachidonic acid as a compound for self-protection." | ( Ortsäter, H, 2011) |
| "Type 2 diabetes is characterized by insulin resistance, impaired glucose-induced insulin secretion, and inappropriately regulated glucagon secretion which in combination eventually result in hyperglycemia and in the longer term microvascular and macrovascular diabetic complications." | ( Hare, KJ; Knop, FK, 2010) |
| "Type 2 diabetes is occurring at alarming rates worldwide and despite available treatment options, the economic and public health burden of this epidemic remains enormous." | ( Aronsohn, RS; Pamidi, S; Tasali, E, 2010) |
| "T2D (Type 2 diabetes mellitus) is a major health issue that has reached epidemic status worldwide." | ( Bushell, M; Ferland-McCollough, D; Ozanne, SE; Siddle, K; Willis, AE, 2010) |
| "Type 2 diabetes is a chronic metabolic disease, and the current treatment for type 2 diabetes targets oxidative stress and postprandial hyperglycemia via the inhibition of α-glucosidase and α-amylase, key enzymes linked to type 2 diabetes." | ( Fahad, K; Philip, RM; Prathapan, A; Raghu, KG; Thomas, BK, 2011) |
| "Type 2 diabetes is increasing at epidemic proportions throughout the world, and diabetic nephropathy is the principal cause of end stage renal failure." | ( da Cunha, FX; Louro, TM; Matafome, PN; Nunes, EC; Seiça, RM, 2011) |
| "Type 2 diabetes is a complex disease with the coexistence of several pathophysiological abnormalities such as a defect of insulin secretion, a relative hyperglucagonaemia, an increased hepatic glucose production and a muscular insulin resistance." | ( Scheen, AJ, 2010) |
| "Type 2 diabetes is characterized by a progressive decline in glycaemic control." | ( Davies, MJ; Kela, R; Khunti, K, 2011) |
| "Type 2 diabetes mellitus is a well-established risk factor for cardiovascular disease (CVD)." | ( Adamidou, F; Anagnostis, P; Athyros, VG; Karagiannis, A; Kita, M; Mikhailidis, DP; Panagiotou, A, 2011) |
| "The incidence of type 2 diabetes is increasing at an alarming rate throughout the world." | ( Desouza, CV, 2010) |
| "Type 2 diabetes mellitus is increasing in prevalence at alarming rates." | ( Giorgino, F; Laviola, L; Leonardini, A; Natalicchio, A, 2011) |
| "Overt type 2 diabetes is associated with diminished islet expression of SCD and Elovl6, and this can disrupt desaturation of saturated FAs to MUFAs, rendering β-cells more susceptible to saturated FA-induced ER stress and apoptosis." | ( Green, CD; Olson, LK, 2011) |
| "Type 2 diabetes is a growing health concern." | ( Dugoua, JJ; Lee, T, 2011) |
| "Although drugs for type 2 diabetes are studied in heterogeneous samples of patients, their efficacy can be predicted by some clinical parameters." | ( Cremasco, F; Lamanna, C; Mannucci, E; Marchionni, N; Monami, M, 2011) |
| "Type 2 diabetes is highly prevalent in human populations, particularly in obese individuals, and is characterized by progressive pancreatic β-cell dysfunction and insulin resistance." | ( Fan, W; Hedlund, M; Jih, A; Kavaler, S; Kim, JJ; Morinaga, H; Varki, A, 2011) |
| "Long-term type 2 diabetes is a known risk factor for pancreatic cancer (PC)." | ( Abbruzzese, JL; Chang, P; Dong, X; Hess, KR; Li, D; Li, Y; Tang, H, 2011) |
| "Type 2 diabetes is a progressive disease and most patients with type 2 diabetes eventually need insulin therapy." | ( Abe, T; Itoh, H; Kawai, T; Kou, K; Kurosawa, H; Meguro, S; Saisho, Y; Shimada, A; Tanaka, K, 2011) |
| "Type 2 diabetes is often associated with high blood cholesterol." | ( Cao, X; Gao, B; Hou, F; Liu, J; Liu, Z; Lu, X; Seo, H, 2011) |
| "Type 2 diabetes is associated with atherogenic abnormalities of postprandial triglyceride-rich lipoproteins." | ( Annuzzi, G; Bozzetto, L; Cipriano, P; Corte, GD; Mangione, A; Patti, L; Riccardi, G; Rivellese, AA, 2011) |
| "Type 2 diabetes mellitus is an independent risk factor for the development of cardiovascular disease." | ( Alvarez de Sotomayor, M; Herrera, MD; Justo, ML; Mingorance, C; Rodríguez-Rodríguez, R, 2011) |
| "Type 2 diabetes mellitus is a complex metabolic disease and its pathogenesis involves abnormalities in both peripheral insulin action and insulin secretion by pancreatic beta cells." | ( Benito, M, 2011) |
| "The incidence of type 2 diabetes mellitus is increasing worldwide." | ( Chawla, S; Ghosh, RK; Ghosh, SM; Jasdanwala, SA, 2012) |
| "Type 2 diabetes is an important risk factor for the development of coronary artery disease (CAD)." | ( Milutinović, A; Petrovič, D; Pleskovič, A; Vraspir-Porenta, O; Zorc, M; Zorc-Pleskovič, R, 2011) |
| "Type 2 diabetes is characterized by insulin resistance and pancreatic beta cell dysfunction, and the latter is known to usually progress during the entire disease history." | ( Ueki, K, 2011) |
| "Type 2 diabetes is a heterogeneous metabolic disease characterized by insulin resistance and β-cell dysfunction leading to hyperglycaemia and dyslipidaemia." | ( Crisóstomo, J; Louro, T; Matafome, P; Nunes, E; Rodrigues, L; Seiça, R, 2011) |
| "Type 2 diabetes is now a pandemic and shows no signs of abatement." | ( Damm, P; Nolan, CJ; Prentki, M, 2011) |
| "Type 2 diabetes mellitus is one of the significant comorbidities of obesity." | ( Eid, WE, 2011) |
| "As obesity and type 2 diabetes are becoming an epidemic in westernized countries, the incidence and prevalence of obesity- and diabetes-related co-morbidities are increasing." | ( Schrauwen, P; Schrauwen-Hinderling, VB; van de Weijer, T, 2011) |
| "The prevalence of type 2 diabetes is increasing alarmingly in both developed and developing countries." | ( Airaksinen, R; Blomstedt, P; Eriksson, JG; Kajantie, E; Kiviranta, H; Rantakokko, P, 2011) |
| "It was studied that type 2 diabetes mellitus is connected with increased plasma lipid peroxidation (lipid peroxidation expressed as malondialdehyde)." | ( Marjani, A, 2010) |
| "Type 2 diabetes mellitus is characterised by beta cell failure, which frequently develops in the setting of insulin resistance." | ( Drucker, DJ; Rosen, CF, 2011) |
| "Obesity and type 2 diabetes are characterized by insulin resistance, and the common basis of these events is a chronic and systemic inflammatory process marked by the activation of the c-Jun N-terminal kinase (JNK) and inhibitor-κB kinase (IKKβ)/nuclear factor-κB (NFκB) pathways, up-regulated cytokine synthesis, and endoplasmic reticulum dysfunction." | ( Araújo, TG; Bagarolli, RA; Boechat, LH; Carvalheira, JB; Guadagnini, D; Oliveira, AG; Prada, PO; Rocha, GZ; Saad, MJ; Santos-Silva, JC; Tobar, N; Zollner, RL, 2011) |
| "Type 2 diabetes mellitus is associated with a 2- to 4-fold increased risk of coronary heart disease (CHD)." | ( Arora, R; Dey, S; Kandhwal, K; Monif, T; Nazarudheen, S; Rao, S; Reyar, S; Singh, MK; Thudi, NR, 2011) |
| "HIV and type 2 diabetes are known risk factors for albuminuria, but no previous reports have characterized albuminuria in HIV-infected patients with diabetes." | ( Dutcher, L; Georgoff, P; Hadigan, C; Kim, PS; Kopp, JB; Mican, JA; Rosenberg, A; Smith, MA; Woods, C, 2011) |
| "Type 2 diabetes mellitus is a growing problem in pediatrics and there is no consensus on the best treatment." | ( Hoffman, RP; Meyer, SL, 2011) |
| "Type 2 diabetes mellitus is associated with a progressive decline in insulin-producing pancreatic β-cells, an increase in hepatic glucose production, and a decrease in insulin sensitivity." | ( Holst, JJ; McGill, MA, 2012) |
| "People with type 2 diabetes are at risk of cognitive impairment and brain atrophy." | ( Bryan, RN; Coker, L; Davatzikos, C; Ding, J; Gerstein, HC; Hirsch, J; Horowitz, KR; Launer, LJ; Lazar, RM; Lipkin, EW; Lovato, J; Lovato, LC; Maldjian, J; Marcovina, S; Margolis, KL; Miller, ME; Murray, AM; O'Connor, P; Sullivan, M; Sunshine, JL; Truwit, C; Williamson, JD, 2011) |
| "Type 2 diabetes is making up to 90% of the all diabetic cases." | ( Gerô, L; Winkler, G, 2011) |
| "Type 2 diabetes is a heterogeneous disorder caused by concomitant impairment of insulin secretion by pancreatic β cells and of insulin action in peripheral target tissues." | ( Bavelloni, A; Billi, AM; Cocco, L; Faenza, I; Fiume, R; Piazzi, M; Ramazzotti, G, 2012) |
| "Since type 2 diabetes is an age related disorder and FOXO proteins play an important role in the regulation of metabolism, we studied the role of common variants in FOXO3 for association with type 2 diabetes." | ( Anilkumar, G; Kumar, H; Nair, AK; Sugunan, D, 2012) |
| "Type 2 diabetes is associated with increased risk of breast, colon, pancreatic and other types of cancer, while type 1 diabetes is associated with increase in stomach, pancreatic, endometrial and cervical cancer." | ( Abdallah, M; Alickaj, A; Asad, S; Forte, V; Mahmud, S; McFarlane, SI; Pandey, A, 2011) |
| "Type 2 diabetes is a key risk factor for ischemia-dependent pathology; therefore, a significant medical need exists to develop novel therapies that increase the formation of new vessels." | ( Belmadani, S; Choi, SK; Galán, M; Matrougui, K; Partyka, M; Trebak, M, 2012) |
| "Type 2 diabetes is a major public health problem." | ( Akbarzadeh, M; Dabbaghmanesh, MH; Eftekhari, MH; Hasanzadeh, J, 2011) |
| "The incidence of type 2 diabetes is increasing among Finnish young adults." | ( Karvonen, M; Kousa, A; Moltchanova, E; Puustinen, N, 2012) |
| "Type 2 diabetes mellitus is frequently accompanied by fatty liver/nonalcoholic fatty liver disease." | ( Ishii, S; Ohta, T; Sakai, K; Shiraishi, M; Tsuchida, T, 2012) |
| "Type 2 diabetes mellitus is likely the third modifiable risk factor for pancreatic cancer after cigarette smoking and obesity." | ( Li, D, 2012) |
| "Depression in Type 2 diabetes is associated with obesity, cardiovascular disease, and mortality." | ( Deary, IJ; Fowkes, FG; Labad, J; Price, JF; Reynolds, RM; Sattar, N; Seckl, JR; Strachan, MW; Walker, BR, 2012) |
| "Type 2 diabetes mellitus is thought to be a significant risk factor for Alzheimer's disease." | ( Kasahara, R; Matsubara, T; Naruse, K; Sato, T; Sobue, K; Suzuki, K; Tanida, M; Taniura, H; Yamamoto, N, 2012) |
| "The prevalence of type 2 diabetes is increasing worldwide." | ( Barnett, AH; Bhartia, M; Tahrani, AA, 2011) |
| "Type 2 diabetes is associated with an increased risk of several types of cancer and with reduced survival after cancer diagnosis." | ( Currie, CJ; Gale, EA; Jenkins-Jones, S; Johnson, JA; Morgan, CL; Poole, CD, 2012) |
| "Type 2 diabetes mellitus is a progressive disease characterized by multiple abnormalities that extend beyond β-cell dysfunction and insulin resistance." | ( Freeman, JS, 2012) |
| "Type 2 diabetes is characterized by oxidative stress and a chronic low-grade inflammatory state, which also play roles in the pathogenesis of this disease and the accompanying vascular complications by increasing the production of free radicals and pro-inflammatory cytokines." | ( Alarcon-Aguilar, FJ; Almanza-Perez, JC; Angeles-Mejia, S; Banderas-Dorantes, TR; Blancas-Flores, G; Diaz-Flores, M; Fortis-Barrera, A; Gomez, J; Jasso, I; Roman-Ramos, R; Zamilpa-Alvarez, A, 2012) |
| "Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications." | ( Armbrecht, J; Brenner, BM; Chaturvedi, N; de Zeeuw, D; Haffner, SM; McMurray, JJ; Nicolaides, M; Parving, HH; Persson, F; Pfeffer, MA; Richard, A; Solomon, SD; Xiang, Z, 2012) |
| "Type 2 diabetes is often associated with obesity, dyslipidemia and cardiovascular anomalies and is a major health problem approaching global epidemic proportions." | ( Clark, S; Hua, Y; Ren, J; Sreejayan, N, 2012) |
| "Type 2 diabetes is associated with low total serum testosterone (TT) identified in several cross-sectional studies and systemic analyses." | ( Elkhiat, Y; Ghazi, S; Shamloul, R; Zohdy, W, 2012) |
| "Type 2 diabetes is a complex metabolic disorder characterised by varying degrees of impairment in insulin secretion and resistance to the action of insulin." | ( Barker, A; Langenberg, C; Wareham, NJ, 2012) |
| "Type 2 diabetes is associated with stroke and cardiac dysfunction." | ( Aalkjaer, C; Brøndum, E; Flyvbjerg, A; Kold-Petersen, H; Nilsson, H, 2012) |
| "Type 2 diabetes is highly prevalent and is the major cause of progressive chronic kidney disease in American Indians." | ( Best, LG; Cochran, BJ; Cole, SA; Dyer, TD; Franceschini, N; Haack, K; Howard, BV; Laston, S; Lee, ET; Maccluer, JW; North, KE; Shara, NM; Umans, JG; Voruganti, VS; Wang, H, 2012) |
| "The prevalence of type 2 diabetes mellitus is high among the elderly population." | ( Marrs, JC, 2012) |
| "Individuals with type 2 diabetes are at increased risk of acquiring melioidosis, a disease caused by Burkholderia pseudomallei infection." | ( Alonso, S; Gamage, AM; Gan, YH; Koh, HQ; Lee, KO; Liu, Y; Low, KC; Tan, GY; Tan, KS, 2012) |
| "Type 2 diabetes mellitus is a multisystem disease that is characterized by hyperglycemia and is associated with the dysfunction and failure of various organs." | ( Kim, KJ; Lee, BY; Yoon, KY, 2012) |
| "Type 2 diabetes mellitus is the main cause of chronic kidney disease in developed countries." | ( Ardiles A, L; Parra L, X; Villarroel R, P, 2012) |
| "Type 2 diabetes mellitus is a major global public health problem in the worldwide and is increasing in aging populations." | ( Cheng, FC; Huang, JH; Lee, JN; Lu, YF; Tsai, LC, 2012) |
| "Taiwanese with type 2 diabetes are at a high risk of breast, prostate, colon, lung, liver and pancreatic cancer." | ( Cheng, SM; Hsieh, MC; Lee, TC; Tseng, CH; Tu, ST; Yen, MH, 2012) |
| "Type 2 diabetes mellitus is increasing over time as result of the obesity epidemics." | ( Castagneto-Gissey, L; Mingrone, G, 2012) |
| "The prevalence of type 2 diabetes is disproportionately high among Asian Indians (AI), one of the fastest growing immigrant groups in the United States (US)." | ( Kaplowitz, SA; Song, WO; Venkatesh, S; Weatherspoon, LJ, 2013) |
| "Patients with type 2 diabetes mellitus are at 2 to 4 times increased risk of cardiovascular events compared with those without diabetes, both among patients with multiple risk factors only and those with established atherothrombosis." | ( Bhatt, DL; Braunwald, E; Davidson, J; Hirshberg, B; Raz, I; Scirica, BM; Steg, PG; Udell, JA, 2012) |
| "Type 2 diabetes mellitus is associated with a higher risk of hepatocellular carcinoma (HCC), which is attenuated by the use of metformin." | ( Chang, CC; Chen, HP; Chen, TT; Lin, JH; Lin, JT; Shieh, JJ; Wu, CY; Wu, MS, 2013) |
| "Many patients with type 2 diabetes are suboptimally managed with currently available therapies." | ( Bailey, CJ; Iqbal, N; List, JF; T'joen, C, 2012) |
| "The pathogenesis of type 2 diabetes is characterized by impaired insulin action and increased hepatic glucose production (HGP)." | ( Han, W; Lee, P; Leong, W; Lim, M; Radda, GK; Tan, T, 2013) |
| "Type 2 diabetes mellitus is characterized by insulin resistance with a relative deficiency in insulin secretion." | ( Bouzakri, K; Halban, PA; Plomgaard, P, 2012) |
| "Type 2 diabetes is closely associated with fragility fracture risk." | ( Hayakawa, N; Suzuki, A, 2012) |
| "The prevalence of type 2 diabetes is on the rise in Australia." | ( Barlow, J; Deed, G; Kuo, I, 2012) |
| "Type 2 diabetes mellitus is associated with risk of congestive heart failure (CHF), cognitive dysfunction and depression." | ( Deary, IJ; Feinkohl, I; Price, JF; Reynolds, RM; Sattar, N; Strachan, MW; Welsh, P, 2012) |
| "Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy." | ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
| "The prevalence of type 2 diabetes is rapidly increasing, with severe socioeconomic impacts." | ( Andrikopoulos, S; Eriksson, U; Falkevall, A; Fam, BC; Hagberg, CE; Lu, L; Mehlem, A; Muhl, L; Nash, A; Nyqvist, D; Ortsäter, H; Proietto, J; Samén, E; Scotney, P; Sjöholm, A; Stone-Elander, S, 2012) |
| "Type 2 diabetes mellitus is characterized by insulin resistance and progressive β cell failure; therefore, β cell secretagogues are useful for achieving sufficient glycemic control." | ( Basit, A; Fawwad, A; Riaz, M, 2012) |
| "Patients with type 2 diabetes mellitus are routinely treated with combinations of glucose-lowering agents." | ( Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME, 2012) |
| "Type 2 diabetes mellitus is a multifactorial and polygenic disease, which is considered as a major life threatening problem all over the world." | ( Abbas, S; Ahmed, F; Fatima, J; Mahdi, F; Raza, ST; Zaidi, ZH, 2012) |
| "Hyperglycaemia in type 2 diabetes is associated with a reduction in postprandial insulin secretion, specifically through a reduction in insulin pulsatility." | ( Heise, T; Kapitza, C; Meier, JJ; Menge, BA; Pennartz, C; Schenker, N; Schmidt, WE; Veldhuis, JD, 2013) |
| "Obesity and type 2 diabetes are emerging global epidemics associated with chronic, low-grade inflammation." | ( Bhatnagar, A; Hellmann, J; Kosuri, M; Spite, M; Tang, Y; Zhang, MJ, 2013) |
| "Type 2 diabetes is a progressive disease that requires stepwise additions of non-insulin and insulin therapies to meet recommended glycaemic goals." | ( Cavaghan, MK; Hoogwerf, BJ; McGill, JB; Tobin, GS, 2012) |
| "Type 2 diabetes is characterized by impaired insulin secretion from pancreatic β-cells." | ( Fukunari, A; Iwasaki, S; Kakimoto, T; Kimata, H; Utsumi, H, 2013) |
| "MODY is characterised by young-onset, familial diabetes which is C-peptide positive, β-cell antibody negative and not associated with metabolic syndrome." | ( Owen, KR, 2013) |
| "Patients with type 2 diabetes are at increased susceptibility to a prolonged QT interval." | ( Amato, S; Baiocco, E; Curione, M; Di Bona, S; Gatti, A; Mandosi, E; Morano, S; Rossetti, M; Salvatore, S; Tarquini, G; Turinese, I; Varrenti, M, 2014) |
| "Type 2 diabetes is a multifactorial disease associated with increased oxidative stress, which may lead to increased DNA damage." | ( Baierl, A; Brath, H; Fastian, T; Forster, E; Henriksen, T; Millner, Y; Müllner, E; Paller, K; Pleifer, S; Poulsen, HE; Schiermayr, C; Wagner, KH; Wallner, M, 2013) |
| "Type 2 diabetes mellitus is a chronic dysmetabolic condition characterized by hyperglycemia and accompanied by dyslipidemia (low HDL, high triglycerides), and hypertension associated with insulin resistance in obesity." | ( de Galan, BE; Simsek, S, 2012) |
| "Cyslipidemia and type 2 diabetes are two of the most significant risk factors for the development of cardiovascular disease." | ( Chilton, R; Chiquette, E; Cobble, M; Ramirez, G; Toth, PP, 2012) |
| "Type 2 diabetes mellitus is associated with reduced incretin effects." | ( Chan, JC; Deng, Y; Fan, RR; Kang, ZF; Laybutt, DR; Luzuriaga, J; Xu, G; Zhou, Y, 2013) |
| "Type 2 diabetes mellitus is widely prevalent and is often coexistent with obesity." | ( Davies, MJ; Kela, R; Khunti, K; Nisal, K, 2012) |
| "Type 2 diabetes is characterized by pancreatic β-cell dysfunction and insulin resistance, and the number of patients has markedly increased worldwide." | ( Kaneto, H; Matsuoka, TA, 2012) |
| "Type 2 diabetes mellitus is a progressive disease characterized by an impairment of insulin action, and failure of pancreatic β-cells to compensate for the enhanced insulin demand." | ( Sesti, G, 2012) |
| "Type 2 diabetes mellitus is characterized by hyperglycaemia." | ( Hak, L; Wolnik, B, 2013) |
| "Type 2 diabetes is a major global health problem and there is ongoing research for new treatments to manage the disease." | ( Christopoulos, A; Furness, SG; Koole, C; Miller, LJ; Pabreja, K; Savage, EE; Sexton, PM; Wootten, D, 2013) |
| "Obesity and type 2 diabetes are characterised by low-grade inflammation, metabolic endotoxaemia (i." | ( Cani, PD; Delzenne, NM; Geurts, L; Muccioli, GG, 2013) |
| "Type 2 diabetes is the most common form of diabetes, accounting for over 90% of cases." | ( Chandra, R; Dubey, M; Kumari, K; Pandey, ND; Singh, P; Vishvakarma, VK, 2013) |
| "Type 2 diabetes is a chronic inflammatory metabolic disease, the key point being insulin resistance." | ( Feng, J; Jiang, C; Kong, W; Li, Y; Pang, Y; Wang, X; Xiang, X; Xu, G; Xu, M; Zhang, H, 2013) |
| "Type 2 diabetes is characterised by impaired glucose-stimulated insulin secretion (GSIS) from pancreatic islets." | ( Bartosinska, B; Eickelmann, P; Gray, NS; Jain, D; Jain, R; Kauschke, SG; Lammert, E; Liu, Q; Piemonti, L; Schumann, D; Wang, J, 2013) |
| "Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control." | ( Eckerle Mize, DL; Salehi, M, 2013) |
| "Type 2 diabetes mellitus is a metabolic noncommunicable disease with an expanding pandemic magnitude." | ( Berlanga-Acosta, J; García-Siverio, M; Guillen-Nieto, G; Herrera-Martínez, L; López-Mola, E; Schultz, GS, 2013) |
| "Type 2 diabetes is a chronic condition in which cells have reduced insulin signalling, leading to hyperglycemia and long-term complications, including heart, kidney and liver disease." | ( Maradana, MR; O'Sullivan, BJ; Thomas, R, 2013) |
| "Type 2 diabetes mellitus is a rising cause of cardiovascular morbidity and mortality." | ( Elisaf, MS; Rizos, CV, 2013) |
| "People with type 2 diabetes are affected by three main glycaemic disorders: chronic hyperglycaemia; glycaemic variability; and iatrogenic hypoglycaemia." | ( Colette, C; Hanefeld, M; Monnier, L; Owens, D; Schnell, O, 2013) |
| "The development of type 2 diabetes is caused by the insulin resistance, hyperglycemia, structural and functional disorders of the pancreatic cells." | ( Chashchyn, MO; Kitam, VO; Kovalenko, VM; Maksymchuk, OV; Rushchak, VV; Voronina, AK, 2012) |
| "Type 2 diabetes is a metabolic disorder characterized by hyperglycemia, caused by insulin resistance." | ( Koh, M; Miyazaki, H; Takaya, R; Takitani, K; Tamai, H; Yoden, A, 2013) |
| "Type 2 diabetes is defined by chronic hyperglycaemia, decreased insulin secretion and increased insulin resistance and is often associated with overweight or obesity, hypertension and dyslipidaemia." | ( , 2013) |
| "CEL-MODY is a monogenic form of diabetes with exocrine pancreatic insufficiency caused by mutations in CARBOXYL-ESTER LIPASE (CEL)." | ( El Ouaamari, A; Gygi, SP; Hu, J; Kahn, CR; Kawamori, D; Kulkarni, RN; Liew, CW; McAllister, FE; Molven, A; Njølstad, PR; Paulo, JA; Ræder, H; Vesterhus, M, 2013) |
| "Type 2 diabetes is extremely common in South Asians, e." | ( Bhopal, R; Bhopal, RS; Douglas, A; Forbes, J; Gill, J; Hutchison, A; Lawton, J; Lean, M; Mcknight, J; Murray, G; Sattar, N; Sharma, A; Sheikh, A; Tuomilehto, J; Wallia, S, 2014) |
| "Type 2 diabetes is characterized by insulin resistance together with progressive loss of beta-cell function." | ( Cetinkalp, S; Ertek, S, 2014) |
| "Type 2 diabetes mellitus is characterized by insulin resistance in peripheral tissues and relative impairment in insulin secretion from pancreatic beta cell." | ( Shimomura, I; Yasuda, T, 2013) |
| "Type 2 diabetes mellitus is the most common endocrine disease all over the world, while existing therapies can only ameliorate hyperglycemia or temporarily improve the response to insulin in target tissues, they cannot retard or improve the progressive β-cell dysfunction persistently." | ( Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W, 2014) |
| "Type 2 diabetes mellitus is a pandemic, with millions of new diagnoses made each year." | ( Davidson, JA; Grimm, M; Nikkel, C, 2013) |
| "Type 2 diabetes is a chronic metabolic disorder characterized by hyperglycemia with insulin resistance and impaired insulin secretion." | ( Goto, M; Hashimoto, S; Jomori, T; Kadowaki, T; Katsuyama, H; Kubota, N; Kubota, T; Nakaya, K; Sato, H; Takamoto, I; Tokuyama, K; Ueki, K, 2013) |
| "Obesity and type 2 diabetes are increasing in prevalence at an alarming rate in developed and developing nations and over 50% of patients with prolonged stages of disease experience forms of autonomic neuropathy." | ( Balemba, O; Gericke, M; Kappmeyer, AJ; Schmalz, JT; Stenkamp-Strahm, CM, 2013) |
| "Type 2 diabetes mellitus is an increasingly common threat to the health of elderly Americans." | ( Marcy, TR; Zhao, Q, 2013) |
| "Type 2 diabetes mellitus is characterized by prolonged hyperinsulinemia, insulin resistance, and progressive hyperglycemia." | ( Berg, RL; Doi, SA; Engel, JM; Glurich, I; Onitilo, AA; Stankowski, RV; Williams, GM, 2014) |
| "Type 2 diabetes is highly prevalent in populations having high rates of overweight and obesity." | ( Arredondo, M; Basfi-fer, K; Carrasco, F; Codoceo, J; Galgani, J; Inostroza, J; López, G; Pérez, A; Perez-Bravo, F; Rojas, P; Ruz, M; Valencia, A; Vásquez, K, 2013) |
| "Type 2 diabetes is a consequence of complex interactions among multiple genetic variants and environmental risk factors." | ( Afroze, D; Bhat, RA; Ganai, BA; Hameed, I; Masoodi, SR; Naykoo, NA, 2013) |
| "Type 2 diabetes is well recognized as a noninsulin-dependent diabetic disease." | ( Li, XC; Zhuo, JL, 2013) |
| "Men with type 2 diabetes are known to have a high prevalence of testosterone deficiency." | ( Channer, KS; Jones, TH; Kapoor, D; Marsh, H; Muraleedharan, V, 2013) |
| "Type 2 diabetes mellitus is increasing dramatically in sub-Saharan Africa, and genetic predisposition is likely involved in that." | ( Bedu-Addo, G; Danquah, I; Frank, LK; Mockenhaupt, FP; Othmer, T; Schulze, MB, 2013) |
| "Type 2 diabetes mellitus is a complex and progressive disease that is showing an apparently unstoppable increase worldwide." | ( Capuano, A; Esposito, K; Giugliano, D; Maiorino, MI; Rossi, F; Sportiello, L, 2013) |
| "Both obesity and type II diabetes mellitus are associated with insulin resistance and abnormal metabolic reactions." | ( Alawad, AO; Ballal, MA; Merghani, TH, 2013) |
| "Type 2 diabetes is characterized by insulin resistance and mitochondrial dysfunction in classical target tissues such as muscle, fat, and liver." | ( Bross, P; Christensen, JH; Kahn, CR; Kleinridders, A; Lauritzen, HP; Mori, MA; Ussar, S, 2013) |
| "Type 2 diabetes is characterised by progressive beta cell dysfunction, with changes in gene expression playing a crucial role in its development." | ( da Silva Xavier, G; Dawe, HR; Harries, LW; Locke, JM; Rutter, GA, 2014) |
| "Type 2 diabetes is associated with an impaired nitric oxide (NO) pathway that probably serves as the key link between metabolic disorders and cardiovascular disease." | ( Aranke, M; Bryan, NS; Garg, HK; Jiang, H; Pierini, D; Potts, A; Torregrossa, AC, 2014) |
| "Most patients with type 2 diabetes are treated every day with numerous drugs because of the presence of comorbidities so that poor drug compliance is a major concern in such a population." | ( Scheen, AJ; Van Gaal, LF, 2013) |
| "Type 2 diabetes mellitus is a troubling chronic disease and diabetic nephropathy is one of the most important complications of diabetes mellitus." | ( Ardalan, MR; Baradaran, A; Mardani, S; Momeni, A; Nasri, H; Rafieian-Kopaei, M, 2013) |
| "Since type 2 diabetes is associated with chronic subclinical inflammation, the objective of this study is to investigate the changes in SAA level in type 2 diabetic patients and to evaluate the relationship between SAA and the capacity of serum to induce cellular cholesterol efflux via the two known cholesterol transporters, scavenger receptor class B type I (SR-BI) and ATP-binding cassette transporter G1 (ABCG1)." | ( Chan, TM; Shiu, SW; Tan, KC; Tsun, JG; Wong, Y; Yung, S, 2013) |
| "Type 2 diabetes mellitus is a major risk factor for melioidosis, which is caused by Burkholderia pseudomallei." | ( Ato, M; Bancroft, GJ; Kewcharoenwong, C; Lertmemongkolchai, G; Rinchai, D; Suwannasaen, D; Utispan, K, 2013) |
| "Type 2 diabetes is a growing health problem worldwide that is particularly severe in India and China." | ( Habicht, SD; Krawinkel, MB; Ludwig, C; Yang, RY, 2014) |
| "Type 2 diabetes is characterized by an insulin secretory defect that cannot compensate for insulin resistance." | ( Paquot, N; Scheen, AJ, 2013) |
| "Type 2 diabetes is frequently associated with co-morbidities, including hypertension." | ( Brouns, AE; Brouwers, O; Daniels, A; Derks, WJ; Janssen, BJ; Munts, C; Schalkwijk, CG; van Bilsen, M; van der Vusse, GJ; van Nieuwenhoven, FA, 2014) |
| "Type 2 diabetes is characterised by a long asymptomatic period of hyperglycaemia and many individuals with type 2 diabetes have complications even at the time of diagnosis." | ( Gupta, A; Gupta, AK; Singh, TP, 2013) |
| "Type 2 diabetes is characterized by significant losses of important micronutrients due to metabolic basis of the disease and its complications." | ( Henry, J; Kaur, B, 2014) |
| "Type 2 diabetes is a chronic disease with potentially debilitating consequences." | ( Argyropoulos, G; Benotti, P; Gabrielsen, JD; Gerhard, GS; Ibele, A; Petrick, AT; Rolston, DD; Still, CD; Strodel, WE; Wood, GC, 2015) |
| "The prevalence of type 2 diabetes is increasing worldwide, and diabetes is a strong adverse prognostic factor among patients with cardiovascular (CV) disease." | ( Barter, PJ; Ong, KL; Waters, DD, 2014) |
| "As obesity and type 2 diabetes are highly associated with inflammation of the adipose tissue and gp130 has been shown to play an important role in adipocytes, we wanted to investigate the effect of SEA on adipocyte signaling and function." | ( Banke, E; Dalla-Riva, J; Degerman, E; Ekelund, M; Lagerstedt, JO; Lindkvist-Petersson, K; Nilson, B; Nilsson, S; Rödström, K, 2014) |
| "Type 2 diabetes is characterized by increased insulin resistance and impaired insulin secretion." | ( Fischer, CP; Ibfelt, T; Pedersen, BK; Plomgaard, P; van Hall, G, 2014) |
| "Type 2 diabetes mellitus is increasingly diagnosed in obese children and adolescents." | ( Narasimhan, S; Weinstock, RS, 2014) |
| "Type 2 diabetes is triggered by reduced insulin production, caused by genetic and environmental factors such as inflammation originating from the innate immune system." | ( Barg, S; Blom, AM; Buda, P; Fex, M; Gandasi, NR; Garcia-Vaz, E; Gomez, MF; King, BC; Krus, U; Nagaraj, V; Ottosson-Laakso, E; Renström, E; Sjölander, J; Storm, P; Vikman, P; Zhang, E, 2014) |
| "Patients with type 2 diabetes are generally treated with various pharmacological compounds and are exposed to a high risk of drug-drug interactions." | ( Iseki, K; Kobayashi, M; Ogura, J; Takahashi, N; Watanabe, M; Yamaguchi, H, 2014) |
| "The prevalence of type 2 diabetes is of major concern since it is reaching global epidemic levels." | ( Camer, D; Huang, XF; Szabo, A; Yu, Y, 2014) |
| "Type 2 Diabetes Mellitus is most common form of diabetes." | ( Garg, K; Kumar, S; Tripathi, CD, 2013) |
| "Type 2 diabetes is a common metabolic disease with the potential for prevention of complications." | ( Frydenberg, M; Juul, L; Maindal, HT; Sandbaek, A; Zoffmann, V, 2014) |
| "Type 2 Diabetes is a heterogeneous disease which harbors several different pathomechanistic entities." | ( Fritsche, A; Häring, HU; Wagner, R, 2014) |
| "Individuals with type 2 diabetes mellitus are at increased risk of developing atherosclerosis." | ( Greenberg, AS; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Obin, MS; Ronxhi, J; Spartano, NL, 2014) |
| "The pathogenesis of type 2 diabetes is characterized by insulin resistance and insulin secretory dysfunction." | ( Chase, JG; Docherty, PD; Fisk, LM; Te Morenga, L, 2014) |
| "Type 2 diabetes is associated with hypersecretion of glucagon during an OGTT, whereas i." | ( Bagger, JI; Holst, JJ; Knop, FK; Lund, A; Vilsbøll, T, 2014) |
| "Type 2 diabetes is caused by interactions between genetic and environmental factors." | ( Chen, Y; Feng, R; Hong, TP; Wang, H; Wang, L; Wei, R; Wen, J; Yang, J; Zhang, L, 2014) |
| "We conclude that type 2 diabetes is more common in mangabeys than in other primate species." | ( Cohen, JK; Collura, L; Courtney, CL; Herndon, JG; Jones, AC, 2014) |
| "Type 2 diabetes is a major health problem in many countries including India." | ( Burke, A; Hecht, FM; McDermott, KA; Murphy, EJ; Nagarathna, R; Nagendra, RH; Rao, MR, 2014) |
| "Type 2 diabetes mellitus is a progressive and heterogeneous disease." | ( de Kalbermatten, B; Jaafar, J; Jornayvaz, FR; Philippe, J, 2014) |
| "Type 2 diabetes mellitus is associated with a poor quality of life and considerable health-care costs and can be difficult to control." | ( Derosa, G; Maffioli, P, 2014) |
| "Type 2 diabetes is a serious problem for developed countries." | ( Apostolidis, E; Ha, KS; Jo, SH; Kim, JG; Kim, SC; Kim, YC; Kwon, YI, 2014) |
| "Type 2 diabetes is known to be associated with increasing cardiovascular mortality." | ( Ban, N; Kawana, H; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Saiki, A; Shirai, K; Tatsuno, I; Yamaguchi, T, 2014) |
| "Type 2 diabetes is associated with increased cardiovascular morbidity and mortality and early vascular ageing." | ( Alexander, MY; Boulton, AJ; Jude, EB; Ndip, A; Wilkinson, FL, 2014) |
| "Type 2 diabetes is associated with cognitive dysfunction and structural brain changes." | ( Biessels, GJ; Geijselaers, SLC; Sep, SJS; Stehouwer, CDA, 2015) |
| "Patients with type 2 diabetes are generally treated in primary care setting and as a final treatment step to obtain good glycaemic control, multiple daily insulin injections (MDI) are generally used." | ( Dahlqvist, S; Hirsch, IB; Lind, M; Pehrsson, NG; Torffvit, O; Tuomilehto, J, 2015) |
| "We find that type 2 diabetes is a possible risk factor for RLS in the Japanese population, and that pramipexole treatment can improve the symptoms of RLS as well as the quality of sleep and glycaemic control in these patients." | ( Harashima, S; Inagaki, N; Liu, Y; Nishimura, A; Osugi, T; Takayama, H; Wang, Y, 2016) |
| "Type 2 diabetes mellitus is highly prevalent among the elderly." | ( Ferriolli, E; Marchesi, JC; Pessanha, FP, 2014) |
| "Type 2 diabetes is a chronic condition that continues to increase in prevalence in the UK." | ( Demuth, D; Evans, M; Garcia Alvarez, L; Muthutantri, A; Nyeland, ME; Ploug, UJ; Richards, A; Skovgaard, R, 2015) |
| "Type 2 diabetes is a chronic and complex disease, due to the differences among affected individuals, which affect choice of treatment." | ( López Simarro, F, 2014) |
| "Type 2 diabetes is characterized by disruption of stress-related processes across multiple biological systems and increased exposure to life stress." | ( Bostock, S; Carvalho, LA; Hackett, RA; Hamer, M; La Marca, R; Lazzarino, AI; Steptoe, A, 2014) |
| "Type 2 diabetes is associated with pancreatic α cell dysfunction, characterized by elevated fasting plasma glucagon concentrations and inadequate postprandial glucose- and insulin-induced suppression of glucagon secretion." | ( Al-Zoairy, R; Ciardi, C; Hermann, M; Khan, MI; Mittermair, C; Niederwanger, A; Pedrini, MT; Salzmann, K; Tatarczyk, T, 2014) |
| "Type 2 diabetes mellitus is affecting more than 382 million people worldwide." | ( Beales, PL; Berggren, PO; Christou-Savina, S; Gerdes, JM; Karlsson-Edlund, P; Leibiger, B; Leibiger, IB; Moede, T; Moruzzi, N; Östenson, CG; Xiong, Y, 2014) |
| "Type 2 diabetes is characterized by pancreatic beta-cell dysfunction and is associated with low-grade inflammation." | ( Alquier, T; Bernard, C; Chevet, E; Guardiola, B; Higa, A; Pepin, E; Schuster-Klein, C; Sulpice, T, 2014) |
| "Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk of cardiovascular disease mortality." | ( Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D, 2014) |
| "Type 2 diabetes is a disease characterized by insulin resistance and β-cell dysfunction." | ( Hazman, Ö; Ovalı, S, 2015) |
| "Considering that type 2 diabetes is a risk factor for cognitive impairment and dementia, the benefits of GLP-1 mimetics on cognition must be considered." | ( García-Arias, C; García-Arnés, JA; García-Casares, N; Gómez-Huelgas, R; González-Santos, P; Valdivielso-Felices, P, 2014) |
| "Type 2 diabetes is characterised by insulin resistance and deficiencywhich explains the multitude of molecules developed for its treatment." | ( Meillet, L, 2014) |
| "Type 2 diabetes is characterised by an age-related decline in insulin secretion." | ( Blair, HR; Brown, AE; Brown, L; Chinnery, PF; Cree, LM; Gunn, DA; Heggie, A; Kumaheri, MA; Miwa, S; Nile, DL; Payne, B; Walker, M, 2014) |
| "Type 2 diabetes is a common metabolic disorder characterized by resistance to the actions of insulin to stimulate skeletal muscle glucose disposal." | ( Dirks-Naylor, AJ; Kouzi, SA; Nuzum, DS; Yang, S, 2015) |
| "Type 2 diabetes is considered a multifactorial disorder, with both environmental and genetic factors contributing to its development." | ( Agustini, BC; Alcazar, LP; Arakaki, PA; Bonfanti, DH; de Moraes Rego, FG; Frigeri, HR; Martins, LT, 2015) |
| "Type 2 diabetes mellitus is one of the most frequent causes of death in Mexico, characterized by chronic hyperglycemia." | ( Allen, K; Flores-Fernandez, JM; Lazcano-Díaz, E; Owolabi, MS; Padilla-Camberos, E; Villanueva-Rodríguez, S, 2014) |
| "The incidence of type 2 diabetes is increasing rapidly worldwide, and the development of novel anti-diabetic drugs is emerging." | ( Chang, W; Chen, L; Hatch, GM, 2015) |
| "Type 2 diabetes is the fastest growing non-communicable chronic disease worldwide." | ( Davis, SN; Hedrington, MS, 2015) |
| "Type 2 diabetes is a metabolic disorder that may cause major problems to several physiological systems." | ( Acharya, UR; De Luca, R; Joy Martis, R; Liboni, W; Meiburger, KM; Molinari, F; Petraroli, G, 2015) |
| "The prevalence of Type 2 diabetes is expected to increase in parallel with obesity rates and the ageing population." | ( Alazawi, W; Syn, WK; Tai, FW, 2015) |
| "Type 2 diabetes is a chronic disease that cannot be treated adequately using the known monotherapies, especially when the disease progresses to an advanced stage." | ( Abdelkader, D; Chen, Y; Hassan, W; Liu, J; Sun, H; Wang, X, 2015) |
| "Type 2 diabetes is a known inflammatory disease." | ( Alummoottil, S; Bester, J; Buys, AV; Kell, DB; Pretorius, E; Soma, P; Vermeulen, N, 2015) |
| "Because rates of type 2 diabetes are on the rise, we wanted to determine whether salicylate could improve insulin resistance in a type 2 rat model, as well as improve retinal function." | ( Bheemreddy, R; Coppess, W; Jiang, Y; Steinle, JJ; Thakran, S; Walker, RJ, 2015) |
| "Type 2 diabetes is a complex disease with multiple defects, which generally requires a combination of several pharmacological approaches to reach glucose control targets." | ( Scheen, AJ, 2015) |
| "Type 2 diabetes is a complex and multifaceted disease requiring an individualized approach." | ( Solini, A, 2016) |
| "Type 2 diabetes mellitus is a progressive disease that requires pharmacologic treatment to prevent microvascular and macrovascular complications." | ( Gurgle, H; McAdam-Marx, C; Schauerhamer, MB, 2015) |
| "Type 2 diabetes mellitus is the predominant form of diabetes." | ( Chang, SL; Lee, YC; Liao, HY; Lin, JG; Sun, MF, 2015) |
| "Type 2 diabetes mellitus is a vast growing progressive disease that almost affects one person among every twelve globally." | ( Abdulla, MM; Badrey, MG; Eldebss, TM; Gomha, SM; Mayhoub, AS, 2015) |
| "Type 2 diabetes is associated with macro- and microvascular complications in man." | ( Ericsson, A; Gan, LM; Grönros, J; Heinonen, SE; Jennbacken, K; Jönsson-Rylander, AC; Miliotis, T; Sabirsh, A; Svedlund, S; Westergren, HU, 2015) |
| "Most persons with type 2 diabetes are treated with oral anti diabetic drugs (OADs)." | ( Gupta, Y; Kalra, S, 2015) |
| "Type 2 diabetes is not only an independent risk factor for cardiovascular (CV) disease but is also associated with a greater incidence of heart failure (HF)." | ( Federici, M; Kappel, BA; Marx, N, 2015) |
| "Type 2 diabetes is associated with abnormal electrical conduction and sudden cardiac death, but the pathogenic mechanism remains unknown." | ( Axelsen, LN; Baandrup, U; Bartels, ED; Braunstein, TH; Calloe, K; Hofgaard, JP; Holstein-Rathlou, NH; Jensen, CF; Jespersen, T; Liang, B; Nielsen, LB; Nielsen, MS; Olsen, KB; Riemann, M, 2015) |
| "Type 2 diabetes is a metabolic disorder caused by abnormal carbohydrate metabolism, and closely associated with abnormal lipid metabolism and hepato-renal dysfunction." | ( Hwang, SY; Kim, BS; Kim, MH; Park, UK; Son, DJ, 2015) |
| "Type 2 diabetes is the most common metabolic disorder, characterized by insulin resistance and pancreatic islet beta-cell failure." | ( Adeghate, E; Amiri, L; Howarth, FC; Jayaprakash, P; John, A; Raza, H; Shafarin, J; Yasin, J, 2015) |
| "This model for type 2 diabetes is widely used since it phenocopies human disease and its co-morbidities including obesity, progressive deterioration in glucose tolerance, hypertension and hyperlipidaemia." | ( Forbes, JM; Gilbert, RG; Harcourt, BE; Sullivan, MA; Xu, P, 2015) |
| "Type 2 diabetes mellitus is characterised by persistent thromboxane (TX)-dependent platelet activation, regardless of disease duration." | ( Davì, G; Pignatelli, P; Santilli, F; Violi, F, 2015) |
| "Type 2 diabetes is a progressive disease characterized by insulin resistance and insulin secretory dysfunction." | ( Hara, K; Kaku, H; Kato, T; Mitsuzaki, K; Muraishi, K; Nakayama, H; Nakayama, S; Ohki, T; Tajiri, Y; Tanaka, K; Tokubuchi, I; Tsuruta, M; Wada, N; Yamada, K, 2015) |
| "Both forms of MODY are characterised by specific beta cell dysfunction, with patients with HNF1A-diabetes having a reduced insulin secretory capacity, while patients with GCK-diabetes have a glucose-sensing defect, but preserved insulin secretory capacity." | ( Østoft, SH, 2015) |
| "Type 2 diabetes is increasingly being recognised as a global health crisis (World Health Organisation)." | ( Kozan, P; Samocha-Bonet, D; Williams, RS, 2016) |
| "Type 2 diabetes is a well described extra-hepatic manifestation of hepatitis C infection (HCV)." | ( Cooper, C; Doyle, MA, 2015) |
| "Type 2 diabetes mellitus is an important risk factor in the development of coronary artery disease (CAD) and is often associated with severe disease." | ( Bhat, NM; Kamath, PK; Mahabala, C; Manjrekar, PA; Pai, ND; Srinivasan, MP, 2015) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that has become the fourth leading cause of death in the developed countries." | ( Lee, CY, 2016) |
| "Patients with type 2 diabetes mellitus are known to have an increased risk of colorectal neoplasia." | ( Abe, Y; Fujiwara, K; Higuchi, K; Iguchi, M; Inoue, T; Kakimoto, K; Kawakami, K; Nouda, S; Okada, T; Takeuchi, T; Yorifuji, N, 2016) |
| "Type 2 diabetes is a chronic disease with disabling micro- and macrovascular complications that lead to excessive morbidity and premature mortality." | ( Henry, RR; Mudaliar, S; Polidori, D; Zambrowicz, B, 2015) |
| "Type 2 diabetes is a risk factor for meibomian gland dysfunction (MGD)." | ( Ding, J; Liu, Y; Sullivan, DA, 2015) |
| "Type 2 diabetes is known to affect bone metabolism." | ( Drevenšek, G; Drevenšek, M; Hudoklin, S; Marc, J; Plut, A; Sprogar, Š; Zupan, J, 2015) |
| "Men with type 2 diabetes are often characterized by abnormal plasma testosterone levels." | ( Gilowski, W; Krysiak, R; Okopień, B, 2016) |
| "Type 2 diabetes is an evolutive disease with a progressive defect of beta-cell insulin secretion." | ( Darmon, P; Raccah, D, 2015) |
| "Type 2 diabetes mellitus is a complex metabolic disease, and cardiovascular disease is a leading complication of diabetes." | ( Antunes, M; Burgeiro, A; Carvalho, E; Carvalho, RA; Cherian, S; Espinoza, D; Fuhrmann, A; Jarak, I; Loureiro, M; Patrício, M, 2016) |
| "Patients with type 2 diabetes mellitus are at risk for accelerated cognitive decline and dementia." | ( Biessels, GJ; Groeneveld, ON; Kappelle, LJ, 2016) |
| "Obesity and type 2 diabetes mellitus are increasing worldwide, reaching pandemic proportions." | ( Celik, A; Celik, BO; Dixon, JB; Gupta, A; Karaca, FC; Pouwels, S; Santoro, S; Ugale, S, 2016) |
| "Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily." | ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016) |
| "Optimal control of type 2 diabetes is challenging in many patient populations including in South Asian patients." | ( Bhurji, N; Gasevic, D; Javer, J; Khan, NA, 2016) |
| "Type 2 diabetes mellitus is the result of impaired systemic control of glucose homeostasis, in part through the dysregulation of the hormone glucagon." | ( Birnbaum, MJ; Miller, RA, 2016) |
| "Type 2 diabetes is associated with increased mortality and progression to heart failure." | ( Bhatnagar, A; Bolli, R; Gibb, AA; Haberzettl, P; Hill, BG; Hong, KU; Li, Q; Lorkiewicz, PK; Mehra, P; Salabei, JK; Wei, X; Wysoczynski, M; Zhang, X, 2016) |
| "Type 2 diabetes mellitus is associated with regulation of several miRNAs in skeletal muscle." | ( Armitage, JA; Heywood, SE; Kingwell, BA; Latouche, C; Natoli, A; Reddy-Luthmoodoo, M, 2016) |
| "Obesity and type 2 diabetes mellitus are risk factors for developing Alzheimer disease." | ( Gupta, D; Jones, AM; Jones, KP; Pratley, RE; Smith, J; Tharp, WG, 2016) |
| "Type 2 diabetes is characterised not only by hyperglycemia, but also by dyslipidemia." | ( Aich, K; Bhattacharyya, M; Chowdhury, S; Das, S; Ghoshal, K; Goswami, S, 2016) |
| "Type 2 diabetes is characterised by decreased HDL levels, as well as the level of apolipoprotein A-I (apoA-I), the main apolipoprotein of HDLs." | ( Arthur, A; Barter, PJ; Charil, A; Cochran, BJ; Gregoire, MC; Hamze, H; Kritharides, L; Meikle, SR; Parmar, A; Reilhac, A; Ryder, WJ; Rye, KA; Tang, S, 2016) |
| "Type 2 diabetes is highly correlated with nonalcoholic fatty liver disease (NAFLD)." | ( Chang, CJ; Hung, HC; Lu, FH; Ou, HY; Su, YC; Wu, CL; Wu, HT; Wu, JS; Yang, YC, 2016) |
| "Patients with type 2 diabetes are at high risk for developing coronary artery disease (CAD)." | ( Fukui, K; Hibi, K; Kishi, S; Michishita, I; Nozue, T; Sozu, T; Takamura, T, 2017) |
| "Type 2 diabetes is a chronic metabolic disorder primarily caused by insulin resistance to which obesity is a major contributor." | ( Benetti, E; Findlay, JBC; Kinsella, GK; Leonard, S, 2016) |
| "Type 2 diabetes is accompanied by premature atherosclerosis and arterial stiffness." | ( de Boer, SA; Glaudemans, AW; Heerspink, HJ; Hovinga-de Boer, MC; Kamphuisen, PW; Lefrandt, JD; Lutgers, HL; Mulder, DJ; Slart, RH; van Roon, AM, 2016) |
| "Type 2 diabetes mellitus is characterized by chronic hyperglycemia and associated with oxidative stress resulting from accumulation of free radicals in body's tissues, which especially affects beta cells in pancreas and is an important factor in the development of diabetes and its complications." | ( Askar, T; Mansour, AA; Mergani, A; Mohammed, MA; Mustafa, AM; Saleh, OM; Zahran, RN, 2016) |
| "The prevalence of type 2 diabetes is rising, and in 2015 more than 5% of adults in the UK were affected by this condition." | ( , 2016) |
| "Type 2 diabetes is characterised by chronic hyperglycaemia and its incidence is highly increased by exaggerated food consumption." | ( Gilon, P, 2016) |
| "Type 2 diabetes mellitus is often complicated by osteoporosis, a process which may involve osteoblast autophagy." | ( Liu, F; Liu, JH; Meng, HZ; Shi, PX; Sun, GH; Yang, B; Yang, MW; Yang, RF; Zhang, WL, 2016) |
| "Type 2 diabetes is a complex disease requiring individualized and often multi-faceted treatment plans." | ( Davis, SN; Lamos, EM, 2016) |
| "Women with type 2 diabetes are difficult to reach." | ( Alderdice, FA; Gough, A; Hamill, LL; Harper, R; Holmes, VA; Loughridge, S; McCance, DR; McKenna, S; Patterson, CC; Spence, M, 2017) |
| "Type 2 diabetes mellitus is a progressive disease associated with significant morbidity and mortality." | ( Anderson, R; Hayes, J; Stephens, JW, 2016) |
| "Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia." | ( Puigserver, P; Rines, AK; Sharabi, K; Tavares, CD, 2016) |
| "Type 2 diabetes mellitus is a complex metabolic disease and its pathogenesis involves abnormalities in both peripheral insulin action and insulin secretion." | ( Álvarez, C; Beneit, N; Benito, M; Chambon, P; Di Scala, M; Diaz-Castroverde, S; Escribano, O; Fernández, S; Fernández-Millán, E; García-Bravo, M; García-Gómez, G; Gómez-Hernández, A; González-Aseguinolaza, G; González-Rodríguez, Á; Perdomo, L, 2016) |
| "Type 2 diabetes mellitus is associated with accelerated cognitive decline." | ( Backes, WH; Edden, RAE; Hofman, PAM; Jansen, JFA; Puts, NAJ; Schram, MT; Stehouwer, CDA; van Boxtel, MPJ; van Bussel, FCG; Wildberger, JE, 2016) |
| "Type 2 diabetes mellitus is closely associated with adipogenesis and their factors." | ( Arasu, MV; Choi, KC; Ilavenil, S; Kim, da H; Lee, JS; Roh, SG; Srigopalram, S; Vijayakumar, M, 2016) |
| "Type 2 diabetes mellitus is associated strongly with an increased risk of micro- and macro-vascular complications, leading to impaired quality of life and shortened life expectancy." | ( Eguchi, K; Higashi, Y; Inoue, T; Ishizu, T; Kadokami, T; Kario, K; Kitakaze, M; Kodera, S; Maemura, K; Matsuhisa, M; Murohara, T; Nanasato, M; Nishio, Y; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Shimabukuro, M; Suzuki, M; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H, 2016) |
| "Type 2 diabetes is increasingly common in HIV-infected individuals." | ( Bisson, GP; Gibert, CL; Gordon, K; Han, JH; Leaf, DA; Rimland, D; Rodriguez-Barradas, MC; Womack, JA, 2017) |
| "Type 2 diabetes mellitus is chronic metabolic disorder." | ( Bhadada, SK; Malik, A; Morya, RK; Rana, S; Sachdeva, N; Sharma, G, 2016) |
| "Type 2 diabetes is a progressive metabolic disorder, which results from defects in insulin secretion and/or insulin action leading to chronic hyperglycaemia and associated cardiovascular complications." | ( Ojo, O, 2016) |
| "Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients." | ( Al-Saber, F; Aldosari, W; Alselaiti, M; Darwish, A; Harb, G; Kaladari, A; Khalfan, H; Khan, G; Koda, A; Kudo, S; Nakajima, M; Rehani, R; Tanaka, T, 2016) |
| "Type 2 diabetes mellitus is characterized by insulin resistance in various insulin target tissues, such as the liver, adipose tissue, and skeletal muscle, and insufficient insulin secretion from pancreatic β-cells." | ( Kaku, K; Kaneto, H; Kimura, T; Matsuoka, TA; Obata, A; Okauchi, S; Shimo, N; Shimoda, M, 2017) |
| "The prevalence of type 2 diabetes is increased in patients with RA." | ( Bacquet, H; Lequerré, T; Nicolau, J; Vittecoq, O, 2017) |
| "Type 2 diabetes is characterized by hyperglycemia and occurs in obese individuals as a result of insulin resistance and inadequate insulin levels." | ( Ghislain, J; Poitout, V, 2017) |
| "Type 2 diabetes is a metabolic syndrome characterized by insulin resistance and relative insulin deficiency." | ( Chen, W; Fang, S; Jiang, T; Li, X; Wang, G; Xu, Q; Zhang, H; Zhao, J, 2016) |
| "The field of type 2 diabetes is undergoing a major transformation." | ( Kosiborod, M, 2017) |
| "Type 2 diabetes mellitus is a polygenic disease with a variable phenotype." | ( Sharma, A; Vella, A, 2017) |
| "Type 2 diabetes is likely to be an independent risk factor for hippocampal-based memory dysfunction, although this complication has yet to be investigated in detail." | ( Inoue, K; Jesmin, S; Liu, YF; Matsui, T; McEwen, BS; Okamoto, M; Shima, T; Soya, H; Soya, M; Torres-Aleman, I, 2017) |
| "Type 2 diabetes mellitus is associated with a progressive decline in insulinproducing pancreatic β-cells, an increase in hepatic glucose production, and a decrease in insulin sensitivity." | ( Holst, JJ; McGill, MA, 2012) |
| "Patients with type 2 diabetes are at increased cardiovascular risk." | ( Boncelj Svetek, M; Eržen, B; Kanc, K; Šabovič, M, 2017) |
| "Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol." | ( Buse, JB; Byington, RP; Corson, M; Elam, MB; Fleg, JL; Friedewald, WT; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, R; Ismail-Beigi, F; Largay, J; Leiter, LA; Lopez, C; Lovato, LC; O'Connor, PJ; Probstfield, J; Rosenberg, Y; Sweeney, ME; Weiss, D, 2017) |
| "Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity." | ( Clar, C; Clegg, A; Colquitt, J; Court, R; Cummins, E; Holt, T; Johnston, R; McGrane, D; O'Hare, JP; Royle, P; Shantikumar, S; Tan, BK; Uthman, O; Waugh, N, 2017) |
| "Type 2 diabetes is associated with altered plasma concentrations of Aβ peptides and is an important source of variation that needs to be taken into account when considering plasma Aβ peptides as biomarkers for Alzheimer's disease." | ( Bruce, DG; Davis, TM; Davis, WA; Martins, RN; Masters, CL; Peters, KE; Taddei, K, 2017) |
| "Type 1 and type 2 diabetes are distinct clinical entities primarily driven by autoimmunity and metabolic dysfunction, respectively." | ( Lagou, V; Liston, A; Todd, JA, 2017) |
| "Type 2 diabetes is characterised by mitochondrial dysfunction, high production of reactive oxygen species (ROS) and low levels of ATP." | ( Bañuls, C; Diaz-Morales, N; Hernandez-Mijares, A; Rocha, M; Rovira-Llopis, S; Victor, VM, 2017) |
| "Type 2 diabetes is a chronic metabolic disease that is of increasing concern in Inuit communities." | ( Chan, HM; Singh, K, 2017) |
| "Type 2 diabetes is a major health problem placing increasing demands on healthcare systems." | ( Berni, ER; Currie, CJ; Holden, SE; Jenkins-Jones, S; Morgan, CL; Qiao, Q, 2017) |
| "Type 2 diabetes mellitus is a pandemic associated with disturbance in haemostasis that could contribute to the development of diabetic vascular disease and accelerated atherosclerosis." | ( Bester, J; Pretorius, E; Soma, P; Swanepoel, AC, 2017) |
| "Type 2 diabetes is associated with cardiovascular complications." | ( Bengtsson Boström, K; Hjerpe, P; Melander, O; Pikkemaat, M, 2017) |
| "Type 2 diabetes mellitus is a progressive disease with multiple underlying pathophysiologic defects." | ( Dey, J, 2017) |
| "Patients with type 2 diabetes are characterised not only by compromised insulin secretion and action, but also by elevated plasma concentrations of the 29-amino acid peptide hormone glucagon, which generally is thought of as a pancreas-derived hormone (produced in and secreted from alpha cells in the islet of Langerhans)." | ( Lund, A, 2017) |
| "Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems." | ( Acurcio, FA; De Oliveira, GL; Godman, B; Guerra Júnior, AA, 2017) |
| "Type 2 diabetes mellitus is a disease with no cure and chronic disease that results in major morbidity and mortality." | ( Abougalambou, AS; Abougalambou, SSI; Ahmed, NO, 2017) |
| "Type 2 Diabetes Mellitus is a very well known metabolic disorder that has reached epidemic proportions worldwide." | ( Achalli, S; Babu, S; Bhat, M; Kumari, S; Madi, M; Madiyal, A; Shetty, S, 2016) |
| "Type 2 diabetes is often associated with arterial atherosclerosis in large blood vessels." | ( Chen, W; Liu, X; Mei, T; Ye, S, 2017) |
| "The prevalence of type 2 diabetes is increasing, which is alarming because of its serious complications." | ( Andersen, ES; Deacon, CF; Holst, JJ, 2018) |
| "Type 2 diabetes is caused by defects in both insulin sensitivity and insulin secretion." | ( Bogan, JS; Hao, M; Toomre, DK; Xu, Y, 2017) |
| "Type 2 diabetes is associated with faster formation of poorly lysable, denser fibrin clots and elevated cellular fibronectin (cFn), a marker of vascular injury." | ( Bryk, AH; Draga, K; Konieczyńska, M; Malinowski, KP; Undas, A, 2017) |
| "Type 2 diabetes is increasingly recognized as a risk factor for Alzheimer's disease, but the underlying mechanisms remain poorly understood." | ( Dey, A; Hao, S; Stranahan, AM; Wosiski-Kuhn, M, 2017) |
| "Obesity and type 2 diabetes are increasing in rural and urban regions of South Asia including India." | ( Gulati, S; Misra, A, 2017) |
| "Type 2 diabetes is a heterogeneous and multifactorial metabolic disorder with some relationship to oxidative stress (OS)." | ( Amezyane, T; Cherrah, Y; Eljaoudi, R; Elomri, N; Ghafir, D; Ibrahimi, A; Laamarti, M, 2017) |
| "Type 2 diabetes mellitus is the most common form of diabetes that occurs in both human and nonhuman primates." | ( Gash, DM; Quintero, JE; Yue, F; Zhang, G; Zhang, Z, 2017) |
| "Type 2 diabetes is a chronic metabolic disease characterized by persistent hyperglycemia resulting from progressive deficient of insulin in patients with a background of insulin resistance." | ( Cao, X; Hu, J; Tan, X; Zhou, M; Zou, P, 2017) |
| "Type 2 diabetes mellitus is a worldwide epidemic and its atherosclerotic complications determine the high morbidity and mortality of diabetic patients." | ( Deleanu, M; Niculescu, LS; Sanda, GM; Sima, AV; Stancu, CS; Toma, L, 2017) |
| "Type 2 diabetes mellitus is characterized by relative insulin deficiency and insulin resistance." | ( Anzaldi, L; Fesseha, B; Galiatsatos, P; Kim, HN; Sidhaye, A; Tsao, A, 2018) |
| "Type 2 diabetes is a chronic inflammatory disease." | ( Cao, MM; Li, YB; Liu, GD; Liu, H; Su, Y; Yin, JJ, 2017) |
| "Type 2 diabetes is a persistent inflammatory response that impairs the healing process." | ( Chai, Y; Chen, H; Dai, J; Li, L; Zhang, X, 2017) |
| "Type 2 diabetes mellitus is associated with increased fracture risk, and recent studies show crosstalk between bone and glucose metabolism." | ( Grimnes, G; Jorde, R; Larsen, AU, 2018) |
| "Type 2 diabetes is associated with a high risk of cognitive impairment and dementia." | ( Arcos, G; Boada, M; Ciudin, A; Diego, S; Hernández, C; Hernández, I; Sanabria, Á; Simó, R; Simó-Servat, O; Sotolongo, Ó, 2017) |
| "Obesity and type 2 diabetes are concomitant with low-grade inflammation affecting insulin sensitivity and insulin secretion." | ( Batto, AF; Bernard, C; Bourron, O; Carlier, A; Ferré, P; Foufelle, F; Gautier, JF; Hainault, I; Hajduch, E; Ktorza, A; Szpigel, A; Venteclef, N, 2018) |
| "The prevalence of type 2 diabetes is increasing in epidemic proportions worldwide." | ( Ambachew, S; Biadgo, B, 2017) |
| "Type 2 diabetes mellitus is a common disease, affecting up to 13." | ( Azinheira, J; Capitão, RM; Sequeira Duarte, J; Tavares Bello, C; Vasconcelos, C, 2017) |
| "Type 2 diabetes is characterized by insulin resistance, hyperinsulinemia and hepatic overproduction of glucose and lipids." | ( Cleland, C; Farese, RV; Foufelle, F; Lee, MC; Sajan, J; Sajan, MP, 2018) |
| "Type 2 diabetes is characterized by insulin resistance in target tissues and hyperglycemia." | ( Jin, Y; Liu, K; Liu, Q; Liu, Z; Meng, Q; Sun, H; Wang, C; Yan, J, 2018) |
| "Type 2 diabetes is a disease involving both inadequate insulin levels and increased glucagon levels." | ( Hædersdal, S; Knop, FK; Lund, A; Vilsbøll, T, 2018) |
| "Type 2 diabetes is characterized by dyslipidemia and the accumulation of lipids in non-adipose tissue, including skeletal muscle." | ( Chen, XF; Gao, Q; He, X; Liang, Q; Min, HY; Song, SY; Wang, L; Wang, Y; Wu, YZ; Yang, Y; Yi, L, 2018) |
| "Type 2 diabetes mellitus is associated with cognitive dysfunction and an increased risk of dementia." | ( Biessels, GJ; Espeland, MA; Janssen, J; Johansen, OE; Mattheus, M; van den Berg, E; Zinman, B, 2018) |
| "Type 2 diabetes is a risk factor for increased QTc (rate-corrected QT interval), QTcd (rate-corrected QTc dispersion: difference between the maximum and the minimum QTc interval), and Tp-e, as well as the rate-corrected Tp-e (Tp-e/QTc ratio)." | ( Du, LY; Jeyadoss, J; Liu, WM; Rao Kadam, V; Thiruvenkatarajan, V; Van Wijk, RM, 2018) |
| "Type 2 diabetes mellitus is a polygenic metabolic disorder resulting from oxidative stress, the root cause of insulin resistance, β-cell dysfunction and impaired glucose tolerance." | ( Chen, Z; Hu, Z; Liu, D; Liu, L; Song, Z; Wang, Y, 2018) |
| "Type 2 diabetes is associated with higher pulse pressure." | ( Alemi, H; Esteghamati, A; Khaloo, P; Mansournia, MA; Meftah, N; Mirmiranpour, H; Nakhjavani, M; Rabizadeh, S; Salehi, SS, 2018) |
| "Type 2 diabetes is still relatively rare in Sweden but it is urgent to obtain a correct diagnosis as the long-term prognosis depends on a prompt pharmacological treatment." | ( Marcus, C, 2018) |
| "Patients with type 2 diabetes are at high risk for cardiovascular disease." | ( Ide, K; Ishikawa, T; Koshizaka, M; Maezawa, Y; Takemoto, M; Tokuyama, H; Tokuyama, T; Yokote, K, 2018) |
| "Type 2 diabetes is a highly prevalent chronic metabolic disorder characterized by hyperglycemia and associated with several complications such as retinopathy, hyperlipidemia and polyneuropathy." | ( Bene, J; Hadzsiev, K; Melegh, B, 2018) |
| "Type 2 diabetes is a condition affecting nearly 30 million American adults." | ( McCarty, BP; McCarty, D; Olenik, A, 2019) |
| "Type 2 diabetes mellitus is now a worldwide health problem with increasing prevalence." | ( Liu, DM; Liu, JM; Mosialou, I, 2018) |
| "HIV infection and type 2 diabetes are associated with altered gut microbiota, chronic inflammation, and increased cardiovascular risk." | ( Aukrust, P; Gaardbo, JC; Gelpi, M; Gerstoft, J; Hoel, H; Holm, K; Hov, JR; Hove-Skovsgaard, M; Kummen, M; Nielsen, SD; Nwosu, F; Rudi, K; Seljeflot, I; Trøseid, M; Ueland, PM; Ullum, H; Valeur, J, 2018) |
| "Type 2 diabetes is associated with endothelial dysfunction leading to cardiovascular disease." | ( Ahmadi, N; Amdur, RL; Domingues, CC; Dore, FJ; Houston, S; Khiyami, A; Kropotova, Y; Kundu, N; Mammadova, A; Rouphael, C; Sen, S; Witkin, L, 2018) |
| "However, women with type 2 diabetes are less aware of and less likely to access pre-pregnancy care (PPC) compared with women with type 1 diabetes." | ( Clark, JDA; Evans, ML; Hambling, C; Harries, AW; Hughes, DJF; Karunakaran, V; Morrish, NJ; Murphy, HR; Rayman, GA; Sampson, MJ; Winocour, PH; Yamamoto, JM, 2018) |
| "Type 2 diabetes is a complex disorder affected by multiple genes and the environment." | ( DeBehnke, S; Gebre, AK; Hansen, P; He, H; Holl, K; Leone-Kabler, S; Parks, JS; Parrington, J; Ruas, M; Solberg Woods, LC; Yeo, CT, 2018) |
| "Type 2 diabetes mellitus is characterized by peripheral insulin resistance and low-grade systemic inflammation." | ( Barden, A; Beilin, L; Hodgson, JM; Mas, E; Mori, TA; Phillips, M; Puddey, I; Shinde, S, 2018) |
| "Type 2 diabetes is an endocrine disorder characterized with hyperglycemia, hyperinsulinemia and insulin resistance." | ( Bumbasirevic, V; Ciric, D; Despotovic, S; Djuricic, D; Kravic-Stevovic, T; Lalic, I; Lalic, K; Martinovic, T; Pantic, I; Rasulic, I, 2018) |
| "Type 2 diabetes is one of the most common noncommunicable diseases worldwide." | ( Glazkova, IV; Kochetkova, AA; Sarkisyan, VA; Smirnova, EA; Vorobieva, IS; Vorobieva, VM; Zhilinskaya, NV, 2018) |
| "Type 2 diabetes is a major health concern worldwide." | ( Kyrø, C; Landberg, R; Olsen, A; Overvad, K; Tjønneland, A, 2018) |
| "Type 2 diabetes is a metabolic disorder that is characterized by an impaired capacity to secrete insulin, insulin resistance, or both." | ( Aoki, K; Terauchi, Y, 2018) |
| "Type 2 diabetes mellitus is a worldwide health problem." | ( Czyrski, A; Hermann, T; Resztak, M, 2018) |
| "Type 2 diabetes is characterized by hyperglycemia derived from insulin resistance in periphery tissue." | ( Jiang, HW; Li, JL; Li, JY; Wang, LN, 2018) |
| "Type 2 diabetes is a serious clinical problem in both India and the UK." | ( Brage, S; Darzi, A; Godsland, IF; Johnston, DG; Majeed, A; Nanditha, A; Oliver, N; Raghavan, A; Ramachandran, A; Satheesh, K; Sharp, S; Simon, M; Snehalatha, C; Srivanichakorn, W; Susairaj, P; Thomson, H; Wareham, N; Westgate, K, 2018) |
| "Patients with type 2 diabetes are at risk of microvascular and macrovascular complications." | ( Cho, HC; Kim, NH; Kim, SG; Kwak, SH; Lee, J; Lee, YH; Lim, S; Moon, JS; Moon, MK, 2018) |
| "Type 2 diabetes is a causal risk factor for the development of atherosclerotic cardiovascular disease (ASCVD)." | ( Barter, PJ; Cochran, BJ; Rye, KA, 2018) |
| "Type 2 diabetes is a complex genetic disorder, and a large number of genetic polymorphisms may be involved in its pathogenesis." | ( Arif, MA; Kanwal, N; Khalid, S; Masood, N; Moeez, S; Niazi, R; Riaz, S, 2019) |
| "Type 2 diabetes mellitus is a common and severe chronic metabolic disease, which confers increased risk of cardiovascular disease and mortality." | ( Christensen, MB; Sørensen, AM, 2018) |
| "Type 2 diabetes is associated with increased mortality." | ( Fava, S; Reiff, S, 2019) |
| "Type 2 diabetes is associated with increased cardiovascular (CV) risk." | ( Alexander, JH; Baanstra, D; Cooper, ME; George, JT; Johansen, OE; Kahn, SE; Marx, N; McGuire, DK; Meinicke, T; Pencina, M; Perkovic, V; Pfarr, E; Rosenstock, J; Schnaidt, S; Toto, RD; von Eynatten, M; Wanner, C; Woerle, HJ; Zinman, B, 2019) |
| "Obesity and type 2 diabetes are a veritable global pandemic." | ( Alexiadou, K; Anyiam, O; Tan, T, 2019) |
| "Type 2 diabetes is often linked with impaired proximal insulin signaling." | ( Dhurandhar, NV; Feizy, Z; Hegde, V; Peddibhotla, S; Shastri, AA, 2018) |
| "The prevalence of type 2 diabetes is escalating rapidly in Asian countries, with the rapid increase likely attributable to a combination of genetic and lifestyle factors." | ( Abdullah, N; Attia, J; Holliday, EG; Ismail, N; Jalal, NA; Jamal, R; Kamaruddin, MA; Murad, NAA; Oldmeadow, C; Scott, RJ, 2018) |
| "Type 2 diabetes is one of the most important public health diseases." | ( Bourron, O; Phan, F, 2019) |
| "Older patients with type 2 diabetes are prone to developing adverse events with aggressive antihyperglycaemic therapy." | ( Hannallah, F; Hooda, A; Mehta, A, 2018) |
| "Type 2 diabetes is the leading cause of impaired kidney function, albuminuria, and renal replacement therapy globally, thus placing a large burden on health-care systems." | ( Heerspink, HJL; Muskiet, MHA; Wheeler, DC, 2019) |
| "Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease." | ( Alexander, JH; Baanstra, D; Cooper, ME; George, JT; Johansen, OE; Kahn, SE; Marx, N; McGuire, DK; Meinicke, T; Perkovic, V; Pfarr, E; Rosenstock, J; Schnaidt, S; Toto, RD; von Eynatten, M; Wanner, C; Zinman, B, 2019) |
| "Type 2 diabetes is associated with reduced tissue perfusion." | ( Finsen, SH; Groen, MB; Hellsten, Y; Knudsen, TA; Mortensen, SP; Pedersen, BK, 2019) |
| "Type 2 diabetes mellitus is among the most common diseases seen in primary care practices and can lead to significant complications." | ( Holley, A; Martinez, LC; Sherling, D, 2019) |
| "Type 2 diabetes mellitus is a major risk factor for cardiovascular disease." | ( Al-Salameh, A; Becquemont, L; Bucher, S; Chanson, P; Ringa, V, 2019) |
| "Type 2 diabetes is a chronic metabolic disease characterized by progressive decrease of islet cell function." | ( Chang, M; Chen, Y; Cui, C; Li, Q; Li, W; Qiu, M; Zhang, X, 2019) |
| "Patients with type 2 diabetes mellitus are at an increased risk of adverse cardiovascular events compared to those without diabetes." | ( Kolluri, N; Lerman, A; Lerman, LO; Sara, JD; Taher, R; Vella, A, 2019) |
| "Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available." | ( Agarwal, R; Bakris, G; Bompoint, S; Brenner, BM; Bull, S; Cannon, CP; Capuano, G; Charytan, DM; Chu, PL; de Zeeuw, D; Edwards, R; Greene, T; Heerspink, HJL; Jardine, MJ; Levin, A; Mahaffey, KW; Meininger, G; Neal, B; Perkovic, V; Pollock, C; Wheeler, DC; Yavin, Y; Zhang, H; Zinman, B, 2019) |
| "Type 2 diabetes is a broad class of diseases characterized by disturbance of glucose homeostasis, i." | ( Matschinsky, FM; Wilson, DF, 2019) |
| "Type 2 diabetes is an age-associated disease in which oxidative stress is involved, and moreover, some studies show that the prevalence is higher in men than in women, and therefore there are sex-associated differences." | ( Abdelaziz, KM; Borrás, C; Díaz, A; Gambini, J; López-Grueso, R; Mas-Bargues, C; Monleón, D; Viña, J, 2019) |
| "Type 2 diabetes is a known risk factor for cardiovascular diseases and is associated with an increased risk to develop aortic heart valve degeneration." | ( Akhyari, P; Barth, M; Fischer, JW; Lichtenberg, A; Ouwens, DM; Raschke, S; Selig, JI; Thoresen, GH, 2019) |
| "Type 2 diabetes is a major driver of pharmaceutical spending." | ( Nunes, B; Pinto, D; Rodrigues, AP, 2019) |
| "Obesity and type 2 diabetes are drivers of non-alcoholic fatty liver disease (NAFLD)." | ( Calanna, S; Francque, S; Hansen, M; Harrison, S; Linder, M; Newsome, P; Ratziu, V; Sanyal, A; Van Gaal, L, 2019) |
| "Type 2 diabetes is a global health priority, given that it is driven, in part, by an ageing population, the role of immune senescence has been overlooked." | ( Ackland, GL; Berryman, V; Callender, LA; Carroll, EC; Finer, S; Henson, SM; Hitman, GA; Hood, GA; Lau, EYM; Pattrick, M, 2019) |
| "Managing type 2 diabetes is complex and necessitates careful consideration of patient factors such as engagement in self-care, comorbidities and costs." | ( Alexopoulos, AS; Buse, JB, 2019) |
| "Type 2 diabetes is related to obesity and altered bone health, and both are affected by gut microbiota." | ( Bray, GA; Chen, Y; DiDonato, JA; Heianza, Y; LeBoff, MS; Li, X; Pei, X; Qi, L; Sacks, FM; Sun, D; Zhou, T, 2019) |
| "Type 2 diabetes is a disease with a high global prevalence, characterized by chronic hyperglycemia, insulin resistance, polyphagia, polydipsia, polyuria, and changes in body weight." | ( Aguilera, P; Barragán-Bonilla, MI; Espinoza-Rojo, M; Illades-Aguiar, B; Mendoza-Bello, JM; Parra-Rojas, I; Ramírez, M, 2019) |
| "To date, type 2 diabetes is considered to be a "bi-hormonal disorder" rather than an "insulin-centric disorder," suggesting that glucagon is as important as insulin." | ( Fujimoto, K; Honzawa, N; Kitamura, T, 2019) |
| "Type 2 diabetes mellitus is a complex metabolic disorder requiring polypharmacology approaches for effective treatment." | ( Babkov, DA; Babkova, VA; Borisov, AV; Borodkin, GS; Brigadirova, AA; Kolodina, AA; Litvinov, RA; Morkovnik, AS; Sochnev, VS; Sokolova, EV; Spasov, AA; Zhukowskaya, ON, 2019) |
| "Type 2 diabetes is associated with cognitive dysfunction and an increased dementia risk, particularly in individuals with concomitant cardiovascular and/or kidney disease." | ( Biessels, GJ; George, JT; Janssen, J; Johansen, OE; Passera, A; Rosenstock, J; Schnaidt, S; van den Berg, E; Verhagen, C; Zinman, B, 2019) |
| "Type 2 diabetes is a common disease worldwide, but its prevalence varies widely by geographical region and by race/ethnicity." | ( Golden, SH; Hanson, RL; Knowler, WC; Phatak, S; Yajnik, C, 2019) |
| "Type 2 diabetes is a chronic, progressive disease with increasing prevalence and still late diagnostic." | ( Capurro, L; Forti, L; Guaita, MS; Mingote, E; Musso, C, 2019) |
| "Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of obesity and type 2 diabetes." | ( Dinarello, CA; Donath, MY; Mandrup-Poulsen, T, 2019) |
| "Type 2 diabetes mellitus is a major health concern worldwide; however, the molecular mechanism underlying its development is poorly understood." | ( Cooper, GJS; Liu, H; McCann, MJ; Nie, T; Vazhoor Amarsingh, G; Zhang, S, 2019) |
| "The prevalence of type 2 diabetes mellitus is expected to rise in the frail elderly population, which will have significant consequences for the health economy." | ( Muraleedharan, V; Rabindranathnambi, A; Sathyanarayanan, A, 2019) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose and/or high serum free fatty acids." | ( Hua, Q; Kong, X; Li, XY; Liu, CX; Lv, K; Ma, MZ; Su, Q; Wang, GD; Yang, H; Yao, XM; Zhang, HM, 2019) |
| "Type 2 diabetes mellitus is a major risk factor for developing cardiovascular disease, and many patients with diabetes have prevalent cardiovascular complications." | ( Ceriello, A; Ferrini, M; La Sala, L; Marx, N; Prattichizzo, F; Rydén, L; Valensi, P, 2019) |
| "Type 2 diabetes mellitus is an important public health problem, with a significant impact on cardiovascular morbidity and mortality and an important risk factor for chronic kidney disease." | ( Foresto, RD; Gonzalez, DE; Ribeiro, AB, 2020) |
| "Type 2 diabetes mellitus is often companied with osteoporosis, a process which involves osteoclast activation." | ( Gong, Y; Lei, X; Liu, H; Song, Z; Xie, J; Yang, M; Zhou, L, 2020) |
| "Obesity and type 2 diabetes mellitus are global emergencies and long noncoding RNAs (lncRNAs) are regulatory transcripts with elusive functions in metabolism." | ( Awazawa, M; Büning, H; Cao, H; Dhaouadi, I; Dieterich, C; Edwards, PA; Fernandez-Rebollo, E; Frommolt, P; Hansmeier, NR; Heeren, J; Heine, M; Jesus, DF; Khani, S; Kiefer, CA; Klemm, P; Knippschild, U; Kornfeld, JW; Kulkarni, RN; Larsen, BD; Lee, RG; Link, JC; Loureiro, R; Meola, N; Oliverio, M; Pradas-Juni, M; Scheja, L; Schmidt, E; Schwarzer, R; Topel, H; Tröder, SE; Ulitsky, I; Vallim, TQA; Yamamoto, M; Yang, L; Zevnik, B, 2020) |
| "Type 2 diabetes is the leading cause of chronic kidney disease (CKD)." | ( McGill, JB; Tuttle, KR, 2020) |
| "Type 2 diabetes mellitus is associated with an increased risk of heart failure." | ( Bondugulapati, LNR; Morgan, H; Nana, M, 2021) |
| "Since type 2 diabetes is a proinflammatory state and since hepcidin, a known suppressor of erythropoiesis, is increased in proinflammatory states, we investigated the possibility that dapagliflozin suppresses hepcidin concentrations and thus increases erythropoiesis." | ( Abuaysheh, S; Batra, M; Chaudhuri, A; Dandona, P; Ghanim, H; Green, K; Hejna, J; Makdissi, A, 2020) |
| "Type 2 diabetes is associated with inflammatory and oxidative stress." | ( Hertig, I; Okulicz, M; Szkudelska, K; Szkudelski, T, 2020) |
| "Incident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis." | ( Ballantyne, CM; Barter, PJ; Black, DM; Kallend, D; Kittelson, J; Laghrissi-Thode, F; Leiter, LA; Leitersdorf, E; McMurray, JJV; Nicholls, SJ; Olsson, AG; Preiss, D; Schwartz, GG; Shah, PK; Tardif, JC, 2020) |
| "Type 2 diabetes is known to abrogate the vascular response." | ( Au-Yeung, F; Jenkins, AL; Josse, R; Jovanovski, E; Komishon, A; Sung, MK; Vuksan, V; Zurbau, A, 2020) |
| "Type 2 diabetes is characterized by glucose intolerance, caused by insulin resistance in peripheral metabolic tissues and by impaired glucose-stimulated insulin secretion, the hallmark of beta-cell dysfunction." | ( Bewick, GA; Pedro, PF; Tsakmaki, A, 2020) |
| "Type 2 diabetes is characterized by peripheral insulin resistance and insufficient insulin release from pancreatic islet β cells." | ( Bornstein, SR; Bozsak, R; Brennand, A; Chen, C; Cohrs, CM; Distler, M; Drotar, DM; Ehehalt, F; Enos, SJ; Kipke, N; Panzer, JK; Schöniger, E; Solimena, M; Speier, S; Weitz, J, 2020) |
| "Type 2 diabetes is one of the most severe chronic diseases and is an increasingly important public health problem worldwide." | ( Gao, X; Ge, Y; Li, Y; Lu, W; Qian, P; Sai, W; Tian, H; Wang, Y; Yao, W, 2020) |
| "Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD)." | ( Alexander, JH; Cooper, ME; George, JT; Johansen, OE; Kahn, SE; Mann, JFE; Marx, N; McGuire, DK; Meinicke, T; Perkovic, V; Pfarr, E; Rosenstock, J; Schnaidt, S; Toto, R; von Eynatten, M; Wanner, C; Zinman, B, 2020) |
| "The incidence of type 2 diabetes is rapidly rising worldwide leading to an increasing burden of cardiovascular and microvascular complications." | ( Chowdhury, A; Chowdhury, TA; Tsoutsouki, J; Wunna, W, 2020) |
| "Type 2 diabetes mellitus is associated with pNET metastasis and not an independent risk factor for poor prognosis in pNETs." | ( Cheng, H; Fan, K; Fan, Z; Gong, Y; Huang, Q; Jin, K; Liu, C; Luo, G; Ni, Q; Yang, C; Yu, X, 2020) |
| "The incidence of type 2 diabetes is increasing more rapidly in adolescents than in any other age group." | ( Barshop, BA; Chen, K; Concepcion, J; Gangoiti, J; Kim, JJ; Mendez, E; Natarajan, L; Nikita, ME; Saito, R; Sharma, K, 2020) |
| "Type 2 diabetes is clinically associated with progressive necroinflammation and fibrosis in nonalcoholic steatohepatitis (NASH)." | ( Ali, M; Charville, GW; Das, S; Dehnad, A; Fan, W; Fish, SR; Jiang, JX; Li, Y; Mozes, G; Olson, KA; Török, NJ; Wong, KA, 2020) |
| "Objectives Type 2 Diabetes mellitus is a progressive metabolic disease characterized by relative insulin insufficiency and insulin resistance resulting in hyperglycemia." | ( Abrahams-October, Z; Adeniyi, OV; Benjeddou, M; Johnson, R; Masilela, CM; Ongole, JJ; Pearce, B; Xhakaza, L, 2020) |
| "Type 2 diabetes is characterized by renal hypoxia, oxidative and endoplasmic reticulum stress, and defective nutrient deprivation signaling, which (acting in concert) are poised to cause both activation of HIF-1α and suppression of HIF-2α." | ( Packer, M, 2021) |
| "Type 2 Diabetes mellitus is associated with aging and shortened telomere length." | ( Abdolahi, A; Block, RC; Brenna, JT; Godugu, K; Holub, A; Mousa, S; Tu, XM, 2020) |
| "Type 2 diabetes is a kind of metabolic disease." | ( Chen, Q; Gao, Y; Han, X; Sun, L; Yu, W; Zeng, M; Zhang, L; Zhou, D, 2020) |
| "Type 2 diabetes is characterized by considerable heterogeneity in its etiopathogenesis and clinical presentation." | ( Anjana, RM; Baskar, V; Jebarani, S; Mohan, V; Nair, ATN; Palmer, C; Pearson, E; Pradeepa, R; Siddiqui, MK; Unnikrishnan, R, 2020) |
| "Type 2 diabetes mellitus is a chronic disease that is characterized by hyperglycemia, insulin resistance, and dysfunctional insulin secretion." | ( Ho, HJ; Komai, M; Shirakawa, H, 2020) |
| "Type 2 diabetes mellitus is a heterogeneous disease." | ( Birkenfeld, AL; Fritsche, A; Gallwitz, B; Häring, HU; Heni, M; Kellerer, M; Peter, A; Wagner, R, 2022) |
| "Type 2 diabetes mellitus is a heterogeneous disease." | ( Birkenfeld, AL; Fritsche, A; Gallwitz, B; Häring, HU; Heni, M; Kellerer, M; Peter, A; Wagner, R, 2022) |
| "The incidence of type 2 diabetes mellitus is increasing worldwide and nowadays T2D already became a global epidemic." | ( Danilova, MM; Glotov, AS; Mikhailova, AA; Nasykhova, YA; Tonyan, ZN, 2020) |
| "Obesity and type 2 diabetes mellitus are the most extended current chronic diseases and also Alzheimer pathology which is a progressive degenerative neurological disorder." | ( Cano-Lamadrid, M; Carbonell-Barrachina, ÁA; Hernández, F; Lech, K; Nowicka, P; Tkacz, K; Turkiewicz, IP; Wojdyło, A, 2021) |
| "Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD)." | ( Guo, W; Lin, L; Tian, W; Xu, X, 2020) |
| "Type 2 diabetes is related to higher intraplatelet concentration of asymmetric dimethylarginine (ADMA), which may result in impaired platelet-derived nitric oxide synthesis and subsequent increased platelet activity, as assessed by the ADP-induced aggregation." | ( Doroszko, A; Fortuna, P; Gajecki, D; Gawryś, J; Gawryś, K; Leśniewska, J; Majda, F; Mlynarz, P; Szahidewicz-Krupska, E; Wiśniewski, J, 2020) |
| "Type 2 diabetes is a leading cause of morbidity and a common risk of several disorders." | ( Almugadam, BS; Chen, SM; Liu, Y; Ren, BW; Shao, CY; Tang, L; Wang, CH, 2020) |
| "Type 2 diabetes is associated with sarcopenia." | ( Hiraki, K; Hishida, Y; Kawanabe, S; Nagai, Y; Sone, M; Tanaka, Y; Yamamoto, Y, 2021) |
| "The prevalence of type 2 diabetes is on the increase worldwide, and it represents about 90% of adults who are diagnosed with diabetes." | ( Feng, QQ; Ojo, O; Ojo, OO; Wang, XH, 2020) |
| "Type 2 diabetes mellitus is responsible for high mortality and morbidity globally and in India." | ( Babu, GR; Gudlavalleti, AG; Lewis, MG; Murthy, GVS; Schaper, NC; van Schayck, OCP, 2020) |
| "Type 2 diabetes is associated with reduced levels of mitochondrial proteins involved in oxidative phosphorylation and an increased abundance of enzymes implicated in fatty acid catabolism in SKLM." | ( Abdul-Ghani, M; Cas, MD; Chavez, AO; Daniele, G; DeFronzo, RA; Fiorentino, TV; Folli, F; Hribal, ML; Kamath, S; Monroy, A; Sesti, G; Sotero, R; Tripathy, D, 2021) |
| "Type 2 diabetes mellitus is characterized by insulin resistance and elevated blood glucose levels." | ( Handschuh, P; Lanzenberger, R; Noe, CA; Noe, CR; Noe-Letschnig, M; Soucek-Noe, D; Wolfslehner, L, 2020) |
| "Type 2 diabetes is associated with both impaired insulin action at target tissues and impaired insulin secretion in pancreatic beta cells." | ( Bakker, SJL; Connelly, MA; de Boer, RA; Douwes, RM; Dullaart, RPF; Flores-Guerrero, JL; Franssen, CFM; Garcia, E; Groothof, D; Kema, IP; Post, A; Schutten, JC; Swarte, JC; Wallimann, T, 2021) |
| "Type 2 diabetes is a syndrome defined by hyperglycaemia that is the result of various degrees of pancreatic β-cell failure and reduced insulin sensitivity." | ( Erazo-Tapia, E; Oscarsson, J; Schrauwen, P; Veelen, A, 2021) |
| "Type 2 diabetes mellitus is strongly associated with cardiac mitochondrial dysfunction, which is one of the main reasons for cardiovascular diseases." | ( Gopala, S; Jayakumari, NR; Parambil, ST; Rajendran, RS; Reghuvaran, AC; Sivasailam, A; Sreelatha, HV, 2021) |
| "Aging, obesity and type 2 diabetes mellitus are associated with perfusion abnormalities leading to cognitive impairment, neurodegeneration and future development of dementia." | ( Barna, S; Budai, Á; Esze, R; Garai, I; Káplár, M; Képes, Z; Nagy, F; Somodi, S; Varga, J, 2021) |
| "Type 2 diabetes is a fast-growing worldwide epidemic." | ( Icart, LP; Lima, LMTR; Souza, FG, 2021) |
| "The prevalence of type 2 diabetes is increased in individuals with mental disorders." | ( Ajjan, RA; Al Azdi, Z; Aslam, F; Churchill, R; Mishu, MP; Philip, S; Siddiqi, N; Stubbs, B; Tirbhowan, N; Uphoff, E; Wright, J, 2021) |
| "Type 2 diabetes is a risk factor for Alzheimer's disease (AD), and AD brain shows impaired insulin signalling." | ( Archer, H; Ballard, C; Bannister, C; Brooks, DJ; Busza, G; Calsolaro, V; Carver, S; Coulthard, E; Donaldson, A; Edison, P; Femminella, GD; Frangou, E; Harrison, J; Holmes, C; Holscher, C; Junaid, K; Karim, S; Knight, L; Koranteng, P; Kshemendran, S; Lawrence, RM; Livingston, NR; Love, S; Macharouthu, A; Malik, N; Mate, V; McFarlane, B; McGuinness, B; Nilforooshan, R; Passmore, AP; Prasanna, A; Raza, S; Ridha, BH; Ritchie, CW; Russell, G; Tadros, G; Tan, T; Thacker, S; Underwood, B; van der Doef, T; Walker, Z, 2021) |
| "Patients with type 2 diabetes are tested for thyroid function in view of the associated weight gain, IR, and changes in metabolism." | ( Kamenov, Z; Yanachkova, V, 2021) |
| "Patients with type 2 diabetes are at increased risk of developing detrimental metabolic and cardiovascular complications." | ( Gupta, P; Hassan, MI; Taiyab, A, 2021) |
| "Youth-onset type 2 diabetes is a disease of pubertal onset, associated with additional burden of pubertal insulin resistance on the β-cell." | ( Hilkin, A; Kelsey, MM; Nadeau, KJ; Pyle, L; Severn, C; Utzschneider, K; Van Pelt, RE; Zeitler, PS, 2021) |
| "Type 2 diabetes is considered to be one of the essential risks of adverse outcomes in coronavirus disease 2019 (COVID-19)." | ( Chen, W; Chen, Y; Cheng, X; Duan, P; Gong, Y; Li, C; Li, F; Li, L; Li, W; Xin, S; Zhou, B; Zhou, X, 2021) |
| "Type 2 diabetes is currently one of the most common metabolic diseases, affecting all ages worldwide." | ( Brzozka, Z; Dobrzyn, A; Janikiewicz, J; Jastrzebska, E; Sokolowska, P; Zukowski, K, 2021) |
| "Type 2 diabetes is an increasing health concern worldwide." | ( Casarsa, V; Catena, C; Cavarape, A; Colussi, G; Da Porto, A; Sechi, LA, 2021) |
| "The global rise in type 2 diabetes is associated with a concomitant increase in diabetic complications." | ( Alakwaa, FM; Andersen, ST; Callaghan, BC; Charles, M; Feldman, EL; Guo, K; Jensen, TS; Jørgensen, ME; Reynolds, EL; Rumora, AE; Savelieff, MG; Tankisi, H; Witte, DR, 2021) |
| "Both type 1 and type 2 diabetes are associated with an increased prevalence of PDs." | ( Barbato, L; Cairo, F; Caliri, M; Dicembrini, I; Mannucci, E; Pala, L; Serni, L, 2021) |
| "Type 2 diabetes is characterized by β and α cell dysfunction." | ( Butler, PC; Elashoff, D; Fraser, SE; Gurlo, T; Junge, JA; Matveyenko, AV; Rosenberger, M; Stevens, RC; Wang, P; Wang, Z; White, KL, 2021) |
| "CAC score in GCK-MODY is similar to control individuals from the same family and/or household and is significantly lower than type 2 diabetes." | ( Dib, SA; Dotto, RP; Franco, LF; Giuffrida, FMA; Moises, RS; Reis, AF; Szarf, G, 2021) |
| "Youth-onset type 2 diabetes is characterised by pathophysiological heterogeneity and inadequate glycaemic control, highlighting the need for new treatment approaches and innovative study designs in populations of varied genetic and cultural backgrounds." | ( Kelsey, MM; Pyle, L, 2021) |
| "Type 2 diabetes is associated with an increased cardiovascular risk." | ( Byrne, S; Cronin, H; O'Donovan, A; Tan, SY; Tuthill, A, 2022) |
| "Type 2 Diabetes is a chronic disease resulting from insulin dysfunction that triggers a low-grade inflammatory state and immune impairment." | ( Bortoleti, BTDS; Concato, VM; Conchon-Costa, I; Custodio, LA; da Costa, IN; Detoni, MB; Gonçalves, MD; Mazzuco, TL; Miranda-Sapla, MM; Pavanelli, WR; Rodrigues, ACJ; Sanfelice, RA; Silva, TF; Simão, ANC; Tomiotto-Pellissier, F, 2021) |
| "Type 2 diabetes is characterized by chronic hyperglycemia." | ( Choi, H; Jun, HS; Lee, CY; Maeng, HJ; Mee Lee, K; Nguyen, TT; Park, EY; Shin, D, 2021) |
| "Type 2 diabetes mellitus is a complicated metabolic disorder with no definite treatment." | ( Akhtar, B; Hassan, SU; Malik, M; Muhammad, F; Saeed, M; Sharif, A, 2022) |
| "Type 2 diabetes is characterised by failure to control glucose homeostasis, with numerous diabetic complications attributable to the resulting exposure of cells and tissues to chronic elevated concentrations of glucose and fatty acids." | ( Billacura, MP; Boocock, DJ; Caton, PW; Colombo, SL; Coveney, C; Doig, CL; Foulds, GA; Hanna, K; Jackisch, L; Lavilla, CJ; McTernan, PG; Miles, AK; Murphy, A; Sale, C; Sayers, SR; Tan, A; Turner, MD, 2021) |
| "Type 2 diabetes is a leading contributor to the global burden of morbidity and mortality." | ( Haan, M; Inoue, K; Jerrett, M; Lee, E; Paul, KC; Ritz, B; Shih, IF; Su, J; Wu, J; Yu, Y, 2021) |
| "Type 2 diabetes mellitus is a severe public health issue worldwide." | ( Alfonsetti, M; Allegretti, M; Brandolini, L; Castelli, V; Cimini, A; Cocchiaro, P; d'Angelo, M; Giorgio, C; Lombardi, F, 2021) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that tends to disarray various metabolic pathways." | ( Jayachandran, M; Li, X; Xu, B, 2021) |
| "Obesity and type 2 diabetes are two interrelated metabolic disorders characterized by insulin resistance and a mild chronic inflammatory state." | ( Cani, PD; Delzenne, NM; Depommier, C; Di Marzo, V; Flamand, N; Manca, C; Silvestri, C; Suriano, F; Van Hul, M, 2022) |
| "Type 2 diabetes is a risk factor for atherosclerosis." | ( Ban, N; Ishihara, N; Murano, T; Murase, T; Nakamura, S; Nakamura, T; Ohira, M; Oka, R; Saiki, A; Tanaka, S; Tatsuno, I; Watanabe, Y; Yamaguchi, T, 2022) |
| "Obesity and type 2 diabetes are often associated with brain insulin resistance, resulting in impaired brain-derived modulation of peripheral metabolism." | ( Birkenfeld, AL; Dannecker, C; Fritsche, A; Fritsche, L; Häring, HU; Heni, M; Hummel, J; Kantartzis, K; Kullmann, S; Machann, J; Peter, A; Preissl, H; Stefan, N; Veit, R; Vosseler, A; Wagner, R, 2022) |
| "Type 2 Diabetes mellitus is a chronic disease considered one of the most severe global health emergencies." | ( Cardullo, N; Floresta, G; Muccilli, V; Rescifina, A; Tringali, C, 2021) |
| "Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of which is increasing worldwide." | ( Catrinoiu, D; Ceriello, A; Chandramouli, C; Cosentino, F; Dombrowsky, AC; Itzhak, B; Lalic, NM; Prattichizzo, F; Schnell, O; Seferović, PM; Standl, E; Valensi, P, 2021) |
| "Type 2 diabetes is a serious public health concern in India, even the indigenous tribal populations are not left unaffected." | ( Chhungi, V; Devi, NK; Mondal, PR; Newmei, MK; Ningombam, SS; Rajkumari, S; Saraswathy, KN, 2022) |
| "Type 2 diabetes is more prevalent (90-95%) in adults than type 1." | ( Ahmad, R; Bari, DG; Gaur, R; Gautam, GK; Parveen, K; Rais, N; Shukla, KS; Singh, AP; Ved, A, 2022) |
| "Type 2 diabetes is characterized by reduced insulin sensitivity, elevated blood metabolites, and reduced mitochondrial metabolism." | ( Hinkle, JS; Rivera, CN; Vaughan, RA, 2022) |
| "Obesity and type 2 diabetes are chronic diseases characterized by insulin resistance, mitochondrial dysfunction and morphological abnormalities." | ( Berg, G; Blanco, G; Carreras, MC; Finocchietto, P; Marotte, C; Miksztowicz, V; Morales, C; Peralta, J; Perez, H; Poderoso, C; Poderoso, JJ, 2022) |
| "Type 2 diabetes mellitus is a complex metabolic disorder associated with obesity, glucose intolerance and insulin resistance." | ( Bo, P; Fang, P; Han, L; Han, S; Huang, Y; Wang, M; Yu, M; Zhang, Z, 2022) |
| "Type 2 diabetes is an established risk factor for tuberculosis, but the underlying mechanisms are largely unknown." | ( Bobadilla, K; Guzmán-Beltrán, S; Hernández, F; Monroy-Mérida, G; Santos-Mendoza, T, 2021) |
| "Type 2 diabetes is a metabolic disorder associated with abnormal glucose homeostasis and is characterized by intrinsic defects in β-cell function and mass." | ( Bernal-Mizrachi, E; Blandino-Rosano, M; Lin, A; Reddy, JK; Romaguera Llacer, P, 2022) |
| "Obesity and type 2 diabetes are associated with cognitive dysfunction." | ( Alcolea, D; Altirriba, J; Bauder, C; Brüning, JC; Chivite, I; Claret, M; Eyre, E; Fernández-Checa, JC; Fortea, J; Garcia-Ruiz, C; Garrabou, G; Gasull, X; Gómez-Valadés, AG; Haddad-Tóvolli, R; Imbernón, M; Jiménez, A; Milà-Guasch, M; Nogueiras, R; Obri, A; Pané, A; Pozo, M; Radosevic, M; Ramírez, S; Ribas, V; Sandi, C; Soto, D; Toledo, M; Van Eeckhout, T; Zalachoras, I, 2022) |
| "Individuals with type 2 diabetes are at higher risk of progression of nonalcoholic fatty liver (steatosis) to steatohepatitis (NASH), fibrosis, and cirrhosis." | ( Dewidar, B; Esposito, I; Fleming, T; Gancheva, S; Kahl, S; Mastrototaro, L; Nawroth, P; Pesta, D; Reichert, AS; Roden, M; Sabah, E; Sarabhai, T; Schlensak, M; Strassburger, K; Weiß, J; Wolkersdorfer, M; Zimmermann, M, 2022) |
| "Type 2 diabetes is associated with the upregulation of neprilysin, a peptidase capable of cleaving glucoregulatory peptides such as glucagon-like peptide-1 (GLP-1)." | ( Akter, R; Barrow, BM; Castillo, JJ; Esser, N; Fountaine, BS; Hull, RL; Larmore, MJ; Mongovin, SM; Mundinger, TO; Parilla, J; Zraika, S, 2022) |
| "Type 2 diabetes is strongly associated with ageing-related β-cell abnormalities that arise through unknown mechanisms." | ( Cai, J; Fan, C; Gao, H; Guo, D; Jia, Z; Quan, L; Sun, Y; Teng, T; Wan, Z; Wang, M; Zhang, H; Zhang, R; Zhong, D, 2022) |
| "Risk factors for type 2 diabetes are multifaceted and interrelated." | ( Carrero, JJ; Dekker, LH; Duan, MJ; Navis, G, 2022) |
| "Type 2 diabetes mellitus is one of the most common and life-threatening diseases found across the globe." | ( Chellappan, DK; Dua, K; Dureja, H; Gulati, M; Gupta, G; Gupta, PK; Gupta, S; Jha, NK; Jha, SK; Khursheed, R; Kumar, B; Pandey, NK; Prasher, P; Sharma, A; Singh, SK; Vishwas, S, 2022) |
| "Type 2 diabetes mellitus is known to be a risk factor for Alzheimer’s disease (AD), but the underlying mechanisms remain unclear." | ( Nomura, S; Shigemori, K; Takeda, S; Tomiyama, T; Umeda, T, 2022) |
| "Type 2 Diabetes is a major public health threat, and its prevalence is increasing worldwide." | ( Caflisch, A; Di Fabio, G; García-Viñuales, S; Ilie, IM; Milardi, D; Romanucci, V; Santoro, AM; Zarrelli, A, 2022) |
| "Type 2 diabetes is a metabolic disease mainly associated with insulin resistance during obesity and constitutes a major public health problem worldwide." | ( Clément, K; Gonthier, MP; Meilhac, O; Taïlé, J; Thouvenot, K; Turpin, T, 2022) |
| "Type 2 diabetes is a common manifestation of metabolic dysfunction due to obesity and constitutes a major burden for modern health care systems, in concert with the alarming rise in obesity worldwide." | ( Bagger, JI; Holst, JJ; Knop, FK; Lund, A; Lutz, TA; Mathiesen, DS, 2022) |
| "Obesity and type 2 diabetes are major contributors to the growing prevalence of non-alcoholic fatty liver disease (NAFLD), a chronic liver condition characterized by the accumulation of fat in individuals without a significant amount of alcohol intake." | ( Morral, N; Qian, G, 2022) |
| "Type 2 diabetes is marked by progressive β-cell failure, leading to loss of β-cell mass." | ( Ayukawa, K; Carbone, K; Clemons, PA; Dancik, V; Joblin-Mills, A; Khodier, C; Kost-Alimova, M; Munkacsi, AB; Small, JC; Wagner, BK, 2022) |
| "Type 2 diabetes mellitus is one of the most globally common chronic diseases." | ( Abuzaid, O; Al-Sheikh, R; Albannawi, M; Alhajjmohammed, D; Alkubaish, Z; Althani, R; Altheeb, L; Altuwajiry, H; Ayoub, H; Khattab, R; Mutwalli, H; Purayidathil, T, 2023) |
| "Hypertension and type 2 diabetes are common complications." | ( Li, X; Wang, B; Yang, Y, 2022) |
| "The prevalence of type 2 diabetes is increasing worldwide, and previous studies have suggested that it is higher in individuals who are seropositive for herpesviruses." | ( Chadeau-Hyam, M; Linkohr, B; Peters, A; Seissler, J; Thorand, B; Waterboer, T; Woelfle, T, 2022) |
| "Type 2 diabetes is a chronic metabolic disease that affects mitochondrial function." | ( Abad-Jiménez, Z; Apostolova, N; Canet, F; de Marañón, AM; Díaz-Morales, N; Díaz-Pozo, P; López-Domènech, S; Morillas, C; Rocha, M; Vezza, T; Víctor, VM, 2022) |
| "Type 2 diabetes is characterised by hyperglucagonaemia and perturbed function of pancreatic glucagon-secreting alpha cells but the molecular mechanisms contributing to these phenotypes are poorly understood." | ( Casanueva-Álvarez, E; Cózar-Castellano, I; Fernández-Díaz, CM; González-Casimiro, CM; Kaestner, KH; Leissring, MA; Merino, B; Perdomo, G; Postigo-Casado, T; Quesada, I, 2022) |
| "The incidence of type 2 diabetes mellitus is increasing among youths." | ( Arslanian, SA; Barrientos-Pérez, M; Bismuth, E; Boucher-Berry, C; Chao, LC; Cho, JI; Cox, D; Dib, S; Hannon, T; Zeitler, P, 2022) |
| "Type 2 diabetes mellitus is a chronic disease associated with obesity and dysregulated human feeding behavior." | ( Allbritton, NL; Sims, CE; Villegas-Novoa, C; Wang, Y, 2022) |
| "Type 2 diabetes is a serious threat to human health." | ( Chen, Y; He, X; Lei, L; Li, F; Li, W; Ming, J; Zeng, K; Zhao, J, 2022) |
| "Type 2 diabetes mellitus is a high-risk factor for acute cardiovascular events." | ( Shao, G, 2022) |
| "MODY2 is characterized by mild, stable fasting hyperglycemia that presents at birth, usually 5." | ( Fang, L; Guan, Q; Jiang, X; Li, G; Li, J; Li, K; Li, Z; Liu, J; Sun, Y; Xu, C, 2022) |
| "Type 2 diabetes mellitus is a global epidemic disease, which leads to a severe complication named increased bone fracture risk." | ( Gong, H; Hu, X; Jia, S; Li, J; Wu, X, 2022) |
| "Type 2 diabetes is associated with an inflammatory phenotype in the pancreatic islets." | ( Armanet, M; Autier, V; Bailbé, D; Carbonne, C; Dairou, J; Domet, T; Gausseres, B; Guillemin, GJ; Kergoat, M; Lim, CK; Liu, J; Movassat, J; Pitasi, CL; Portha, B; Raynal, S; Zhen, D, 2022) |
| "Youth with type 2 diabetes are at higher risk of adverse kidney outcomes than their type 1 counterparts." | ( Chan, JCN; Chow, E; Fan, Y; Kong, APS; Lau, ESH; Luk, AOY; Ma, RCW; So, WY; Wu, H; Yang, A, 2022) |
| "Type 2 diabetes is more common in adults, but is becoming the major concern in children and adolescent recently." | ( Feng, Y; Ge, Y; He, Y; Hou, L; Huo, M; Ji, Y; Li, H; Liu, X; Liu, Y; Luo, Q; Qian, F; Wang, J; Wei, Y; Wu, S; Wu, Y; Xue, F; Yu, Y, 2022) |
| "Although type 2 diabetes is a risk factor for increased sarcopenia, the relationship between prediabetes and sarcopenia has not been elucidated." | ( Kadowaki, S; Kaga, H; Kakehi, S; Kawamori, R; Naito, H; Sato, M; Someya, Y; Sugimoto, D; Suzuki, R; Tabata, H; Tamura, Y; Watada, H; Yamasaki, N, 2022) |
| "Type 2 diabetes mellitus is a chronic disease most often characterized by increased glucose levels." | ( Ashchi, A; Berner, J; Goldfaden, R; Gore, A; Huston, J; Langley, L; Schaffner, H; Sheikh-Ali, M; Skrable, B; Sutton, D, 2022) |
| "Type 2 diabetes is a risk factor for dementia and Parkinson's disease (PD)." | ( Duijn, CMV; Fernandes, M; Ghose, U; Launer, LJ; Li, QS; Linden, AB; Molero, Y; Nevado-Holgado, AJ; Newby, D; Sproviero, W; Winchester, L, 2022) |
| "Patients with type 2 diabetes are at higher risk for fracture risk because of attenuated bone turnover and impaired bone microarchitecture." | ( Au, ICH; Cheung, CYY; Chow, WS; Fong, CHY; Ho Man Tang, E; Lam, KSL; Lee, CH; Lui, DTW; Tan, KCB; Wong, CK; Wong, CKH; Woo, YC; Wu, T, 2022) |
| "Older people with type 2 diabetes are at an increased risk for macrovascular (damage to arteries that can lead to myocardial infarction or stroke) and microvascular (damage to small blood vessels including retinopathy and nephropathy) disease." | ( Early, NK; Pogge, EK, 2022) |
| "Obesity and Type 2 diabetes mellitus are growing health problems all over the world." | ( Keskin, L; Yaprak, B, 2022) |
| "Type 2 diabetes is a disease that causes numerous complications disrupting the functioning of the entire body." | ( Dziedziejko, V; Kotrych, K; Marchelek-Mysliwiec, M; Nalewajska, M; Pawlik, A; Sulikowski, T; Turoń-Skrzypińska, A, 2022) |
| "Type 2 diabetes is a high-profile global public health problem, particularly in Asia." | ( Cao, YQ; Tang, HB; Zhu, LY; Zhu, SH, 2022) |
| "Type 2 diabetes is associated with a higher risk of cardiac arrhythmias, especially in presence of cardiovascular disease and/or heart failure." | ( Scheen, AJ, 2022) |
| "Type 2 diabetes mellitus is considered to be a substantial socioeconomic burden worldwide on both patients and governments." | ( Abdelwahab, MF; AlYahya, KA; Ibrahim, HM; Khalil, HE; Mohamed, AA; Radwan, AS; Waz, S, 2022) |
| "Type 2 diabetes mellitus is a metabolic disorder resulting from impaired insulin secretion and resistance." | ( Chhabria, S; Mathur, S; Mishra, P; Paital, B; Sahoo, DK; Vadakan, S, 2022) |
| "Type 2 diabetes mellitus is a metabolic disorder resulting from impaired insulin secretion and resistance." | ( Chhabria, S; Mathur, S; Mishra, P; Paital, B; Sahoo, DK; Vadakan, S, 2022) |
| "The presence of type 2 diabetes is the most powerful predictive risk factor for hepatic fibrosis in patients with NAFLD." | ( Jun, DW; Ko, E; Yoon, EL, 2023) |
| "The presence of type 2 diabetes is the most powerful predictive risk factor for hepatic fibrosis in patients with NAFLD." | ( Jun, DW; Ko, E; Yoon, EL, 2023) |
| "Type 2 diabetes is a major health burden to the society." | ( Bumbasirevic, V; Ciric, D; Jovanovic, S; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V, 2023) |
| "Type 2 diabetes is a major health burden to the society." | ( Bumbasirevic, V; Ciric, D; Jovanovic, S; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V, 2023) |
| "Type 2 diabetes is a major public health problem for the global community." | ( Cedillo, YE; Denton, JJ, 2023) |
| "Obesity and type 2 diabetes are causally related, yet there is considerable heterogeneity in the consequences of both conditions and the mechanisms of action are poorly defined." | ( Atabaki-Pasdar, N; Coral, DE; Cox, NJ; Fernandez-Tajes, J; Fitipaldi, H; Franks, PW; Giordano, GN; Kalamajski, S; Miller-Fleming, TW; Mutie, PM; Pearson, ER; Pomares-Millan, H; Poveda, A; Tsereteli, N; Zhong, X, 2023) |
| "T2DM (Type 2 diabetes mellitus) is considered a disease that affects old age group." | ( Eid, Y; Elhalawany, S; Elhefnawy, M; Halawa, M; Hegab, A; Hendawy, L, 2022) |
| "Polypharmacy in type 2 diabetes is an issue of major concern as the prescription of multiple medi-cations for the management of diabetes-associated comorbidities can lead to drug-to-drug interactions, which can pose serious risks to patients' health." | ( Furton, KG; Gennimata, D; Kabir, A; Panderi, I; Parla, A; Samanidou, V; Stamou, P, 2023) |
| "Youth-onset type 2 diabetes is becoming increasingly prevalent, especially among Latino youth, and there is limited information on its pathophysiology and causative factors." | ( Alderete, TL; Durazo-Arvizu, R; Goran, MI; Vidmar, AP; Weigensberg, MJ, 2023) |
| "Type 2 diabetes is associated with many complications, including skeletal muscle atrophy." | ( Fan, M; Li, Y; Nie, C; Qian, H; Wang, L; Wang, Y; Xue, L; Yang, Z, 2023) |
| "Type 2 diabetes is more prevalent in African American (AA) than Caucasian (C) adults." | ( Biagioni, EM; Broskey, NT; Claiborne, A; Cortright, RN; DeVente, JE; Houmard, JA; Isler, C; Jevtovic, F; Lopez, CA; May, LE; Zheng, D, 2023) |
| "The incidence of type 2 diabetes is reported to be lower in frequent coffee drinkers than in non-coffee drinkers." | ( Ando, M; Asahara, SI; Ihara, Y; Inoue, H; Kabutoya, H; Kido, Y; Kimura-Koyanagi, M; Seike, M, 2023) |
| "Type 2 diabetes is associated with both dietary iron intake and single-nucleotide polymorphism (SNP) of intronic rs10830963 in melatonin receptor 1B (MTNR1B); however, it is unclear whether they interact." | ( He, X; Liu, H; Lu, Y; Shen, L; Su, J; Wang, Z; Wu, C; Zang, J; Zhu, Z, 2023) |
| "Type 2 diabetes is characterized by insulin hypersecretion followed by reduced glucose-stimulated insulin secretion (GSIS)." | ( Bartosinska, B; Belgardt, BF; Eberhard, D; Gebel, D; Griess, K; Herebian, D; Kirschner, P; Köster, A; Krupenko, NI; Krupenko, SA; Lammert, E; Mrugala, J; Nortmann, O; Pelligra, A; Schrader, J; Steckel, B; Weber, APM; Westhoff, P, 2023) |
| "Type 2 diabetes mellitus is associated with an increased risk of dementia, potentially through multifactorial pathologies, including neuroinflammation." | ( Ihara, M; Iwasa, M; Iwashita, K; Kato, H; Kato, S; Kawamoto, A; Nishimura, H; Saito, S; Satoh-Asahara, N; Suganami, T; Tanaka, M; Yamakage, H, 2023) |
| "Type 2 diabetes mellitus is a globally prevalent chronic disease characterised by hyperglycaemia and oxidative stress." | ( Acevedo, F; Folch, C; Galarce-Bustos, O; Obregón, C; Vallejos-Almirall, A, 2023) |
| "Type 2 diabetes is a risk factor for the development of cognitive impairment." | ( Azarbayjani, MA; Peeri, M; Shekarchian, M, 2023) |
| "Type 2 diabetes mellitus is characterized by hyperglycemia and insulin resistance." | ( Ahmed Rasheed, R; Asim, M; Aysha Iftikhar, Z; Chen, TW; Farooq, M; Musaed Almutairi, S; Mushtaq, U; Ubaid, M; Ul Ain, I, 2023) |
| "Patients with type 2 diabetes are known to have a higher risk of the factor for AD progression." | ( Ali, N; Bin Jardan, YA; Lim, KG; Muthuraman, A; Paramakrishnan, N; Paramaswaran, Y; Shazly, GA; Waseem, M, 2023) |
| "Management of type 2 diabetes is advancing beyond glycemic control and is increasingly based on cardiovascular risk stratification." | ( Avgerinos, I; Bekiari, E; Karagiannis, T; Liakos, A; Malandris, K; Tsapas, A, 2023) |
| "Type 2 diabetes mellitus is a chronic metabolic disease with no cure." | ( Krause-Hauch, M; Lui, A; Patel, NA; Patel, RS; Sparks, RP, 2023) |
| "The incidence of type 2 diabetes is increasing every year and has become a serious public health problem." | ( Ren, Y; Wu, Y; Xiao, X; Yu, J; Zeng, Y; Zhang, Q, 2023) |
| Excerpt | Reference |
|---|
| "In conclusion, 1) NIDDM patients treated with chlorpropamide showed higher fasting insulin levels with 46." | ( Tai, TY; Tseng, CH, 1992) |
| "Twelve NIDDM patients were randomized to treatment with either placebo or Acipimox in pharmacological doses (250 mg x 3) for three months." | ( Beck-Nielsen, H; Vaag, AA, 1992) |
| "Twenty-eight of 60 patients with NIDDM achieved the predetermined improvement in plasma glucose concentration on glyburide therapy." | ( Grunberger, G, 1992) |
| "Twenty-four NIDDM patients who fulfilled these criteria were randomized to treatment with Protaphan human insulin in the morning or at bedtime (22 +/- 1 IU) plus 3." | ( Ekstrand, A; Eriksson, JG; Franssila-Kallunki, A; Groop, LC; Saloranta, C; Schalin-Jäntti, C; Widén, E, 1992) |
| "The usual choice of therapy in NIDDM diabetes, using oral anti-diabetic compounds, insulin or associated treatments, is based on the results of treatment evaluated empirically using glycemic profiles." | ( Cortinovis, A; Crippa, A; Romano, E, 1992) |
| "Ten patients with NIDDM and moderate hypertension were studied in a double-blind, placebo-controlled, crossover study encompassing 6 weeks of placebo treatment and 6 weeks of perindopril treatment given in random order." | ( Bak, JF; Gerdes, LU; Pedersen, O; Sørensen, NS, 1992) |
| "Ten patients with NIDDM were first investigated while still taking oral hypoglycemic agents, and then randomized to a crossover study with two eight-week periods of insulin treatment (oral treatment having been stopped) given either as mainly intermediate-acting insulin twice daily (2-dose) or as preprandial regular insulin and intermediate-acting insulin at bedtime (4-dose)." | ( Arnqvist, HJ; Lindström, T; Ludvigsson, J; von Schenck, HH, 1992) |
| "Six insulin-treated patients with Type 2 diabetes and no known cardiac disease took part in the study." | ( Arnqvist, HJ; Jorfeldt, L; Lindström, T; Tegler, L, 1992) |
| "Many NIDDM patients also have raised serum triglyceride and low-density lipoprotein (LDL) cholesterol levels, which may require drug therapy, as well as increased plasma nonesterified fatty acid concentrations." | ( Alberti, KG; Jones, IR; Laker, MF; Swai, AB; Taylor, R, 1990) |
| "In brief, 94 NIDDM aged 43 to 70, after a pretreatment period of at least 3 months, were treated with 100 mg acarbose t." | ( Fischer, S; Hanefeld, M; Leonhardt, W; Schulze, J; Spengler, M, 1991) |
| "In hypertensive patients with NIDDM, a diuretic-free therapy based on the Ca2+ antagonist verapamil and/or the ACE inhibitor enalapril can effectively decrease blood pressure without adversely affecting carbohydrate and lipid metabolism." | ( Beretta-Piccoli, C; Ferrari, P; Ferrier, C; Keller, U; Riesen, WF; Weidmann, P, 1991) |
| "Among NIDDM patients, abnormal IgA concentrations were especially prevalent among those being treated with oral hypoglycemics." | ( Camiña, MF; Del Río, R; Paz, JM; Rodríguez-Segade, S, 1991) |
| "Nineteen patients with Type 2 diabetes were treated with glipizide for 2." | ( Chen, YD; Foley, JE; Hollenbeck, CB; Jeng, CY; Reaven, GM; Wu, MS, 1991) |
| "In 39 patients with type 2 diabetes who had attained basal normoglycaemia by therapy with diet alone, a sulphonylurea, a basal insulin supplement or basal plus prandial insulin the mean glycosylated haemoglobin (HbA1) values were at the upper end (mean +/- 1SD, 8." | ( Holman, RR; Steemson, J; Turner, RC, 1991) |
| "Before treatment, the NIDDM group had a somewhat higher plasma triglyceride level (154 +/- 58." | ( Bagdade, JD; Lane, JT; Otto, ME; Subbaiah, PV, 1991) |
| "Twenty-two black patients with NIDDM in near-normoglycemic remission who were receiving no pharmacologic therapy for NIDDM were evaluated for insulin sensitivity by the euglycemic insulin clamp, plasma insulin levels, degree of obesity, glucose metabolism, serum total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol levels, and fasting plasma triglyceride levels." | ( Banerji, MA; Lebovitz, HE, 1991) |
| "In eight patients with uncomplicated non insulin dependent diabetes mellitus, serum insulin levels, serum C-peptide levels and blood glucose levels were measured before and after oral administration of glibenclamide 0." | ( Mulder, H; Schopman, W; van der Lely, AJ, 1991) |
| "We conclude that metabolic control in NIDDM patients failing to respond to therapy with maximum dose GB or GZ is not improved by switching to the alternate SGS." | ( Kidd, GS; McDermott, MT; Simcic, KJ; White, JC, 1991) |
| "Ninety-four NIDDM subjects, aged 43-70 yr with average body mass index of 28 kg/m2 and undergoing a pretreatment period of at least 3 mo with diet alone, were treated with 100 mg acarbose three times daily or placebo for 24 wk." | ( Fischer, S; Fücker, K; Hanefeld, M; Schollberg, K; Schulze, J; Spengler, M; Wargenau, M, 1991) |
| "Overall, patients with NIDDM can benefit from insulin therapy." | ( Galloway, JA, 1990) |
| "Thirty one obese subjects, 12 with non insulin dependent diabetes mellitus (NIDDM), 9 with impaired glucose tolerance (IGT) and 10 with normal glucose tolerance (NGT) each underwent four OGTTS (75 g), at 1 week intervals, after administration in random order of placebo or glipizide 0." | ( Perfetti, MG; Pontiroli, AE; Pozza, G, 1991) |
| "The role of insulin in the therapy of NIDDM is still under discussion." | ( Huupponen, R; Karvonen, I; Rytömaa, K; Sotaniemi, EA; Vierimaa, E; Vuoti, MJ, 1990) |
| "Twenty non-insulin-dependent diabetic (NIDDM) patients with secondary failure to sulphonylureas were given combined insulin-glibenclamide therapy." | ( Adamson, U; Lins, PE; Liu, D; Wettergren, M, 1990) |
| "Eight obese subjects and 9 obese NIDDM patients were restudied after 4 wk of therapy with metformin (850 mg twice a day)." | ( Benzi, L; Brunetti, A; Cecchetti, P; Ciccarone, A; Marchetti, P; Navalesi, R; Squatrito, S; Trischitta, V; Vigneri, R, 1990) |
| "Fasting plasma PST in NIDDM patients was not different from healthy controls, although a slightly higher level of PST was observed in patients treated with sulfonylurea among NIDDM patients." | ( Funakoshi, A; Matsumoto, M; Shinozaki, H; Tateishi, K; Wakasugi, H, 1990) |
| "In conclusion, most NIDDM patients with secondary failure to OHAs may be successfully treated with the addition of a single low-dose bedtime NPH insulin injection, and residual beta-cell function evaluation is not able to predict the effectiveness of the combined treatment." | ( Borzi, V; Italia, S; Mazzarino, S; Squatrito, S; Tribulato, A; Trischitta, V; Vigneri, R, 1989) |
| "In 13 non-obese patients with Type 2 diabetes mellitus who failed to achieve adequate blood glucose control on dietary treatment (fasting blood glucose 13." | ( van Koetsveld, PM; Verschoor, L; Weber, RF; Weeks, L; Wolffenbuttel, BH, 1989) |
| "In conclusion, our data suggest that NIDDM subjects may benefit from therapeutic chronic administration of magnesium salts." | ( D'Onofrio, F; Paolisso, G; Passariello, N; Pizza, G; Sgambato, S; Varricchio, M, 1989) |
| "In this study, 55 NIDDM women on insulin therapy (mean age 28 +/- 8." | ( Abdella, N; Al-Muhtaseb, N; Al-Yusuf, AR; Fenech, F, 1989) |
| "Seven patients with NIDDM (age 51 +/- 4 yr, body mass index 28 +/- 2 kg/m2) were studied before and 3 wk after achieving normoglycemia with evening insulin therapy." | ( Helve, E; Nurjhan, N; Sane, T; Taskinen, MR; Yki-Järvinen, H, 1989) |
| "non-obese type 2 diabetes patients with fasting glucose levels above 10 mmol/l do not improve on dietary treatment alone; in obese type 2 diabetics weight reduction is essential and results in metabolic improvement, irrespective of the preceding fasting blood glucose concentrations." | ( Van Koetsveld, PM; Verschoor, L; Weber, RF; Wolffenbuttel, BH, 1989) |
| "10 patients with type 2 diabetes mellitus, in stable weight and diet therapy, followed a 2 months nutritional supplementation with guar, 15 g/day." | ( Biso, P; Capelli, M; Casimirri, F; Martelli, E; Melchionda, N; Pasquali, R, 1987) |
| "We suggest that treatment of type 2 diabetes mellitus with hypoglycemic sulfonylureas could improve insulin effects by inhibiting cellular transglutaminase activity." | ( Arroyo, J; Casamitjana, R; Casanovas, A; Coves, MJ; Gomis, R; Rivera, F; Sarto, A; Vilardell, E, 1988) |
| "It is concluded that patients with type 2 diabetes in whom oral therapy fails show favorable responses to insulin therapy." | ( Eero, H; Esko, N; Marja-Riitta, T; Yki-Järvinen, H, 1988) |
| "Healthy volunteers and NIDDM patients ingested a standard low-carbohydrate breakfast, and glibenclamide was administered 110-120 min later either as an intravenous bolus (12." | ( Efendić, S; Grill, V; Regitz, G, 1986) |
| "Present treatment of type II diabetes mellitus often fails to normalize post-prandial glucoses." | ( Abraira, C; Lawrence, AM; Reich, A, 1987) |
| "It is concluded that in NIDDM patients with second failure to glibenclamide ot glipizide therapy, the responsiveness to glibenclamide may be at least partially restored by a short period of insulin treatment." | ( Adamson, U; Lins, PE; Lundblad, S; Persson-Trotzig, E, 1988) |
| "In untreated NIDDM oral glucose induced a significant (p less than 0." | ( Arner, P; Bolinder, J, 1988) |
| "Furthermore, when the same patient with NIDDM was studied on two occasions, similar values for HGP were not uniformly obtained unless measurements were made at least 4 h after [3-3H] glucose administration." | ( Chen, YD; Jeng, CY; Juang, JH; Reaven, GM; Swislocki, AL, 1988) |
| "In the group of insulin-treated NIDDM multiple logistic regression analysis revealed the number of daily injected insulin units as a significant predictor for MVC and PVD (t = 1." | ( Janka, HU; Mehnert, H; Standl, E; Ziegler, AG, 1987) |
| "Once NIDDM is diagnosed in the older patient, the propensity for these patients to develop atherosclerotic vascular complications involving every organ system and the socioeconomic sequela of the disease make treatment prudent." | ( Coon, PJ; Goldberg, AP, 1987) |
| "We have assessed 22 patients with NIDDM who commenced insulin therapy in order to identify those characteristics which were associated with an improvement in glycaemic control." | ( Bruce, DG; Campbell, LV; Chisholm, DJ; Clark, EM, 1987) |
| "If the hyperglycemia of patients with type II diabetes mellitus is not corrected by diet and exercise, glyburide can be used as adjunctive therapy." | ( Feldman, JM, 1985) |
| "Since in NIDDM the protein-rich meal and meat extract ingestion produced an exaggerated rise in plasma PP while the PP responses to the intravenous arginine administration were rather impaired compared with normal subjects, we suggest that the entero-PP axis is overactive in NIDDM." | ( Imura, H; Kuzuya, H; Mori, K; Seino, S; Seino, Y; Takemura, J; Tsuda, K, 1983) |
| "After 3 mo of glyburide treatment in NIDDM, fasting plasma glucose declined from 198 to 141 mg/dl (P less than 0." | ( Barrett, E; Bevilacqua, S; Carlson, R; DeFronzo, RA; Ferrannini, E; Simonson, DC; Smith, D, 1984) |
| "The subjects comprised 25 patients with NIDDM, of which 12 cases and 13 cases were treated with gliclazide and glibenclamide respectively." | ( Abe, M; Ikeda, Y; Minami, N, 1983) |
| "In patients with NIDDM, we evaluated the effect of treatment with an oral hypoglycemic agent (glyburide) on [Ca2+]i levels, ATP content, and the phagocytosis of PMNLs." | ( Alexiewicz, JM; Klin, M; Kumar, D; Massry, SG; Smogorzewski, M, 1995) |
| "Twelve obese male NIDDM subjects were treated for 16 weeks with bedtime insulin after a 4-week sulfonylurea washout." | ( Comstock, JP; Cunningham, GR; Cusi, K, 1995) |
| "Intense stepped insulin therapy in NIDDM patients who have failed glycemic control on pharmacological therapy is effective in maintaining near-normal glycemic control for > 2 years without excessive severe hypoglycemia, weight gain, hypertension, or dyslipidemia." | ( Abraira, C; Colwell, JA; Comstock, JP; Emanuele, NV; Henderson, W; Lee, HS; Levin, SR; Nagel, NJ; Nuttall, FQ; Sawin, CT, 1995) |
| "Eighty NIDDM patients were randomized to treatment with either three preprandial doses of regular insulin (daytime group D) or a bedtime dose of NPH insulin (nocturnal insulinization, group N), both regimens being combined with 10." | ( Adamson, U; Arner, P; Bolinder, J; Landstedt-Hallin, L; Lins, PE, 1995) |
| "A total of 110 patients with NIDDM was randomly assigned to multiple insulin injection treatment group (MIT group) or to conventional insulin injection treatment group (CIT group)." | ( Araki, E; Furuyoshi, N; Isami, S; Kishikawa, H; Kojima, Y; Miyata, T; Motoyoshi, S; Ohkubo, Y; Shichiri, M, 1995) |
| "In 10 obese patients with NIDDM, we used a combination of isotope dilution, indirect calorimetry, bioimpedance, and tissue-balance techniques to assess the effects of metformin on systemic lactate, glucose, and free-fatty-acid turnover; lactate oxidation and the conversion of lactate to glucose; skeletal-muscle glucose and lactate metabolism; body composition; and energy expenditure before and after four months of treatment." | ( Dailey, G; Gerich, JE; Nurjhan, N; Perriello, G; Stumvoll, M, 1995) |
| "Studies were performed in NIDDM subjects 2 weeks after complete withdrawal of antidiabetic treatment and again after intensive insulin therapy." | ( Baron, AD; Brechtel, G; Denne, SC; Johnson, A; Liechty, EA, 1995) |
| "We conclude that (1) most of the NIDDM patients had esophageal motility disorders and (2) a 2-week oral erythromycin therapy can improve diabetic esophagoparesis, as evaluated by non-invasive REET." | ( ChangLai, SP; Kao, CH; Pan, DY; Tsai, SC; Wang, SJ, 1995) |
| "Thirty black NIDDM subjects who recently had developed near-normoglycemia were followed with no treatment or were randomly assigned to a 3-year, double-blind glipizide or placebo treatment." | ( Banerji, MA; Chaiken, RL; Lebovitz, HE, 1995) |
| "A total of 290 patients with NIDDM and fasting plasma glucose levels of at least 140 mg/dL were randomized to receive treatment TID with acarbose 200 mg, tolbutamide 250 to 1,000 mg, a combination of both drugs, or placebo." | ( Bray, GA; Coniff, RF; Seaton, TB; Shapiro, JA, 1995) |
| "Eight hypertensive patients with noninsulin dependent diabetes mellitus (NIDDM) were administered the experimental drug pyrazinoylguanidine (PZG) either alone or in combination with calcium-channel or beta-blockers." | ( Beyer, KH; Chambers, CE; Demers, LM; Passananti, GT; Seaton, TD; Vesell, ES, 1994) |
| "Forty-two NIDDM patients receiving glipizide therapy." | ( Bantle, JP; Brinkley, L; Chen, YD; Coulston, AM; Garg, A; Griver, KA; Grundy, SM; Henry, RR; Huet, BA; Raatz, SK, 1994) |
| "Fifty-five NIDDM subjects with normal BP or mild, untreated hypertension were randomized to treatment with the ACE-inhibitor fosinopril or placebo for 6 months in a randomized, double-blind trial to determine the effect of fosinopril on echocardiographic measurements." | ( Ellis-Pegler, EM; Gamble, GD; Greaves, SC; Holdaway, IM; Sanders, GA; Sharpe, N, 1994) |
| "Twenty-four NIDDM patients were treated with captopril and 18 with conventional drugs." | ( Campese, VM; Huang, TP; Liou, HH, 1995) |
| "21 patients with NIDDM that was well controlled using either glyburide or insulin therapy and with low-density lipoprotein (LDL) cholesterol levels more than 3." | ( Garg, A; Grundy, SM, 1994) |
| "Ninety-six NIDDM patients (35-70 years of age, body mass index [BMI] < or = 35), insufficiently treated with diet alone (HbA1c 7-9%) were randomized into three groups and treated for 24 weeks with acarbose, glibenclamide, or placebo." | ( Hoffmann, J; Spengler, M, 1994) |
| "Insulin treatment of patients with type 2 diabetes causes hyperinsulinaemia and improves glycaemic control." | ( Arnqvist, HJ; Lindström, T; Olsson, AG; von Schenck, H; Wallentin, L, 1994) |
| "Insulin treatment of patients with type 2 diabetes and secondary failure to oral hypoglycaemic agents causes hyperinsulinaemia and improves or has no unfavourable effect on several cardiovascular risk factors." | ( Arnqvist, HJ; Lindström, T; Olsson, AG; von Schenck, H; Wallentin, L, 1994) |
| "Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, during which they received either repaglinide or glibenclamide twice daily." | ( Kruseman, AC; Menheere, PP; Müller, PG; Nijst, L; Sels, JP; Wolffenbuttel, BH, 1993) |
| "An estimated 10-30% of patients with NIDDM withdraw from their prescribed regimen within 1 year of diagnosis, and of the remainder, nearly 20% administer insufficient medication to facilitate an adequate reduction in blood glucose." | ( Markowski, DJ; Sclar, DA; Skaer, TL; Won, JK, 1993) |
| "Thirty subjects with NIDDM; 17 on oral hypoglycemic agents; 13 untreated at study entry." | ( Gradman, TJ; Laws, A; Reaven, GM; Thompson, LW, 1993) |
| "Eight male subjects with untreated NIDDM ingested 25 g glucose, 25 g galactose with or without 25 g glucose, or 50 g lactose as a breakfast meal in random sequence." | ( Ercan, N; Gannon, MC; Nuttall, FQ; Redmon, JB; Sheridan, KJ, 1993) |
| "In subjects with NIDDM and impaired glucose tolerance, prospective studies have not shown a deleterious effect of insulin treatment per se, nor have they consistently shown a significantly increased risk for those with higher endogenous insulin levels." | ( Elliott, TG; Viberti, G, 1993) |
| "Seven male subjects with untreated NIDDM ingested 50 g CHO alone or 50 g CHO with 5, 15, 30, or 50 g fat as a breakfast meal." | ( Ercan, N; Gannon, MC; Nuttall, FQ; Westphal, SA, 1993) |
| "Patients with NIDDM (n = 7), IGT (n = 4), and matched nondiabetic controls (n = 5) were studied under three separate protocols that involved administration of glucose at either a constant rate of 6 mg/kg per min for 28 h or in one of two oscillatory patterns at the same overall mean rate." | ( O'Meara, NM; Polonsky, KS; Sturis, J; Van Cauter, E, 1993) |
| "Metabolic and hemodynamic index, including cardiac output estimation by impedance cardiography, were measured at baseline and at the end of each treatment period." | ( Chan, JC; Cockram, CS; Critchley, JA; Tomlinson, B; Walden, RJ, 1993) |
| "In normotensive NIDDM patients, treatment with metformin was associated with greater reductions in body weight, plasma total cholesterol concentration, and erect diastolic blood pressure, whereas the systemic vascular resistance index increased after treatment with glibenclamide." | ( Chan, JC; Cockram, CS; Critchley, JA; Tomlinson, B; Walden, RJ, 1993) |
| "Diet treatment of newly diagnosed Type 2 diabetes, with modest weight loss, results primarily in improvement of insulin secretory capacity, rather than insulin sensitivity." | ( Bhatnagar, D; Boulton, AJ; France, M; Gordon, C; Hosker, JP; Kumar, S, 1993) |
| "Thirty-eight subjects with NIDDM were treated with intensive conventional diabetes therapy after an initial metabolic evaluation and psychological and pharmacological testing." | ( Feinglos, MN; Lane, JD; McCaskill, CC; Ross, SL; Surwit, RS, 1993) |
| "Nondiabetic subjects and NIDDM patients who were withdrawn from sulfonylurea therapy had impaired insulin secretion during a 75-g oral glucose tolerance test, with similar basal levels as nondiabetic subjects (54 +/- 12 vs." | ( Kelley, DE; Mandarino, LJ; Mokan, M, 1993) |
| "We studied 5 untreated NIDDM patients in a meal study (Ensure, 240 ml/M2) and a 2-h hyperglycemic glucose clamp study (glucose 5." | ( Bryer-Ash, M; Elahi, D; Meneilly, GS, 1993) |
| "Progression of NIDDM may be responsible for the development of secondary sulfonylurea failure in NIDDM patients treated with oral sulfonylurea drugs." | ( Cook, DD; Ewing, RC; Rae, CE, 1993) |
| "Six patients with type 2 diabetes underwent detailed metabolic studies before and after a minimum of 3 months' glibenclamide therapy." | ( Baynes, C; Elkeles, RS; Henderson, AD; Johnston, DG; Richmond, W, 1993) |
| "Nine patients with Type 2 diabetes receiving insulin therapy were treated with acarbose 100 mg thrice daily for 1 week to investigate the effect of acarbose on blood glucose control." | ( Haga, T; Hotta, N; Kakuta, H; Koh, N; Okuyama, M; Sakakibara, F; Sakamoto, N; Sano, T, 1993) |
| "The treatment of Type II diabetes (NIDDM) includes an appropriate diet and prudent exercise program." | ( Josse, RG, 1995) |
| "In 14 male patients with NIDDM, treated with either diet alone (n = 6) or diet plus insulin, (mean age 59 years) and 14 age-pair-matched control subjects, forearm skin perfusion following multiple doses of iontophoretically applied 1% acetylcholine and 0." | ( Morris, SJ; Shore, AC; Tooke, JE, 1995) |
| "Seven male subjects with untreated NIDDM were studied after an 11-hour overnight fast." | ( Fang, S; Gannon, MC; Gupta, V; Lane, JT; Nuttall, FQ; Sandhofer, CR, 1996) |
| "Sixty-two normotensive patients with Type 2 diabetes mellitus and microalbuminuria but normal renal function were randomized to receive either enalapril 5 mg day-1 or no treatment." | ( Chaya, S; Hara, T; Hotta, N; Kawamura, T; Matsumae, H; Matsuo, S; Nakayama, M; Sakamoto, N; Sano, T; Sasaki, H, 1996) |
| "Ten obese patients with NIDDM were studied before and after 8 weeks of treatment with a weight-maintaining diet in combination with the sulphonylurea gliclazide." | ( Bjørbaek, C; Lund, S; Pedersen, O; Vestergaard, H, 1995) |
| "A total of 135 Caucasian NIDDM subjects treated with oral therapy or diet alone were classified by the presence or absence of retinopathy, and fasting blood samples were taken for assay of PAI-1 antigen and activity, tissue plasminogen activator (t-PA), t-PA complexed with PAI-1, euglobulin clot lysis time (a measure of overall fibrinolytic activity), glucose, HbA1c, cholesterol, triglyceride, and insulin levels." | ( Grant, PJ; Mansfield, MW, 1995) |
| "We conducted a prospective study of 23 NIDDM patients (11 with normoalbuminuria and 12 with microalbuminuria) receiving standard clinical care, including antihypertensive treatment, attending the outpatient clinic and 8 healthy control subjects." | ( Hansen, KW; Mogensen, CE; Nielsen, S; Poulsen, PL; Schmitz, A, 1995) |
| "Of the poorly controlled female NIDDM patients on sulfonylurea treatment, 18 were randomly selected from the outpatient diabetic clinic for study." | ( Adalar, N; Bayraktar, M; Van Thiel, DH, 1996) |
| "A total of 13 patients with NIDDM were studied before and after treatment with glipizide gastrointestinal therapeutic system (GITS) in a randomized double-blind placebo-controlled fashion." | ( Albert, SG; Bernbaum, M; Mooradian, AD; Plummer, S, 1996) |
| "Thirty NIDDM patients, in ideal metabolic control, who were being treated with GL-PHEN were divided in two groups." | ( Halvatsiotis, PG; Raptis, AE; Raptis, SA; Tountas, NB; Yalouris, AG, 1996) |
| "The study included 55 subjects with NIDDM who manifested secondary failure to first-generation sulfonylurea therapy." | ( Kabadi, UM; Moshiri, S; Sami, T, 1996) |
| "The results suggest that in NIDDM hypertriglyceridemia should be treated to reduce the high risk for atherosclerosis." | ( Hoogerbrugge, N; Jacobs, ML; Jongkind, JF; Postema, PT; Verkerk, A, 1996) |
| "Many facets of Type 2 diabetes, therefore, could be envisaged as a consequence of a lack of GLP-1 effects; they appear to be corrected by the exogenous administration of this gut peptide in short-term experiments." | ( Nauck, M, 1996) |
| "Of the previously treated NIDDM patients, 416 entered this multicenter randomized double-blind placebo-controlled fixed-dose study." | ( Muchmore, DB; Rosenstock, J; Samols, E; Schneider, J, 1996) |
| "At this time in the natural history of NIDDM, evening insulin combined therapy is more effective than a single injection of insulin alone, and just as effective as a more complex multiple-injection regimen without an oral agent." | ( Riddle, MC, 1996) |
| "We studied 20 NIDDM subjects and 8 nondiabetic controls in a randomized, double blind, placebo-controlled trial to determine the effect of 15 weeks of treatment with metformin or placebo on glucose and lactate metabolism." | ( Consoli, A; Cusi, K; DeFronzo, RA, 1996) |
| "1-year treatment of NIDDM patients with ramipril or atenolol does not influence metabolic control, the changes in serum lipids were similar." | ( Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C, 1996) |
| "Nine patients with NIDDM and 9 healthy subjects received 4 single-blind single-dose treatments of metformin HCL (850 mg, 1,700 mg, 2,550 mg, and placebo) and a multiple-dose treatment of 850 mg metformin HCL (3 times daily for 19 doses)." | ( Benet, LZ; Chiang, J; Goodman, AM; Karam, JH; Lin, ET; Liu, CY; O'Conner, M; Sambol, NC, 1996) |
| "In patients with Type 2 diabetes mellitus, in which residual endogenous insulin secretion is common, characterization of the disease may help in the choice of therapy for the individual patient (insulin, sulphonylureas or combined therapy)." | ( Castillo, MJ; Lefèbvre, PJ; Scheen, AJ, 1996) |
| "The treatment of NIDDM patients with secondary failure to sulfonylureas is still a debated problem." | ( Condorelli, L; Cordaro, G; Grasso, G; Lunetta, M; Rabuazzo, MA; Sangiorgio, L, 1996) |
| "Patients with NIDDM were divided in the groups according to: sex, duration of disease, a kind of complications and a way of treatment." | ( Knapik-Kordecka, M; Piwowar, A; Warwas, M, 1996) |
| "The observed erythrocyte LPO in NIDDM decreased after a short-term adaptive insulin therapy." | ( Clerc, M; Couchouron, A; Delmas-Beauvieux, MC; Dubourg, L; Gin, H; Perromat, A; Peuchant, E; Thomas, MJ, 1997) |
| "Subjects with NIDDM were administered either aspirin (100 mg/day) or a combination of basic amino acids consisting of L-arginine (2 g/day) plus L-lysine (0." | ( Blanco, MC; Camejo, M; Contreras, I; Giansante, E; Gonzalez, F; Lopez, T; Martinez, N; Molina, M; Postalian, S; Reiser, KM; Sanchez, MR; Suarez, N, 1997) |
| "The case notes of metformin-treated NIDDM patients (mean age 62 years) attending a United Kingdom university hospital diabetes clinic over a 3-month period were reviewed according to criteria reflecting a pragmatic view of current prescribing recommendations." | ( Bosman, D; Krentz, AJ; Sulkin, TV, 1997) |
| "Routine lifestyle treatments for NIDDM may be continued during ongoing use of this agent." | ( McDaniel, PA; Riddle, MC; Tive, LA, 1997) |
| "Twelve patients with NIDDM and secondary failure were studied on oral agents and then switched to insulin treatment." | ( Arnqvist, HJ; Leckström, A; Lindström, T; Westermark, P, 1997) |
| "Conventional treatment of obese noninsulin dependent diabetes mellitus (NIDDM) patients is often unsatisfactory." | ( Brooks, BA; Burns, CM; Capstick, F; Steinbeck, KS; Yue, DK; Zilkens, RR, 1997) |
| "A total of 118 non insulin dependent diabetes mellitus (NIDDM) patients treated with diet/oral drugs and having a HbA(1c) level < 7." | ( Acosta, D; Astorga, R; García de Pesquera, F; Losada, F; Morales, F; Pumar, A; Relimpio, F, 1997) |
| "Sera were collected from 40 NIDDM patients, who had history of secondary failure to treatment with sulfonylurea, for analysis of fasting c-peptide and GAD-Ab." | ( Aguilar Diosdado, M; Rattarasarn, C; Soonthornpun, S, 1997) |
| "Sixteen NIDDM patients (4 patients treated with diet therapy alone and 12 receiving a sulfonylurea) were given 0." | ( Emoto, M; Inaba, M; Ishimura, E; Kawagishi, T; Morii, H; Nishizawa, Y; Okuno, Y; Tanaka, S; Taniwaki, H, 1997) |
| "A total of 23, diet-treated, NIDDM subjects received either TR, 200 mg once daily (n = 11) or placebo (PL) (n = 12) for 45 days." | ( Eastmond, R; Foot, EA, 1997) |
| "Individuals being treated for type 2 diabetes (180 men and women) were divided randomly into three groups and supplemented with: 1) placebo, 2) 1." | ( Anderson, RA; Bryden, NA; Cheng, N; Chi, J; Feng, J; Polansky, MM, 1997) |
| "Hypertensive NIDDM subjects were treated for 3 months with captopril, nifedipine, or doxazosin." | ( Canessa, ML; Castellino, P; DeFronzo, RA; Giordano, M; Solini, A, 1997) |
| "Subjects with NIDDM in four treatment strata: 77 on diet alone, 83 also treated with metformin, 103 also treated with sulfonylurea and 91 also treated with insulin." | ( Chiasson, JL; Hunt, JA; Josse, RG; Palmason, C; Rodger, NW; Ross, SA; Ryan, EA; Tan, MH; Wolever, TM, 1997) |
| "In subjects with NIDDM on weight-maintaining diets, long-term acarbose therapy results in a small weight loss, but has no effect on energy or nutrient intakes." | ( Chiasson, JL; Hunt, JA; Josse, RG; Palmason, C; Rodger, NW; Ross, SA; Ryan, EA; Tan, MH; Wolever, TM, 1997) |
| "Meanwhile we observed that UAE of early NIDDM was increased before treatment." | ( Gan, P; Han, Q; Li, J; Xiao, X; Yu, M, 1996) |
| "Ninety-six patients with NIDDM (35-70 years of age, body mass index (BMI) < or = 35 kg/m2, insufficiently treated with diet alone, glycated hemoglobin (HbA1c; 7% to 11%) were randomized into 3 groups and treated for 24 weeks with acarbose, 3 x 100 mg/day, or metformin, 2 x 850 mg/day, or placebo." | ( Hoffmann, J; Spengler, M, 1997) |
| "458 patients with newly diagnosed type 2 diabetes that could not be controlled with diet and had hyperglycemic symptoms or fasting plasma glucose levels greater than 15 mmol/L during the initial 3 months of diet therapy (primary diet failure group) and 1620 patients in whom disease was controlled by diet therapy and who had fasting plasma glucose levels of 6 to 15 mmol/L and no hyperglycemic symptoms while receiving diet therapy alone." | ( , 1998) |
| "In gliclazide-treated NIDDM patients, PDH activity in circulating lymphocytes recovered." | ( Bruno, R; Curto, M; Gamba, S; Mioletti, S; Mostert, M; Piccinini, M; Rabbone, I; Rinaudo, MT, 1998) |
| "GLP-1 lowers blood glucose in both NIDDM and IDDM patients and may be therapeutically useful for treatment of patients with diabetes." | ( Drucker, DJ, 1998) |
| "Some patients with type 2 diabetes present with ketoacidosis and require insulin treatment." | ( Goldberg, RB; Machado, R, 1998) |
| "Twelve diet-treated NIDDM women with obesity were randomly given two dose levels (850 mg or 1700 mg) of metformin or placebo at 0800 for three consecutive days followed by a meal test on the third day on three occasions using a 3x3 Latin square design." | ( Lee, A; Morley, JE, 1998) |
| "Nine obese patients with type 2 diabetes were treated with a monounsaturated fatty acid (MUFA)-enriched weight-reducing formula diet and compared with eight obese patients with type 2 diabetes treated with a low-fat, high-CHO weight-reducing formula diet." | ( Gumbiner, B; Low, CC; Reaven, PD, 1998) |
| "An additional 4 Hispanic children with type 2 diabetes treated in other clinics were also identified, yielding a total of 21 subjects who were used to describe the characteristics of childhood type 2 diabetes." | ( Chen, YD; Landon, C; Neufeld, ND; Raffel, LJ; Vadheim, CM, 1998) |
| "In this study nine patients with Type 2 diabetes mellitus were subjected to four treatments in random order on separate days: (A) endurance exercise after the administration of 3." | ( Bungert, S; Gudat, U; Heinemann, L; Kemmer, F, 1998) |
| "Gliclazide administration to NIDDM patients inhibits the increased adhesiveness of diabetic monocytes to endothelial cells and reduces the production of TNF-alpha by these cells." | ( Desfaits, AC; Renier, G; Serri, O, 1998) |
| "Before treatment, the hemodynamic and rheologic responses to L-arginine were significantly lower in patients (P < 0." | ( Acampora, R; Coppola, L; D'Onofrio, F; Giugliano, D; Giunta, R; Marfella, R, 1998) |
| "We studied 128 patients with type 2 diabetes (32 men, 96 women, aged 30-69 years), treated by diet or diet plus oral antidiabetic drugs, in the Bahia Federal University Hospital, Brazil." | ( Barbosa, K; Canguçu, V; Cruz, T; de Lordes Lima, M; Pousada, JC; Rodrigues, LE, 1998) |
| "Initiation of insulin therapy in type 2 diabetes improves glycemic control effectively, has little influence on physical and psychological well-being dimensions, and does not affect treatment satisfaction." | ( Colly, LP; de Sonnaville, JJ; Devillé, W; Heine, RJ; Snoek, FJ; Wijkel, D, 1998) |
| "In the NIDDM group, the ratio of insulin treatment tended to be higher in subjects homozygous for the G3 allele, although the genotype was not significantly associated with basal C-peptide levels." | ( Hayashi, H; Ichikawa, F; Ishiyama, S; Kohno, S; Nonaka, K; Shoji, S; Yamada, K; Yuan, X, 1998) |
| "Thirty seven patients with type 2 diabetes mellitus taking insulin for at least 1 year prior to study and treated with > or = 40 U of insulin per day were recruited for a randomized, double-blind, placebo-controlled, crossover trial." | ( Bursey, DL; DeAtkine, DD; English, JS; Feinglos, MN; Lobaugh, B; McNeill, DB; Thacker, CR, 1998) |
| "As IDDM and non-obese NIDDM presented great similarities before treatment, even for C-peptide levels, a point score system is proposed to classify these two groups at baseline." | ( Cuisinier-Raynal, JC; Darrack, R; Delcourt, C; Lokrou, A; Papoz, L; Ponton-Sanchez, A; Touré, IA, 1998) |
| "3867 newly diagnosed patients with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment had a mean of two fasting plasma glucose (FPG) concentrations of 6." | ( , 1998) |
| "In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks." | ( , 1998) |
| "In the treatment of type 2 diabetes (NIDDM) we possess three groups of oral hypoglycaemic drugs: sulfonyl urea derivatives, biguanides (metformin) and alpha-glucosidase (acarbose) inhibitors." | ( Perusicová, J, 1998) |
| "These results indicated that in obese Type 2 diabetes, 30 min of low intensity bicycle exercise significantly enhances the lower level of insulin-induced glucose uptake shortly after exercise and might be useful for the treatment of post-prandial hyperglycemia." | ( Asai, K; Iriyama, A; Kakumu, S; Kusunoki, M; Okabayashi, N; Sakakibara, H; Sato, Y; Usui, K; Yajima, M; Yamanouchi, K, 1998) |
| "Metformin is a biguanide used to treat type II diabetes mellitus." | ( Gilbert, FJ; McCartney, MM; McHardy, K; Murchison, LE; Murray, AD; Pearson, D, 1999) |
| "Six late dumping patients with NIDDM were orally administered alpha-glucosidase inhibitor, acarbose (50 or 100 mg), three times a day before each meal for 1 month." | ( Harada, H; Hasegawa, T; Kyouda, T; Makino, I; Nakamura, K; Ohnishi, K; Yoneda, M; Yoshida, Y, 1998) |
| "Six male NIDDM patients (N) and six male controls (C) of similar age, body weight, % body fat, and VO2peak were studied in two experimental sessions administered in a randomized counterbalanced order." | ( Dasilva, SG; Goss, FL; Kang, J; Kelley, DE; Robertson, RJ; Suminski, RR; Utter, AC, 1999) |
| "The treatment of NIDDM patients with secondary failure to sulphonylurea is a common problem." | ( Anello, M; Guardabasso, V; Italia, S; Licciardello, C; Mazzarino, S; Raimondo, M; Runello, F; Sangiorgi, L; Trischitta, V; Vigneri, R, 1998) |
| "The short-term IIT in patients with NIDDM and secondary failure to SU is effective in reducing hyperglycaemia, and in most of them makes possible to continue the oral antidiabetic treatment with SU." | ( Jedynasty, K; Kasperska-Czyzykowa, T; Nowaczyk, R; Stepień, K, 1998) |
| "Subjects with type 2 diabetes treated with diet or sulfonylureas (n = 54) were enrolled in a 20-week behavioral weight control program." | ( Considine, RV; Lang, W; Mullen, M; Williams, KV; Wing, RR, 1999) |
| "Twenty-five postmenopausal women with NIDDM were treated with 2 mg of 17-beta-oestradiol orally for 3 months in a double-blind, crossover, placebo-controlled trial." | ( Andersson, B; Hahn, L; Mattsson, LA; Tengborn, L, 1999) |
| "Individuals with type 2 diabetes mellitus (n = 105; age 36-71 years) on diet therapy alone, and with quite good glycaemic control (mean HbA1c approximately 7." | ( Bowen, K; Campbell, L; Lintott, CJ; Scott, R; Welborn, T; Zimmet, P, 1999) |
| "Treatment of type 2 diabetes mellitus with metformin from diagnosis also offers greater protection against the chronic vascular complications of type 2 diabetes mellitus." | ( Bailey, CJ; Howlett, HC, 1999) |
| "43 patients with poorly controlled type 2 diabetes who were receiving insulin therapy." | ( Avilés-Santa, L; Raskin, P; Sinding, J, 1999) |
| "Forty patients with type 2 diabetes mellitus who were on conventional insulin therapy (subcutaneous insulin therapy consisting of regular and NPH insulin, two times a day) were included in the study." | ( Gedik, O; Güvener, N, 1999) |
| "Renal haemodynamics was examined at the end of the treatment." | ( Fujimura, A; Sugimoto, K; Tsuruoka, S, 1999) |
| "Thirteen patients with type 2 diabetes, on combined insulin and glibenclamide treatment, were studied during hypoglycaemia, and eight of them participated in the euglycaemic experiment." | ( Adamson, U; Englund, A; Landstedt-Hallin, L; Lins, PE, 1999) |
| "We aimed to examine the survival in NIDDM patients with IHD using various types of oral antidiabetic treatments over a 5-year follow-up period." | ( Behar, S; Benderly, M; Fisman, EZ; Goldbourt, U; Motro, M; Tenenbaum, A, 1999) |
| "Thirty-one NIDDM patients with poor control were administered troglitazone 400 mg/day." | ( Itoh, Y; Miyashita, Y; Murano, T; Sasaki, H; Shirai, K; Totsuka, M; Watanabe, H, 1999) |
| "Oral therapy for early type 2 diabetes can be relatively inexpensive, and evidence of its cost-effectiveness is accumulating." | ( Riddle, MC, 1999) |
| "Thirty-nine hypertensive patients with type 2 diabetes mellitus were followed under long-term treatment (mean, 20." | ( Fujita, R; Hayashi, Y; Inoue, M; Iwamoto, Y; Kageyama, S; Kitamura, S; Makino, F; Okuda, Y; Shiba, T; Tada, H; Takahasi, C, 2000) |
| "Despite the high prevalence of type 2 diabetes, existing treatment strategies often fail." | ( Caro, JJ; Copley-Merriman, C; Flegel, KM; Kavanagh, PL; Klittich, WS; O'Brien, JA; Raggio, G; Shomphe, LA; Sigler, C, 2000) |
| "Patients had poorly controlled type 2 diabetes mellitus despite glyburide therapy." | ( Caro, JJ; Copley-Merriman, C; Flegel, KM; Kavanagh, PL; Klittich, WS; O'Brien, JA; Raggio, G; Shomphe, LA; Sigler, C, 2000) |
| "A total of 898 men and women with type 2 diabetes mellitus and hypertension, receiving antihypertensive treatment with one single drug and whose BP was > 140 and/or 90 mmHg." | ( Coca, A; de la Cámara, AG; de la Figuera, M; de la Sierra, A; Fernández, R; Garrido, J; Luque-Otero, M; Moreno, E; Ruilope, LM, 1999) |
| "As insulin secretion is impaired in type 2 diabetes, we explored whether exogenous administration of this peptide exerts antidiabetogenic action." | ( Ahrén, B; Efendic, S; Holst, JJ, 2000) |
| "Current agents for the treatment of Type 2 diabetes mellitus improve the metabolic profile but do not reinstate normality." | ( Bailey, CJ; Nattrass, M, 1999) |
| "13 subjects with type 2 diabetes mellitus were treated with diet and placebo for 4 weeks and then randomized to one of two treatments: ciprofibrate 100 mg or placebo for four weeks." | ( Ascaso, JF; Carmena, R; Hernández-Mijares, A; Lluch, I; Martínez-Triguero, ML; Vizcarra, E, 2000) |
| "Hypercholesterolaemic patients with type 2 diabetes had a significant reduction in LDL cholesterol and total cholesterol concentrations after cerivastatin treatment once daily." | ( Chajek-Shaul, T; Maislos, M; Maritz, FJ; Markel, A; Rubinstein, A; Soule, SG; Stolero, D; Tal, S, 1999) |
| "Forty-seven patients with type 2 diabetes mellitus were randomly treated for 4 weeks with glibenclamide (n = 23) or troglitazone (n = 24)." | ( Kato, K; Midorikawa, S; Sato, W; Watanabe, T; Yamada, D, 2000) |
| "Seven healthy nonsmoking subjects with type 2 diabetes were studied before and after completion of 3 months of troglitazone (400 mg/day) therapy." | ( Cline, GW; Dufour, S; Inzucchi, S; Krssak, M; Petersen, KF; Shulman, GI, 2000) |
| "Patients with type 2 diabetes who were treated previously with insulin or oral hypoglycemic agents and who had a glycosylated hemoglobin (HbA1c) level >9% or a fasting blood glucose level >8 mmol/L were included." | ( Bets, D; Elte, JW; Lehert, P; Ponssen, HH; Schouten, JP, 2000) |
| "A total of 6 patients with type 2 diabetes were studied with 4-h isoglycemic-hyperinsulinemic clamps (approximately 8 mmol/l and 500-600 pmol/l, respectively) before treatment (Prestudy), after 3 weeks of thalidomide (150 mg orally at bedtime), and after 3 weeks of placebo." | ( Boden, G; Iqbal, N; Zayed, M, 2000) |
| "One hundred eleven untreated Japanese NIDDM subjects (fasting glucose < 10 mmol/L) were assessed for insulin action (homeostasis model assessment [HOMA-IR] = fasting serum insulin (microU/mL) x fasting plasma glucose (mmol/L)/22." | ( Arakawa, H; Doi, K; Fukushima, M; Kataoka, K; Nagasaka, S; Nagata, I; Nakai, Y; Sakai, M; Taniguchi, A; Tokuyama, K, 2000) |
| "We enrolled 340 NIDDM outpatients adjusted for sex, age, body mass index, alcohol intake and oral treatment regimen with glibenclamide." | ( D'Anchino, M; Della Loggia, F; Della Vecchia, R; Formisano, S; Guagnano, MT; Merlitti, D; Pace-Palitti, V; Sensi, S, 2000) |
| "A rational approach to therapy in a type 2 diabetes patient who fails to sufficiently lower blood sugar with diet and weight loss is to begin therapy with a sulfonylurea or metformin and to add another oral agent if the desired glycaemic control is not achieved." | ( Janssen, JA, 2000) |
| "The use of sulphonylureas for type 2 diabetes has been debated since 1970, when the University Group Diabetes Program (UGDP) reported increased cardiovascular mortality with tolbutamide treatment." | ( Asvold, BO; Grill, V; Jonsbu, M, 2000) |
| "Sixty patients with type 2 diabetes with acceptable glycemic control and an HDL cholesterol level > or = 1 mmol/l were recruited after cessation of lipid-altering treatments." | ( Benhamou, PY; Boizel, R; Foulon, T; Halimi, S; Laporte, F; Lardy, B, 2000) |
| "Six mild NIDDM subjects and six mild hypercholesterolemic subjects were treated with the powder of roots of W." | ( Andallu, B; Radhika, B, 2000) |
| "Recent advances in type 2 diabetes therapy have seen the development of the thiazolidinediones (troglitazone, rosiglitazone, and pioglitazone), which improve insulin resistance in patients whose diabetes is poorly controlled by diet and exercise therapy." | ( Reasner, CA, 1999) |
| "Ten male subjects with untreated type 2 diabetes were given, in random sequence, 50 g protein in the form of very lean beef or only water at 0800 h and studied over the subsequent 8 h." | ( Damberg, G; Gannon, MC; Gupta, V; Nuttall, FQ; Nuttall, JA, 2001) |
| "A 68-year-old woman, with type 2 diabetes mellitus, hypercholesterolemia, and prior long-term simvastatin therapy, self-resumed troglitazone after running out of metformin." | ( Caldwell, SH; Hespenheide, EE; von Borstel, RW, 2001) |
| "Subjects with diet-treated type 2 diabetes but without the confounding collection of cardiovascular risk factors seen in the metabolic syndrome were treated with metformin 500 mg twice daily (n = 29) or placebo (n = 15) for 12 weeks." | ( Anderson, TJ; Mather, KJ; Verma, S, 2001) |
| "A total of 54 patients with Type 2 diabetes were treated for 4 weeks with either diet alone, sulphonylurea or insulin." | ( Matsumoto, K; Miyake, S; Nakamura, H; Tominaga, T; Ueki, Y, 2001) |
| "In the treatment of our patients with Type 2 diabetes, drugs like rosiglitazone which directly reduce insulin resistance are very welcome but more data on its combined use with insulin are needed." | ( Huijberts, MS; Sels, JP; Wolffenbuttel, BH, 2001) |
| "Medications used to treat type 2 diabetes are designed to correct one or more of these metabolic abnormalities." | ( Feinglos, MN; Luna, B, 2001) |
| "Classification for probable type 2 diabetes was based on weight per age > or =85th percentile or presence of acanthosis nigricans at diagnosis, elevated C-peptide or insulin, family history for type 2 diabetes, or use of oral hypoglycemic agents with or without insulin or absence of current treatment 1 year after diagnosis." | ( Fagot-Campagna, A; Gohdes, D; Harwell, TS; Helgerson, SD; McDowall, JM; Moore, K, 2001) |
| "A major goal in the treatment of type 2 diabetes is to maintain blood glucose values in the normal or near normal range." | ( Cunningham, MA, 2001) |
| "A new approach to the treatment of type 2 diabetes are thiasolinediones, insulin-sensitizing substances, the molecular basis of their action being via activation of PPAR gamma-nuclear receptors with subsequent change in expression of genes participating in carbohydrate and lipid metabolism." | ( Rybka, J, 2001) |
| "Patients with type 2 diabetes and mild or moderate impairment of renal function may be treated with repaglinide without special precautions." | ( Abbasi, I; Hasslacher, C; Hatorp, V; Sattler, K; Schumacher, S; Sieber, J; Weise, D, 2001) |
| "Seven obese patients with type 2 diabetes were treated with troglitazone (400 mg/day) for 4 weeks." | ( Aljada, A; Assian, E; Dandona, P; Garg, R; Ghanim, H; Hamouda, W; Mohanty, P, 2001) |
| "We studied 53 patients with type 2 diabetes, 23 treated with diet alone and 30 treated with sulfonylureas, who had normal renal function." | ( Aso, Y; Fujiwara, Y; Inukai, T; Takanashi, K; Takemura, Y; Tayama, K, 2001) |
| "In conclusion, in long-standing type 2 diabetes the acute administration of gliclazide significantly enhances second phase insulin release at a moderately elevated blood glucose level." | ( Ligtenberg, JJ; Reitsma, WD; van Haeften, TW, 2001) |
| "In 2504 unselected patients with type 2 diabetes mellitus (mean age 63+/-10 years) blood pressure, cardiovascular, renal, and metabolic parameters were assessed at baseline and during a treatment period of 1 year with the ACE inhibitor cilazapril by primary care physicians." | ( Delles, C; Hilgers, KF; Schmieder, RE; Veelken, R, 2001) |
| "Diet or tablet-treated patients with Type 2 diabetes (n = 256; age 40-75 years, body mass index (BMI) 20-35 kg/m2, HbA1c 4." | ( Dejgaard, A; Kilhovd, B; Lager, I; Madsbad, S; Mustajoki, P, 2001) |
| "Treatment of hypertensive patients with Type 2 diabetes using atenolol or captopril was equally effective." | ( Adler, A; Clarke, P; Cull, C; Gray, A; Holman, R; Neil, A; Raikou, M; Stevens, R; Stratton, I, 2001) |
| "Of 770 patients with Type 2 diabetes, 44% were treated with UDP support, 29% by their GPs alone, and 27% at out-patient clinics." | ( Blankestijn, JG; de Valk, HW; Maaijen, J; Rutten, GE; Valkenburg, AC, 2001) |
| "Seventy-five subjects with type 2 diabetes, treated only with oral agents, were recruited for this 12-week clinical study." | ( Bellman, M; DeShields, S; Elashoff, R; Go, VL; Heber, D; Murray, S; Saltsman, P; Thames, G; Wang, HJ; Yip, I, 2001) |
| "Hypertension often complicates type 2 diabetes mellitus, and angiotensin converting enzyme inhibitor treatment has been shown to improve insulin resistance in such cases." | ( Ebina, Y; Houchi, H; Ishizawa, K; Kishi, K; Minakuchi, K; Nakaya, Y; Takishita, E; Tamaki, T; Tsuchiya, K; Yoshizumi, M, 2001) |
| "A 45-year-old man with well-controlled type 2 diabetes mellitus experienced an abrupt worsening of his diabetes after 3 years of olanzapine therapy His hemoglobin A1c (HbA1c) level rose from a baseline of 5." | ( Bechara, CI; Goldman-Levine, JD, 2001) |
| "For most patients with type 2 diabetes, Niaspan is a safe and effective therapy for dyslipidemia and does not exacerbate glycemic control." | ( Addesse, E; Bakst, G; Busch, RS; Hamilton, RA; Kane, MP, 2001) |
| "The treatment of type 2 diabetes and insulin resistance in obese or non-obese subjects should therefore aim at normalising fatty acid fluxes because this can be expected to enhance insulin action and ameliorate the atherogenic lipoprotein abnormalities." | ( Camejo, G; Ljung, B; Oakes, N, 2001) |
| "Thus, in patients with Type II diabetes mellitus, treatment with glibenclamide is associated with an attenuated response to K(ATP) opening as compared with treatment with acarbose." | ( Abbink, EJ; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ; van Rosendaal, AJ, 2002) |
| "Therefore, glibenclamide treatment of Type 2 diabetes mellitus may have hazardous cardiovascular effects when used under conditions of ischaemia." | ( Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ, 2002) |
| "Two groups of 12 Type 2 diabetes mellitus patients participated in a double-blind randomized cross-over study consisting of two 8-week periods, in which treatment with orally administered glibenclamide (15 mg/day) was compared with either glimepiride or metformin (6 mg and 1500 mg/day, respectively)." | ( Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ, 2002) |
| "Chronic treatment of Type 2 diabetes mellitus with glimepiride or metformin has similar effects on vascular K(ATP) channels compared with chronic glibenclamide treatment." | ( Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ, 2002) |
| "For patients with type 2 diabetes in whom maximal sulfonylurea therapy failed, the addition of the insulin sensitizer troglitazone seemed to have greater benefits on several traditional and novel CVRF than metformin therapy." | ( Armstrong, D; Baxi, S; Caulfield, M; Chu, NV; Deutsch, R; Henry, RR; Kim, DD; Kong, AP; Mudaliar, SR; Reaven, PD; Reitz, R, 2002) |
| "GLP-1 could be a new treatment for type 2 diabetes, though further investigation of the long-term effects of GLP-1 is needed." | ( Holst, JJ; Madsbad, S; Madsen, JL; Zander, M, 2002) |
| "In patients with type 2 diabetes, pioglitazone as monotherapy and in combination with sulfonylureas or an alpha-glucosidase inhibitor significantly reduced fasting blood glucose, HbA1c, triglycerides, and free fatty acids, and significantly increased HDL-cholesterol." | ( Baba, S, 2001) |
| "Fifty patients with type 2 diabetes on regular Gb therapy (1." | ( Hallengren, B; Jönsson, A; Melander, A; Rydberg, T, 2001) |
| "Obese and overweight type 2 diabetes patients treated with insulin for at least 1 year, and with poor glycaemic control (HbA1c > upper reference level + 2%), were included in a randomised, double-blind, placebo-controlled study." | ( Hermann, LS; Kalén, J; Katzman, P; Lager, I; Nilsson, A; Norrhamn, O; Sartor, G; Ugander, L, 2001) |
| "Intensive insulin treatment in type 2 diabetes can improve beta-cell function." | ( Andersson, G; Efendic, S; Grill, V; Kärvestedt, L, 2002) |
| "Poorly controlled patients with type 2 diabetes may have moderate elevations of serum ALT that will decrease with improved glycemic control during treatment with rosiglitazone or other antihyperglycemic agents." | ( Freed, MI; Kreider, M; Lebovitz, HE, 2002) |
| "Prospective trials in patients with type 2 diabetes that lasted longer than one month were included if they evaluated metformin, alone or in combination with other treatments, compared to placebo or any other glucose-lowering therapy." | ( Greyber, E; Pasternak, G; Salpeter, E; Salpeter, S, 2002) |
| "Insulin treatments in subjects with type 2 diabetes had no effect on muscle mitochondrial protein synthesis and cytochrome C oxidase, a key enzyme for ATP production." | ( Bigelow, M; Halvatsiotis, P; Nair, KS; Short, KR, 2002) |
| "Seven male subjects with untreated type 2 diabetes were given 50 g protein in the form of very lean beef at 8 AM after an overnight fast." | ( Gannon, MC; Jones, SA; Nuttall, FQ; Saeed, A, 2002) |
| "Patients aged over 34 years with Type 2 diabetes who had at least 6 months exclusive therapy with OHAs (sulphonylureas or metformin) prior to insulin treatment were identified." | ( Donnan, PT; Evans, JM; Morris, AD, 2002) |
| "Post-menopausal women with Type 2 diabetes (n = 61) were randomized in a double-blind fashion to receive either continuous combined hormone replacement therapy (n = 29) with conjugated equine oestrogen (0." | ( Allum, AR; de Jong, SA; Jones, SD; Manning, PJ; Sutherland, WH, 2002) |
| "Management of type 1 and type 2 diabetes mellitus with intensive insulin therapy usually includes an intermediate- or long-acting basal component for between-meal and nocturnal glycemic control, together with preprandial bolus injections of a short-acting insulin for control of meal-stimulated increases in serum glucose levels." | ( Gerich, JE, 2002) |
| "For this purpose, 22 patients with type 2 diabetes and combined dyslipidemia were randomized to treatment with either a statin or gemfibrozil for 3 months." | ( Abbasi, F; Lamendola, C; Leary, E; McLaughlin, T; Reaven, GM, 2002) |
| "In patients with type 2 diabetes, mealtime administration of the human amylin analog pramlintide markedly improves postprandial glucose excursions." | ( Fineman, M; Kolterman, OG; Maggs, DG; Strobel, S; Weyer, C, 2002) |
| "The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Study evaluated the renal protective effects of losartan versus placebo on a background of non-ACE-I/non-AIIA conventional antihypertensive therapy in 1513 patients with type 2 diabetes and nephropathy." | ( Brenner, B; Carides, GW; Gerth, WC; Hannedouche, T; Martinez-Castelao, A; Remuzzi, G; Shahinfar, S; Viberti, G, 2002) |
| "Thus, earlier detection of Type 2 diabetes and treatment of hyperglycaemia and related metabolic abnormalities is of vital importance." | ( De Lorenzo, A; Di Daniele, N; Linder, R; Mohamed, EI; Perriello, G; Pöppl, SJ, 2002) |
| "The patients had been treated for type 2 diabetes for 3 or more months with rosiglitazone (4 mg b." | ( LaCivita, KA; Villarreal, G, 2002) |
| "A total of 390 patients whose type 2 diabetes was controlled with insulin therapy completed a randomized controlled double-blind trial with a planned interim analysis after 16 weeks of treatment." | ( Bets, D; Borger van der Burg, B; Donker, AJ; Kooy, A; Lehert, P; Ogterop, JC; Stehouwer, CD; Wulffelé, MG, 2002) |
| "Surprisingly, MODY3 patients exhibit hypersensitivity to the hypoglycemic actions of sulfonylurea therapy." | ( Boileau, P; Shih, DQ; Stoffel, M; Wolfrum, C; Wolkoff, AW; Yang, TA, 2002) |
| "Insulin therapy in type 2 diabetes is also accompanied by untoward weight gain." | ( Baron, AD; Kim, D; Weyer, C, 2002) |
| "A female patient with Type 2 diabetes and end-stage nephropathy was treated with combined pancreas and kidney transplantation." | ( Büsing, M; Klempnauer, J; Meier, JJ; Nauck, MA; Pox, C; Ritzel, R; Schmiegel, W, 2002) |
| "Twenty patients with type 2 diabetes were treated with pioglitazone (30 mg q." | ( Hayashi, Y; Imaeda, K; Itoh, M; Kamiya, F; Kato, T; Miyachi, N; Okayama, N; Shimizu, M; Takeuchi, T; Takeuchi, Y, 2003) |
| "A total of 17 elderly patients with type 2 diabetes received 12 weeks of treatment with glimepiride." | ( Fukatsu, A; Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Miyazaki, A; Nomura, N; Suzuki, Y; Tsunekawa, T, 2003) |
| "Poorly controlled patients with type 2 diabetes mellitus (n=36), smokers (n=10), and untreated hyperlipidemic subjects (n=10) were studied." | ( Badimon, JJ; Crandall, J; Degen, M; Fuster, V; Hathcock, J; Nemerson, Y; Osende, J; Sambola, A, 2003) |
| "Patients with a clinical diagnosis of type 2 diabetes but positive for GAD-AB could not clearly be identified as having latent autoimmune diabetes in adults (LADA), since some of them did not need insulin therapy up to 10 years after the diagnosis of diabetes." | ( Pfohl, M; Reinsch, B; Schatz, H; Zimmy, S, 2003) |
| "To achieve glycemic control in type 2 diabetes mellitus, the American Diabetes Association (ADA) recommends intensification of glucose-lowering therapy when the glycosylated hemoglobin (HbA1c) level exceeds 8." | ( Brown, JB; Nichols, GA, 2003) |
| "Four hundred eighty-one patients with type 2 diabetes and hypertension (systolic BP > or =140 mm Hg, <180 mm Hg, diastolic BP <110 mm Hg) were randomly assigned (age 59+/-9 years, 77% previously treated for hypertension)." | ( De Leeuw, PW; Erdogan, G; Halimi, S; Hamani, A; Hess, B; Jermendy, G; Luger, A; Mechmeche, R; Mogensen, CE; Nolan, J; Ribeiro, A; Ritz, E; Ruilope, L; Rull, J; Sanchez, R; Sareli, P; Scheen, A; Sirotiakova, J; Taton, J; Thomas, SM; Viberti, G; Widimsky, J, 2003) |
| "For the treatment of type 2 diabetes we now have available a wide spectrum of oral antidiabetic agents and insulins that make it possible to offer the patient an individualized, pathophysiologically oriented therapy." | ( Fischer, S; Hanefeld, M, 2003) |
| "Treatment of hypertension in type 2 diabetes provides dramatic benefit." | ( Hayward, RA; Vijan, S, 2003) |
| "Treatment of hypertension in type 2 diabetes, with blood pressure goals of 135/80 mm Hg, provides dramatic benefits." | ( Hayward, RA; Vijan, S, 2003) |
| "This is the case in type 2 diabetes mellitus which requires several drugs, either to treat diabetes or to prevent cardiovascular complications." | ( Penfornis, A, 2003) |
| "In this study, patients with type 2 diabetes who had been receiving twice-daily MIR achieved comparable glycemic control when therapy was switched to once-daily MXR at the same or a greater total daily dose." | ( Fujioka, K; Joyal, S; Pans, M, 2003) |
| "Pioglitazone treatment in type 2 diabetes 1) decreases hepatic fat content and improves insulin-mediated suppression of EGP and 2) augments splanchnic and peripheral tissue glucose uptake." | ( Bajaj, M; Cersosimo, E; DeFronzo, RA; Glass, L; Hardies, LJ; Miyazaki, Y; Pratipanawatr, T; Pratipanawatr, W; Suraamornkul, S, 2003) |
| "The worldwide epidemic of type 2 diabetes has been stimulating the quest for new concepts and targets for the treatment of this incurable disease." | ( Docsa, T; Gergely, P; Hadady, Z; Nagya, V; Somsák, L, 2003) |
| "We screened 600 patients with type 2 diabetes treated with biguanides (phenformin or metformin) for a mean of 11." | ( Bonovas, S; Filioussi, K; Katsaros, T, 2003) |
| "Ten females with type 2 diabetes being treated with oral hypoglycaemic agents and with normal serum and urine calcium levels were enrolled in the study." | ( Borissova, AM; Dakovska, L; Kirilov, G; Kovacheva, R; Tankova, T, 2003) |
| "Prospective trials in patients with type 2 diabetes that lasted longer than one month were included if they evaluated metformin, alone or in combination with other treatments, compared to placebo or any other glucose-lowering therapy." | ( Greyber, E; Pasternak, G; Salpeter, E; Salpeter, S, 2003) |
| "Patients with type 2 diabetes are often treated with oral antidiabetic agents plus a basal insulin." | ( Fritsche, A; Häring, HU; Schweitzer, MA, 2003) |
| "695 patients with type 2 diabetes who were previously treated with oral antidiabetic agents." | ( Fritsche, A; Häring, HU; Schweitzer, MA, 2003) |
| "The odds of newly reported type 2 diabetes in patients who received risperidone were not significantly different from those in untreated patients (12-month odds ratio [OR] = 1." | ( Gianfrancesco, F; Grogg, A; Mahmoud, R; Meletiche, D; Wang, RH, 2003) |
| "Many patients with type 2 diabetes mellitus (DM) with inadequate long-term blood glucose control with sulfonylurea or metformin monotherapy require additional treatment." | ( Goldstein, BJ; Pans, M; Rubin, CJ, 2003) |
| "In 22 patients with type 2 diabetes and diabetic nephropathy in stages 3-5, treatment with the ACEI lisinopril was initiated." | ( Amann, B; Angelkort, B; Tinzmann, R, 2003) |
| "In 45 patients with type 2 diabetes mellitus (DM), we prospectively analyzed urinary excretion of N-acetyl-beta-glucosaminidase (NAG), a marker of tubular renal damage; the potential relationship with urinary protein excretion; and effects of pentoxifylline (PTF) administration." | ( Garca, J; Maca, M; Mora, C; Muros, M; Navarro, JF, 2003) |
| "Many patients with type 2 diabetes fail to achieve or maintain the American Diabetes Association's recommended treatment goal of glycosylated hemoglobin levels." | ( Bruce, S; Dandona, P; Donovan, DS; Garber, AJ; Park, JS, 2003) |
| "Treating patients with hypertension, type 2 diabetes and overt nephropathy using irbesartan was both cost- and life-saving compared with amlodipine and control." | ( Annemans, L; Cordonnier, DJ; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2003) |
| "A total of 16 patients with type 2 diabetes who were being treated with oral hypoglycemic agents were enrolled." | ( Egan, JM; Elahi, D; Greig, N; Habener, JF; Meneilly, GS; Tildesley, H, 2003) |
| "Metformin is a key treatment option in type 2 diabetes." | ( Bets, D; Borger van der Burg, B; Donker, AJ; Kooy, A; Lehert, P; Ogterop, JC; Stehouwer, CD; Wulffelé, MG, 2003) |
| "A total of 745 patients with type 2 diabetes, treated with insulin and not known with a contraindication for the use of metformin, were approached; 390 gave informed consent and entered the study." | ( Bets, D; Borger van der Burg, B; Donker, AJ; Kooy, A; Lehert, P; Ogterop, JC; Stehouwer, CD; Wulffelé, MG, 2003) |
| "In patients with type 2 diabetes, 16 weeks of treatment with metformin reduces levels of folate and vitamin B12, which results in a modest increase in homocysteine." | ( Bets, D; Borger van der Burg, B; Donker, AJ; Kooy, A; Lehert, P; Ogterop, JC; Stehouwer, CD; Wulffelé, MG, 2003) |
| "Current clinical management of type 2 diabetes is focused on treatment of the signs and symptoms of late-stage disease rather than addressing potential underlying causes, which may be amenable to currently available therapies, based on a broad understanding of existing data, practice experience, and rational speculation." | ( Buchanan, TA, 2003) |
| "Hypercholesterolemia in type 2 diabetes, even when mild, must be treated in an aggressive way, due to the more strict therapeutic goals than in the non diabetic population." | ( CarloTonolo, G; Carrozza, C; Lulli, P; Musumeci, S; Santini, SA; Zuppi, C, 2003) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | ( Bilinska, M; Paradowski, B, 2003) |
| "Initial treatment of Type 2 diabetes with glimepiride was associated with a significantly greater decrease in body weight and body mass index than treatment with glibenclamide, while providing equivalent glycaemic control." | ( Beuth, J; Kolb, H; Martin, S; Scherbaum, WA; Schneider, B; van Leendert, R, 2003) |
| "A cohort of patients with type 2 diabetes, prescribed glyburide/metformin tablets, experienced significantly greater improvements in glycaemic control compared to patients receiving glyburide co-administered with metformin." | ( Blonde, L; Kreilick, C; Seymour, AA; Wogen, J, 2003) |
| "In patients with type II diabetes mellitus combination therapy with antioxidant probucol decreased the severity of oxidative stress and stabilized carbohydrate metabolism without increasing the dose of hypoglycemic preparations." | ( Antonova, KV; Balabolkin, MI; Belenkov, YN; Konovalova, GG; Lankin, VZ; Lisina, MO; Nedosugova, LV; Tikhaze, AK, 2003) |
| "We studied 42 patients with Type 2 diabetes, including 19 subsequently treated with sulphonylurea, 23 treated with insulin and 48 control subjects." | ( Aso, Y; Inukai, T; Kanda, T; Kobayashi, I; Okumura, K; Takemura, Y; Tayama, K; Yoshida, N, 2003) |
| "Eighty subjects with Type 2 diabetes were randomized to 13 weeks' open-label treatment with repaglinide 4 mg t." | ( Furlong, NJ; Hardy, KJ; Hulme, SA; O'Brien, SV, 2003) |
| "Metformin therapy for type 2 diabetes mellitus has been shown to reduce total mortality rates compared with other antihyperglycemic treatments but is thought to increase the risk of lactic acidosis." | ( Greyber, E; Pasternak, GA; Salpeter, EE; Salpeter, SR, 2003) |
| "Given that the prevalence of type 2 diabetes is increasing dramatically and that current treatment strategies appear inadequate, there is a critical need for well-designed studies to address treatment of coronary artery disease in patients with diabetes to help guide clinical decision making in this setting." | ( Frye, RL, 2003) |
| "Patients with type 2 diabetes mellitus (DM) and renal impairment whose disease is inadequately controlled on a sulfonylurea (SU) have limited oral combination treatment options." | ( Agrawal, A; Jones, NP; Sautter, MC, 2003) |
| "Treating patients with hypertension, type 2 diabetes and nephropathy using irbesartan lowers the cumulative incidence of ESRD and is cost-saving compared to amlodipine or control." | ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| "In conclusion, PIO treatment in type 2 diabetes causes a 3-fold increase in plasma adiponectin concentration." | ( Bajaj, M; Cersosimo, E; DeFronzo, RA; Glass, L; Hardies, LJ; Miyazaki, Y; Piper, P; Pratipanawatr, T; Suraamornkul, S, 2004) |
| "Patients with type 2 diabetes who are failing on oral agents will generally gain a large amount of body fat when switched to insulin treatment." | ( de Boer, H; Jansen, M; Koerts, J; Verschoor, L, 2004) |
| "Because patients with type 2 diabetes often have excess hepatic glucose output, use of metformin is effective in lowering glycosylated hemoglobin (HbA1c) by 1 to 2 percentage points when used as monotherapy or in combination with other blood glucose-lowering agents or insulin." | ( Campbell, RK; Iltz, JL; Setter, SM; Thams, J, 2003) |
| "Thirty-one volunteers with type 2 diabetes mellitus, 16 on dietary therapy and 15 on sulfonylurea monotherapy (SU), were treated with metformin for 12 weeks." | ( Abbasi, F; Chu, JW; Lamendola, C; Leary, ET; McLaughlin, T; Reaven, GM, 2004) |
| "Patients with type 2 diabetes and macroalbuminuria generally experience progressive glomerular filtration rate (GFR) decline despite angiotensin-converting enzyme inhibition (ACEI) and blood pressure (BP) control but this therapy generally stabilizes GFR in those without macroalbuminuria." | ( Chuahirun, T; Harrist, RB; Hudson, C; Khanna, A; Seipel, T; Simoni, J; Wesson, DE, 2004) |
| "Insulin therapy in patients with type 2 diabetes can lead to improved glycemic control, insulin sensitivity, lipid profile, and endothelial function and may impact the incidence and severity of cardiovascular disease." | ( Yki-Järvinen, H, 2003) |
| "Eighteen patients with type 2 diabetes mellitus--seven on diet only and 11 on metformin monotherapy--participated in the study." | ( Abrahamian, H; Dzien, A; Francesconi, M; Loiskandl, A; Prager, R; Weitgasser, R, 2004) |
| "Many patients with type 2 diabetes have difficulty attaining the recommended HbA(1c) goal despite normal/near-normal FPG levels; thus, pharmacologic treatment targeting PPG levels may prove beneficial." | ( Abrahamson, MJ, 2004) |
| "Treatment options for type 2 diabetes mellitus currently consist of insulin sensitizers, alpha-glucosidase inhibitors, secretagogues, and insulin." | ( Bell, DS, 2004) |
| "In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it." | ( Corradi, L; Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Preti, P; Zoppi, A, 2004) |
| "The authors treated 18 patients with type 2 diabetes after transplantation with rosiglitazone." | ( Baldwin, D; Duffin, KE, 2004) |
| "Patients with treated type 2 diabetes (mean duration 5." | ( Brizolara, A; Fitzgerald, P; Osman, A; Otero, J; Stouffer, G; Uretsky, BF; Waxman, S, 2004) |
| "Current medical treatments for type 2 diabetes include stimulation of insulin secretion, inhibition of endogenous glucose production and enhancement of insulin sensitivity." | ( Lind, P, 2004) |
| "Prevention and treatment of type 2 diabetes mellitus (T2DM) and the metabolic syndrome represent a major clinical challenge, because effective strategies such as fat restriction and exercise are difficult to implement into diabetes treatment." | ( Roden, M; Stingl, H, 2004) |
| "Thirty subjects with diet-controlled Type 2 diabetes were randomized to 3 months treatment with pioglitazone (n = 19) or placebo (n = 11)." | ( Levy, JC; Matthews, DR; Wallace, TM, 2004) |
| "In the case of manifest type 2 diabetes mellitus, a graded schedule is used for differential management, which should be based on nutritional and exercise therapy." | ( Müller, B; Trepp, R, 2004) |
| "In 129 patients with type 2 diabetes previously treated with NPH insulin, A1C decreased significantly (p<0." | ( Bakst, G; Busch, RS; Hamilton, RA; Kane, MP; Stroup, J, 2004) |
| "Treating patients with hypertension, type 2 diabetes and overt nephropathy using irbesartan was both cost- and life-saving compared to amlodipine and control in the Spanish setting." | ( Annemans, L; de Alvaro, F; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| "Early initiation of therapy for type 2 diabetes with a once-daily combination of metformin and rosiglitazone provides the greatest opportunity to achieve A1cs within the normal range." | ( Bell, DS; Ovalle, F, 2004) |
| "159 patients with type 2 diabetes were parallelly assigned to a slow-released-gliclazide or gliclazide group in a randomized, open, multi-center phase III study to compare the efficacy of slow-released-gliclazide and gliclazide on overall diabetes control through HbA1c and the adverse events including hypoglycemic episodes and change of vital signs, electrocardiogram and clinical laboratory parameters after a 12-week treatment period." | ( Gao, Y; Guo, XH; Li, GW; Li, HB; Pan, CY; Tian, H; Xing, XY; Yang, WY; Yuan, SY, 2004) |
| "If the pharmacotherapy of type 2 diabetes should be tailored to the underlying pathophysiology, it would be necessary to use a combination of agents with complementary mechanisms of action." | ( Mooradian, AD, 2004) |
| "Forty-five normotensive type 2 diabetes patients with microalbuminuria were randomized to 12-month treatment with pioglitazone (30 mg/d, n = 15), glibenclamide (5 mg/d, n = 15), or voglibose (0." | ( Kawagoe, Y; Koide, H; Matsuda, T; Nakamura, T; Ogawa, H; Sekizuka, K; Takahashi, Y, 2004) |
| "Persons with Type 2 diabetes who were poorly controlled on oral therapy were randomly assigned to monotherapy with repaglinide or combination therapy with repaglinide plus metformin." | ( Banerji, MA; Crouse, RJ; Feinglos, MN; Goff, DC; Herrington, DM; Jovanovic, L; Lipkin, EW; Pettitt, DJ; Probstfield, JL; Reboussin, DM; Steffes, M; Summerson, J; Williamson, J, 2004) |
| "Irbesartan treatment of patients with type 2 diabetes, hypertension, and microalbuminuria may lead to major improvements in long-term patient outcomes, with substantial cost savings as an added bonus to third party payers." | ( Palmer, AJ; Rodby, RA, 2004) |
| "A total of 17 subjects with type 2 diabetes, inadequately controlled on a maximized oral antihyperglycemic double regimen of glimepiride and metformin, were randomized to the addition of rosiglitazone or insulin to their treatment regimens for a period of 6 months." | ( Bell, DS; Ovalle, F, 2004) |
| "Many patients with type 2 diabetes require treatment with more than one antihyperglycemic drug to achieve optimal glycemic control." | ( Cox, SL, 2004) |
| "Patients with type 2 diabetes aged > or =18 years who had begun treatment with pioglitazone or insulin between January 1999 and December 2001 were identified using the PharMetrics Patient-Centric database." | ( Fernandes, AW; Khan, M; Murray, FT; Rajagopalan, R; Rosenson, RS, 2004) |
| "However, in fasted type 2 diabetes model rats, plasma mannose concentrations that were higher compared with normal rats did not change after the administration of glucose." | ( Asano, N; Miwa, I; Mizutani, T; Nakajima, H; Taguchi, T; Yabuuchi, M; Yamashita, E, 2005) |
| "Subjects with type 2 diabetes were divided into three groups, receiving the following treatments: (i) glibenclamide (n=59); (ii) gliclazide (n=30); and (iii) glibenclamide + metformin (n=29)." | ( Hayaishi-Okano, R; Hori, M; Kaneto, H; Katakami, N; Kosugi, K; Matsuhisa, M; Ohtoshi, K; Yamasaki, Y, 2004) |
| "In proteinuric individuals with type 2 diabetes, losartan therapy reduced ESRD and hospitalizations for heart failure and was well tolerated at all levels of renal function." | ( Brenner, BM; Carides, GW; de Zeeuw, D; Dimitrov, BD; Hille, DA; Perna, A; Remuzzi, G; Ruggenenti, P; Shahinfar, S, 2004) |
| "In patients with type 2 diabetes, pioglitazone monotherapy or in combination with sulfonylurea therapy significantly improves HbA1c, FBG and PBG levels and reserves the beta-cell function with beneficial effects on serum triglyceride and HDL-C levels." | ( Fan, J; Gao, H; Li, Y; Liao, Z; Wang, C; Wang, Y; Yu, H; Yu, Y; Zhao, W, 2003) |
| "In patients with type 2 diabetes treated with insulin, metformin treatment was associated with improvement of endothelial function, which was largely unrelated to changes in glycaemic control, but not with improvement of chronic, low-grade inflammation." | ( Bets, D; De Jager, J; Donker, AJ; Kooy, A; Lehert, P; Schalkwijk, CG; Scheffer, PG; Stehouwer, CD; Teerlink, T; Wulffelé, MG, 2005) |
| "Many patients with type 2 diabetes go on to require insulin therapy to achieve adequate control." | ( Andrikopoulos, S; Proietto, J, 2004) |
| "Therefore, treatment of IGT and type 2 diabetes should aim at restoring the normal relation between insulin sensitivity and secretion." | ( Ahrén, B; Pacini, G, 2005) |
| "Patients with type 2 diabetes, treated for 26 weeks with insulin detemir plus insulin aspart at mealtimes, experienced comparable glycaemic control but significantly lower within-subject variability and less weight gain compared to patients treated with NPH insulin and insulin aspart." | ( Draeger, E; Haak, T; Suntum, M; Tiengo, A; Waldhäusl, W, 2005) |
| "In patients with type 2 diabetes mellitus (T2DM), combination therapy is usually required to optimize glucose metabolism as well as to help patients achieve aggressive targets for low-density lipoprotein cholesterol (LDL-C) and other lipid parameters associated with cardiovascular risk." | ( Gaudiani, LM; Lewin, A; Meneghini, L; Mitchel, Y; Perevozskaya, I; Plotkin, D; Shah, S, 2005) |
| "39 patients with type 2 diabetes age 34-75 years were randomly allocated to the two treatment groups." | ( Amini, M; Aminian, T; Aminorroaya, A; Gharavi, M; Janghorbani, M; Rezvanian, H, 2005) |
| "In subjects with type 2 diabetes poorly controlled on OADs, initiating insulin therapy with twice-daily BIAsp 70/30 was more effective in achieving HbA(1c) targets than once-daily glargine, especially in subjects with HbA(1c) >8." | ( Allen, E; Bode, B; Gabbay, RA; Garber, A; Hollander, P; Hu, P; Lewin, A; Raskin, P, 2005) |
| "A 57-year-old Caucasian woman with Type 2 diabetes treated for seven years with diet and oral combination hypoglycaemic therapy was referred because of the progressive deterioration of glycaemic control." | ( Atkin, SL; González, S; Kilpatrick, ES, 2005) |
| "Patients with type 2 diabetes mellitus who showed poor glycemic control with glimepiride (4 mg/d) were randomized to rosiglitazone (4 mg/d) and metformin (500 mg bid) treatment groups." | ( Cho, YM; Jung, HS; Kim, SY; Lee, HK; Park, HJ; Park, KS; Shin, CS; Youn, BS; Yu, KY, 2005) |
| "In patients with type 2 diabetes mellitus, the traditional method of initiating therapy with a sulfonylurea and increasing the dosage until maximum levels are reached before adding an insulin-sensitizing agent has persisted and should be re-evaluated." | ( Bell, DS, 2004) |
| "Eighty patients with type 2 diabetes, half of them also treated for hypertension, who received 3-day pulse methylprednisolone between January 1999 and December 2002 for eye disorders and were monitored according to a written protocol." | ( Benrabah, R; Feldman-Billard, S; Héron, E; Kassaei, R; Lissak, B, 2005) |
| "Control consisted of 38 patients with type 2 diabetes (T2DM group) matched for sex, age, duration of diabetes, body mass index, treatment, and degree of glycemic control, which was determined by glycoalbumin." | ( Fujiwara, F; Ishida, W; Ishii, M; Kaneko, Y; Kato, A; Miura, M; Satoh, J; Suzuki, K; Takebe, N; Taneichi, H; Toshihiro, M, 2005) |
| "In 50 patients with type 2 diabetes and hypertension, treated with diabetes drugs and enalapril, we evaluated the glycemic and lipid profile together with the HOMA insulin-resistance index, blood pressure and microalbuminuria at baseline and 3 months after the addition of valsartan." | ( Cimpanelli, M; Crespi, C; Gaudio, G; Grandi, AM; Guasti, L; Klersy, C; Riganti, G; Schizzarotto, A; Simoni, C; Venco, A, 2005) |
| "In patients with Type 2 diabetes and inadequate glucose control while on insulin or insulin and oral agent(s) combination therapy, treatment with a twice-daily insulin lispro mixture plus metformin, which targets both post-prandial and pre-meal BG, provided clinically significant improvements in A1c, significantly reduced post-prandial BG after each meal, and reduced nocturnal hypoglycaemia as compared with once-daily glargine plus metformin, a treatment that targets fasting BG." | ( Augendre-Ferrante, B; Bai, S; Campaigne, BN; Malone, JK; Reviriego, J, 2005) |
| "Their potential for treating Type 2 diabetes is limited by short biological half-life owing to degradation by dipeptidyl peptidase IV (DPP IV)." | ( Ardill, J; Bell, PM; Duffy, NA; Flatt, PR; Lindsay, JR; McKillop, AM; O'Harte, FP, 2005) |
| "Sixteen diet-treated Caucasians with type 2 diabetes (mean HbA(1c) 8." | ( Cozma, LS; Dunseath, GJ; Luzio, SD; Owens, DR; Underwood, PM, 2005) |
| "A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications." | ( Ahn, CW; Cha, BS; Kang, ES; Kim, HJ; Kim, KR; Lee, HC; Lim, SK; Nam, M; Park, SY, 2005) |
| "Sixteen subjects with insulin-treated type 2 diabetes and without overt cardiovascular disease were randomly assigned to receive either 45 mg of pioglitazone or matching placebo for 3 months." | ( Bhattacharyya, T; Daher, E; DiCarli, MF; Grunberger, G; McMahon, GT; Plutzky, J, 2005) |
| "Twenty-seven patients with type 2 diabetes mellitus were randomly assigned to two groups, and pioglitazone (n=13) or glibenclamide (n=14) was administered for 6 months." | ( Anazawa, T; Kanmatsuse, K; Kushiro, T; Tani, S; Watanabe, I, 2005) |
| "Ten subjects with type 2 diabetes, treated with diet alone were recruited in a crossover randomized study." | ( Anastasopoulou, I; Boutati, E; Karafoullidou, A; Karambakalis, N; Katsilambros, N; Kyriaki, D; Lourida, E; Perea, D; Perrea, D; Raptis, SA; Tentolouris, N; Tselepis, AD; Tsoukala, C, 2005) |
| "Patients with type 2 diabetes and high cardiovascular risk are not always under antiplatelet treatment despite the ADA recommendations, particularly for primary prevention." | ( Bruno, A; Dani, F; Degiovanni, M; Grassi, G; Maghenzani, G; Pagano, G, 2005) |
| "Fifty patients with type 2 diabetes were given simvastatin 20 mg and placebo, simvastatin 20 mg and ramipril 10 mg, or ramipril 10 mg and placebo daily during each 2-month treatment period." | ( Ahn, JY; Han, SH; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Quon, MJ; Shin, EK, 2005) |
| "A total of 263 patients with type 2 diabetes treated with oral agents or insulin, age (mean +/- SD) 60 +/- 10 years, body mass index (BMI) 31." | ( Franken, AA; Vincent, HH; Wolffenbuttel, BH, 2005) |
| "The early use of insulin therapy in type 2 diabetes may prove beneficial to prevent further beta-cell loss and need for exogenous insulin." | ( Giorgino, F; Laviola, L; Leonardini, A, 2005) |
| "The hallmark of type 2 diabetes is insulin resistance and insufficient insulin secretion, and appropriate therapy should be selected for each patient." | ( Gorogawa, S; Hazama, Y; Kaneto, H; Kawamori, D; Matsuhisa, M; Ohtoshi, K; Yamasaki, Y; Yoshiuchi, K, 2005) |
| "A 56 year-old man suffering from type 2 diabetes, hypertension and dyslipidemia developed critical ischemia of the right leg and was treated with iloprost." | ( Carlioz, R; Geffroy, S; Godreuil, C; Naoum, E; Perrier, E; Quiniou, G, 2005) |
| "Fourteen diet-treated subjects with type 2 diabetes were served a high-GI breakfast (white bread) and subsequent high-GI lunch (mashed potatoes with meatballs)." | ( Björck, IM; Frid, AH; Holst, JJ; Nilsson, M, 2005) |
| "This study of patients with Type 2 diabetes failed to find evidence that short-term pioglitazone use was associated with an elevated risk of hospitalization for CHF relative to the standard, first-line diabetes therapy." | ( Ahmed, AT; Karter, AJ; Liu, J; Moffet, HH; Parker, MM, 2005) |
| "Subjects (BMI 27-42 kg/m(2)) with Type 2 diabetes who were previously treated with an OAD (oral anti-diabetic drug) monotherapy (69% with metformin), and had HbA(1c) < or = 10% were enrolled." | ( An, B; Feinglos, MN; Pi-Sunyer, FX; Saad, MF; Santiago, O, 2005) |
| "A total of 198 patients with type 2 diabetes mellitus were treated with rosiglitazone (4 mg/d) for 12 weeks without a change in previous medications." | ( Ahn, CW; Cha, BS; Kang, ES; Kim, CS; Kim, HJ; Lee, HC; Lim, SK; Nam, CM; Park, SY, 2005) |
| "Twenty patients with type 2 diabetes were involved in this pilot trial: 10 were treated with the 70/30 insulin algorithm and 10 received a physician-determined traditional SSI regimen." | ( Gresham, DG; Rice, DA; Schoeffler, JM, 2005) |
| "Five of the older patients with type 2 diabetes (BMI, 29 +/- 1 kg/m2; age, 72 +/- 2 yr) were treated with continuous sc glucagon-like peptide-1 (GLP-1) (7-36) amide infusion for 6 wk, and a second 2-h hyperglycemic clamp was performed." | ( Elahi, D; Meneilly, GS; Veldhuis, JD, 2005) |
| "Ninty-four patients with Type 2 diabetes mellitus (35-70 year-old) were divided into 3 groups: glimepiride treated group (n=33), metformin treated group (n=29) and glimepiride plus metformin treated group (n=32)." | ( Feng, Q; Mao, JP; Tang, JZ; Tang, WL; Yang, ZF; Zhou, ZG, 2004) |
| "In hypertensive patients with type 2 diabetes mellitus in the BENEDICT (BErgamo NEphrologic DIabetes Complications Trial), trandolapril/verapamil SR prolonged the time to the onset of persistent microalbuminuria compared with placebo, as did trandolapril monotherapy." | ( Keam, SJ; Reynolds, NA; Wagstaff, AJ, 2005) |
| "Patients with type 2 diabetes have low serum concentrations of sulfatide, and some animal models of type 2 diabetes have low pancreatic expression of C16:0 sulfatide; administration of this increases insulin secretion and improves first-phase insulin response in Zucker fatty rats." | ( Blomqvist, M; Buschard, K; Fredman, P; Osterbye, T, 2005) |
| "Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial glucose levels." | ( Campbell, IW, 2005) |
| "To determine, in patients with type 2 diabetes mellitus, whether an association exists between thiazolidinedione therapy or other diabetes therapies and hospital admission for heart failure." | ( Bultemeier, NC; Hartung, DM; Haxby, DG; Touchette, DR, 2005) |
| "This study aimed to evaluate hemodynamic changes associated with propionyl-L-carnitine and L-carnitine administration and its correlation with biochemical markers of cardiac vascular function." | ( Lango, R; Lysiak-Szydłowska, W; Rogowski, J; Siebert, J; Smoleński, RT; Słomińska, EM; Wujtewicz, M; Yacoub, MH, 2005) |
| "Significant improvement of hemodynamics following propionyl-L-carnitine administration in diabetic patients undergoing on-bypass coronary surgery was accompanied by reduced trans-cardiac endothelin difference and rapid hypoxanthine washout during reperfusion suggesting improvement of metabolism or vascular function." | ( Lango, R; Lysiak-Szydłowska, W; Rogowski, J; Siebert, J; Smoleński, RT; Słomińska, EM; Wujtewicz, M; Yacoub, MH, 2005) |
| "In hypertensive patients with Type 2 diabetes, a greater reduction of urinary albumin excretion can be obtained with the perindopril/indapamide association compared with an angiotensin-converting enzyme inhibitor administered as monotherapy." | ( Waeber, B, 2005) |
| "The study of 279 patients with type 2 diabetes consisted of a 4-week run-in phase where patients received placebo and a 12-week active treatment phase where they received one of the following dosages of vildagliptin: 25 mg twice daily, 25, 50 or 100 mg once daily (qd), or placebo." | ( Byiers, S; Foley, J; Holmes, D; Ristic, S, 2005) |
| "A 60-year-old man with diet-treated Type 2 diabetes and hypertension presented with generalized muscle weakness and serum potassium of 1." | ( Advani, A; Taylor, R, 2005) |
| "In persons with type 2 diabetes and nephropathy, treatment with ruboxistaurin reduced albuminuria and maintained eGFR over 1 year." | ( Anderson, PW; Bakris, GL; Hu, K; McGill, JB; Toto, RD; Tuttle, KR, 2005) |
| "Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days." | ( Aisporna, M; Baron, AD; Fineman, MS; Kim, D; Nielsen, LL; Taylor, K, 2005) |
| "Patients with type 2 diabetes without proteinuria, were treated with RAS inhibitors, the first being an ACE inhibitor (ACEI) and the second, an angiotensin II (ATII) receptor blocker (ARB) for 8 weeks each." | ( Hashimoto, N; Saito, Y; Seki, N; Suzuki, Y; Yagui, K, 2006) |
| "Untreated type 2 diabetes leads to several complications such as hyperlipidemia, hypertension and atherosclerosis--collectively known as Syndrome X." | ( Chakrabarti, R; Das, SK, 2005) |
| "Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy." | ( Barter, P; Best, J; Colman, P; d'Emden, M; Davis, T; Drury, P; Ehnholm, C; Forder, P; Glasziou, P; Hunt, D; Keech, A; Kesäniemi, YA; Laakso, M; Pillai, A; Scott, R; Simes, RJ; Sullivan, D; Taskinen, MR; Whiting, M, 2005) |
| "Patients with a diagnosis of type 2 diabetes for a minimum of 1 year received glimepiride (titrated sequentially from 2 to 4 to 8 mg/d over 6 weeks, followed by 20 weeks of maintenance therapy) or placebo in combination with an established regimen of immediate- or extended release metformin and rosiglitazone or pioglitazone." | ( Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J, 2005) |
| "In these patients with type 2 diabetes that was not adequately controlled by dual combination therapy with metformin and a thiazolidinedione, the addition of glimepiride improved glycemic control compared with placebo with an acceptable tolerability profile." | ( Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J, 2005) |
| "24 patients with type 2 diabetes, who after the combined hypolipidemic treatment (pravastatin 20 mg + micronized fenofibrate 200 mg per day) cannot reach the recommended target values for long time, received for three consecutive months supplementation of 3,6 g PUFA n-3 per day or a placebo (olive oil)." | ( Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M, 2005) |
| "Nineteen postmenopausal women with type 2 diabetes were randomized to receive 40 mg/day pravastatin or no treatment for 6 weeks followed by a 2-week washout period, and crossed over for a further 6 weeks." | ( Barrett, PH; Chan, DC; Ching, HL; Martins, IJ; Ng, TW; Redgrave, TG; Sakai, N; Stuckey, BG; Uchida, Y; Watts, GF; Yamashita, S, 2005) |
| "Metformin is widely used for treating type 2 diabetes mellitus, but its actions are poorly understood." | ( Casauban, L; Farese, RV; Gomez-Daspet, J; Luna, V; Miura, A; Powe, JL; Rivas, J; Sajan, MP; Standaert, ML, 2006) |
| "Since aPKC activation is defective in type 2 diabetes, we evaluated effects of metformin therapy on aPKC activity in muscles of diabetic subjects during hyperinsulinaemic-euglycaemic clamp studies." | ( Casauban, L; Farese, RV; Gomez-Daspet, J; Luna, V; Miura, A; Powe, JL; Rivas, J; Sajan, MP; Standaert, ML, 2006) |
| "In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin or a sulphonylurea, induced both long- and short-term improvements in glycaemic control and serum lipid profiles." | ( Easthope, S; Keating, GM; Plosker, GL; Robinson, DM; Waugh, J, 2006) |
| "In the treatment of elderly type 2 diabetes, it is important to detect hypoglycemia correctly, because the elderly patients often exhibit atypical symptoms from hypoglycemia." | ( Hashizume, K; Komatsu, M, 2006) |
| "A total of 101 subjects with type 2 diabetes were treated either with sulfonylureas (n = 32), with insulin (n = 40), with sulfonylureas + insulin (n = 17) or with diet alone (n = 12)." | ( Abramczyk, M; Borowska, M; Dworacka, M; Kuczynski, S; Szczawinska, K; Winiarska, H, 2006) |
| "In treating Type 2 diabetes (T2DM), UK guidelines recommend metformin in obese and overweight patients, and either sulphonylureas or metformin in normal weight patients." | ( Doney, AS; Donnelly, LA; Hattersley, AT; Morris, AD; Pearson, ER, 2006) |
| "Fifteen patients with Type 2 diabetes were investigated on three occasions: at baseline without oral hypoglycaemic drug treatment, and after 6 weeks' treatment with repaglinide or glibenclamide, respectively, in an open randomized cross-over study." | ( Hjemdahl, P; Ostenson, CG; Wallén, NH; Yngen, M, 2006) |
| "Prospective trials in patients with type 2 diabetes that lasted longer than one month were included if they evaluated metformin, alone or in combination with other treatments, compared to placebo or any other glucose-lowering therapy." | ( Greyber, E; Pasternak, G; Salpeter, E; Salpeter, S, 2006) |
| "In subjects of normal weight with type 2 diabetes, baseline IGF-II concentration is inversely related to future weight gain, independent of treatment effect, strengthening the putative role for IGF-II in regulating fat mass." | ( Anderson, SG; Brismar, K; Cruickshank, JK; Gibson, JM; Grill, V; Heald, AH; Kärvestedt, L; Knowles, A; McLaughlin, J; White, A; Wong, L, 2006) |
| "Older adults with type 2 diabetes receiving metformin monotherapy received add-on therapy with either rosiglitazone, a thiazolidinedione insulin sensitizer, or glyburide." | ( Cobitz, AR; Freed, MI; Rood, JA; Ryan, CM; Strachan, MW; Waterhouse, BR, 2006) |
| "Seventy-four patients with NIDDM-associated PAD were treated with PLC (2 g/day) or placebo for 12 months." | ( Gabriella, C; Gea, OC; Giuseppe, M; Giuseppe, P; Luigi, DP; Margherita, F; Massimiliano, A; Roberto, F; Santo, SS; Sergio, N, 2006) |
| "Thirty-two subjects (total group) with type 2 diabetes receiving treatment by NPH insulin injection twice a day in the morning and evening were switched to basal bolus insulin (BBI) therapy (fast-acting insulin after each meal and NPH insulin before bedtime)." | ( Ebisuno, M; Endoh, K; Koide, N; Miyashita, Y; Ohhira, M; Ohtsuka, M; Oyama, T; Saiki, A; Shirai, K, 2006) |
| "We report on a patient whose type 2 diabetes mellitus resolved during IFN-alpha therapy for hepatitis C virus (HCV)." | ( Bowler, L; Coates, P; Singh, P; Tahrani, A, 2006) |
| "Thirty patients with type 2 diabetes mellitus and hyperlipidemia were enrolled to receive rosiglitazone monotherapy at 4 mg/day for 3 months and then atorvastatin at 10 mg/day was added for 3 more months as combined therapy." | ( Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC, 2006) |
| "Novel approaches to the treatment of type 2 diabetes are now at various stages of development or regulatory approval." | ( Lebovitz, H, 2006) |
| "A total of 4400 type 2 diabetes patients with normoalbuminuria will be randomized to treatment with 40 mg of olmesartan medoxomil once daily or placebo." | ( Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Mimran, A; Rabelink, AJ; Remuzzi, G; Ritz, E; Ruilope, LM; Rump, LC; Viberti, GC, 2006) |
| "Subjects (40-80 years) with type 2 diabetes and on insulin were randomised to 9 weeks of pioglitazone therapy (30 mg/day; n=14) or placebo (n=15)." | ( Ball, CI; Elston, LM; Gooding, KM; Mawson, DM; Piper, J; Shore, AC; Sriraman, R; Tooke, JE; Urquhart, R, 2006) |
| "Thirty-four patients with type 2 diabetes mellitus who were administrated glibenclamide were randomly divided into two groups." | ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
| "Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder." | ( Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R, 2006) |
| "Both prevention and treatment of type 2 diabetes should focus on mitochondrial targets for the improvement of nutrient-stimulated insulin secretion and their utilization in peripheral tissues." | ( Wiederkehr, A; Wollheim, CB, 2006) |
| "Adults with type 2 diabetes (newly diagnosed, treated with diet and exercise only, or previously treated with oral diabetic medications) were randomly assigned to receive one of three extended-release metformin treatment regimens (1,500 mg/day q." | ( Berner, B; Chiang, YK; Cramer, M; Fonseca, V; Lewin, A; Schwartz, S, 2006) |
| "Treatment of patients with type 2 diabetes with pioglitazone for 24 weeks reduced skin NO production, thus probably reducing nitrosative stress without a demonstrable effect on SkBF." | ( Barlow, PM; Casellini, CM; Parson, HK; Ullal, J; Vinik, AI, 2006) |
| "A total of 81 Japanese type 2 diabetes were randomly assigned to the EPA (1800 mg/day) treated group or the control group." | ( Hirose, T; Kawamori, R; Kinoshita, J; Mita, T; Nomiyama, T; Ogawa, O; Ogihara, T; Shimizu, T; Tanaka, Y; Watada, H, 2007) |
| "The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis." | ( Grant, I; McKnight, JA; Nyirenda, MJ; Price, G; Sandeep, T, 2006) |
| "Twenty-four outpatients with type 2 diabetes treated with oral PG for 6 mo (BMI, 26." | ( Itoh, Y; Mori, Y; Obata, T; Tajima, N, 2006) |
| "In study II, 41 patients with type 2 diabetes and mild hyperhomocysteinaemia were analysed after 6 months treatment with 5 mg of folic acid or placebo." | ( Brouwer, CB; Rauwerda, JA; Smulders, YM; Spoelstra-de Man, AM; Stehouwer, CD; Teerlink, T, 2006) |
| "Weight gain and type 2 diabetes mellitus (DM) are often linked to antipsychotics treatment." | ( Mou, XD; Shang, XF; Sun, J; Wang, CJ; Zhang, TQ; Zhang, XB; Zhang, XR; Zhang, ZJ, 2006) |
| "In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin, or a sulfonylurea, induced both long- and short-term improvements in glycemic control and serum lipid profiles." | ( Easthope, S; Keating, GM; Plosker, GL; Robinson, DM; Waugh, J, 2006) |
| "In patients with type 2 diabetes inadequately controlled on metformin monotherapy, add-on glimepiride or pioglitazone results in similar overall improvements in glycemic control." | ( Issa, M; Umpierrez, G; Vlajnic, A, 2006) |
| "Seventy-eight Japanese subjects with type 2 diabetes and hypercholesterolaemia were treated with atorvastatin (10 mg/day), and its effects on lipid and glycaemic profiles were measured 12 weeks after treatment initiation." | ( Ishibashi, S; Kusaka, I; Matsuoka, H; Nagasaka, S; Nakata, M; Yada, T, 2006) |
| "In patients with type 2 diabetes, insulin therapy is commonly initiated with either a single dose of basal insulin or twice-daily premixed (basal plus prandial) insulin despite no widely accepted recommendation." | ( Jacober, SJ; Scism-Bacon, JL; Zagar, AJ, 2006) |
| "Patients with type 2 diabetes and arterial hypertension were randomly assigned to one of two treatment sequences (nebivolol-enalapril, enalapril-nebivolol)." | ( Eckers, U; Heise, T; Kaiser, T; Nosek, L; Sawicki, PT, 2006) |
| "Insulin treatment in Type 1 and Type 2 diabetes has come a long way since its discovery by Banting and Best in 1922." | ( Chatterjee, S; Davies, MJ; Tringham, JR, 2006) |
| "A subgroup of patients with type 2 diabetes treated with pioglitazone responded with increased eye protrusion." | ( Dorkhan, M; Frid, A; Groop, L; Hallengren, B; Lantz, M, 2006) |
| "Five adult patients with type 2 diabetes with suboptimal control using combinations of short and long acting insulin plus metformin who were adherent to their dietary regimen were treated by the addition of gliclazide at different doses." | ( Brown, N, 2006) |
| "Twenty-six hypertensive patients with type 2 diabetes at the baseline were administered 5 mg of enalapril once daily for 12 weeks." | ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| "In animal models of type 2 diabetes in the nonfasted state, circulating glucagon and glucose levels were decreased after treatment with compound 1." | ( Birzin, ET; Cashen, DE; Jacks, TM; Nowak, KW; Patchett, AA; Rohrer, SP; Schaeffer, JM; Singh, V; Smith, RG; Strowski, MZ; Yang, L, 2006) |
| "The treatment of type 2 diabetes and the metabolic syndrome poses a challenge for pediatric endocrinologists." | ( Miller, JL; Silverstein, JH, 2006) |
| "For patients with type 2 diabetes mellitus and metabolic syndrome, combined treatment with metformin and rosiglitazone or pioglitazone is safe and effective, However, the pioglitazone combination also reduced the plasma Lp(a) levels whereas the rosiglitazone combination did not." | ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA, 2006) |
| "Nineteen patients with type 2 diabetes were treated with folic acid (10mg/day for 2 weeks) versus placebo in a randomized, placebo-controlled, cross-over study with an 8-week washout period between treatments." | ( Giddens, K; McQueen, MJ; Nassar, BA; Title, LM; Ur, E, 2006) |
| "Two patients with type 2 diabetes taking rosiglitazone for glycemic control developed paradoxically low HDL-C levels during rosiglitazone therapy." | ( Favreau, CM; Gutschi, LM; Malcolm, JC; Ooi, TC, 2006) |
| "When type 2 diabetes is managed with glucose-lowering monotherapy, glycemic control ultimately deteriorates due to the inability of the beta-cell to overcome insulin resistance." | ( Seufert, J, 2006) |
| "In subjects with type 2 diabetes inadequately controlled by oral agents, preprandial administration of INH delivered by a MDI provided a comparable metabolic control to bedtime GLA and did not show any safety concerns during a 4-week treatment." | ( Buchwald, A; Dellweg, S; Genova, P; Hausmann, M; Heinemann, L; Heise, T; Osborn, C; Rosskamp, R, 2006) |
| "To evaluate risk of new-onset type 2 diabetes associated with use of selected antipsychotic agents, the authors conducted a new-user cohort study in a national sample of US Veterans Health Administration patients with schizophrenia (and no preexisting diabetes)." | ( Cunningham, FE; Dalack, GW; Hur, K; Lambert, BL; Miller, DR, 2006) |
| "Fifty patients with type 2 diabetes were given simvastatin 20 mg and placebo, simvastatin 20 mg and ramipril 10 mg, or ramipril 10 mg and placebo daily during each treatment period." | ( Ahn, JY; Han, SH; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2007) |
| "To review the pathophysiology of type 2 diabetes (T2DM), the role of incretins, the potential of incretin-based therapies to address unmet therapeutic needs in T2DM, and the potential impact this will have on the contribution of managed care pharmacy to diabetes therapy." | ( Blonde, L; Rosenstock, J; Triplitt, C, 2006) |
| "Traditionally, Type 2 diabetes is first treated with medical nutrition therapy (reduced food intake and increased physical activity), followed by stepwise addition of oral antidiabetes therapies and, ultimately, exogenous insulin, as required." | ( Holcombe, JH; Kendall, DM; Stonehouse, AH, 2006) |
| "Insulin therapy in type 2 diabetes is initiated when glycemic control is inadequate despite the combination of antihyperglycemic drugs." | ( Ceponis, J; Varanauskaite, I; Varanauskiene, E, 2006) |
| "In the hypertensive patients with type 2 diabetes, all markers except adiponectin decreased significantly after 3 months of CR nifedipine treatment." | ( Inami, N; Iwasaka, T; Kimura, Y; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A, 2007) |
| "Except for the outcome incidence of type 2 diabetes in acarbose versus no treatment (two studies), meta-analyses were not possible." | ( Akkermans, RP; De Grauw, WJ; Lucassen, PL; Van de Laar, FA; Van de Lisdonk, EH, 2006) |
| "Patients with type 2 diabetes and complete HbA(1c) (A1C) data and treated with metformin or sulfonylurea monotherapy for at least three visits before receiving dual oral therapy were included (n = 644)." | ( Constantino, MI; Molyneaux, LM; Ong, CR; Twigg, SM; Yue, DK, 2006) |
| "Of 381 patients who had type 2 diabetes and were on treatment with sulfonylurea or sulfonylurea plus metformin, 260 (63% male, 37% female) showed evidence of volume expansion as defined by an absolute reduction in hematocrit (Hct) of > or =0." | ( Buckingham, R; Karalliedde, J; Lorand, D; Starkie, M; Stewart, M; Viberti, G, 2006) |
| "We have previously used the renal haemodynamic response to angiotensin-converting enzyme (ACE) inhibition to demonstrate the state of RAS activation, and thus measured renal plasma flow (RPF) and glomerular filtration rate (GFR) before and after administration of captopril at 0 month and at three months." | ( Ahmed, S; Coletti, C; Gordon, MS; Hollenberg, NK; Lansang, MC, 2006) |
| "Considering that patients with type 2 diabetes often have hyperlipidemia, colestimide therapy may have a clinically useful dual action in such patients." | ( Kadonosono, K; Okamura, A; Takano, T; Utsunomiya, H; Yamakawa, T, 2007) |
| "The therapeutic options for treating type 2 diabetes have been widened by the introduction of exenatide as the first incretin mimetic." | ( Gallwitz, B, 2006) |
| "About 115 patients with type 2 diabetes were treated with gliclazide for 8 weeks." | ( Kuang, H; Liu, X; Xing, H; Yi, R; Zhang, H, 2007) |
| "Twenty patients with diet-treated type 2 diabetes (13 women, seven men) were randomized to receive either rosiglitazone (n = 9; 8 mg/d) or metformin (n = 11; 2 g/d) for 16 wk." | ( Eriksson, P; Fisher, RM; Hamsten, A; Kannisto, K; Kolak, M; Tiikkainen, M; Yki-Järvinen, H, 2007) |
| "In everyday practice, patients with type 2 diabetes who are inadequately controlled on OADs benefit from add-on basal insulin treatment with insulin glargine as they demonstrate improved glycaemic control without weight gain." | ( Haak, T; Schreiber, SA, 2007) |
| "Fifty patients with type 2 diabetes who had been initially treated with oral antidiabetic agents without a satisfactory response were included in this study." | ( Cetinkalp, S; Erdogan, M; Karadeniz, M; Ozbek, M; Ozgen, AG; Saygili, F; Tuzun, M; Yilmaz, C, 2006) |
| "One hundred twenty (120) patients with type 2 diabetes mellitus were randomized and treated with glimepiride plus rosiglitazone or glimepiride plus metformin for 12 weeks." | ( Ahn, CW; Cha, BS; Chung, CH; Kang, ES; Kim, DJ; Kim, HJ; Kim, SH; Lee, HC; Lee, KW; Nam, CM; Nam, M, 2007) |
| "Forty subjects with type 2 diabetes and inadequate glycemic control on sulfonylurea and metformin therapy received 24 weeks of add-on therapy with either RSG 4mg daily or IG 10 units daily." | ( Karounos, DG; Kingsley, FJ; Reynolds, LR; Tannock, LR, 2007) |
| "Twelve patients with type 2 diabetes were randomly assigned to treatment with either pioglitazone or placebo in a double-blinded 8-week protocol." | ( Howell, ME; Stuart, CA; Yin, D, 2007) |
| "Novel therapeutic strategies for type 2 diabetes are needed, since the current treatment options neither address all pathophysiological mechanisms nor achieve the glycemic target goals." | ( Gallwitz, B, 2007) |
| "Clinical trials in patients with type 2 diabetes treated with subcutaneous exenatide twice daily demonstrated sustained improvements in glycemic control, evidenced by reductions in postprandial and fasting glycemia and glycosylated hemoglobin (HbA(1c)) levels." | ( Kolterman, O; Schnabel, CA; Wintle, M, 2006) |
| "Many patients with type 2 diabetes have dyslipidemia, which requires treatment with three hydroxy-3-methyl glutaryl coenzyme (HMG-CoA) reductase inhibitors (statins), hence, concurrent use of exenatide and statins is likely." | ( Fineman, M; Han, J; Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, M; Pena, A; Reddy, S; Skrivanek, Z, 2007) |
| "Ninety-three patients with type 2 diabetes and major depressive disorder (MDD) received bupropion hydrochloride in a two-phase, open-label treatment trial." | ( Clouse, RE; Lustman, PJ; Nix, BD; Sayuk, GS; Williams, MM, 2007) |
| "In both IDDM and NIDDM diabetic neuropathic patients, chronic sildenafil treatment exhibited a significant decrease in total sperm output and sperm concentration (p<0." | ( Ali, ST; Rakkah, NI, 2007) |
| "Novel aspects in the treatment of type 2 diabetes by GLP-1 receptor stimulation further include its influence on the insulin secretory pattern, insulin/glucagon ratio, body weight and possibly even pancreatic beta cell mass." | ( Erdmann, E; Reuter, H, 2007) |
| "In these subjects with type 2 diabetes, 12 weeks of colesevelam treatment were associated with significant reductions in HbA(1c) and in fructosamine and postprandial glucose levels compared with placebo." | ( Bailey, WL; Jones, MR; Kalin, MF; Schwartz, SL; Zieve, FJ, 2007) |
| "Twenty-seven insulin-treated men with type 2 diabetes [body mass index 30." | ( Damholt, B; Endahl, L; Heise, T; Klein, O; Lynge, J; Nosek, L, 2007) |
| "Early-onset type 2 diabetes is associated with marked visceral obesity and extreme insulin resistance, but its pathogenesis and response to treatment are not completely understood." | ( Burns, N; Finucane, FM; Gasparro, D; Gastaldelli, A; Gilman, M; Hatunic, M; Mari, A; Murphy, M; Nolan, JJ, 2007) |
| "We evaluated 32 patients with Type 2 diabetes who underwent such course of treatment, with view of establishing whether the interruption has any detrimental effect on the success of the therapy in terms of weight loss and diabetes compensation." | ( Owen, K; Svacina, S, 2006) |
| "120 patients with type 2 diabetes mellitus were randomly divided into four equal groups: Group I, receiving no intervention therapy as control group, Group II, given folic acid orally (5 mg/d), Group III, receiving intramuscular injection of methylcobalamin (500 microg qd), and Group IV, treated with methylcobalamin (500 microg qd) in addition to folic acid (5 mg/d)." | ( Dou, JT; Gu, WJ; Guo, QH; Lu, JM; Mu, YM; Pan, CY; Yang, GQ, 2007) |
| "The treatment of type 2 diabetes in a patient with CRF is a challenge for the general practitioner, because of the accumulation of drugs and/or specific metabolites." | ( Berwert, L; Teta, D; Zanchi, A, 2007) |
| "Despite the increased prevalence of type 2 diabetes mellitus (T2DM) in the pediatric population, there is limited information about the relative effectiveness of treatment approaches." | ( Epstein, L; Grey, M; Hirst, K; Kaufman, F; Tamborlane, W; Wilfley, D; Zeitler, P, 2007) |
| "Twenty patients with diet-treated type 2 diabetes, diagnosed within the past 5 years, were included." | ( Dejgaard, A; Gredal, C; Hilsted, J; Rosenfalck, AM, 2007) |
| "In patients with type 2 diabetes and mixed hyperlipoproteinaemia, short-term atorvastatin as well as fenofibrate therapy had no significant effects on adiponectin, ghrelin or resistin levels." | ( Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M, 2007) |
| "She had type 2 diabetes for 15 years, with proliferative diabetic retinopathy that had been treated with panretinal photocoagulation." | ( Akova, YA; Eren, E; Küçükerdönmez, C; Yilmaz, G, 2007) |
| "Insulin treatment in patients with type 2 diabetes mellitus affects the expression of inflammatory cytokines and subsequently modifies the thrombotic mechanisms in patients with coronary atherosclerosis, independently from the duration of diabetes and the extend of coronary artery disease." | ( Antoniades, C; Bosinakou, E; Latsios, G; Marinou, K; Papageorgiou, N; Siasos, G; Stefanadi, E; Stefanadis, C; Tentolouris, C; Tousoulis, D; Tsioufis, C, 2007) |
| "A 74-year-old woman with type 2 diabetes mellitus who had been treated with a sulfonylurea for 6 years began experiencing frequent episodes of hypoglycemia." | ( Chang, WH; Chen, TL; Lei, WY; Wang, CY; Wang, TE; Yang, TL, 2007) |
| "Although the pharmodynamic properties of the thiazolidinedione (TZD) insulin-sensitizing agents in the treatment of type 2 diabetes are well established, there are no studies comparing the pharmacoefficacy of these drugs in different ethnic groups." | ( Baker, J; Clarke, R; Connolly, S; Elder, P; Frampton, C; Scott, R; Shand, B; Yeo, J, 2007) |
| "This was a study in patients with type 2 diabetes previously untreated with medication and untreated mild hypertension (diastolic blood pressure [DBP] >90 and <105 mm Hg)." | ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Salvadeo, S, 2007) |
| "As understanding of type 2 diabetes mellitus pathophysiology expands, treatments continue to evolve and new pharmacologic targets emerge." | ( Jennings, HR; Langley, AK; Suffoletta, TJ, 2007) |
| "150 out-patients with type 2 diabetes mellitus visiting 3 hospitals in Beijing were randomly divided into two equal groups: study group treated with extended-release metformin 1500 mg qd for 12 weeks, and control group treated with Glucophage (tablet of metformin, 500 mg, tid) and in for 12 weeks." | ( Gao, HW; Hong, TP; Xiao, WH; Yang, JK; Yang, WY; Yang, Y; Zhang, JP, 2007) |
| "The epidemic of type 2 diabetes in the latter part of the 20th and early 21st centuries and the recognition that achieving specific glycemic goals can substantially reduce morbidity, have made effective treatment of hyperglycemia a top priority." | ( Sabán Ruiz, J; Sánchez Sánchez, O, 2007) |
| "We examined 31 patients with type 2 diabetes mellitus during both a baseline period and a period of treatment with pioglitazone." | ( Anan, F; Eshima, N; Fukunaga, N; Iwao, T; Kaneda, K; Masaki, T; Okada, K; Saikawa, T; Teshima, Y; Umeno, Y; Wakasugi, K; Yonemochi, H; Yoshimatsu, H, 2007) |
| "Exenatide is an adjunctive therapy for type 2 diabetes, and preliminary evidence suggests that its glucoregulatory effects may be similar in the absence of oral therapy." | ( Fineman, M; Guan, X; Nelson, P; Poon, T; Schnabel, C; Wintle, M, 2007) |
| "TZDs are approved for the treatment of Type 2 diabetes, and have been studied as a diabetes-prevention strategy." | ( Aquilante, CL, 2007) |
| "In patients with type 2 diabetes, TZD treatment might have slight adverse effects on ventricular contractility and fluid dynamics at the beginning of the therapy." | ( Atar, A; Biyiklioglu, Z; Dogruk Unal, A; Güvener Demirag, N; Türkmen Kemal, Y; Yildirir, A, 2007) |
| "Five patients with type 2 diabetes, three of them treated with insulin and two with oral antidiabetic drugs, receiving imatinib due to chronic myeolid leukaemia are reported." | ( Chodorowski, Z; Hellmann, A; Prejzner, W; Sein Anand, J, 2007) |
| "One hundred sixty-eight patients with type 2 diabetes mellitus (T2DM) prospectively received simvastatin as a single-agent therapy (20mg day-1 p." | ( An, CY; Gao, YY; Liu, XM; Sun, YM; Ying, S, 2007) |
| "Patients with type 2 diabetes mellitus (T2DM) exhibit reduced total and intact GLP-1 levels, and exogenous administration of the hormone via continuous infusion results in glucose profiles similar to those in non-diabetic subjects." | ( Deacon, CF, 2007) |
| "Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic control is suboptimal, though evidence supporting specific insulin regimens is limited." | ( Davies, MJ; Farmer, AJ; Holman, RR; Keenan, JF; Levy, JC; Paul, S; Thorne, KI, 2007) |
| "The increasing prevalence of type 2 diabetes has sparked interest in the development of agents that treat and prevent the disease." | ( Kasibhatla, B; Peters, KG; Wos, J, 2007) |
| "Thirty subjects with type 2 diabetes were initiated on intensive insulin therapy (continuous subcutaneous insulin infusion [n = 12] or multiple daily injections [n = 18]) and then randomized to either pioglitazone (PIO group;45 mg/day), ramipril (RAM group; 10 mg/day), or placebo (PLC group) for 36 weeks." | ( Cersosimo, E; Cusi, K; DeFronzo, R; Fernandez, M; Musi, N; Sriwijilkamol, AA; Triplitt, C; Wajcberg, E, 2008) |
| "Most patients with type 2 diabetes mellitus will eventually require insulin therapy to achieve or maintain adequate glycaemic control." | ( Le Roith, D, 2007) |
| "Present treatment strategies of type 2 diabetes are unsatisfactory." | ( Jornayvaz, F; Philippe, J, 2007) |
| "Many patients with type 2 diabetes fail to achieve adequate glycaemic control with available treatments, even when used in combination, and eventually develop microvascular and macrovascular diabetic complications." | ( Carr, RD; Deacon, CF; Holst, JJ, 2008) |
| "The burden of type 2 diabetes and its associated premature morbidity and mortality is rapidly growing, and the need for novel efficacious treatments is pressing." | ( Butler, AA; Clifton, PG; Elmquist, JK; Evans, ML; Heisler, LK; Lam, DD; McCrimmon, RJ; Oksanen, LJ; Rochford, JJ; Semple, RK; Sutton, GM; Thornton-Jones, ZD; Yueh, CY; Zhou, L, 2007) |
| "A total of 103 newly diagnosed type 2 diabetes patients without taking any drug were enrolled and treated with rosiglitazone maleate (4 or 8 mg/d) for 24 weeks." | ( Bao, YQ; Hu, C; Jia, WP; Lu, JX; Wang, CR; Xiang, KS; Xu, J; Zhang, H; Zhang, R, 2007) |
| "Insulin is an effective treatment for type 2 diabetes (T2D), a progressive condition in which insulin deficiency is one of the core defects." | ( Ilag, LL; Kerr, L; Malone, JK; Tan, MH, 2007) |
| "Insulin is an effective treatment for type 2 diabetes (T2D), a progressive condition in which insulin deficiency is one of the core defects." | ( Ilag, LL; Kerr, L; Malone, JK; Tan, MH, 2007) |
| "(1) When type 2 diabetes is inadequately controlled with oral antidiabetic therapy, one option is to add subcutaneous insulin injections (or to accept less stringent glycaemic control)." | ( , 2007) |
| "The optimal treatment of type 2 diabetes is currently uncertain." | ( Grant, P; McIntyre, HF, 2007) |
| "Insulin resistance, hyperglycemia, and type 2 diabetes are among the sequelae of metabolic syndromes that occur in 60-80% of human immunodeficiency virus (HIV)-positive patients treated with HIV-protease inhibitors (PIs)." | ( Cade, WT; Cam, M; Carper, MJ; Ramanadham, S; Shalev, A; Yarasheski, KE; Zhang, S, 2008) |
| "Novel therapeutic strategies for type 2 diabetes are needed, since the current treatment options neither address all pathophysiological mechanisms nor achieve the glycemic target goals." | ( Gallwitz, B, 2007) |
| "Twenty-one patients with type 2 diabetes mellitus were observed for more than 6 months after treatment with pioglitazone, and 31 patients with type 2 diabetes mellitus were observed for more than 6 months after the treatment with metformin." | ( Fujita, T; Hayakawa, N; Horikawa, Y; Imamura, S; Inagaki, K; Itoh, M; Kakizawa, H; Oda, N; Suzuki, A; Takeda, J; Uchida, Y, 2008) |
| "GLIM monotherapy in patients with type 2 diabetes mellitus (T2DM)." | ( Chou, HS; Hamann, A; Matthaei, S; Rosenstock, J; Seidel, DK, 2008) |
| "methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0." | ( Brock, B; Krarup, T; Kølendorf, K; Le-Thi, T; Lervang, HH; Levin, K; Madsbad, S; Perrild, H; Schmitz, O; Vilsbøll, T; Zdravkovic, M, 2008) |
| "Current therapeutic agents to treat Type 2 diabetes are insufficient and thus, newer approaches are desperately needed." | ( Bouzakri, K; Koistinen, HA; Zierath, JR, 2005) |
| "Subjects with type 2 diabetes mellitus were studied before and after a 6-month behavioral intervention therapy, during fasting and during a hyperinsulinemic normoglycemic clamp." | ( Bugianesi, E; Hanson, RW; Kalhan, SC; Kelley, DE; McCullough, AJ, 2008) |
| "One hundred cases of type 2 diabetes mellitus patients were randomly divided into the control group treated with oral administration of Diaformin and the observation group treated with oral administration of Diaformin combined with acupuncture at Baihui (GV 20), Fengfu (GV 16), 50 cases in each group." | ( Kong, L; Shen, PF, 2007) |
| "Patients with type 2 diabetes naïve to insulin can be effectively treated with once-daily insulin detemir (+/- OADs) to achieve improved glycaemic control with no adverse effect on weight and a low risk of hypoglycaemia." | ( Dornhorst, A; Hansen, JB; Kozlovski, P; Looij, BJ; Lüddeke, HJ; Meneghini, L; Sreenan, S, 2008) |
| "In these patients with type 2 diabetes and a history of TIA, patterns of platelet inhibition differed significantly according to whether treatment was with ER-DP+ASA or clopidogrel with or without ASA." | ( Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL, 2008) |
| "All the patients had a diagnosis of type 2 diabetes mellitus (T2DM) given at least 3 years previously and evidence of stable treatment using oral hypoglycemic agents, insulin, or both for at least 12 months." | ( DePaula, AL; Halpern, A; Macedo, AL; Machado, CA; Mota, BR; Rassi, N; Schraibman, V; Silva, LQ; Vencio, S, 2008) |
| "For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide optimal glycaemic control, necessitating insulin therapy." | ( Davies, M; Gomis, R; Lavalle-González, F; Storms, F, 2008) |
| "Patients with type 2 diabetes mellitus often begin treatment by taking oral agents, usually metformin or a sulfonylurea, and then progress to the combination of these two agents." | ( Alvarez, C; Edwards, KL; Fields, J; Irons, BK, 2008) |
| "In clinical trials, patients with type 2 diabetes treated with exenatide demonstrate sustained improvements in glycemic control, with reductions in fasting and postprandial glucose levels and improvements in glycosylated hemoglobin levels." | ( Henry, RR; Mafong, DD, 2008) |
| "In patients with advanced type 2 diabetes at high risk for cardiovascular events, pioglitazone treatment resulted in significant risk reductions in MACE composite end points to 3 years." | ( Erdmann, E; Kupfer, S; Wilcox, R, 2008) |
| "In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride." | ( De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K, 2008) |
| "In this study of patients with type 2 diabetes, treatment with TZDs was associated with a significant improvement in adiponectin levels, although no significant effects were seen on leptin levels and arterial elasticity." | ( Baran, I; Cangur, S; Dirican, M; Ersoy, C; Eryilmaz, S; Fazlioglu, M; Gul, CB; Imamoglu, S; Ocak, N; Oz, O; Tuncel, E, 2008) |
| "Incidence of type 2 diabetes mellitus (T2DM) has increased in young people in recent years and new therapies are required for its effective treatment." | ( Wang, AR; Yu, BS, 2008) |
| "Ten long-standing, insulin-treated type 2 diabetes patients, 11 subjects with impaired fasting glucose, impaired glucose tolerance and/or recently diagnosed type 2 diabetes, and 12 healthy, normoglycaemic controls, matched for age and body composition and with low habitual physical activity levels were studied." | ( De Feyter, HM; Nicolay, K; Praet, SF; Prompers, JJ; van den Broek, NM; van Loon, LJ, 2008) |
| "A total of 400 patients with type 2 diabetes, who were > or = 35 years old and who had been treated with metformin and a sulphonylurea for at least 6 months, completed questionnaires during their usual primary care office visit." | ( Krishnarajah, G; Lyu, R; Mavros, P; Vexiau, P; Yin, D, 2008) |
| "Patients with type 2 diabetes who added a sulphonylurea or a thiazolidinedione to ongoing metformin therapy on a date (index date) from January 2001 through January 2006 and who had at least one haemoglobin A1C (HbA1C) measurement in the 12-month period before the visit date were eligible." | ( Alvarez Guisasola, F; Krishnarajah, G; Lyu, R; Mavros, P; Tofé Povedano, S; Yin, D, 2008) |
| "Twenty-one patients with Type 2 diabetes treated with oral glucose-lowering agents were randomized in this two-period crossover study to an equivalent 24-h dose of continuous subcutaneous infusion of insulin aspart and subsequently once-daily bedtime subcutaneous injection of insulin glargine, or vice versa, for eight consecutive days." | ( Christiansen, JS; Hartvig, H; Lauritzen, T; Laursen, T; Parkner, T; Smedegaard, JS; Vestergaard, ET, 2008) |
| "Thus, targeting the hyperglycemia in type 2 diabetes mellitus (DM) alone will not eliminate all of the excess cardiovascular risk; rather aggressive treatment is needed for all of the modifiable cardiometabolic risk factors." | ( Gerich, JE, 2007) |
| "Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance." | ( Kendall, D; Maggs, D; Okerson, T; Stonehouse, A, 2008) |
| "All patients with type 2 diabetes not adequately controlled on their previous therapy, and who were prescribed BIAsp30 as monotherapy, or in combination with oral hypoglycaemic agents, were eligible for the study." | ( Jang, HC; Lee, SR; Vaz, JA, 2009) |
| "Seventeen patients with type 2 diabetes were treated with acarbose and sixteen with pioglitazone for three months." | ( Inoue, D; Ishikawa, T; Ochiai, H; Okazaki, R; Ooka, H; Shida, C, 2008) |
| "Compared with the type 2 diabetes group, 12 weeks of EGB treatment caused very slight pathological changes in the Leydig cells, significantly increased the concentrations of blood LH and T, markedly elevated the levels of mRNA in StAR and P450scc and induced an ascending tendency of the expressions of P450c17, 17beta-HSD3 and 3beta-HSD1." | ( Chen, GR; Fang, ZX; Wang, RR; Wang, WY; Wu, XY; Xie, L, 2008) |
| "Twenty-eight patients with type 2 diabetes were randomized to receive either twice-daily 50/50 premixed insulin lispro (Mix50 group) or BB (NPH insulin at bedtime and preprandial insulin lispro) therapy (BB group) for 12 weeks." | ( Atsuda, K; Inoue, G; Irie, J; Kitaoka, A; Masuda, H; Sakamoto, M; Shiono, K; Yamada, S, 2008) |
| "In patients with type 2 diabetes, the application of SMBG as an adjunct to oral antidiabetic agent therapy results in further reductions in HbA1c." | ( Azizi, F; Barnett, AH; Embong, M; Imamoglu, S; Krentz, AJ; Perusicová, J; Sieradzki, J; Strojek, K; Uliciansky, V; Winkler, G, 2008) |
| "Patients with type 2 diabetes or metabolic syndrome remain at high residual risk of cardiovascular events even after intensive statin therapy." | ( Franssen, R; Kastelein, JJ; Stroes, ES; Vergeer, M, 2009) |
| "Ten subjects with type 2 diabetes on sulfonylurea therapy were treated with pioglitazone (30 mg daily) for 16 weeks." | ( Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Ravikumar, B; Taylor, R, 2008) |
| "The treatment of type 2 diabetes mellitus (T2DM) in elderly people is made more difficult than in their younger counterparts, primarily owing to the impact of co-morbidities, complications and hypoglycaemia as well as technical difficulties with insulin injections." | ( Janka, HU, 2008) |
| "In the early treatment of type 2 diabetes mellitus (T2DM), the addition of a basal insulin, such as insulin glargine, to existing oral therapy can help patients attain recommended glycaemic control targets, including haemoglobin A(1c) (HbA(1c)) <7% and fasting blood glucose <5." | ( Raccah, D, 2008) |
| "For many patients with type 2 diabetes mellitus, metformin plus appropriate treatment for cardiovascular risk factors form the cornerstone of drug therapy." | ( , 2008) |
| "Treatment of type 2 diabetes includes lifestyle adaptations and drug treatment with the recent availability of many new substances." | ( Philippe, J; Spada, A, 2008) |
| "Forty-two non-smoking type 2 diabetes subjects with mildly elevated HbA1c (>7 but < 9%) and severely elevated (>9%) were randomized to one of two non-surgical periodontal therapy protocols." | ( Boyd, LD; Chiodo, G; Herriges, B; Laughlin, G; Madden, TE; Rosenstein, D, 2008) |
| "Treatment of type 2 diabetes mellitus (T2DM) patients with pioglitazone results in a more favorable lipid profile, and perhaps more favorable cardiac outcomes, than treatment with rosiglitazone." | ( Beysen, C; Boyle, PJ; Decaris, M; Fong, A; Hellerstein, MK; Murphy, EJ; Nagaraja, H; Riiff, T, 2008) |
| "The insulin treatment in type 2 diabetes mellitus (DM 2) is an explosive subject within health economics." | ( Fritsche, A, 2008) |
| "Twenty-seven patients with type 2 diabetes mellitus were divided into pioglitazone-treated (Pio), metformin-treated (Met), and exercise-treated (Ex) groups." | ( Araki, T; Emoto, M; Inaba, M; Koyama, H; Lee, E; Mori, K; Nishizawa, Y; Shoji, T; Teramura, M; Yokoyama, H, 2008) |
| "Hypertensive patients with type 2 diabetes and microalbuminuria were randomly assigned to valsartan or amlodipine treatment groups for 24 weeks." | ( Kashiwagi, A; Maegawa, H; Sawaguchi, M; Uzu, T, 2008) |
| "Treatment of type 2 diabetes (T2DM) is based on lifestyle changes and oral antidiabetic agents or insulin." | ( Debaty, I; Halimi, S; Muller, M; Villaret, L, 2008) |
| "Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control." | ( Bethel, MA; Holman, RR; Matthews, DR; Neil, HA; Paul, SK, 2008) |
| "Patients aged >or=18 years with type 2 diabetes were randomly assigned to receive exenatide 5 microg, exenatide 10 microg, or placebo administered SC BID." | ( Brodows, RG; Macconell, LA; Milton, DR; Moretto, TJ; Okerson, T; Ridge, TD; Wolka, AM, 2008) |
| "In these patients with type 2 diabetes naive to treatment with antidiabetic agents, exenatide monotherapy was associated with improved HbA(1c), improved fasting and postprandial glucose control, reduced weight, improved beta-cell function (HOMA-B), and improved blood pressure, and was well tolerated." | ( Brodows, RG; Macconell, LA; Milton, DR; Moretto, TJ; Okerson, T; Ridge, TD; Wolka, AM, 2008) |
| "New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia." | ( Bode, B; Garber, A; Garcia-Hernandez, PA; Hale, PM; Henry, R; Olvera-Alvarez, I; Ratner, R; Rodriguez-Pattzi, H; Zdravkovic, M, 2009) |
| "The prevalence of type 2 diabetes (T2DM) is increasing, creating a need for T2DM animal models for the study of disease pathogenesis, prevention, and treatment." | ( Baskin, DG; Cummings, BP; Digitale, EK; Graham, JL; Griffen, SC; Havel, PJ; Reed, BJ; Stanhope, KL; Sweet, IR, 2008) |
| "Oral therapy for type 2 diabetes mellitus, when used appropriately, can safely assist patients to achieve glycaemic targets in the short to medium term." | ( Bailey, CJ; Krentz, AJ; Patel, MB, 2008) |
| "In subjects with type 2 diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin." | ( Düring, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, IH; Nauck, M; Shah, NS; Tankova, T; Zdravkovic, M, 2009) |
| "Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride." | ( Mogensen, CE; Sadikot, SM, 2008) |
| "The diagnosis and treatment of type 2 diabetes in the elderly is challenging, as age-related changes alter the clinical presentation of diabetic symptoms." | ( Abbatecola, AM; Maggi, S; Paolisso, G, 2008) |
| "Platelets are hyperactive in Type 2 diabetes mellitus (T2DM), and antiplatelet treatment with glycoprotein (GP) IIb/IIIa inhibitors provides better thrombotic protection in DM than in non-diabetic subjects." | ( Hjemdahl, P; Li, N; Ostenson, CG; Razmara, M, 2008) |
| "Patients with type 2 diabetes and coronary artery disease undergoing clinically indicated coronary angiography or percutaneous coronary intervention are randomized to receive rosiglitazone or glipizide for 18 months using a titration algorithm designed to provide comparable glycemic control between treatment groups." | ( Cannon, CP; Fitzgerald, PJ; Gerstein, HC; Kolatkar, NS; Kravitz, BG; Nesto, RW; Ratner, RE; Serruys, PW; Van Es, GA; Zalewski, A, 2008) |
| "In animal models, treatment of type 2 diabetes mellitus rats with BBR lowered fasting blood glucose and fasting serum insulin, increased insulin sensitivity, and elevated InsR mRNA as well as PKC activity in the liver." | ( Jiang, JD; Kong, WJ; Li, ZR; Pan, HN; Shan, N; Si, SY; Song, DQ; Wang, YM; Wei, J; Xue, R; Yang, P; You, XF; Zhang, H; Zhao, LX; Zhao, W; Zhou, ZX, 2009) |
| "Sitagliptin therapy in individuals with type 2 diabetes has been found to lower significantly hemoglobin A1c (Hb1c) levels with a minimum of adverse side effects such as weight gain or hypoglycemia." | ( Feinglos, M; Green, J, 2008) |
| "Thirty-three subjects with type 2 diabetes and 32 normal controls were included; patients were examined at baseline and after 5 months of rosiglitazone treatment (4 mg/day)." | ( Capek, P; Ceska, R; Doležalová, R; Kasalová, Z; Marinov, I; Stulc, T; Svobodová, H, 2009) |
| "A total of 80 patients with type 2 diabetes were recruited and divided into two groups: Tongxinluo therapy group (n = 40) and conventional therapy group (n = 40)." | ( Chen, H; Li, LJ; Ren, JY; Wu, B; Xu, CB; Yang, SW, 2008) |
| "In patients with type 2 diabetes inadequately controlled by glyburide monotherapy, the addition of alogliptin resulted in clinically significant reductions in HbA1c without increased incidence of hypoglycaemia." | ( Fleck, PR; Kipnes, MS; Mekki, Q; Pratley, RE; Wilson, C, 2009) |
| "Thirty-two patients with type 2 diabetes or impaired glucose tolerance and stable CAD received six weeks of double-blind treatment with simvastatin 80 mg daily (S80; n = 16) or ezetimibe 10 mg and simvastatin 10 mg daily (E10/S10; n = 16)." | ( Böhm, F; Hjemdahl, P; Malmström, RE; Pernow, J; Settergren, M, 2009) |
| "Adults having type 2 diabetes mellitus for > or =1 year, aged 40-70 years and not requiring insulin therapy (n 109) were recruited." | ( Gutschall, MD; Lawrence, FR; Miller, CK; Mitchell, DC, 2009) |
| "comparison of 35 type 2 diabetes patients treated with insulin to 35 controls treated with oral hypoglycemic agents." | ( Achour, A; Aouididi, F; Dakhli, S; Lamine, F; Lamine, S; Mami, FB; Trabelsi, N; Zouaoui, C, 2007) |
| "All subjects with type 2 diabetes requiring insulin and considered suitable for BIAsp 30 therapy based on their physician's clinical judgment were eligible to enter the study." | ( Baruah, MP; Das, AK; Ganapathi, B; Kalra, S; Kumar, A; Sahay, RK; Shah, S; Unnikrishnan, AG, 2009) |
"Subjects had type 2 diabetes, A1C 7-11% (previous oral antidiabetes drug [OAD] monotherapy >or=3 months) or 7-10% (previous OAD combination therapy >or=3 months), and BMI | ( Blonde, L; Buse, JB; Gerich, J; Hale, PM; Lewin, A; Raskin, P; Schwartz, S; Zdravkovic, M; Zinman, B, 2009) | |
| "Melatonin administration in NIDDM patients resulted in a significant increase in the morning melatonin concentration and SOD-1 activity, and a reduction in the MDA level and Cp oxidase activity." | ( Bartosz, G; Czuczejko, J; Kedziora, J; Kedziora-Kornatowska, K; Kornatowski, T; Kozakiewicz, M; Pawluk, H; Szewczyk-Golec, K, 2009) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "The increasing prevalence of type 2 diabetes provides impetus for both development of new drugs to improve glycemic control and for reconsideration of treatment strategies with existing agents." | ( Baron, MA; Israel, MK; Istvan, E, 2008) |
| "Sialic acid changes in NIDDM patients were investigated following bitter melon (55 ml/24h) and rosiglitazone (4 mg/24h) treatment." | ( Bashir, M; Iqbal, M; Khan, R; Malik, SA, 2009) |
| "Women with type 2 diabetes treated with sulfonylureas should not be discouraged from breastfeeding." | ( Djokanovic, N; Finkelstein, Y; Garcia-Bournissen, F; Glatstein, MM; Koren, G, 2009) |
| "Treatment naive patients with type 2 diabetes received 15-30 mg/day pioglitazone monotherapy." | ( Fukushima, T; Kutoh, E, 2009) |
| "Twenty-seven per cent patients of type 2 diabetes use insulin therapy but less than 1/2 achieves recommended HbA1c level 7 per cent or less." | ( Das, AK, 2008) |
| "Thirty-six subjects with type 2 diabetes, treated with metformin and bed-time insulin, were randomised to supplementation with cholecalciferol (40,000 IU per week) versus placebo for 6 months." | ( Figenschau, Y; Jorde, R, 2009) |
| "The increasing prevalence of type 2 diabetes is associated with increasing health costs, especially for the treatment of cardiovascular disease." | ( Brown, L; Iyer, A; Patel, J, 2009) |
| "In Yucatán, 52% of patients with type 2 diabetes (DT2) present secondary failure to treatment associated with sulphonylurea and metformin." | ( García-Escalante, MG; Laviada-Molina, H; López-Avila, MT; Pinto-Escalante, Ddel C; Suárez-Solís, VM, 2009) |
| "The 77 patients with type 2 diabetes and treated only with oral hypoglycemic agents were divided in two groups, with and without the metabolic syndrome." | ( Aloui, F; Bastide, D; Frachebois, C; Julier, I; Mavrakanas, T; Soualah, A, 2009) |
| "Study subjects were 99 patients with type 2 diabetes mellitus aged over 20 years who were judged to require insulin therapy due to poor glucose control (HbA1c level of > or =7." | ( Aoki, S; Kato, M; Kijima, H; Koike, T; Komori, K; Kurihara, Y; Manda, N; Ono, Y; Wada, N; Yanagisawa, K; Yoshioka, N, 2009) |
| "We studied nineteen patients with type 2 diabetes and nonalcoholic fatty liver disease diagnosed and treated between 2005 and 2008 at Health Center of Budaörs." | ( Abel, T; Dinya, E; Fehér, J; Gamal Eldin, M; Kovács, A, 2009) |
| "In patients with type 2 diabetes, glycemic control to target goals can only be achieved for a while by single-drug treatment." | ( Forst, T; Karagiannis, E; Pfützner, A; Posseldt, RE; Schöndorf, T, 2009) |
| "Main inclusion criteria were type 2 diabetes, metformin monotherapy, and an initial hemoglobin A1c (HbA1c) value between 6." | ( Forst, T; Karagiannis, E; Pfützner, A; Posseldt, RE; Schöndorf, T, 2009) |
| "The arterial stiffness and haemodynamic response to intravenous L-nitro-monomethyl arginine (L-NMMA 3mg/kg) was assessed at baseline and at the end of each treatment phase." | ( Brillante, DG; Brillante, RE; Howes, LG; O'Sullivan, AJ, 2009) |
| "Patients with type 2 diabetes inadequately controlled on basal insulins may improve their glycaemic control by intensification to BIAsp 30 therapy." | ( Benroubi, M; Borzi, V; Gumprecht, J; Kawamori, R; Ligthelm, R; Shaban, J; Shah, S; Shestakova, M; Valensi, P; Wenying, Y, 2009) |
| "Adults with inadequately controlled type 2 diabetes on maximally tolerated doses of metformin, sulphonylurea, or both, were stratified by previous oral antidiabetic therapy and randomly assigned to receive additional liraglutide 1." | ( Blonde, L; Brett, JH; Buse, JB; Montanya, E; Rosenstock, J; Schmidt, WE; Sesti, G; Zychma, M, 2009) |
| "Two hundred and fifty-six patients with Type 2 diabetes who had never previously received peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists or lipid-lowering treatment were treated with 4 mg of rosiglitazone daily for 12 weeks without any adjustment to their glucose-lowering regimen." | ( Ahn, CW; Cha, BS; Kang, ES; Kim, DH; Kim, SK; Lee, HC; Lee, JH; Park, SE, 2009) |
| "Known treatments of type 2 diabetes mellitus have limitations such as weight gain, and hypoglycaemias." | ( Verspohl, EJ, 2009) |
| "Twenty patients (ten women) with type 2 diabetes who were on an intensified insulin therapy participated." | ( Krayenbühl, P; Schmid, C; Seifert, B; Uthoff, H; Wiesli, P, 2009) |
| "Of all drugs used in the treatment of Type 2 diabetes, the insulin sensitizers thiazolidinediones (e." | ( Abdel-Gaber, SA; Ashour, OM; Fouad, AA; Morsy, MA, 2010) |
| "Previous data suggest patients with Type 2 diabetes develop greater symptomatic and hormonal responses to hypoglycaemia at higher glucose concentrations than non-diabetic controls and these responses are lowered by insulin treatment." | ( Amiel, SA; Choudhary, P; Emery, CJ; Heller, SR; Lonnen, K; MacDonald, IA; MacLeod, KM, 2009) |
| "Due to the increasing prevalence of type 2 diabetes, suboptimal management of the associated hyperglycemia, morbidity and mortality associated with the disease, and the limitations of currently available therapies, novel therapeutic strategies are needed for its treatment." | ( Brooks, AM; Thacker, SM, 2009) |
| "Twenty-four subjects with Type 2 diabetes treated with diet and/or metformin were randomized in a double-blind study to receive 30 mg pioglitazone, 8 mg rosiglitazone or placebo once daily for 3 months." | ( Brackenridge, AL; Hovorka, R; Jackson, N; Jefferson, W; Russell-Jones, D; Shojaee-Moradie, F; Stolinski, M; Umpleby, AM, 2009) |
| "In patients with Type 2 diabetes and normal lipids, treatment with rosiglitazone or pioglitazone had no significant effect on lipoprotein metabolism compared with placebo." | ( Brackenridge, AL; Hovorka, R; Jackson, N; Jefferson, W; Russell-Jones, D; Shojaee-Moradie, F; Stolinski, M; Umpleby, AM, 2009) |
| "Sixty type 2 diabetes mellitus subjects were randomly assigned to receive pioglitazone (30 mg/d, n = 19), rosiglitazone (4 mg/d, n = 20), or placebo (medical nutrition therapy, n = 21) for 12 weeks." | ( Ersoy, C; Guclu, M; Gul, CB; Imamoglu, S; Kiyici, S; Oral, AY; Oz Gul, O; Tuncel, E; Ulukaya, E; Yilmaz, Y, 2010) |
| "Advances in type 2 diabetes genetics have raised hopes that genetic testing will improve disease prediction, prevention and treatment." | ( Florez, JC; Grant, RW; Hivert, M; Meigs, JB; Nathan, DM; Pandiscio, JC, 2009) |
| "People with type 2 diabetes form a heterogeneous group; treatment regimens and therapeutic targets must take these individual circumstances into account." | ( Woo, VC, 2009) |
| "They improve metabolic control in type 2 diabetes in monotherapy and also in combination with metformin, sulphonylurea and thiazolidinediones." | ( Ahrén, B, 2009) |
| "A rat model of type 2 diabetes (OLETF) and its control (LETO) were treated with tauroursodeoxycholic acid (TUDCA) (100 mg ." | ( Hotta, H; Ishikawa, S; Miki, T; Miura, T; Sato, T; Shimamoto, K; Takada, A; Tanno, M; Terashima, Y; Yano, T, 2009) |
| "In patients with recent-onset type 2 diabetes, treatment with insulin or metformin compared with placebo did not reduce inflammatory biomarker levels despite improving glucose control." | ( Cook, NR; Everett, BM; Pradhan, AD; Ridker, PM; Rifai, N, 2009) |
| "glimepiride in patients with type 2 diabetes and failure of diet/lifestyle plus metformin monotherapy." | ( Gallwitz, B; Guzmán, JR; Kazda, C; Kraus, P; Nicolay, C; Rose, L; Schernthaner, G; Simó, R, 2009) |
| "Forty-five patients with type 2 diabetes and moderate to severe chronic periodontitis were selected and randomly assigned to one of the following three treatment modalities (15 subjects each): scaling and root planing (SRP) only, SRP plus systemic doxycycline, and SRP plus PDT." | ( Al-Sherbini, MM; Al-Zahrani, MS; Alhassani, AA; Bamshmous, SO, 2009) |
| "To compare mortality risks among type 2 diabetes (T2D) patients being treated with glibenclamide, gliclazide, or glimepiride." | ( Khalangot, M; Kovtun, V; Kravchenko, V; Tronko, M, 2009) |
| "Under metformin therapy, she developed type 2 diabetes and acanthosis nigricans." | ( Belgorosky, A; Di Palma, MI; Guercio, G; Mazza, C; Pepe, C; Prieto, M; Rivarola, MA; Saraco, NI; Saure, C, 2009) |
| "Due to the natural progression of type 2 diabetes (T2D), most patients require combination therapy to maintain glycemic control." | ( Allen, E; Chen, R; Hollander, P; Li, J, 2009) |
| "The impact of the three treatments for type 2 diabetes on survival and cumulative incidence of cardiovascular, ocular, or renal events and costs were estimated at three time periods: 10, 20, and 30 years." | ( Alfonso-Cristancho, R; Blonde, L; Conner, C; Hammer, M; Sullivan, SD, 2009) |
| "In type 1 and type 2 diabetes, insulin exerts an inhibitory effect on oxidative stress, a metabolic disorder that is significantly activated by sustained hyperglycaemia and glucose variability in non-insulin-treated type 2 diabetes." | ( Boegner, C; Colette, C; Cristol, JP; Mas, E; Michel, F; Monnier, L; Owens, DR, 2010) |
| "Groups of db/db mice, with obesity and type 2 diabetes, were treated with aliskiren (3, 6, 12 and 25 mg kg(-1) day(-1)) or hydralazine (80 mg kg(-1) day(-1)) for 6 weeks, and the protective effects were extensively compared among groups." | ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y, 2010) |
| "Patients with type 2 diabetes and stable coronary artery disease undergoing elective percutaneous coronary intervention (PCI) were randomized to bolus dose of 500 mg bosentan (n = 4), a dual endothelin receptor blocker, or intracoronary administration of 0." | ( Bengtsson, M; Kalani, M; Papadogeorgos, NO, 2009) |
| "placebo in patients with Type 2 diabetes treated with combined metformin-sulphonylurea therapy in the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive)." | ( Betteridge, DJ; Birkeland, K; Charbonnel, B; Scheen, AJ; Schmitz, O; Tan, MH, 2009) |
| "To compare costs among patients with type 2 diabetes mellitus treated with exenatide or insulin glargine from a US third-party payer perspective." | ( Boye, KS; Fabunmi, R; Lage, MJ; Misurski, D, 2009) |
| "Insulin-naive subjects with type 2 diabetes suboptimally controlled on oral glucose-lowering drugs (OGLDs) (including at least metformin) were randomized to 24-week treatment with either insulin glargine once-daily or insulin detemir twice-daily, titrated to obtain fasting plasma glucose <100 mg/dL." | ( Dain, MP; DeVries, JH; Hoekstra, JB; Holleman, F; Snoek, FJ; Swinnen, SG, 2009) |
| "Forty-five type 2 diabetes mellitus patients with low-density lipoprotein cholesterolemia were enrolled and treated with pitavastatin 2 mg/day for 12 months." | ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T, 2009) |
| "In many patients with type 2 diabetes mellitus and stable ischemic coronary disease in whom angina symptoms are controlled, similar to those enrolled in the percutaneous coronary intervention stratum, intensive medical therapy alone should be the first-line strategy." | ( Adler, D; Chaitman, BR; Frye, RL; Gebhart, S; Grogan, M; Hardison, RM; Ocampo, S; Ramires, JA; Schneider, D; Sopko, G, 2009) |
| "Patients with type 2 diabetes and those with metabolic syndrome must lose weight and increase their physical activity, and drugs must be administered whenever applicable, to reach body mass index (BMI) guided and waist circumference objectives." | ( Alvarez-Sala, L; Armario, P; Brotons, C; Conthe, P; de Alvaro, F; de Santiago, A; del Río, A; Gil-Núñez, A; Lizarbe, V; Lizcano, A; Lobos, JM; Luengo, E; Maiques, A; Martíonez, M; Mauricio, D; Rico, O; Royo-Bordonada, MA; Sans, S; Vargas, MA; Villar, F, 2009) |
| "One hundred overweight/obese type 2 diabetes mellitus patients, with inadequate glycemic control (hemoglobin A(1c) >7%) despite combined treatment with gliclazide plus metformin, were randomized using a 2 x 2 factorial design to 4 equivalent (n = 25) groups, as follows: (1) CO: maintenance of habitual activities, (2) RSG: add-on therapy with rosiglitazone (8 mg/d), (3) EX: adjunctive exercise training, and (4) RSG + EX: supplementary administration of rosiglitazone (8 mg/d) plus exercise training." | ( Alevizos, M; Angelopoulou, N; Athanasiadou, Z; Iliadis, F; Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Liapis, CD; Sailer, N; Vitta, I; Vrabas, IS, 2010) |
| "Metformin treatment of Type 2 diabetes is not usually associated with weight gain, and may assist with weight reduction." | ( Begg, EJ; Doogue, MP; Lunt, H; Moore, MP; Pemberton, CJ; Zhang, M, 2009) |
| "Eighteen patients with Type 2 diabetes were studied before and after 6 weeks of metformin treatment, which was titrated to 1 g b." | ( Begg, EJ; Doogue, MP; Lunt, H; Moore, MP; Pemberton, CJ; Zhang, M, 2009) |
| "Treatment of Type 2 diabetes with metformin was associated with increased plasma ghrelin concentrations, without associated changes in hunger and satiety." | ( Begg, EJ; Doogue, MP; Lunt, H; Moore, MP; Pemberton, CJ; Zhang, M, 2009) |
| "* Patients with Type 2 diabetes are likely to have or to develop renal impairment, which affects the pharmacokinetics of some antidiabetic treatments." | ( Hindsberger, C; Jacobsen, LV; Robson, R; Zdravkovic, M, 2009) |
| "The advantage to treat anaemia in type 2 diabetes for reducing the risk of adverse cardiovascular outcomes remains to be demonstrated." | ( Bonora, E; Chonchol, M; Lippi, G; Muggeo, M; Negri, C; Pichiri, I; Stoico, V; Targher, G; Zoppini, G, 2010) |
| "A patient diagnosed with type 2 diabetes mellitus and Parkinson's disease developed a compulsive eating disorder when treated with a dopamine agonist, pramipexole." | ( Khan, W; Rana, AQ, 2010) |
| "In many patients with type 2 diabetes, hyperglycemia can be reduced with appropriate changes in diet and exercise, however, some patients with type 2 diabetes and insulin resistance syndromes need pharmacological therapy to improve their metabolic control." | ( Jarosz-Chobot, P; Nowowiejska, B; Otto-Buczkowska, E; Stańczyk, J, 2009) |
| "A total of 250 patients with type 2 diabetes mellitus were treated with pioglitazone (30 mg/d) for 24 weeks without a change in previous medications." | ( Chang, SJ; Chen, HC; Hsiao, JY; Hsieh, MC; Lin, KD; Lin, SR; Shing, SJ; Tien, KJ; Tu, ST, 2010) |
| "For patients with Type 2 diabetes or gestational diabetes, oral hypoglycemic agents (OHAs) represent an attractive alternative to insulin therapy." | ( Feig, DS; Koren, G; Pollex, EK, 2010) |
| "Most patients with ketosis-prone type 2 diabetes (KPD) discontinue insulin therapy and remain in near-normoglycemic remission." | ( Gosmanov, AR; Kitabchi, AE; Peng, L; Robalino, G; Siqueira, JM; Smiley, D; Umpierrez, GE, 2010) |
| "The treatment of type 2 diabetes mellitus (T2DM) has been revolutionized by the introduction of novel therapeutic regimens following the clinical approval of the long-acting basal insulin glargine 10 years ago, followed by insulin detemir and, more recently, agents that target the glucagon-like peptide (GLP)-1 system with dipeptidyl peptidase 4 (DPP-4)-resistant products, such as liraglutide and exenatide, and DPP-4 inhibitors, such as sitagliptin, saxagliptin, alogliptin, and vildagliptin." | ( Garg, SK, 2010) |
| "Treatment options for type 2 diabetes based on the action of the incretin hormone glucagon-like peptide-1 (GLP-1) were first introduced in 2005." | ( Gallwitz, B, 2010) |
| "To test this strategy in a model of type 2 diabetes, we treated 2-month-old diabetic Lprdb/db mice with losartan, paricalcitol, or a combination of losartan and paricalcitol for 3 months." | ( Chang, A; Deb, DK; Kong, J; Li, YC; Ning, G; Shi, H; Sun, T; Wong, KE; Zhang, Y; Zhang, Z, 2010) |
| "In hemodialysis patients who have type 2 diabetes and are treated with acetylsalicylic acid, PF4-H-ABs are associated with sudden and all-cause death." | ( Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K, 2010) |
| "Mainstays of therapy for type 2 diabetes involve drugs that are insulin-centric, i." | ( Robertson, RP, 2010) |
| "Low HDL-C levels are common in type 2 diabetes but are not currently recommended as a target for treatment because of the lack of definitive cardiovascular outcome studies supporting this goal, and because of the difficulty in raising HDL-C." | ( Dunn, FL, 2010) |
| "A total of 4733 participants with type 2 diabetes were randomly assigned to intensive therapy, targeting a systolic pressure of less than 120 mm Hg, or standard therapy, targeting a systolic pressure of less than 140 mm Hg." | ( Basile, JN; Bigger, JT; Buse, JB; Byington, RP; Corson, MA; Cushman, WC; Cutler, JA; Evans, GW; Friedewald, WT; Gerstein, HC; Goff, DC; Grimm, RH; Ismail-Beigi, F; Katz, L; Peterson, KA; Probstfield, JL; Simons-Morton, DG, 2010) |
| "We randomly assigned 5518 patients with type 2 diabetes who were being treated with open-label simvastatin to receive either masked fenofibrate or placebo." | ( Bigger, JT; Buse, JB; Byington, RP; Crouse, JR; Cushman, WC; Elam, MB; Friedewald, WT; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, RH; Ismail-Beigi, F; Leiter, LA; Linz, P; Lovato, LC; Probstfield, J; Simons-Morton, DG, 2010) |
| "A total of 104 newly diagnosed type 2 diabetes patients (69 men, 35 women) were recruited and treated with repaglinide for 24 weeks." | ( Bao, YQ; Hu, C; Jia, WP; Lu, JY; Qin, W; Wang, CR; Xiang, KS; Yu, WH; Zhang, R, 2010) |
| "For patients with type 1 or type 2 diabetes, achieving good glycemic control is critical for successful treatment outcomes." | ( Muchmore, DB; Vaughn, DE, 2010) |
| "A total of 3,095 patients with type 2 diabetes were randomized 2:1 to bromocriptine-QR or placebo in conjunction with the patient's usual diabetes therapy (diet controlled only or up to two antidiabetes medications, including insulin)." | ( Cincotta, AH; Ezrokhi, M; Gaziano, JM; Ma, ZJ; O'Connor, CM; Rutty, D; Scranton, RE, 2010) |
| "Patients with type 2 diabetes, coronary artery disease, cerebrovascular disease or peripheral arterial disease referred by general practitioners to the medical specialist at the University Medical Center (UMC) Utrecht (a setting with a vascular screening programme of systematic screening of risk factors followed by treatment advice) and the Leiden UMC (a setting without such a screening programme), were enrolled in the study." | ( Algra, A; Bollen, EL; Brouwer, BG; Doevendans, PA; Greving, JP; Kappelle, LJ; Moll, FL; Pijl, H; Romijn, JA; van Bockel, JH; van der Graaf, Y; van der Wall, EE; Visseren, FL, 2010) |
| "Treatment of patients with type 2 diabetes mellitus (T2DM) traditionally has involved a progression of phases, from conventional lifestyle interventions and monotherapy, to combination therapy involving oral agents, to insulin initiation and its use either alone or with oral pharmacotherapy." | ( Cefalu, WT, 2010) |
| "In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status." | ( Achenbach, U; Alkhalaf, A; Bakker, SJ; Bilo, HJ; Gans, RO; Kleefstra, N; Klooster, A; Mijnhout, GS; Navis, GJ; Slingerland, RJ; van Oeveren, W, 2010) |
| "Patients with type 2 diabetes are reported to have a worse response to cancer chemotherapy, have more complications, and have a poorer prognosis than patients with cancer without diabetes." | ( Gallagher, EJ; LeRoith, D, 2010) |
| "In patients with type 2 diabetes, adding sitagliptin to metformin monotherapy improved glycaemic control over 2 years, similar to the glucose-lowering efficacy observed with adding glipizide, but with greater durability and generally better maintenance of beta-cell function." | ( Amatruda, JM; Davies, MJ; Kaufman, KD; Nauck, M; Seck, T; Sheng, D; Stein, PP; Sunga, S, 2010) |
| "A 52-year-old obese man with type 2 diabetes for 10 years initiated therapy with 2 oral antidiabetic drugs (OADs)." | ( Lavernia, F, 2010) |
| "In general, patients with type 2 diabetes should be treated to their lowest targeted glycemic goals as soon as they are diagnosed, for as long as possible, as safely as possible, and as rationally as possible." | ( Parkin, CG; Unger, J, 2010) |
| "New treatments of type 2 diabetes have been developed, especially with the use of the properties of incretins, gastrointestinal hormones involved in glucose homeostasis." | ( Guerci, B; Halter, C, 2010) |
| "Recently detected 152 IGT and 158 type 2 diabetes patients aged between 30 and 69 years, never treated with any antidiabetic drug, lipid lowering agent, angiotension converting enzyme (ACE) inhibitor and/or angiotensin receptor blocker (ARB) were evaluated." | ( Chowdhury, S; Mukhopadhyay, P; Mukhopadhyay, S; Pandit, K; Sanyal, D, 2009) |
| "Twenty-six patients with type 2 diabetes mellitus, hypertension and albuminuria were randomised to 2-month treatments with placebo or aliskiren 150 mg, 300 mg or 600 mg once daily, in random order." | ( Boomsma, F; Danser, AH; Frandsen, E; Juhl, T; Parving, HH; Persson, F; Reinhard, H; Rossing, P; Schalkwijk, C; Stehouwer, CD, 2010) |
| "390 patients with type 2 diabetes receiving treatment with insulin." | ( Bets, D; de Jager, J; Donker, AJ; Kooy, A; Lehert, P; Stehouwer, CD; van der Kolk, J; Verburg, J; Wulffelé, MG, 2010) |
| "Children (10-17 years) diagnosed with type 2 diabetes were screened for participation in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study." | ( Arslanian, S; Copeland, KC; Cuttler, L; Kaufman, F; Klingensmith, GJ; Laffel, L; Linder, B; Marcovina, S; Pyle, L; Tollefsen, SE; Weinstock, RS, 2010) |
| "In patients with Type 2 diabetes inadequately controlled with metformin, addition of vildagliptin provided similar HbA(1c)-lowering efficacy compared with gliclazide after 52 weeks of treatment." | ( Filozof, C; Gautier, JF, 2010) |
| "Treatment of type 2 diabetes (T2DM) with pioglitazone changes abdominal fat in the opposite direction as treatment with glipizide." | ( Basu, A; Basu, R; Jensen, MD; Pattan, V; Rizza, RA, 2010) |
| "Recent guidelines for treatment of type 2 diabetes suggest starting intensive therapy of hyperglycemia at an early stage of diabetes and recommend therapeutic options that provide the possibility of reaching HbA1c goals individually, with a low risk of hypoglycemia or other adverse effects of treatment." | ( Raslova, K, 2010) |
| "Combined PIO and BEZA therapy in Type 2 diabetes does not decrease intrahepatic triglyceride content or postprandial endogenous glucose production." | ( Balasubramanian, R; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Taylor, R, 2010) |
| "We report four patients with Type 2 diabetes prescribed long-term statin treatment who, following treatment with fusidic acid, presented atypically with painless, severe flaccid paralysis suggestive of Guillain-Barré syndrome." | ( Collidge, TA; Deighan, CJ; Mann, AC; Nolan, C; Razvi, S; Russell, AJ; Stirling, C; Whittle, M, 2010) |
| "Chronic exenatide treatment in type 2 diabetes is associated with improved glucose control and fasting lipid levels, as well as weight loss." | ( Koska, J; Mullin, MP; Reaven, PD; Schwartz, EA; Schwenke, DC; Syoufi, I, 2010) |
| "Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment." | ( Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P, 2010) |
| "In Japanese patients with type 2 diabetes, once-daily sitagliptin monotherapy showed greater efficacy and better tolerability than thrice-daily voglibose over 12 weeks." | ( Amatruda, JM; Arjona Ferreira, JC; Iwamoto, Y; Kadowaki, T; Nishii, M; Nonaka, K; Tajima, N; Taniguchi, T, 2010) |
| "From 450 type 2 diabetes mellitus insulin-treated patients attending the ER with a capillary glucose level >13." | ( Tentolouris, N; Voulgari, C, 2010) |
| "Among the new treatments discussed for type 2 diabetes were the analogues of the incretin hormones glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), namely, the GLP-1 receptor agonists-as well as the inhibitors of dipeptidyl peptidase-4 (DPP-4), the enzyme that regulates the bioactivity of the endogenous incretin hormones." | ( Fonseca, VA; Goldfine, AB; Nauck, MA; Plutzky, J; Zinman, B, 2010) |
| "Patients with type 2 diabetes mellitus (n = 47) whose glycemia was not controlled adequately with oral hypoglycemic agents at maximum recommended therapeutic doses were initiated on exenatide therapy." | ( Anjana, RM; Fathima, M; Mohan, V; Sudhakaran, C; Unnikrishnan, RI, 2010) |
| "In a group of select Asian Indian type 2 diabetes patients with secondary failure to oral hypoglycemic agents seen at a diabetes center, exenatide treatment in combination with oral drug regimens resulted in significant lowering of glycated hemoglobin similar to insulin glargine or NPH insulin but with the additional benefit of weight loss, albeit a small amount." | ( Anjana, RM; Fathima, M; Mohan, V; Sudhakaran, C; Unnikrishnan, RI, 2010) |
| "Included were 100 type 2 diabetes patients whose blood glucose was suboptimally controlled on their previous antidiabetes treatment." | ( Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Lee, SJ; Park, SY; Yoo, HJ, 2010) |
| "Exenatide therapy in insulin-treated type 2 diabetes and obesity was associated with very significant reductions in weight and insulin doses." | ( Baskar, V; Govindan, J; Kalupahana, D; Nayak, UA; Singh, BM, 2010) |
| "Thiazolidinediones are used to treat type 2 diabetes." | ( Anand, S; Bailey, SD; Diaz, R; Do, R; Engert, JC; Gerstein, HC; Keavney, B; Mohan, V; Montpetit, A; Xie, C; Yusuf, S, 2010) |
| "The PBMCs from 15 type 2 diabetes mellitus (DM) patients and 13 healthy controls were used for cell analysis and culture with or without treatment by glucose and insulin or stimulation by lipopolysaccharide (LPS) for 1, 2, and 3 days." | ( Chuang, DY; Kuo, SF; Wu, HP; Wu, SY, 2010) |
| "In patients with type 2 diabetes mellitus in the BARI 2D Trial, a strategy of revascularization with coronary artery bypass graft surgery (CABG) or PCI resulted in no difference in mortality compared with optimal medical therapy." | ( Addo, T; Holper, EM, 2010) |
| "Forty type 2 diabetes mellitus patients with high serum low-density lipoprotein cholesterol (LDL-C) were enrolled and treated with ezetimibe 10 mg/day for 6 months." | ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Nagumo, A; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T, 2010) |
| "Such Type 2 diabetes conception brings various possibilities in the treatment and prevention." | ( Skrha, J, 2010) |
| "Patients with type 2 diabetes mellitus (T2DM) are generally treated with many pharmacological compounds and are exposed to a high risk of drug-drug interactions." | ( Scheen, AJ, 2010) |
| "Treating patients with type 2 diabetes and advanced-stage CKD with AST-120 appears to extend life and reduce costs." | ( Akizawa, T; Asano, Y; Fukuhara, S; Hayashino, Y; Kurokawa, K; Onishi, Y; Wakita, T, 2010) |
| "Pioglitazone treatment in type 2 diabetes mellitus produced significant improvements in glycaemic control, plasma lipids, blood pressure and inflammation." | ( Alemdar, R; Aydin, M; Basar, C; Caglar, O; Ordu, S; Ozhan, H; Yalcin, S; Yazici, M, 2010) |
| "Pioglitazone treatment in type 2 diabetes mellitus produced significant improvements in measures of glycaemic control and diastolic ventricular function." | ( Alemdar, R; Aydin, M; Basar, C; Caglar, O; Ordu, S; Ozhan, H; Yalcin, S; Yazici, M, 2010) |
| "Forty-nine Japanese patients with type 2 diabetes mellitus were randomly assigned into the withdrawal group after 3-month treatment with pioglitazone (15 or 30 mg daily) and the non-withdrawal group." | ( Asano, T; Hiramatsu, S; Iida, M; Iwase, M; Ogo, A; Sakai, Y; Sasaki, N; Yoshizumi, H, 2010) |
| "One therapy for type 2 diabetes, glyburide, suppressed IAPP-mediated IL-1β production in vitro." | ( Becker, C; Chen, Z; Coll, RC; Dunne, A; Franchi, L; Harris, J; Hull, RL; Kahn, SE; Lavelle, EC; Masters, SL; Mielke, LA; Mills, KH; Mok, KH; Mullooly, N; Newsholme, P; Nuñez, G; O'Neill, LA; Sharp, FA; Subramanian, SL; Tannahill, GM; Yodoi, J; Yoshihara, E, 2010) |
| "Patients with type 2 diabetes are at an increased risk for disease and treatment related complications after the initial approach of oral mono/dual antidiabetic therapy has failed." | ( Binz, C; Bramlage, P; Deeg, E; Gitt, AK; Krekler, M; Plate, T; Tschöpe, D, 2010) |
| "In the design of therapeutics to treat type 2 diabetes, researchers have exploited the observation that oral ingestion of nutrients leads to the secretion of glucose homeostasis-regulating incretin hormones (for example, glucagon-like-peptide-1) from the gut." | ( Kulkarni, RN, 2010) |
| "Male participants with type 2 diabetes (n = 10) and controls (n = 10) were evaluated before and after 2 months of sulodexide administration (200 mg/day)." | ( Broekhuizen, LN; Holleman, F; Lemkes, BA; Meuwese, MC; Mooij, HL; Nieuwdorp, M; Schlingemann, RO; Stroes, ES; Verberne, H; Vink, H, 2010) |
| "Adult patients suffering from type 2 diabetes mellitus and hospitalized for DFI (Texas classification of at least B2) were treated with 400 mg moxifloxacin intravenously (IV) or orally (PO) once daily." | ( Czaika, V; Drewelow, B; Gussmann, A; Klar, E; Koch, H; Kujath, P; Lobmann, R; Luebbert, C; Majcher-Peszynska, J; Mundkowski, RG; Ruf, BR; Sass, M; Schareck, W; Schipper, S, 2011) |
| "Intensive treatment of patients with Type 2 diabetes mellitus (T2DM) from the moment of diagnosis facilitates β-cell recovery." | ( Abad, R; Calle-Pascual, AL; Del Valle, L; Durán, A; Fernández, M; Martín, P; Pérez, N; Runkle, I; Sanz, MF, 2010) |
| "Patients with Type 2 diabetes mellitus (T2DM) are often treated with multiple glucose-lowering and cardiovascular agents." | ( Charbonnel, B; Erdmann, E; Spanheimer, R, 2010) |
| "A total of 39,275 patients with type 2 diabetes were treated with exenatide twice daily, and 381,218 patients were treated with other glucose-lowering therapies." | ( Best, JH; Herman, WH; Hoogwerf, BJ; Hussein, MA; Pelletier, EM; Smith, DB; Wenten, M, 2011) |
| "New classes of treatments for type 2 diabetes have been developed recently and are now available in the UK." | ( Barnett, AH, 2011) |
| "Despite advances in the management of type 2 diabetes, glycaemic control remains suboptimal for many patients because of the complexities of disease progression and the need to balance improved glycaemic control against adverse treatment effects, particularly weight gain and hypoglycaemia." | ( Unger, J, 2010) |
| "Treatment goals for patients with type 2 diabetes should be aligned with the basic defects of the disease." | ( Klonoff, DC, 2010) |
| "We report the case of a type 2 diabetes subject who developed severe leucopenia associated with treatment with the dipeptidil-peptidase 4 enzyme inhibitor Sitagliptin and highlights DPP4 inhibitors as a possible cause of unexplained hematolgical abnormalities in patients receiving DPP4-inhibitor treatment." | ( Caputo, S; Ghirlanda, G; Martini, F; Musella, T; Pitocco, D; Scavone, G; Zaccardi, F, 2011) |
| "Treatment with atorvastatin in type 2 diabetes did not change median total plasma plant sterol concentrations, but LDL cholesterol was reduced most efficaciously in high cholesterol synthesisers with low intestinal cholesterol absorption." | ( Ceglarek, U; Farmer, A; Holman, RR; Neil, HA; Paul, S; Thiery, J, 2010) |
| "In 87 patients with type 2 diabetes who failed to achieve glycaemic control on metformin monotherapy, effects of 6-month sulphonylurea in addition to metformin on reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels were evaluated." | ( Dobrikova, M; Habalova, V; Javorsky, M; Klimcakova, L; Kozarova, M; Rudikova, M; Schroner, Z; Tkac, I; Tkacova, R; Zidzik, J, 2011) |
| "The two major deficits in type 2 diabetes, insulin resistance and impaired beta cell function, are often treated with metformin and incretin-based drugs, respectively." | ( Cho, YM; Kieffer, TJ, 2011) |
| "Insulin resistance and type 2 diabetes (T2D) are commonly seen in human immunodeficiency virus (HIV) infection and are related to antiretroviral therapy." | ( Bastard, JP; Batard, ML; Capeau, J; Chene, G; Cheret, A; Deloumeaux, J; Foucan, L; Lamaury, I; Maachi, M; Muller, P; Sow-Goerger, MT; Velayoudom, FL, 2011) |
| "From 1731 type 2 diabetes patients (GLA: n = 1150; DET: n = 581) with statutory health insurance status and pretreatment with either GLA or DET for at least 6 months as part of a basal-bolus therapy, total direct costs of diabetes care (for insulins, oral antidiabetic drugs, test strips, needles, lancets, Hypokits®) were calculated from total recorded expenditures, for a period of six months, from the perspective of statutory health insurance." | ( Bierwirth, RA; Holle, R; Kohlmann, T; Landgraf, W; Moock, J, 2010) |
| "detemir based basal-bolus therapy in type 2 diabetes patients was associated with lower total costs of diabetes care Δ: -128 euro/patient) mainly caused by savings of consumables." | ( Bierwirth, RA; Holle, R; Kohlmann, T; Landgraf, W; Moock, J, 2010) |
| "Patients with type 2 diabetes participated in either a single-dose trial (n = 62) or a repeated-administration trial (n = 45)." | ( Aisporna, M; Cirincione, B; Diamant, M; Fineman, M; Flanagan, S; Kothare, P; Li, WI; MacConell, L; Mace, KF; Shen, LZ; Taylor, K; Walsh, B, 2011) |
| "We studied 2388 patients with type 2 diabetes (T2DM) not adequately controlled by monotherapy on either metformin (MET) or sulphonylurea (SU)." | ( Archimandritis, A; Charalampidou, E; Drossinos, V; Karamanos, B; Sourmeli, S; Thanopoulou, A, 2011) |
| "Older patients with type 2 diabetes--like patients with renal insufficiency an important and populous subgroup--also have issues with therapy selection and dosing regimens." | ( Fonseca, VA, 2011) |
| "Patients with type 2 diabetes treated with metformin and SU dual therapy were recruited by 54 investigators between January 2009 and August 2009." | ( Deleskog, A; Journath, G; Pettersson, B; Rosenqvist, U; Wändell, P, 2011) |
| "in patients with type 2 diabetes and inadequate glycaemic control on metformin monotherapy, the addition of sitagliptin or glimepiride led to similar improvement in glycaemic control after 30 weeks." | ( Arechavaleta, R; Chen, Y; Duran, L; Goldstein, BJ; Kaufman, KD; Krobot, KJ; O'Neill, EA; Seck, T; Williams-Herman, D, 2011) |
| "Most patients with type 2 diabetes (T2D) will require combining a lipid-lowering therapy with therapeutic lifestyle changes to achieve optimal lipid levels." | ( Al Badarin, F; Bell, DS; O'Keefe, JH, 2011) |
| "Most treatments for type 2 diabetes fail over time, necessitating combination therapy." | ( Bode, B; Chang, CT; Garber, A; Hale, P; Henry, RR; Ratner, R, 2011) |
| "Clinical trials in subjects with type 2 diabetes have shown that in periods of 12 weeks or more, these treatments reduce HbA(1c) by ≈ 0." | ( Ahrén, B, 2011) |
| "Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT." | ( Bahouth, SW; Cheema, P; Fain, JN; Garrett, E; Sacks, HS; Samaha, J; Wolf, RY; Wolford, D, 2011) |
| "In MS and type 2 diabetes with CAD, proinflammatory and anti-inflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment." | ( Bahouth, SW; Cheema, P; Fain, JN; Garrett, E; Sacks, HS; Samaha, J; Wolf, RY; Wolford, D, 2011) |
| "For the patients with newly diagnosed type 2 diabetes, additional administration of CDDP to the conventional treatment could exert beneficial effects on blood glucose controling, and lipid profile improvement and delay of arterial intima-media proliferation." | ( Liu, D; Tang, JY; Yan, L, 2010) |
| "The study cohort consisted of type 2 diabetes mellitus patients (n = 80) on regular therapy with glibenclamide either alone or with concomitant metformin." | ( Adithan, C; Agrawal, A; Anichavezhi, D; Pradhan, SC; Rajan, S; Subrahmanyam, DK; Surendiran, A, 2011) |
| "In conclusion, since patients with type 2 diabetes often have hyperlipidemia as well, colestimide therapy may have a clinically useful dual action in such patients." | ( Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T, 2011) |
| "A total of 47 newly diagnosed type 2 diabetes patients were randomized 1:1 to receive a 4-week treatment with repaglinide or gliclazide." | ( Bu, P; Lei, MX; Liao, EY; Luo, J; Mo, ZH; Xie, YH; Zhang, H, 2011) |
| "Treatment of patients with type 2 diabetes with Irbesartan decreased urinary excretion of MG-H1, G-H1 and 3-NT, which may result from decreased exposure to these AGEs." | ( Adaikalakoteswari, A; Parving, HH; Rabbani, N; Rossing, K; Rossing, P; Tarnow, L; Thornalley, PJ, 2012) |
| "Patients with type 2 diabetes mellitus and mixed hyperlipidemia have an increased cardiovascular risk and may not achieve recommended LDL-C and non-HDL-C goals on statin monotherapy." | ( Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A, 2011) |
| "Patients with insulin-treated type 2 diabetes and high insulin requirements are subject to undesirable treatment-related weight gain." | ( Lane, W; Rappaport, J; Weinrib, S, 2011) |
| "Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| "This study shows that adherence to type 2 diabetes treatment guidelines for initial treatment is implemented on a large scale." | ( Bouvy, ML; Dekker, JM; Hugtenburg, JG; Lamberts, EJ; Nijpels, G; Souverein, PC; Welschen, LM, 2011) |
| "Patients with type 2 diabetes frequently do not receive add-on therapy required for achieving the target values of glycaemic control." | ( Daniela, L; Ludvik, B, 2011) |
| "Twenty men with type 2 diabetes (aged 50-70 years) treated with diet, metformin or sulfonylurea alone were recruited from North Glasgow University National Health Service Trusts' diabetes clinics and randomised to either metformin or gliclazide for 10 weeks." | ( Boyle, JG; Cleland, SJ; Connell, JM; Jones, GC; Logan, PJ; Salt, IP; Sattar, N; Small, M, 2011) |
| "Participants (n = 65, 52 with Type 2 diabetes) were treated for a maximum of 16 weeks." | ( Bell, PM; Hughes, CM; Irwin, CR; Lagan, KM; Shaw, J; Stevenson, MR, 2011) |
| "In patients with type 2 diabetes mellitus undergoing hemodialysis, atorvastatin significantly reduces the risk of fatal and nonfatal cardiac events and death from any cause if pretreatment LDL-cholesterol is >145 mg/dl (3." | ( Drechsler, C; Genser, B; Grammer, TB; Holdaas, H; Holme, I; Krane, V; März, W; Ritz, E; Scharnagl, H; Stojakovic, T; Wanner, C; Winkler, K, 2011) |
| "Current treatment of hyperglycemia in type 2 diabetes (T2DM) is often ineffective and has unwanted effects." | ( Cassader, M; Gambino, R; Musso, G; Pagano, G, 2012) |
| "A recent treatment advance for type 2 diabetes is the oral therapy with DPP IV inhibitors." | ( Gallwitz, B, 2011) |
| "For patients with type 2 diabetes who have failed to achieve glycemic control through diet and exercise, liraglutide may be an important treatment option." | ( Bode, B, 2011) |
| "A total of 81 patients with type 2 diabetes were randomly assigned to one of three treatment groups for 4 weeks." | ( Azizi, F; Bahadoran, Z; Hedayati, M; Hosseinpanah, F; Hosseinpour-Niazi, S; Mirmiran, P, 2011) |
| "In patients with type 2 diabetes, this novel antidiabetic treatment usually leads to successful reduction in fasting as well as postprandial glycaemia and glycosylated haemoglobin." | ( Svacina, S, 2011) |
| "This paper reviews the link between type 2 diabetes and age-related hypogonadism and the treatment options for hypogonadism." | ( Jobe, LJ; Ryan, GJ, 2011) |
| "Primary goals in the treatment of type 2 diabetes mellitus (T2DM) include lowering blood glucose levels sufficiently to prevent micro- and macrovascular complications while limiting side effects, such as hypoglycemia and excessive weight gain." | ( Niswender, KD, 2011) |
| "Overall, 1121 patients treated for type 2 diabetes mellitus by 134 general practitioners were enrolled in this representative, national, cross-sectional survey and were followed retrospectively from the start of diabetes treatment." | ( Brändle, M; Gerber, PA; Keller, U; Lehmann, R; Spirk, D; Thoenes, M, 2011) |
| "Are we treating our type 2 diabetes subjects appropriately? To aid practicing clinicians various professional bodies like American Diabetes Association (ADA), European Association for Study of Diabetes (EASD), Canadian Diabetes Association (CDA), etc." | ( Baruah, MP; Ganapathy, B; John, M; Kalra, S; Sahay, RK; Unnikrishnan, AG, 2011) |
| "A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years." | ( Brooks, MM; Frye, RL; Genuth, S; Hardison, RM; Huber, K; Krishnaswami, A; McBane, RD; Pratley, RE; Schneider, DJ; Sobel, BE; Wolk, R, 2011) |
| "Fourteen patients with type 2 diabetes on metformin monotherapy received an add-on therapy with insulin glargine over 8 weeks." | ( Meier, JJ; Menge, BA; Nauck, MA; Pennartz, C; Schenker, N; Schmidt, WE, 2011) |
| "Insulin resistance and Type 2 diabetes not only accelerate the histological and clinical progression of chronic hepatitis C, but also reduce the virological response to IFN-α-based therapy." | ( Kaddai, V; Negro, F, 2011) |
| "Twenty subjects with type 2 diabetes (10 sulfonylurea-treated and 10 insulin-treated) and 10 controls without diabetes of similar age and weight underwent stepped hyperinsulinemic hypoglycemic clamps." | ( Choudhary, P; Emery, CJ; Freeman, JV; Heller, SR; Lonnen, K; McLeod, KM, 2011) |
| "We randomized 235 patients with type II diabetes mellitus into the treatment group (mean age 58." | ( Gerss, J; Hammes, HP; Haritoglou, C; Kampik, A; Ulbig, MW, 2011) |
| "Half of asymptomatic patients with type 2 diabetes mellitus and microalbuminuria had significant atherosclerosis in at least one vascular territory despite receiving intensive multifactorial treatment for CV risk reduction." | ( Hansen, PR; Jacobsen, PK; Kjær, A; Parving, HH; Petersen, CL; Reinhard, H; Rossing, P; Wiinberg, N; Winther, K, 2011) |
| "Incretin-based therapy for type 2 diabetes is based on the antidiabetic effects of glucagon-like peptide-1 (GLP-1) and instituted by GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors targeting the key islet defects of the disease." | ( Ahrén, B, 2011) |
| "In the AVOID study, 599 patients with type 2 diabetes, hypertension and nephropathy received 6 months aliskiren (150 mg force titrated to 300 mg once daily after 3 months) or placebo added to losartan 100 mg and optimal antihypertensive therapy." | ( Hans-Henrik, P; Hollenberg, NK; Lewis, EJ; Lewis, JB; Persson, F; Rossing, P, 2012) |
| "In the treatment of type 2 diabetes aimed at prevention of cardiovascular events impacting the prognosis of affected patients, it is critically important not only to lower HbAlc values but to find a way to improve postprandial hyperglycemia without causing hypoglycemia thus minimizing drastic glycemic variations or to maintain favorable glycemic control with daily glycemic variations in mind." | ( Mori, Y, 2011) |
| "Forty-four subjects with type 2 diabetes were randomly assigned to receive sitagliptin or medical nutrition therapy (MNT) for 12 weeks." | ( Cander, S; Ersoy, C; Ertürk, E; Gül, CB; Imamoğlu, S; Kırhan, E; Kıyıcı, S; Öz, Ö; Sarandol, E; Sığırlı, D; Tuncel, E; Ünal, OK; Yorulmaz, H, 2011) |
| "In this study of patients with type 2 diabetes, treatment with sitagliptin was associated with a significant decrease in serum ghrelin levels." | ( Cander, S; Ersoy, C; Ertürk, E; Gül, CB; Imamoğlu, S; Kırhan, E; Kıyıcı, S; Öz, Ö; Sarandol, E; Sığırlı, D; Tuncel, E; Ünal, OK; Yorulmaz, H, 2011) |
| "Thus many patients with type 2 diabetes will ultimately require treatment with insulin." | ( Migdalis, IN, 2011) |
| "In patients with type 2 diabetes mellitus on hemodialysis, KIF6 Trp719Arg genotypes were not associated with adverse cardiovascular outcomes during follow-up or with the efficacy of atorvastatin therapy." | ( Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C, 2011) |
| "In newly diagnosed type 2 diabetes mellitus (T2DM) patients, short-term insulin therapy might improve β-cell function and glycemic control." | ( Deng, H; Li, X; Lu, H; Mu, P; Wang, M; Zeng, L, 2012) |
| "For treating patients with type 2 diabetes, gliptins can primarily be used in combination with metformin." | ( Jermendy, G, 2011) |
| "In patients with type 2 diabetes mellitus, treatment with metformin is associated with a lower cardiovascular morbidity and mortality, compared with alternative glucose-lowering drugs." | ( de Boer, RA; El Messaoudi, S; Riksen, NP; Rongen, GA, 2011) |
| "In newly diagnosed type 2 diabetes, therapy with oral drugs + insulin has had favourable outcomes on recovery and maintenance of β-cell function and protracted glycaemic remission compared with treatment with oral drugs alone." | ( Chen, YM; Lu, HY; Mu, PW; Shu, J; Wang, MM; Wen, XQ; Xie, RY; Zeng, LY; Zhang, YH, 2012) |
| "The close link between type 2 diabetes and excess body weight highlights the need to consider the weight effects of different treatment regimens." | ( Caputo, S; Damçi, T; Khunti, K; Liebl, A; Meneghini, LF; Orozco-Beltran, D; Ross, SA, 2011) |
| "Patients with type 2 diabetes (age ≥ 18 years) who were treated with a stable dose of a sulphonylurea with or without metformin for at least 3 months prior to screening, who had an HbA(1c) < 10% and who expressed their intention to daytime fast during Ramadan were eligible for this open-label study." | ( Al Elq, A; Al Omari, M; Al Sifri, S; Al Tayeb, K; Basiounny, A; Davies, MJ; Echtay, A; Engel, SS; Girman, CJ; Harman-Boehm, I; Kaddaha, G; Katzeff, HL; Mahfouz, AS; Musser, BJ; Ozesen, C; Radican, L; Suryawanshi, S, 2011) |
| "A total of 101 patients with type 2 diabetes were treated for 12 weeks with pioglitazone (15 mg/day)." | ( Azarpira, N; Dabbaghmanesh, MH; Namvaran, F; Rahimi-Moghaddam, P, 2011) |
| "For most patients with type 2 diabetes that is inadequately controlled with metformin monotherapy, the addition of a sulphonylurea represents the most cost-effective second-line therapy." | ( Cameron, C; Klarenbach, S; Singh, S; Ur, E, 2011) |
| "Real-world data comparing outcomes of type 2 diabetes mellitus (T2DM) patients initiating different insulin regimens can help with treatment decisions and patient management." | ( Baser, O; Du, J; Pan, C; Wei, W; Xie, L, 2011) |
| "Fifty-nine drug-naïve patients with type 2 diabetes (T2D) were randomized to either 1 year treatment with the DPP-4 inhibitor vildagliptin (100 mg, once daily; n = 29) or placebo (n = 30)." | ( Bunck, MC; Diamant, M; Eekhoff, EM; Foley, JE; Heine, RJ; Nijpels, G; Poelma, M; Schweizer, A, 2012) |
| "In this mouse model of type 2 diabetes, Smad7 gene therapy significantly inhibited diabetic kidney injury, compared with mice treated with empty vectors." | ( Chao, TK; Chen, A; Huang, XR; Hung, YJ; Ka, SM; Lan, HY; Lin, TJ; Wu, CC; Yeh, YC; Yu, CP, 2012) |
| "In Japanese patients with type 2 diabetes or impaired glucose tolerance and coronary artery disease, adding ezetimibe (10 mg/day) to atorvastatin (10 mg/day) significantly improved the lipid profile compared with atorvastatin monotherapy at 20 mg/day." | ( Ishii, H; Koyasu, M; Matsubara, T; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M; Yoshikawa, D, 2012) |
| "Patients newly diagnosed with type 2 diabetes mellitus generally initiate therapy with either metformin [Met] or a sulfonylurea [SU] drug, followed by the addition of a second agent (Met, an SU drug, or a thiazolidinedione [TZD] drug) if the diabetes is not well controlled." | ( Cheng, LI; Lopez, D; Rascati, KL; Richards, KM; Wilson, JP, 2011) |
| "The majority of patients with type 2 diabetes mellitus will eventually require combination therapy involving two or more agents to achieve their glycemic target as their disease progresses." | ( Goldman-Levine, JD, 2011) |
| "We studied 52 consecutive patients with type 2 diabetes who had poor glycemic control despite treatment with metformin and/or sulfonylurea." | ( Aso, Y; Hara, K; Haruki, K; Inukai, T; Morita, K; Naruse, R; Ozeki, N; Shibazaki, M; Suetsugu, M; Takebayashi, K; Terasawa, T, 2012) |
| "Patients with type 2 diabetes show low GLP-1 concentrations in response to a meal, making treatment with incretin mimetics specifically indicated in this patient subset." | ( Avogaro, A, 2011) |
| "Within the new type 2 diabetes group, patients were further randomized into 4 mg rosiglitazone treatment group and life style adjustment group." | ( Guo, XH; Hui, Y; Yuan, GH; Zhang, WY, 2011) |
| "As it relates to specific treatment of type 2 diabetes mellitus, clinicians have traditionally initiated lifestyle intervention and progressed therapy using various drug treatments first as monotherapy and then as combination therapy throughout the course of the disease." | ( Cefalu, WT, 2012) |
| "Studies in animals and humans with type 2 diabetes showed that oral administration of sebacic acid improved glycaemic control, probably by enhancing insulin sensitivity, and reduced hepatic gluconeogenesis and glucose output." | ( Castagneto-Gissey, L; Macé, K; Mingrone, G, 2013) |
| "The increased burden of type 2 diabetes (T2D) necessitates the need for effective and safe novel drugs to treat this epidemic disease and its complications." | ( Gallwitz, B; Raz, I, 2011) |
| "Although newer treatments for type 2 diabetes (T2D) patients have produced continual improvements in outcome, a large and growing population with prediabetes remains under-treated." | ( Garber, AJ, 2011) |
| "This study confirmed that type 2 diabetes was associated with poorer prognosis after incident cancer, but that the association varied according to diabetes therapy and cancer site." | ( Currie, CJ; Gale, EA; Jenkins-Jones, S; Johnson, JA; Morgan, CL; Poole, CD, 2012) |
| "The pharmacological treatment of type 2 diabetes (T2DM) is becoming increasingly complex, especially since the availability of incretin-based therapies." | ( Scheen, AJ, 2012) |
| "In patients with Type 2 diabetes, well controlled with metformin monotherapy, addition of liraglutide improves several cardiovascular risk markers beyond glycaemic control." | ( Anders, S; Forst, T; Michelson, G; Mitry, M; Pfützner, A; Ratter, F; Weber, MM; Wilhelm, B, 2012) |
| "We enrolled 28 patients with type 2 diabetes complicated by dyslipidemia who had been treated with statins for at least one year." | ( Miwa, T; Odawara, M; Sasaki, J, 2012) |
| "The glucose levels of 21 type 2 diabetes patients admitted for glycemic control were monitored for three consecutive days by CGM after stable glycemic control was achieved with bolus or basal-bolus insulin therapy." | ( Matsuura, K; Mori, Y; Nakamura, A; Utsunomiya, K; Yokoyama, J, 2012) |
| "TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) is a federally funded multicenter randomized clinical trial comparing three treatments of youth onset type 2 diabetes." | ( Chang, N; Grey, M; Hale, D; Higgins, L; Hirst, K; Izquierdo, R; Laffel, L; Larkin, M; Macha, C; Pham, T; Wauters, A; Weinstock, RS, 2012) |
| "Patients with Type 2 diabetes inadequately controlled with sitagliptin plus metformin were randomly assigned to 20 weeks of treatment with twice-daily exenatide plus placebo and metformin (SWITCH, n = 127) or twice-daily exenatide plus sitagliptin and metformin (ADD, n = 128)." | ( Bachmann, OP; Chan, JY; Lüdemann, J; Oliveira, JH; Reed, VA; Violante, R; Yoon, KH; Yu, MB, 2012) |
| "One hundred and one patients with type 2 diabetes who failed to achieve HbA1c<7% on previous metformin monotherapy were included to the study." | ( Babjakova, E; Fabianova, M; Javorsky, M; Klimcakova, L; Kozarova, M; Salagovic, J; Schroner, Z; Tkac, I; Tkacova, R; Zidzik, J, 2012) |
| "Interestingly, type 2 diabetes patients treated with insulin displayed lower serum zinc compared to those not injecting insulin." | ( Giacconi, R; Jansen, J; Karges, W; Mocchegiani, E; Overbeck, S; Rink, L; Rosenkranz, E; Warmuth, S; Weiskirchen, R, 2012) |
| "Glycemic control in type 2 diabetes generally worsens over time, requiring intensification of therapy." | ( Best, JD; Davis, TM; Drury, PL; Keech, AC; Kesäniemi, YA; Pardy, C; Scott, R; Taskinen, MR; Voysey, M, 2012) |
| "In clinical studies in patients with type 2 diabetes, colesevelam, added to existing metformin, sulfonylurea or insulin therapy, reduced hemoglobin A(1c) (HbA(1c)) by a mean of 0." | ( Davis, SN; Younk, LM, 2012) |
| "A total of 134 type 2 diabetes mellitus patients on maintenance aspirin and clopidogrel therapy were studied." | ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012) |
| "In obese patients with uncontrolled type 2 diabetes, 12 months of medical therapy plus bariatric surgery achieved glycemic control in significantly more patients than medical therapy alone." | ( Abood, B; Bhatt, DL; Brethauer, SA; Kashyap, SR; Kirwan, JP; Nissen, SE; Pothier, CE; Schauer, PR; Thomas, S; Wolski, K, 2012) |
| "CASES SUMMARY: A 91-year-old woman with Type 2 diabetes on metformin and glibenclamide, also under treatment with oral antihypertensive drugs, platelet antiaggregant, low-molecular- weight heparin and buprenorphine, was prescribed levofloxacin for a bacterial infection." | ( Micheli, L; Nencini, C; Sbrilli, M, 2012) |
| "Treatment of patients with type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonist exenatide has showed improvements in glycaemic control coupled with weight loss and lowered blood pressure (BP)." | ( Best, J; Han, J; Klein, K; Maggs, D; Paul, S, 2012) |
| "One hundred seventy-one type 2 diabetes patients, naive to antidiabetes therapy and with poor glycemic control, were instructed to take metformin for 8±2 months up to a mean dosage of 2,500±500 mg/day; then they were randomly assigned to add vildaglipin 50 mg twice a day or placebo for 12 months." | ( Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D, 2012) |
| "30 patients with type 2 diabetes from Nader Kazemi Clinic, Shiraz, Iran were randomly divided into 2 groups; vitamin C treatment group (1000 mg d(-1)) and placebo group from May to September 2010." | ( Ahmadi, A; Ansar, H; Dabbaghmanesh, MH; Hejazi, N; Mazloom, Z; Tabatabaei, HR, 2011) |
| "Fasting whole blood specimens of 392 type 2 diabetes patients treated with metformin (n=199) or not (n=193) were collected." | ( Jia, W; Li, Q; Liu, F; Lu, F; Lu, H; Shen, Y; Tang, J; Zheng, T, 2012) |
| "24 male or female patients with type 2 diabetes were randomized to pioglitazone (45 mg/day) or placebo in addition to current therapy for 12 weeks using a prospective double blind crossover protocol following a run-in period >1 week and a 2 week washout period at crossover." | ( Chaturvedi, N; Coady, E; Hughes, AD; Khir, A; March, K; Park, C; Thom, SA, 2013) |
| "Despite the increasing prevalence of type 2 diabetes in youth, there are few data to guide treatment." | ( Arslanian, S; Copeland, K; Cuttler, L; Hirst, K; Kaufman, F; Linder, B; Nathan, DM; Pyle, L; Tollefsen, S; Wilfley, D; Zeitler, P, 2012) |
| "Adherence to therapy in patients with type 2 diabetes mellitus is contingent upon a number of variables, including variables specific to the patient, to the provider, and to the treatment." | ( Nau, DP, 2012) |
| "The Goto-Kakizaki (GK) rat, a type 2 diabetes model, has increased pancreatic islet and white adipose tissue (WAT) blood flow, and this can be normalized by acute administration of SR59230A, a β₃ -adrenoceptor antagonist." | ( Jansson, L; Pettersson, US; Sandberg, M, 2012) |
| "Patients with long-standing type 2 diabetes can switch safely from BHI to BIAsp therapy, even if they receive intensified treatment, and they have no problems changing the timing of their insulin injections." | ( Crenier, L; D'Hooge, D; Nobels, F, 2012) |
| "Patients with type 2 diabetes (n = 126) receiving basal-bolus insulin therapy with NPH insulin plus rapid-acting insulin analogues were recruited." | ( Abe, N; Kobayashi, M; Kuribayashi, N; Matoba, K; Oishi, M; Tomonaga, O; Yokoyama, H, 2012) |
| "Our findings suggest that Type 2 diabetes mellitus in the studied rats is associated with obesity, and that both diabetes and obesity can be prevented or improved by treatment with Actinomycetales immune modulators." | ( Alet, N; Bottasso, O; Gayol, Mdel C; McIntyre, G; Picena, JC; Stanford, C; Stanford, J; Tarrés, MC, 2012) |
| "In a patient with type 2 diabetes mellitus, the addition of the incretin mimetic exenatide and the dipeptidyl peptidase-4 inhibitor sitagliptin to glipizide therapy appeared effective and safe." | ( Edgerton, LP; Elmore, LK; Patel, MB; Whalin, LM, 2012) |
| "The cohort consisted of people with type 2 diabetes who were newly treated with oral hypoglycaemic agents between 1 January 1988 and 31 December 2009." | ( Assayag, J; Azoulay, L; Filion, KB; Majdan, A; Pollak, MN; Suissa, S; Yin, H, 2012) |
| "For patients with Type 2 diabetes inadequately controlled with oral anti-hyperglycaemic medications, glycaemic control when initiating and intensifying with LM25 therapy was found to be non-inferior to treatment with glargine + insulin lispro therapy." | ( Bowering, K; Felicio, J; Felicio, JS; Ji, L; Landry, J; Oliveira, J; Reed, VA, 2012) |
| "In people with type 2 diabetes, a dipeptidyl peptidase-4 (DPP-4) inhibitor is one choice as second-line treatment after metformin, with basal insulin recommended as an alternative." | ( Aschner, P; Chan, J; Dain, MP; Echtay, A; Fonseca, V; Owens, DR; Picard, S; Pilorget, V; Wang, E, 2012) |
| "Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin." | ( Basson, BR; Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Guzman, J; Kiljański, J; Sapin, H; Schernthaner, G; Simó, R; Trautmann, M, 2012) |
| "We randomized inpatients with type 2 diabetes and chronic renal failure to treatment with two different dose levels of insulin glargine and glulisine and studied control of hyperglycemia and the frequency of hypoglycemia." | ( Baldwin, D; DeLange-Hudec, S; Emanuele, MA; Glossop, V; Lee, H; Molitch, M; Munoz, C; Raghu, P; Smallwood, K; Zander, J, 2012) |
| "To investigate the association between type 2 diabetes, glucose-lowering therapies (monotherapy with either metformin, sulphonylurea or insulin) and cancer risk in Taiwan." | ( Cheng, SM; Hsieh, MC; Lee, TC; Tseng, CH; Tu, ST; Yen, MH, 2012) |
| "The Japanese 400 patients with type 2 diabetes on basal-bolus insulin therapy whose basal insulin was switched from NPH insulin to insulin glargine were followed-up." | ( Fukagawa, M; Kimura, M; Kondo, M; Kuriyama, Y; Miyatake, H; Miyauchi, M; Sato, H; Suzuki, D; Tanaka, E; Toyoda, M; Umezono, T; Yamamoto, N, 2012) |
| "Thirty-one type 2 diabetes patients treated with metformin (glycosylated hemoglobin [HbA1c] 6." | ( Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D, 2012) |
| "A total of 282 patients with type 2 diabetes were randomly assigned to one of four treatment groups." | ( Bailey, CJ; Iqbal, N; List, JF; T'joen, C, 2012) |
| "Patients with treatment-naive type 2 diabetes (N = 16) were treated with insulin and metformin for a 3-month lead-in period, then assigned triple oral therapy (metformin, glyburide, and pioglitazone) or continued treatment with insulin and metformin." | ( Duong, J; Leonard, D; Lingvay, I; Roe, ED; Szczepaniak, LS, 2012) |
| "Glycaemic control in patients with type 2 diabetes (T2DM) is often not achieved or not sustained using monotherapy such as metformin, necessitating the addition of other antihyperglycaemic agents." | ( Meinicke, T; Rafeiro, E; Ross, SA; Toorawa, R; Weber-Born, S; Woerle, HJ, 2012) |
| "We report a 48-year-old woman with type 2 diabetes who was diagnosed with rheumatoid arthritis (RA) after continued polyarthritis and an increase in rheumatoid factor up to 86 IU/mL after three months of treatment with sitagliptin, a DPP-4 inhibitor." | ( Igaki, N; Yokota, K, 2012) |
| "University of California-Davis-type 2 diabetes mellitus (UCD-T2DM) rats with nonfasting blood glucose levels in the range of 150-200 mg/dl were treated with the sEH inhibitor 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU) for 6 wk." | ( Chiamvimonvat, N; Cummings, BP; Despa, F; Despa, S; Dong, H; Dutrow, G; Evans, JE; Graham, J; Guglielmino, K; Hammock, BD; Harris, TR; Havel, PJ; Jackson, K; Vu, V, 2012) |
| "Prevention and treatment of type 2 diabetes includes recommendation to perform aerobic exercise, but evidence indicates that high-intensity exercise training may confer greater benefit." | ( Bender, SB; Crissey, JM; Jenkins, NT; Laughlin, MH; Martin, JS; Padilla, J; Rector, RS; Thyfault, JP, 2012) |
| "Some patients with type 2 diabetes mellitus (T2DM) receiving monotherapy with a sulfonylurea (SU) are unable to meet recommended glycemic targets over the long term and require additional pharmacologic agents to maintain glycemic control." | ( Arvay, L; Lewin, AJ; Liu, D; Patel, S; von Eynatten, M; Woerle, HJ, 2012) |
| "A proactive approach to treating type 2 diabetes is recommended: therapy should be individualised with early consideration of combination therapy and ongoing reinforcement of lifestyle modification messages." | ( Barlow, J; Deed, G; Kuo, I, 2012) |
| "There is great interest in whether type 2 diabetes and its treatments alter breast cancer risk and prognosis, but previous studies are inconclusive." | ( Ben-Shlomo, Y; Jeffreys, M; Martin, RM; May, MT; Redaniel, MT, 2012) |
| "Despite half of all type 2 diabetes mellitus (T2DM) patients being over 65 and treatment being complicated by an elevated risk of iatrogenic hypoglycaemia, information about antidiabetic treatment is scarce in this age group." | ( Bourdel-Marchasson, I; Dejager, S; Penfornis, A; Quere, S, 2012) |
| "Forty-one patients with type 2 diabetes using dietary control or oral glucose-lowering treatment were randomised to receive add-on esomeprazole 40 mg (n = 20) or placebo (n = 21) for 12 weeks." | ( Brøns, C; Færch, K; Hove, KD; Karlsen, AE; Lund, SS; Petersen, JS; Rehfeld, JF; Rossing, P; Vaag, A, 2013) |
| "The majority of patients with type 2 diabetes mellitus (T2DM) do not achieve the glycaemic goals recommended by leading diabetes organizations using monotherapy alone, and often require multiple antihyperglycaemic agents to achieve glycaemic control." | ( Bell, DS, 2013) |
| "Then healthy and type 2 diabetes mellitus (T2DM) rats were each divided into control and RA decoction (RAD) administration groups-healthy, healthy-RAD, T2DM, T2DM-RAD; pharmacokinetics of pioglitazone was carried out after RAD was administrated to rats for 7 days." | ( Gao, JW; Huang, M; Huang, P; Lu, YS; Shi, Z; Yao, MC; Yuan, YM, 2012) |
| "Patients with type 2 diabetes mellitus are routinely treated with combinations of glucose-lowering agents." | ( Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME, 2012) |
| "Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8-week treatment period with insulin glargine." | ( Heise, T; Kapitza, C; Meier, JJ; Menge, BA; Pennartz, C; Schenker, N; Schmidt, WE; Veldhuis, JD, 2013) |
| "Hypertensive patients with type 2 diabetes mellitus and microalbuminuria under treatment with a combination of a standard dose of telmisartan (40 mg/day) and trichlormethiazide (1 mg/day) were randomly assigned to receive either an increased dose of telmisartan (80 mg/day) combined with trichlormethiazide [increased dose angiotensin receptor blocker (ARB) group, n = 20] or a combination consisting of telmisartan (40 mg/day), trichlormethiazide, and amlodipine (5 mg/day) (triple combination group, n = 20) for 6 months." | ( Dohi, Y; Kimura, G; Kojima, M; Ohashi, M, 2013) |
| "Treatment algorithms for type 2 diabetes call for intensification of therapy over time as the disease progresses and glycaemic control worsens." | ( Balena, R; Barnett, AH; Hensley, IE; Miller, S, 2013) |
| "Metformin is the first-line therapy in type 2 diabetes." | ( Bonora, E; Del Prato, S; Giorda, CB; Maggioni, AP; Masulli, M; Mocarelli, P; Nicolucci, A; Riccardi, G; Rivellese, AA; Squatrito, S; Vaccaro, O, 2012) |
| "These were primary care patients with type 2 diabetes who had metformin monotherapy as their first treatment and who then initiated on relevant second-line, glucose-lowering regimens during the study period 2000-2010." | ( Barnett, AH; Currie, CJ; Evans, M; Jenkins-Jones, S; Morgan, CL; Poole, CD, 2012) |
| "As patients with type 2 diabetes receiving oral antidiabetic drugs are often concomitantly treated with other drugs, they are of increased risk for drug interactions." | ( Fromm, MF; Klatt, S; König, J, 2013) |
| "Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1), via a computer-generated randomisation sequence with a voice response system, to receive injections of once-daily liraglutide (1·8 mg) or once-weekly exenatide (2 mg)." | ( Boardman, MK; Buse, JB; Fineman, M; Forst, T; Gao, A; Heilmann, CR; Hoogwerf, BJ; Nauck, M; Porter, L; Schernthaner, G; Shenouda, SK; Sheu, WH, 2013) |
| "As newer treatments are approved for type 2 diabetes, the choice and-paradoxically-the complexity of treatment increases." | ( Freeman, JS; Horton, ES, 2012) |
| "2,019 individuals with type 2 diabetes, moderate anemia, and CKD from the placebo arm of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) followed up for 2." | ( Chen, CY; Cooper, ME; Ivanovich, P; Lin, J; McMurray, JJ; Nissenson, AR; Parfrey, PS; Pfeffer, MA; Remuzzi, G; Rossert, J; Scott-Douglas, NW; Singh, AK; Skali, H; Toto, R; Uno, H, 2013) |
| "MDA levels increased in type 2 diabetes, especially in patients on insulin therapy." | ( Almeida, TC; Becker, AM; Coelho, AC; da Silva, DB; De Carvalho, JA; Garcia, SC; Hermes, CL; Kaefer, M; Moreira, AP; Moresco, RN; Moretto, MB; Piva, SJ; Sangoi, MB; Tonello, R, 2012) |
| "The treatment of type 2 diabetes mellitus patients with sitagliptin reverses vascular endothelial dysfunction, as evidenced by increase in the FMD, and improvement of the adiponectin levels." | ( Ikeda, T; Kirinoki-Ichikawa, S; Kubota, Y; Miyamoto, M; Mizuno, K; Takagi, G; Tanaka, K, 2012) |
| "In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide once weekly or twice daily for 30 weeks." | ( Chilton, R; Chiquette, E; Cobble, M; Ramirez, G; Toth, PP, 2012) |
| "Most of the drugs available to treat type 2 diabetes mellitus (T2DM) act either in the pancreas by increasing insulin secretion or in tissues such as the liver or muscle by improving insulin sensitivity." | ( Donato, J, 2012) |
| "A total of 52,419 type 2 diabetes patients were enrolled in the IMPROVE™ study (pre-study therapy subgroups: no pharmaceutical therapy, n = 8966; oral antidiabetic drugs [OADs] only, n = 33,797; insulin ± OADs, n = 9568; missing information on pre-study therapy, n = 88)." | ( Benroubi, M; Borzì, V; Gumprecht, J; Kawamori, R; Ligthelm, R; Shaban, J; Shah, S; Shestakova, M; Valensi, P; Wenying, Y, 2013) |
| "Twenty patients with type 2 diabetes and mixed hyperlipidemia were sequentially treated with simvastatin (20 mg/day) and fenofibrate (200 mg/day) in a randomized cross-over study (12 weeks each treatment)." | ( Ceska, R; Marinov, I; Skrha, J; Stulc, T, 2012) |
| "Overweight or obese patients with type 2 diabetes or those with insulin resistance are good candidates for liraglutide therapy because liraglutide use is associated with weight loss (about 2%-4% of initial body weight) and improved β-cell function." | ( Gross, B, 2013) |
| "Theoretically, in type 2 diabetes mellitus patients, the combination of a GLP-1 analogue with insulin seems attractive, because of the weight loss perceived in users of GLP-1 analogues in contrast to the weight gain seen in most patients starting insulin therapy, leading to even more insulin resistance." | ( van der Klauw, MM; Wolffenbuttel, BH, 2012) |
| "Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease have an increased risk of micro- and macrovascular disease, but limited options for antihyperglycemic therapy." | ( Arjona Ferreira, JC; Barzilai, N; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Marre, M; Sisk, CM, 2013) |
| "Acarbose is a well-known drug used in type 2 diabetes treatment, particularly in the early phase." | ( Beato-Pérez, JL; Martínez-Peguero, J; Polo-Romero, FJ; Rocha-Honor, E; Sánchez-Beteta, P; Santisteban-López, Y, 2014) |
| "Worldwide, >366 million people with type 2 diabetes mellitus remain at excess risk of cardiovascular disease and face a lifetime of treatment escalation for this progressive disorder." | ( Holman, RR, 2013) |
| "Patients with type 2 diabetes with risk factors, such as family history, smoking, or exposure to certain forms of chemotherapy may need to consider other anti-hyperglycemic agents." | ( Al-Mallah, MH; Ferwana, M; Firwana, B; Hasan, R; Kim, S; Montori, VM; Murad, MH, 2013) |
| "As the pandemic of type 2 diabetes spreads globally, clinicians face many challenges in treating an increasingly diverse patient population varying in age, comorbidities, and socioeconomic status." | ( Inzucchi, SE; Majumdar, SK, 2013) |
| "Nine patients (eight with type 2 diabetes mellitus) with moderate to severe hypothalamic obesity were treated with GLP-1 analogues for up to 51 months." | ( Buchfelder, M; Droste, M; Mayr, B; Schöfl, C; Zoicas, F, 2013) |
| "Current treatment approaches for type 2 diabetes include diet, exercise, and a variety of pharmacologic agents, including insulin, biguanides, sulfonylureas, and thiazolidinediones." | ( Chandra, R; Dubey, M; Kumari, K; Pandey, ND; Singh, P; Vishvakarma, VK, 2013) |
| "Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment." | ( Bailey, CJ; Gross, JL; Hennicken, D; Iqbal, N; List, JF; Mansfield, TA, 2013) |
| "The administration of L-carnitine in type 2 diabetes mellitus is associated with an improvement in glycaemia and plasma lipids." | ( Burgos-Peláez, R; Calvo-Gracia, F; Cuerda-Compés, C; Luengo-Pérez, LM; Martínez-Faedo, C; Valero-Zanuy, MÁ; Vidal-Casariego, A, 2013) |
| "In patients with type 2 diabetes, long-term treatment remained weight-neutral but had persistent beneficial effects on short-term, intermediate-term, and long-term biomarkers of metabolic control, as well as on low-density lipoprotein cholesterol levels and insulin requirement." | ( Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E, 2013) |
| "In patients with type 2 diabetes and inadequate glycaemic control, treatment with Xiaoke Pill led to significant reduction in risk of hypoglycemia and similar improvements in glycemic control after 48 weeks compared to Glibenclamide." | ( Chen, Y; Gao, Y; Guo, X; Ji, L; Li, H; Li, Q; Li, Y; Liu, M; Ning, G; Paul, S; Tian, H; Tong, X; Wang, H; Wang, Y; Yang, G; Yang, H; Zhang, L; Zhang, Z; Zhou, H; Zhou, Z, 2013) |
| "In female patients with type 2 diabetes and hypercholesterolemia, 16 weeks pravastatin therapy did not affect on serum total adiponectin or HMW adiponectin levels." | ( Chang, SA; Kim, JH; Lee, JM; Lee, MR; Lee, SS; Shin, JA; Yoon, KH; You, SJ, 2013) |
| "These data suggest that normal-weight type 2 diabetes patients would derive the same benefits from first-line treatment with metformin as overweight and obese patients, and are not at increased risk of excess weight loss." | ( Guo, X; Hu, R; Ji, L; Li, H; Li, Y; Zhu, Z, 2013) |
| "Fifty-six type 2 diabetes mellitus patients who had been treated with 50 mg of sitagliptin, ≥ 1,000 mg of metformin, and ≤ 1 mg of glimepiride with an HbA1c level of <7." | ( Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M, 2013) |
| "TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) was an international, randomized, double-blind trial of ranolazine versus placebo in patients with diabetes, CAD, and stable angina treated with 1 to 2 antianginals." | ( Arnold, SV; Belardinelli, L; Ben-Yehuda, O; Chaitman, BR; Jones, PG; Katz, A; Kosiborod, M; Li, Y; McGuire, DK; Olmsted, A; Spertus, JA; Yue, P, 2013) |
| "29 patients with type 2 diabetes mellitus (19 males, 10 females) with a mean age 59±11(mean±SD) years (range 24-75) and treated with oral drugs for at least 6 months and a HbA1c >7." | ( Dette, H; Herrmann, BL; Huptas, M; Kasser, C; Keuthage, W; Klute, A, 2013) |
| "Body weight and type 2 diabetes parameters, including HbA1c and plasma levels of glucose, insulin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon, were analyzed after a standard meal before, during, and 1 week after DJBL treatment." | ( Bloom, SR; Bouvy, ND; Buurman, WA; de Jonge, C; Greve, JW; le Roux, CW; Rensen, SS; Schaper, NC; Verdam, FJ; Vincent, RP, 2013) |
| "Hypertensive patients with type 2 diabetes and albuminuria (30-600 mg/g creatinine) under antihypertensive treatment (mean age 67." | ( Dohi, Y; Hirota, H; Isaka, N; Ito, M; Kato, T; Kimura, G; Kojima, M; Machida, H; Makino, K; Miyagawa, K; Mizubayashi, R; Mizuno, O; Nakatani, K; Okamoto, S; Okubo, S; Okura, T; Takeuchi, M, 2013) |
| "In patients with type 2 diabetes inadequately controlled on metformin, lixisenatide 20 μg once daily administered in the morning or evening significantly improved glycemic control, with a pronounced postprandial effect, and was well tolerated." | ( Ahrén, B; Aronson, R; Leguizamo Dimas, A; Miossec, P; Saubadu, S, 2013) |
| "Elderly patients with type 2 diabetes mellitus (T2DM) present therapeutic challenges related to co-morbidities, treatment adherence, and safety." | ( DiGenio, A; Gao, L; Pandya, N; Patel, M, 2013) |
| "In men with type 2 diabetes, trials of therapy may need to be given for much longer than 3-6 months suggested in current guidelines." | ( Bhartia, M; Cole, N; Hackett, G; Kennedy, D; Raju, J; Wilkinson, P, 2013) |
| "We have found that type 2 diabetes model KK-Ay/TaJcl (KK-Ay) mice develop tumors within a short period after treatment with azoxymethane (AOM)." | ( Imai, T; Ishigamori, R; Ito, K; Mutoh, M; Ohta, T; Takahashi, M, 2013) |
| "Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0." | ( Flint, A; Kapitza, C; Zdravkovic, M, 2013) |
| "When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control." | ( Aronson, R; Forst, T; Ping, L; Riddle, MC; Rosenstock, J; Sauque-Reyna, L; Silvestre, L; Souhami, E, 2013) |
| "Treatment response in patients with type 2 diabetes mellitus (T2DM) varies because of different genotypic and phenotypic characteristics." | ( Boye, KS; Chen, L; Curtis, BH; Hardin, DS; Jiang, HH; Lipkovich, IA; Rohwer, RD; Zagar, A, 2013) |
| "Insulin treatment in type 1 and type 2 diabetes (T1D and T2D) is highly efficacious, but in practice, non-adherence and ineffective dose titration limit its effectiveness." | ( Josse, RG; Woo, V, 2013) |
| "The study enrolled patients with type 2 diabetes who were receiving a stable regimen of diet and exercise alone or a stable dose of metformin monotherapy, thiazolidinedione monotherapy, or metformin plus thiazolidinedione combination therapy." | ( Alessi, T; Baron, MA; Henry, RR; Logan, D, 2013) |
| "We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S." | ( Adams, J; Cersosimo, E; DeFronzo, RA; Garduno-Garcia, Jde J; Solis-Herrera, C; Triplitt, C, 2013) |
| "Thirty-five patients with treated type 2 diabetes and HgA1c ≥ 8." | ( Battler, A; Dadush, O; Kornowski, R; Leshem-Lev, D; Lev, EI; Rigler, M; Singer, J; Vaduganathan, M, 2014) |
| "The following patients with type 2 diabetes mellitus were recruited for the study: those aged 18-79 years, on a stable dose of metformin monotherapy ≥1,500 mg/day for ≥12 weeks, with an HbA1c ≥7." | ( Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L, 2013) |
| "Thirty adults with type 2 diabetes mellitus were treated with aspirin 81 mg/d for 7 days, then with fish oil 4 g/day for 28 days, then the combination of fish oil and aspirin for another 7 days." | ( Abdolahi, A; Block, RC; Brenna, JT; Cai, X; Cui, H; Georas, S; Meednu, N; Mousa, S; Smith, B; Thevenet-Morrison, K, 2013) |
| "In Part B, 6 subjects with type 2 diabetes mellitus (T2DM) participated in 3 dose periods where they received RE (50 mg and 500 mg) or placebo (2:1 active to placebo per treatment period)." | ( Dobbins, RL; Hompesch, M; Hussey, EK; James, CD; Kapur, A; Mikoshiba, I; Nunez, DJ; O'Connor-Semmes, R; Polli, JW; Smith, GA; Tao, W, 2013) |
| "Sitagliptin treatment for type 2 diabetes was effective and well tolerated." | ( Tang, Y; Wu, F; Xu, T; Zhan, M, 2012) |
| "A total of 59 patients with type 2 diabetes were treated with liraglutide (0." | ( Abe, M; Fukagawa, M; Kimura, M; Kuriyama, Y; Miyatake, H; Miyauchi, M; Sato, H; Suzuki, D; Tanaka, E; Toyoda, M; Umezono, T; Yamamoto, N, 2013) |
| "When treating an adult patient with type 2 diabetes, the physician must focus on the following (in order of importance): smoking cessation and other lifestyle interventions, blood pressure control, metformin use, lipid control, and glycemic control." | ( Erlich, DR; Shaughnessy, A; Slawson, DC, 2013) |
| "Third-line agents for the treatment of type 2 diabetes are similar in terms of glycemic control but differ in their propensity to cause weight gain and hypoglycemia." | ( Cameron, C; Dolovich, L; Houlden, R; McIntosh, B; Singh, SR; Yu, C, 2012) |
| "The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial showed superiority of metformin plus rosiglitazone (M+R) over metformin alone (M), with metformin plus lifestyle (M+L) intermediate in maintaining glycemic control." | ( , 2013) |
| "The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates (38." | ( , 2013) |
| "A prospective study of patients with Type 2 diabetes and chronic kidney disease stage IIIB/IV undergoing intravenous iron or erythropoiesis-stimulating agent therapy." | ( Atkin, SL; Bhandari, S; Cooke, M; Cox, H; Kilpatrick, ES; Konya, J; Lewis, N; Ng, JM, 2013) |
| "A substantial minority of type 2 diabetes mellitus (T2DM) patients treated with metformin develop severe gastrointestinal (GI) symptoms leading to drug discontinuation, depriving them of the potentially cardioprotective pleiotropic effects of this first-line oral agent." | ( Ahn, SA; Hermans, MP; Rousseau, MF, 2013) |
| "New drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due regulatory requirements from the Food and Drug Administration." | ( Dicembrini, I; Fiordelli, I; Mannucci, E; Monami, M; Nardini, C, 2014) |
| "Among patients with type 2 diabetes mellitus and coronary artery disease in the BARI 2D trial, neither on-treatment nor propensity-matched analysis supported an association of rosiglitazone treatment with an increase in major ischemic cardiovascular events." | ( Bach, RG; Brooks, MM; Donner, TW; Frye, RL; Garber, A; Genuth, S; Kelsey, SF; Kennedy, L; Lombardero, M; Monrad, ES; Pop-Busui, R, 2013) |
| "Barriers to insulin initiation in type 2 diabetes mellitus (T2DM) include fear of treatment complexity and perceived lack of time and resources by primary care physicians." | ( Andersen, H; Liebl, A; Svendsen, AL; Vora, J; Yale, JF, 2013) |
| "Twenty patients with type 2 diabetes and overt proteinuria and with knee and/or low back pain were treated with skin patches containing 100 mg loxoprofen on the knee or back for 24 h per day for 5 consecutive days." | ( Araki, H; Araki, S; Isshiki, K; Kashiwagi, A; Kume, S; Kuwagata, S; Maegawa, H; Morita, Y; Soumura, M; Uzu, T; Yamahara, K, 2014) |
| "The study included 10 type 2 diabetes patients requiring insulin therapy who were being tube-fed with a high-carbohydrate liquid diet (HCD)." | ( Mori, Y; Ohta, T; Utsunomiya, K; Yokoyama, J, 2013) |
| "Depression in patients with type 2 diabetes was associated with greater cognitive decline in all domains, across all treatment arms, and in all participant subgroups assessed." | ( Akpunonu, BE; Bryan, RN; Gerstein, HC; Horowitz, KR; Johnson, J; Katon, WJ; Launer, LJ; Lovato, LC; Marcovina, S; Miller, ME; Murray, AM; Sullivan, MD; Williamson, J; Yale, JF, 2013) |
| "A key to successful therapy for type 2 diabetes is the insight that this condition is progressive and that the need for additional agents over time is normative." | ( Bailey, T, 2013) |
| "The progressive nature of type 2 diabetes (T2D) requires practitioners to periodically evaluate patients and intensify therapy when glycemic targets become unattainable with their current treatment regimen." | ( Meneghini, LF, 2013) |
| "DiaRegis included 3810 patients with type 2 diabetes in which antidiabetic therapy was intensified." | ( Binz, C; Bramlage, P; Deeg, E; Gitt, AK; Krekler, M; Tschöpe, D, 2013) |
| "A total of 390 patients with type 2 diabetes treated with insulin were included." | ( Bets, D; de Jager, J; Donker, AJ; Kooy, A; Lehert, P; Schalkwijk, C; Stehouwer, CD; van der Kolk, J; Wulffelé, MG, 2014) |
| "We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy." | ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, PR; Heller, SR; Kupfer, S; Mehta, CR; Nissen, SE; Perez, AT; White, WB; Wilson, C; Zannad, F, 2013) |
| "The objective in developing a new type 2 diabetes therapy is to achieve greater safety and better efficacy." | ( Kvapil, M, 2013) |
| "Because many individuals with type 2 diabetes appear to have an inadequacy or defect in one or both of these processes, compounds that can activate GK may serve as effective treatments for type 2 diabetes." | ( Aicher, TD; Boyd, SA; Chicarelli, MJ; Condroski, KR; DeWolf, WE; Hinklin, RJ; Lee, PA; Lee, W; Singh, A; Thomas, L; Voegtli, WC; Williams, L, 2013) |
| "Recent data suggest that type 2 diabetes patients who are considered as being "at risk" because of the presence of cardiac disease still take benefit from metformin therapy, with a reduction of morbidity and mortality compared with other glucose-lowering agents." | ( Paquot, N; Scheen, AJ, 2013) |
| "It is licensed in the UK in adults with type 2 diabetes as monotherapy when diet and exercise alone do not provide adequate glycaemic control and who are unable to tolerate metformin; or, as add-on therapy, with other glucose-lowering agents including insulin, when these, with diet and exercise, do not provide adequate glycaemic control." | ( , 2013) |
| "The aim of therapy in type 2 diabetes in terms of blood glucose control is to reduce to target levels HbA1c and to reduce glycaemic variability in order to avoid both hypoglycaemia and wide excursions of postprandial glucose." | ( Marangoni, A; Zenari, L, 2013) |
| "Among Japanese obese patients with type 2 diabetes mellitus who had been hospitalized in our department, we selected 20 patients with moderate to severe untreated OSAS (apnea-hypoxia index, AHI, of ≥15 events/hour)." | ( Hirata, A; Kashine, S; Kitamura, T; Onodera, T; Otsuki, M; Shimomura, I; Tamada, D, 2013) |
| "However, in patients with type 2 diabetes who are already being treated with satins, it remains unclear whether it is more effective to add ezetimibe or to increase the statin dose." | ( Arao, T; Hajime, M; Inokuchi, N; Kurozumi, A; Matsuoka, H; Mori, H; Narisawa, M; Okada, Y; Tanaka, K; Tanaka, Y; Torimoto, K; Yamamoto, S, 2013) |
| "We will randomize 130 patients with type 2 diabetes mellitus, stable metabolic control and impaired left ventricular (LV) systolic or diastolic function, to either eplerenone (target dose 50mg) or matching placebo, in addition to optimal medical therapy for 12 months." | ( Heritier, S; Leung, DY; Leung, M; Mihailidou, AS; Wong, VW, 2013) |
| "Treatments for type 2 diabetes were as follows: diet alone (n = 1,394 subjects), metformin monotherapy (n = 1,631), insulin monotherapy (n = 1,116), sulfonylurea monotherapy (n = 1,083), metformin plus sulfonylurea (n = 1,565), and metformin plus insulin (n = 1,000); 905 subjects experienced a POE and 708 died." | ( Andersson, C; Caterson, I; Coutinho, W; Finer, N; Ghotbi, AA; James, WP; Køber, L; Sharma, AM; Torp-Pedersen, C; Van Gaal, LF, 2013) |
| "In obese patients with type 2 diabetes and high risk of cardiovascular disease, monotherapy with metformin or diet-only treatment was associated with lower risk of cardiovascular events than treatment with insulin." | ( Andersson, C; Caterson, I; Coutinho, W; Finer, N; Ghotbi, AA; James, WP; Køber, L; Sharma, AM; Torp-Pedersen, C; Van Gaal, LF, 2013) |
| "Many patients with type 2 diabetes mellitus (T2DM) initiate insulin therapy when other treatments fail; how best to do this is poorly defined." | ( Gao, L; Riddle, MC; Rosenstock, J; Vlajnic, A, 2014) |
| "People with type 2 diabetes in poor glycaemic control starting treatment with insulin detemir reported significant improvements in glycaemic control with improved treatment tolerability, irrespective of prior treatment and geographical region, after 24 weeks." | ( El Naggar, N; Haddad, J; Shah, S; Shen, C; Zilov, A, 2013) |
| "A subset of 112 insulin-naïve type 2 diabetes patients from a randomized, parallel-group trial (IDegAsp versus IGlar, each added to metformin) underwent 72 h continuous interstitial glucose (IG) monitoring after 16 weeks of treatment." | ( Davidson, J; Dykiel, P; Heise, T; Liebl, A; Mersebach, H; Tack, CJ, 2013) |
| "Because of the progressive nature of type 2 diabetes mellitus (T2DM), insulin therapy will eventually become necessary in most patients." | ( Elizarova, S; Galstyan, GR; Wolffenbuttel, BH, 2014) |
| "In insulin-treated persons with type 2 diabetes, it is usual to recommend that plasma insulin concentrations remain within a 50-200 pmol/L range in order to avoid overinsulinization, a potential causative factor for increased mitogenicity." | ( Colette, C; Monnier, L; Owens, D, 2013) |
| "A 42-year-old man with type 2 diabetes treated with metformin 1,500 mg/day and liraglutide 1." | ( Ambrosio, ML; Di Bari, M; Mannucci, E; Marchionni, N; Monami, M; Sati, L, 2014) |
| "Many Type 2 Diabetes Mellitus (T2DM) patients refuse insulin therapy even when they require this modality of treatment." | ( Abu Hassan, H; Long Bidin, MB; Mohd Amin, R; Muthupalaniappen, L; Omar, K; Tohid, H, 2013) |
| "Most patients with type 2 diabetes are treated every day with numerous drugs because of the presence of comorbidities so that poor drug compliance is a major concern in such a population." | ( Scheen, AJ; Van Gaal, LF, 2013) |
| "Many patients with type 2 diabetes continue to have poor glycaemic control and would benefit from insulin therapy." | ( Cos, X; Khunti, K; Rutten, G, 2014) |
| "MTT was applied to previously untreated Type 2 Diabetes Mellitus (T2DM) subjects." | ( Fujioka, Y; Inoue, K; Izawa, S; Kato, M; Matsuzawa, K; Nakanishi, R; Ohkura, H; Ohkura, T; Shiochi, H; Sumi, K; Taniguchi, S; Yamamoto, K; Yamamoto, N, 2013) |
| "A total of 86 people with type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), median age 64 years, were randomized to receive either pioglitazone 30 mg/day or placebo for 1 year, in addition to their usual diabetes treatments." | ( Bolland, M; Drury, PL; Fenwick, S; Gamble, G; Grey, A; Horne, A; Reid, IR, 2014) |
| "RCTs enrolling subjects with type 2 diabetes inadequately controlled on metformin monotherapy were included." | ( Barnett, AH; Goring, S; Hawkins, N; Roudaut, M; Townsend, R; Wood, I; Wygant, G, 2014) |
| " The majority of the patients with type 2 diabetes of short duration did not meet any of the treatment goals as recommended in the current practice guidelines." | ( Bała, MM; Czupryniak, L; Jankowski, M; Leśniak, W; Michałejko, M; Płaczkiewicz-Jankowska, E; Sieradzki, J; Strzeszyński, L; Topór-Mądry, R, 2013) |
| "Many patients with type 2 diabetes mellitus (T2DM) on insulin therapy have inadequate glycaemic control." | ( Bergenheim, K; McEwan, P; Pompen, M; Roudaut, M; Townsend, R; van Haalen, HG, 2014) |
| "Patients with type 2 diabetes have increased cancer risk and cancer-related mortality, which can be reduced by metformin treatment." | ( Gorak, EJ; Quddus, F; Yin, M; Zhou, J, 2013) |
| "For patients with type 2 diabetes who are uncontrolled on a combination of two oral antidiabetic agents, addition of the long-acting basal insulin glargine is a well established treatment option." | ( Bramlage, P; Pegelow, K; Seufert, J, 2013) |
| "Advanced type 2 diabetes mellitus (T2DM) needing insulin therapy is common." | ( Dabaghian, FH; Khalighi-Sigaroodi, F; Kianbakht, S, 2013) |
| "Current strategies for the treatment of type 2 diabetes mellitus promote individualized plans to achieve target glucose levels on a patient-by-patient basis while minimizing treatment related risks." | ( Corathers, SD; Peavie, S; Salehi, M, 2013) |
| "A 56-year-old woman with obesity, type 2 diabetes treated with sitagliptin and metformin, and HCV-related cirrhosis was given triple therapy with pegylated interferon-alpha, ribavirin and telaprevir." | ( Frossard, JL; Himschoot, T; Negro, F; Tallón de Lara, P, 2014) |
| "Participants had type 2 diabetes, were taking stable doses of medications, had HbA1c levels between 7% and less than 9%, and untreated chronic periodontitis." | ( Engebretson, SP; Gelato, MC; Hanson, NQ; Hou, W; Hyman, LG; Katancik, JA; Lewis, CE; Michalowicz, BS; Oates, TW; Orlander, PR; Paquette, DW; Reddy, MS; Schoenfeld, ER; Seaquist, ER; Tripathy, D; Tsai, MY, 2013) |
| "Patients with type 2 diabetes not adequately controlled on monotherapy were enrolled into the study, and randomised into either the vildagliptin arm or control arm with another OAD at the discretion of the treating physician." | ( Brada, M; Dohnalová, L; Edelsberger, T; Gerle, J; Haluzík, M; Houdová, J; Veselá, V, 2013) |
| "We studied ten obese type 2 diabetes mellitus patients starting GLP-1 analogue therapy at a hospital-based diabetes service." | ( Corrigan, MA; Gaoatswe, G; Hogan, AE; Lynch, L; O'Connell, J; O'Shea, D; Woods, C, 2014) |
| "In individuals with type 2 diabetes mellitus, GLP-1 analogue therapy reduces the frequency of inflammatory macrophages." | ( Corrigan, MA; Gaoatswe, G; Hogan, AE; Lynch, L; O'Connell, J; O'Shea, D; Woods, C, 2014) |
| "With the increasing prevalence of type 2 diabetes in young adulthood, treatment of diabetes in pregnancy faces new challenges." | ( Delaney, JA; Knox, CA; Winterstein, AG, 2014) |
| "Patients treated for type 2 diabetes with sulphonylurea in monotherapy (n = 21) or in combination with metformin (n = 135) were provided with glucose-monitoring devices and instructed to measure fasting blood glucose levels once per week and additionally at any signs and symptoms suggesting low blood glucose for a period of three months." | ( Dolžan, V; Janež, A; Klen, J, 2014) |
| "This sample of patients with type 2 diabetes and at high cardiovascular risk, had acceptable metabolic control, facilitated by drug therapy." | ( Estébanez-De Miguel, E; Hidalgo-García, C; Lucha-López, AC; Lucha-López, MO; Salavera-Bordás, C; Tricás-Moreno, JM; Vidal-Peracho, C, 2014) |
| "Men with type 2 diabetes not treated with insulin [n = 9, age 54." | ( Fischer, CP; Harder-Lauridsen, NM; Holst, JJ; Krogh-Madsen, R; Leick, L; Pedersen, BK; Plomgaard, P, 2014) |
| "Patients with type 2 diabetes were treated with vildagliptin or an active comparator, acarbose, for four weeks, in a randomized cross-over trial." | ( Gresnigt, MS; Netea, MG; Smits, P; Tack, CJ; van Poppel, PC, 2014) |
| "Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks." | ( Li, CJ; Lu, S; Yu, DM; Yu, P; Yu, Q; Yu, TL; Zhang, QM, 2014) |
| "We included type 2 diabetes patients with HbA1c levels of ≥7% who were not under insulin treatment and were administered sitagliptin (50mg/day for 6 months)." | ( Hirata, T; Inukai, K; Ishida, H; Katayama, S; Morimoto, J, 2014) |
| "It was developed for the treatment of type 2 diabetes mellitus." | ( Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y, 2014) |
| "A variety of patients with type 2 diabetes may benefit from treatment with vildagliptin." | ( Davis, SN; Lamos, EM; Stein, SA, 2014) |
| "To investigate the effect of CE on type 2 diabetes in vivo, we further performed oral glucose tolerance tests and insulin tolerance tests in type 2 diabetes model rats administered with CE." | ( Ariga, T; Honma, N; Hosono, T; Jia, LN; Kobayashi, K; Seki, T; Shen, Y; Shindo, K, 2014) |
| "Thirty-seven subjects with type 2 diabetes requiring >100 units of insulin daily administered either by continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDIs) with or without metformin were randomized to receive either liraglutide plus insulin (LIRA) or intensive insulin only (controls)." | ( Hale, C; Lane, W; Rappaport, J; Weinrib, S, 2014) |
| "The primary outcome was incidence of type 2 diabetes, analysed by intention to treat." | ( Alberti, KG; Chaturvedi, N; Godsland, IF; Johnston, DG; Majeed, A; Nanditha, A; Oliver, N; Ram, J; Ramachandran, A; Selvam, S; Shetty, AS; Simon, M; Snehalatha, C; Toumazou, C, 2013) |
| "In patients with type 2 diabetes, improving adherence to medication is important in order to maintain favourable glycaemic control during long-term treatment and, thus, prevent the onset or aggravation of complications." | ( Funao, N; Inagaki, N; Kaku, K; Kuroda, S; Onouchi, H; Sano, H, 2014) |
| "The increasing prevalence of Type 2 diabetes has emphasized the need to optimize treatment regimens." | ( Florez, JC; Todd, JN, 2014) |
| "In older patients with type 2 diabetes affected by mild cognitive impairment, DPP-4I administration improves glucose control and protects against worsening in cognitive functioning." | ( Angellotti, E; Barbieri, M; Boccardi, V; Marfella, R; Paolisso, G; Rizzo, MR, 2014) |
| "The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study was the first multiethnic, multicenter randomized trial in the United States to compare 3 treatment approaches in obese youth with new-onset type 2 diabetes (n=699; ages 10-17 years): monotherapy with metformin, metformin with rosiglitazone, and metformin with an intensive lifestyle intervention." | ( Narasimhan, S; Weinstock, RS, 2014) |
| "A 59-year-old man with type 2 diabetes mellitus (without treatment two weeks before the intoxication) intentionally ingested a substantial amount of ethanol along with ~750 mL of laminate floor cleaner containing citric acid." | ( Beijnen, JH; Brandjes, DP; Daling, R; Hendrikx, JJ; Hooijberg, JH; Huitema, AD; Lagas, JS; Schellens, JH, 2014) |
| "Patients with type 2 diabetes were selected if initiated with metformin or sulphonylurea monotherapy as their first-line glucose-lowering regimen 2000-2012." | ( Currie, CJ; Holden, SE; Jenkins-Jones, S; Morgan, CL; Mukherjee, J, 2014) |
| "When patients with type 2 diabetes start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 (GLP-1) receptor agonists and basal insulins." | ( Boardman, MK; Diamant, M; Guerci, B; Han, J; Malloy, J; Stranks, S; Trautmann, ME; Van Gaal, L, 2014) |
| "Patients with type 2 diabetes are generally treated with various pharmacological compounds and are exposed to a high risk of drug-drug interactions." | ( Iseki, K; Kobayashi, M; Ogura, J; Takahashi, N; Watanabe, M; Yamaguchi, H, 2014) |
| "In China, TMXK Tablet is used to treat type 2 diabetes." | ( Li, M; Li, WH; Ping, F; Wang, ZX; Xiao, XH; Yu, M; Zhang, HB; Zhang, Q; Zheng, J, 2014) |
| "Outpatients with type 2 diabetes whose glycemic control is poor (Hb Alc value >7 %) despite receiving at least 3-months long insulin treatment (insulin alone or insulin with oral antidiabetics) were included." | ( Arslan, MS; Cakal, E; Cakir, E; Calıskan, M; Delibasi, T; Demirci, T; Gungunes, A; Karbek, B; Ozbek, M; Sahin, M; Ucan, B; Unsal, IO, 2014) |
| "All 169 patients with type 2 diabetes (men, n=99; women, n=70) aged between 18 and 90 years who acquired follow-up treatment from the endocrinology clinic in the month of September 2013." | ( Al-Dubai, SA; Ganasegeran, K; Manaf, RA; Renganathan, P, 2014) |
| "Patients with uncontrolled type 2 diabetes mellitus (T2DM), despite therapy with 2 oral antidiabetic drugs (OADs), may add a third OAD or a glucagon-like peptide-1 receptor agonist (GLP-1) or initiate insulin therapy." | ( Baser, O; Levin, PA; Wei, W; Xie, L; Zhou, S, 2014) |
| "It was hypothesized that patients with type 2 diabetes mellitus (T2DM) and treatment-resistant hypertension excrete plasmin(ogen) in urine in proportion to albumin and that plasmin confers to urine the ability to activate ENaC." | ( Bistrup, C; Buhl, KB; Friis, UG; Jacobsen, IA; Jensen, BL; Oxlund, CS; Svenningsen, P, 2014) |
| "A total of 9872 outpatients with type 2 diabetes, who had received OADs (monotherapy or combination therapy) for at least 3 months were recruited in this study." | ( Guo, L; Ji, L; Jia, W; Lu, J; Tian, H; Weng, J; Xing, X; Zhu, D, 2015) |
| "This retrospective analysis was done in type 2 diabetes patients to study whether treatment with either sitagliptin or other Dipeptidyl peptidase-4 (DPP-4) inhibitors increased the risk of pancreatitis." | ( Nandith, A; Ramachandran, A; Shetty, AS; Snehalath, C, 2013) |
| "For example, treatment of patients with type 2 diabetes mellitus (T2DM) with sequestrants causes substantial reductions in plasma levels of glucose and HbA1c." | ( Bloks, VW; Groen, AK; Kuipers, F, 2014) |
| "Approximately 2000 people with Type 2 diabetes mellitus who were drug-naive or who were treated with metformin for less than 1 month, and who have HbA1c of 48-58 mmol/mol (6." | ( Del Prato, S; Foley, JE; Kothny, W; Kozlovski, P; Matthews, DR; Paldánius, PM; Stumvoll, M, 2014) |
| "Inclusion criteria were 1) diagnosis of type 2 diabetes before 1 January 2007, 2) treatment with metformin, and 3) at least one assessment of renal function between 2007 and 2012." | ( Corvino, FA; Gottwald-Hostalek, U; Guedes, S; Richy, FF; Sabidó-Espin, M, 2014) |
| "A total of 95,820 participants with type 2 diabetes who started taking metformin and other oral antidiabetes medications within 12 months of their diagnosis (initiators) were followed up for first incident cancer diagnosis without regard to any subsequent changes in pharmacotherapy." | ( Allen, NE; Ashby, D; Capothanassi, D; Ioannidis, JP; Lopez, DS; Rizos, EC; Sacerdote, C; Tsilidis, KK; Tzoulaki, I; van Veldhoven, K; Vineis, P, 2014) |
| "33 subjects with type 2 diabetes and 32 healthy controls were included; patients were examined at baseline and after 5 months of rosiglitazone treatment (4 mg/d)." | ( Češka, R; Doležalová, R; Krupičková, Z; Marinov, I; Štulc, T; Svobodová, H, 2014) |
| "Current type 2 diabetes mellitus (T2DM) treatment involves progressive interventions from lifestyle changes to pharmacological therapies." | ( Ayyagari, R; Bozas, A; Bron, M; Chen, K; Sharma, H; Wu, E, 2014) |
| "In this cohort of patients with type 2 diabetes receiving systemic chemotherapy for invasive BC, the use of metformin was not associated with improved outcomes." | ( Eaton, A; King, TA; Oppong, BA; Oskar, S; Patil, S; Pharmer, LA; Stempel, M, 2014) |
| "Treatment of type 2 diabetes mellitus (T2DM) continues to present challenges, with many patients failing to achieve glycemic targets." | ( Chung, SH; Kim, GW, 2014) |
| "The model of type 2 diabetes was established by high-fat diet and streptozotocin treatment." | ( Hu, G; Li, KJ; Lin, YJ; Wei, J; Zhao, YF; Zhen, YZ, 2015) |
| "Twelve subjects with type 2 diabetes and 12 body mass index and age-matched healthy subjects underwent anterograde and retrograde DBE under nurse-administered propofol sedation on two separate days." | ( Hassan, H; Hendel, JW; Holst, JJ; Knop, FK; Rhee, NA; Vilmann, P; Vilsbøll, T, 2014) |
| "Exenatide therapy is indicated in type 2 diabetes after failure of oral antidiabetic agents (OAD)." | ( Barthélémy, M; Boullu Sanchis, S; Jeandidier, N; Moreau, F; Pinget, M; Reix, N; Sigrist, S, 2015) |
| "Hypertensive patients with type 2 diabetes mellitus treated with amlodipine exhibited an improved pattern of pulse wave reflection in comparison with those treated with losartan." | ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2014) |
| "Japanese adults with type 2 diabetes mellitus, who had been treated without sulphonylureas or glinides for >3 months, were randomly assigned to two groups to receive either 0." | ( Aoki, K; Kamiko, K; Kamiyama, H; Nakajima, S; Shinoda, K; Taguri, M; Terauchi, Y, 2014) |
| "Subjects with type 2 diabetes who progressed to first-line treatment with metformin or sulphonylurea monotherapy were selected and matched to people without diabetes." | ( Bannister, CA; Currie, CJ; Halcox, JP; Holden, SE; Jenkins-Jones, S; Morgan, CL; Mukherjee, J; Schernthaner, G, 2014) |
| "Patients with type 2 diabetes initiated with metformin monotherapy had longer survival than did matched, non-diabetic controls." | ( Bannister, CA; Currie, CJ; Halcox, JP; Holden, SE; Jenkins-Jones, S; Morgan, CL; Mukherjee, J; Schernthaner, G, 2014) |
| "In this study, 148 patients with type 2 diabetes mellitus (T2DM) were assigned randomly to receive either glipizide alone or glipizide plus Aralia root bark extract (ARBE) for 8 weeks to test the effects of ARBE plus glipizide therapy on glycemic control and lipid profiles in these patients." | ( Fang, XF; Han, CC; Li, XM; Liu, XH; Ma, L, 2015) |
| "In subjects with type 2 diabetes inadequately controlled with pioglitazone-based therapy, add-on colesevelam therapy improved glycemic control and lipid parameters and was well tolerated." | ( Baz-Hecht, M; Chou, HS; Ford, DM; Rosenstock, J; Tao, B; Truitt, KE, 2014) |
| "Increased urinary betaine excretions in type 2 diabetes are further increased by fibrate treatment, sometimes to more than their dietary intake." | ( Chambers, ST; Elmslie, JL; George, PM; Krebs, JD; Lever, M; Lunt, H; McEntyre, CJ; Parry-Strong, A; Slow, S, 2014) |
| "A 44-year-old man with type 2 diabetes of five years' duration was admitted for the management of poor glycemic control despite the administration of insulin therapy." | ( Fujita, N; Furuya, M; Hayashino, Y; Iburi, T; Ishii, H; Kitatani, M; Kuwata, H; Mashitani, T; Okamura, S; Tsujii, S, 2014) |
| "Seventy patients with type 2 diabetes, inadequately controlled despite on-going treatment with metformin 500 mg/day, were enrolled in this randomized controlled trial." | ( Ban, N; Kawana, H; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Saiki, A; Shirai, K; Tatsuno, I; Yamaguchi, T, 2014) |
| "Both sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection." | ( Best, JD; d'Emden, MC; Jenkins, AJ; Keech, AC; Li, L; Mann, KP; Park, K; Saltevo, J; Stuckey, BG; Zannino, D, 2014) |
| "The treatment for patients with type 2 diabetes mellitus (T2DM) follows a stepwise progression." | ( Curtis, BH; Gahn, JC; Murphy, DR; Smolen, HJ; Yu, X, 2014) |
| "Patients with type 2 diabetes are generally treated in primary care setting and as a final treatment step to obtain good glycaemic control, multiple daily insulin injections (MDI) are generally used." | ( Dahlqvist, S; Hirsch, IB; Lind, M; Pehrsson, NG; Torffvit, O; Tuomilehto, J, 2015) |
| "Overweight and obese patients with type 2 diabetes and impaired glycaemic control treated with MDI were randomised to liraglutide or placebo over 24 weeks." | ( Dahlqvist, S; Hirsch, IB; Lind, M; Pehrsson, NG; Torffvit, O; Tuomilehto, J, 2015) |
| "Treatment naïve subjects with type 2 diabetes received 12." | ( Hirate, M; Kaneoka, N; Kutoh, E, 2015) |
| "Patients aged ≥18 years with type 2 diabetes treated with metformin (±sulfonylurea) for at least 3 months with a baseline HbA1c 7." | ( Carr, MC; Cirkel, DT; Perry, C; Pratley, R; Stewart, M; Weissman, PN; Ye, J, 2014) |
| "We find that type 2 diabetes is a possible risk factor for RLS in the Japanese population, and that pramipexole treatment can improve the symptoms of RLS as well as the quality of sleep and glycaemic control in these patients." | ( Harashima, S; Inagaki, N; Liu, Y; Nishimura, A; Osugi, T; Takayama, H; Wang, Y, 2016) |
| "20,000 patients with type 2 diabetes will be registered into two groups of 10,000 each: group A patients will be treated with alogliptin, while group B patients will be treated with non-DPP-4 inhibitor OHA(s)." | ( Inagaki, N; Kadowaki, T; Nakamura, J; Nishimura, R; Shimomura, I; Tanizawa, Y; Ueki, K; Watada, H; Yamada, Y; Yamazaki, T, 2014) |
| "To analyze the changes of patients with type 2 diabetes in different stages in glucagon (GC) and free fatty acid (FFA) in fasting, OGT and L-Arg experiments, and discusses the role of pancreatic alphabeta cells in diabetes pathogenesis by studying the relations among indexes such as glucagon (GC), free fatty acid (FFA) and blood glucose (BG), insulin, insulin homeostasis model (HOMA) and glucose metabolism hormone secretion curve, in order to provide theoretical basis for the treatment of diabetes." | ( Qiu, YX; Shi, M; Wang, YG; Xu, T, 2014) |
| "Treatment algorithms for type 2 diabetes recommend weight loss for disease management." | ( Bohannon, NJ; Dvorak, RV; Garvey, WT; Kushner, RF; Rueger, M; Ryan, DH; Troupin, B, 2014) |
| "Ten patients with type 2 diabetes mellitus (T2DM) were treated for 3 days with teneligliptin (20 mg/day)." | ( Nakamura, S; Nakazato, M; Sakoda, H; Tsubouchi, C; Tsuchimochi, W; Ueno, H; Yamashita, E, 2015) |
| "Rat models with type 2 diabetes, established by high-fat and high-glucose diet combined with streptozotocin (STZ) injection, were treated with a low dose of metformin, Meilian Xiaoke capsule, or both for 4 weeks by gavage." | ( Hu, C; Jin, X; Tong, L; Zhang, S, 2014) |
| "Insulin replacement therapy in type 2 diabetes should no longer be viewed as the treatment of last resort." | ( King, AB; Moghissi, E, 2014) |
| "Metformin, a standard therapy in type 2 diabetes, reduces vitamin B12 levels." | ( Adaikalakoteswari, A; Anjana, RM; Gokulakrishnan, K; Jayashri, R; Kumar, S; McTernan, PG; Mohan, V; Patel, V; Pradeepa, R; Saravanan, P; Sukumar, N; Tripathi, G; Venkataraman, H, 2014) |
| "A total of 394 patients with type 2 diabetes treated with metformin and sulfonylurea (S+M group, n = 299) or metformin and insulin (I+M group, n = 95) were consecutively recruited." | ( Ahn, YB; Kang, D; Ko, SH; Lim, TS; Park, YM; Yun, JS, 2014) |
| "Current type 2 diabetes (T2D) treatment guidelines include weight maintenance or loss, avoidance of hypoglycemia, and targets for blood pressure and circulating lipids, in addition to glycemic control." | ( Ross, SA, 2015) |
| "The paper gives an update on type 2 diabetes mellitus concurrent with thyroid dysfunction and on the development of vascular events, atherogenesis and evaluates the impact of therapy on the course of both diseases." | ( Suslina, AA; Tereshchenko, IV, 2014) |
| "The recent type 2 diabetes American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) position statement suggested insulin is the most effective glucose-lowering therapy, especially when glycated haemoglobin (HbA1c) is very high." | ( Buse, JB; Diamant, M; Donsmark, M; Furber, S; Han, J; MacConell, L; Maggs, D; Peters, A; Russell-Jones, D, 2015) |
| "The programme includes insulin-naive type 2 diabetes, insulin-treated type 2 and type 1 diabetes which are investigated as basal-bolus therapy, basal plus oral therapy, and basal vs." | ( Jain, SM; Kumar, A; Kumar, H; Mithal, A, 2014) |
| "We report a pediatric patient with MODY3 treated with a GLP-1 receptor agonist, liraglutide." | ( Habu, M; Okuno, M; Suzuki, J; Takahashi, S; Urakami, T; Yorifuji, T, 2015) |
| "Numerous treatments are available for type 2 diabetes mellitus (T2DM), which can improve insulin sensitivity or stimulate its secretion." | ( Boyle, LD; Wilding, JP, 2014) |
| "Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach." | ( Ampudia-Blasco, FJ; Benhamou, PY; Charpentier, G; Consoli, A; Diamant, M; Gallwitz, B; Khunti, K; Mathieu, C; Phan, TM; Ridderstråle, M; Seufert, J; Stoevelaar, H; Tack, C; Vilsbøll, T, 2015) |
| "Established treatments for type 2 diabetes mellitus (T2DM) have side effects that limit their use in specific populations." | ( Barnett, AH, 2015) |
| "We enrolled 106 patients with type 2 diabetes mellitus (T2DM), treated with liraglutide (N." | ( Abiru, N; Ando, T; Fujishima, K; Haraguchi, A; Imaizumi, M; Kawakami, A; Matsumoto, K; Mori, F; Takamura, N; Yamasaki, H, 2014) |
| "To assess initial pharmacotherapy of Type 2 diabetes with the sodium-glucose cotransporter-2 inhibitor dapagliflozin." | ( Bailey, CJ; List, JF; Morales Villegas, EC; Ptaszynska, A; Tang, W; Woo, V, 2015) |
| "wightii for type 2 diabetes therapy is first of its kind." | ( Geetharamani, D; Lakshmanasenthil, S; Marudhupandi, T; Suganya, P; Suja, G; Vinoth Kumar, T, 2015) |
| "In 33 hypertensive patients with type 2 diabetes mellitus treated with a calcium channel blocker other than cilnidipine, we evaluated the influence of switching to cilnidipine on blood pressure, heart rate, catecholamine, plasma renin and aldosterone concentration, brain natriuretic peptide, urine liver-type fatty acid binding protein, and urinary albumin excretion ratio in the same patients by a cross-over design." | ( Ichihara, A; Itoh, H; Nishimura, T; Sekioka, R; Tanaka, M, 2014) |
| "Seven subjects with untreated type 2 diabetes were studied." | ( Almokayyad, RM; Gannon, MC; Nuttall, FQ, 2015) |
| "We present a case of a patient with type 2 diabetes (T2D) and CIDP whose treatment response was measurable with the Sudoscan sudomotor function test." | ( Névoret, ML; Vinik, AI, 2015) |
| "Sixty-six patients with type 2 diabetes between the ages of 18 and 65 y were randomized to receive glutamine 30 g/d (10 g powder, three times a day) or placebo, in a double-blind, placebo-controlled trial during a 6-wk treatment period." | ( Heshmat, R; Hosseini, S; Larijani, B; Mansour, A; Mohajeri-Tehrani, MR; Qorbani, M, 2015) |
| "People with HNF1A-MODY were included and analysed according to treatment with insulin alone (n = 34), sulfonylurea (n = 30), meglitinides (n = 22) or lifestyle (n = 28)." | ( Grulich-Henn, J; Holl, RW; Konrad, K; Meissner, T; Raile, K; Scheuing, N; Schober, E; Thon, A; Wölfle, J, 2015) |
| "Of note, 40% of people with HNF1A-MODY and medical treatment were receiving insulin alone and thus were not being treated in line with up-to-date International Society for Pediatric and Adolescent Diabetes/International Diabetes Federation guidelines, despite insulin treatment being associated with worse metabolic control and the risk of hypoglycaemia." | ( Grulich-Henn, J; Holl, RW; Konrad, K; Meissner, T; Raile, K; Scheuing, N; Schober, E; Thon, A; Wölfle, J, 2015) |
| "In addition, prediction of reduced type 2 diabetes risk by high circulating adiponectin concentrations suggests that adipokines have the potential to be used as biomarkers for individual treatment success and disease progression, to monitor clinical responses and to identify non-responders to anti-obesity interventions." | ( Blüher, M; Mantzoros, CS, 2015) |
| "In the treatment of type 2 diabetes mellitus, we found that berberine with lifestyle intervention tended to lower the level of FPG, PPG and HbA1c than lifestyle intervention alone or placebo; the same as berberine combined with oral hypoglycaemics to the same hypoglycaemics; but there was no statistical significance between berberine and oral hypoglycaemics." | ( Dong, F; Fan, J; Lan, J; Sun, G; Yan, Z; Zhao, Y; Zheng, W, 2015) |
| "The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs." | ( Caveney, E; De Oliveira, C; Gourgiotis, L; Mittermayer, F; Puri, M; Tai, LJ; Turner, JR, 2015) |
| "Published guidelines for treatment of type 2 diabetes mellitus (T2DM) agree on initial pharmacotherapy." | ( Baltz, JC; Bouchard, JR; Lian, J; Meah, YA; Moretz, DC; Slabaugh, SL; Stacy, JN; Xu, Y, 2015) |
| "Patients with type 2 diabetes mellitus were randomized to receive empagliflozin 25 mg once daily for 5 days and either HCTZ 25 mg once daily for 4 days followed by HCTZ 25 mg once daily plus empagliflozin 25 mg once daily for 5 days or TOR 5 mg once daily for 4 days followed by TOR 5 mg once daily plus empagliflozin once daily for 5 days in 1 of 4 sequences, with at least a 7-day washout period between treatments." | ( Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015) |
| "In conclusion, treatment of type 2 diabetes with vildagliptin might prevent the progression of atherosclerotic cardiovascular disease in diabetic patients by decreasing the serum PAI-1 levels and improving TG metabolism." | ( Hirayama, A; Nagao, K; Takahashi, A; Tani, S, 2015) |
| "A 71-year-old woman with type 2 diabetes mellitus, chronic kidney disease stage IV, primary hypothyroidism and osteoarthritis, whose prescribed treatment included miglitol 50 mg thrice daily with the first bite of meals, reported that she suffered visual hallucinations while taking miglitol, which resolved within a few days of stopping the drug." | ( Bahtiyar, G; Ezeji, GC; Inoue, T; Sacerdote, A, 2015) |
| "In the treatment of type 2 diabetes mellitus (T2DM), a relatively new class of oral agents inhibits sodium-glucose cotransporter 2 (SGLT2), reducing reabsorption of filtered glucose and increasing urinary glucose excretion." | ( Dailey, G, 2015) |
| "The treatment of patients with type 2 diabetes is typically accompanied by hypoglycemia, if insulin or derivatives of sulfonylurea are used within the treatment." | ( Pelikánová, T, 2014) |
| "In BOT, treatment persistence among type 2 diabetes patients initiating basal insulin is influenced by type of insulin, antidiabetic co-medication, and patient characteristics." | ( Chou, E; Dippel, FW; Kostev, K; Pscherer, S; Rathmann, W, 2015) |
| "In patients with insulin-treated type 2 diabetes with a mean single-injection volume dose of basal insulin of 50." | ( Berard, L; Cameron, B; Woo, V, 2015) |
| "In patients with type 2 diabetes insulin glargine administered by SoloSTAR® or ClikSTAR® pens, education on insulin injection and on self-management of diabetes was associated with clinically meaningful improvements in HbA1c and FPG without a mean collective weight gain." | ( Gasser, UE; Gerber, PA; Lehmann, R; Mathis, A; Riebenfeld, D; Spirk, D; Villiger, L, 2015) |
| "Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take salicylate-based drugs [i." | ( Blümer, RM; Bujak, AL; Crane, JD; Day, EA; Ford, RJ; Fullerton, MD; Gerstein, HC; Kemp, BE; Marcinko, K; Oakhill, JS; Pinkosky, SL; Scott, JW; Smith, BK; Steinberg, GR, 2015) |
| "Patients with type 2 diabetes who were inadequately controlled on twice-daily premixed insulin were randomly assigned (1:1) to receive either insulin lispro mix (mix 50 before breakfast and lunch plus mix 25 before dinner) or basal-bolus therapy (insulin glargine at bedtime plus prandial insulin lispro thrice-daily) for 24 weeks." | ( Ahn, KJ; Bao, Y; Chen, L; Chuang, LM; Gao, F; Ji, Q; Jia, W; Li, P; Pang, C; Tu, Y; Xiao, X; Yang, J, 2015) |
| "Patients with type 2 diabetes and an acute coronary syndrome event in the previous 15-90 days were randomly assigned alogliptin or placebo plus standard treatment for diabetes and cardiovascular disease prevention." | ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "In a mouse model of type 2 diabetes mellitus (T2DM), long-term treatment with DXM improved islet insulin content, islet cell mass and blood glucose control." | ( Berggren, PO; Eberhard, D; Eglinger, J; Ferrer, J; Fischer, A; Heise, T; Herebian, D; Klemen, MS; Kletke, O; Klöcker, N; Köhler, M; Kragl, M; Lammert, E; Marquard, J; Mayatepek, E; Meissner, T; Otter, S; Piemonti, L; Rupnik, MS; Schliess, F; Stirban, A; Stožer, A; Thorens, B; Welters, A; Wnendt, S, 2015) |
| "Treatment of type 2 diabetes mellitus invariably requires the use of multiple daily medications which can impact negatively on patient adherence." | ( Aronson, R, 2015) |
| "During the first week, type 2 diabetes patients (T2D) who experienced metformin GI intolerance took 500 mg metformin along with their assigned NM504 (GIMM) or placebo treatment with breakfast and with dinner." | ( Burton, JH; Greenway, FL; Heiman, ML; Hsia, DS; Johnson, J; Johnson, M, 2015) |
| "Many patients with type 2 diabetes mellitus(T2DM) do not achieve satisfactory glycemic control by monotherapy alone, and often require multiple oral hypoglycemic agents (OHAs)." | ( Nagai, Y, 2015) |
| "Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks." | ( Castel, H; Chartrand, G; Chiasson, JL; de Guise, J; Gilbert, G; Julien, AS; Massicotte-Tisluck, K; Olivié, D; Rabasa-Lhoret, R; Soulez, G; Tang, A; Wartelle-Bladou, C, 2015) |
| "Insulin therapy in the management of Type 2 diabetes is often postponed and/or not adequately intensified to maintain glycemic control because of the risk of weight gain and hypoglycemia." | ( Knop, FK; Vedtofte, L; Vilsbøll, T, 2015) |
| "Patients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1 analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with a 2 weeks wash-out period." | ( Faber, R; Michelsen, MM; Mygind, ND; Pena, A; Prescott, E; Zander, M, 2015) |
| "Due to its reliable effects on type 2 diabetes mellitus (T2DM) remission, Roux-en-Y gastric bypass (RYGB) has recently been investigated as a treatment option for nonseverely obese patients with T2DM (body mass index (BMI) <35 kg/m(2))." | ( Billeter, AT; Büchler, MW; Clemens, G; Fischer, L; Kenngott, HG; Müller-Stich, BP; Nawroth, PP; Probst, P; Schulte, T; Senft, J; Zech, U, 2015) |
| "This antihyperglycemic treatment for type 2 diabetes mellitus (DM) has attracted increased clinical attention not only for its antihyperglycemic action but also for its potential extrapancreatic effects." | ( Hieshima, K; Jinnouchi, H; Jinnouchi, T; Kajiwara, K; Kurinami, N; Matsui, K; Miyamoto, F; Sugiyama, S; Suzuki, T; Yoshida, A, 2015) |
| "Treatment of type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists may be limited by gastrointestinal side effects (GISE) in some patients." | ( Blann, AD; Gupta, PS; Ryder, RE; Thong, KY, 2015) |
| "Glucose-lowering treatment options for type 2 diabetes mellitus patients with chronic kidney disease are limited." | ( Crowe, S; McGill, JB; von Eynatten, M; Woerle, HJ; Yki-Järvinen, H, 2015) |
| "Due to the progressive nature of type 2 diabetes (T2D), the majority of patients require increasing levels of therapy to achieve and maintain good glycemic control." | ( Merker, L; Morales, J, 2015) |
| "For patients with type 2 diabetes, we recently showed that peripheral insulin sensitivity was increased during hyperbaric oxygen treatment (HBOT)." | ( Chapman, I; Heilbronn, L; Mahadi, MK; Nolting, M; Wilkinson, D, 2015) |
| "Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial." | ( Bode, BW; Buse, JB; Gough, SC; Linjawi, S; Reiter, PD; Rodbard, HW; Woo, VC; Zacho, M, 2015) |
| "db/db mice, a model of obese type 2 diabetes, were subjected to transient cerebral ischemia by 17 min of bilateral common carotid artery occlusion (BCCAO), and were administered (1) vehicle or (2) linagliptin for 8 weeks or 1 week." | ( Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Lin, B; Ma, M; Nakagawa, T; Toyama, K; Uekawa, K, 2015) |
| "Screening for type 2 diabetes to reduce the lead time between diabetes onset and clinical diagnosis and to allow for prompt multifactorial treatment is warranted." | ( Borch-Johnsen, K; Brown, MB; Davies, MJ; Griffin, SJ; Herman, WH; Khunti, K; Lauritzen, T; Rutten, GE; Sandbaek, A; Simmons, RK; Wareham, NJ; Ye, W, 2015) |
| "The treatment of newly diagnosed type 2 diabetes mellitus is diverse, with no clear consensus regarding the initial drug regimen or dosing to achieve optimal glycemic control." | ( George, TM; Jennings, AS; Jennings, JS; Lovett, AJ, 2015) |
| "For patients with type 2 diabetes who do not achieve target glycaemic control with conventional insulin treatment, advancing to a basal-bolus insulin regimen is often recommended." | ( Blonde, L; Fahrbach, JL; Gross, J; Jendle, J; Jiang, H; Milicevic, Z; Woo, V, 2015) |
| "Patients (aged ≥18 years) with type 2 diabetes inadequately controlled with conventional insulin treatment were randomly assigned (1:1:1), via a computer-generated randomisation sequence with an interactive voice-response system, to receive once-weekly dulaglutide 1·5 mg, dulaglutide 0·75 mg, or daily bedtime glargine." | ( Blonde, L; Fahrbach, JL; Gross, J; Jendle, J; Jiang, H; Milicevic, Z; Woo, V, 2015) |
| "Among 1158 new Type 2 diabetes mellitus patients, 302 (26%) did not receive glucose-lowering therapy within the first year, 723 (62%) received monotherapy [685 (95%) with metformin], and 133 (12%) received more than one drug." | ( Beck-Nielsen, H; Berencsi, K; Brandslund, I; Christiansen, JS; Friborg, S; Mor, A; Nielsen, JS; Rungby, J; Svensson, E; Sørensen, HT; Thomsen, RW; Vaag, A, 2015) |
| "It is unclear whether treatments for type 2 diabetes are capable of promoting or inhibiting VC." | ( Agha, A; Ashley, DT; Cummins, PM; Davenport, C; Forde, H; Mahmood, WA; McAdam, B; McDermott, J; McGrath, F; Smith, D; Sreenan, S; Thompson, CJ, 2015) |
| "Participants with Type 2 diabetes (n = 24) but without known cardiovascular disease were randomized in a three-way crossover design to 2-week treatment periods with aspirin 100 mg once daily, 200 mg once daily or 100 mg twice daily." | ( Bethel, MA; Coleman, RL; Harrison, P; Hill, L; Holman, RR; Kennedy, I; Oulhaj, A; Sourij, H; Sun, Y; Tucker, L; White, S, 2016) |
| "The use of heat therapy in people with type 2 diabetes mellitus revealed a striking reduction of 1% unit in the glycated hemoglobin, suggesting this therapy for the treatment of diabetes." | ( Heck, TG; Krause, M; Ludwig, MS; Takahashi, HK, 2015) |
| "In this cohort of patients with type 2 diabetes mellitus receiving newly initiated insulin therapy, once-daily detemir improved the glycemic control, with low incidence of hypoglycemia and a significant reduction of the weight." | ( Artola-Menéndez, S; Orozco-Beltrán, D, 2016) |
| "In this investigation, a model of type 2 diabetes mellitus (T2DM) with insulin resistance was established by feeding a high-fat diet (HFD) and injecting streptozocin (STZ) to Sprague-Dawley (SD) rats, targeting the exploration of more details of the mechanism in the therapy of T2DM." | ( Cai, H; Gao, Y; Wu, T; Xu, M; Zhang, M; Zhang, Z, 2015) |
| "Patients with type 2 diabetes, either drug naive or treated with any glucose-lowering agents, who had inadequate glycaemic control (HbA1c 6." | ( Foley, JE; Kothny, W; Lukashevich, V; Rendell, MS; Schweizer, A, 2015) |
| "Patients with type 1 or type 2 diabetes who experience nausea, vomiting, or malaise or develop a metabolic acidosis in the setting of SGLT-2 inhibitor therapy should be promptly evaluated for the presence of urine and/or serum ketones." | ( Buschur, EO; Buse, JB; Cohan, P; Diner, JC; Hirsch, IB; Peters, AL, 2015) |
| "Thirty patients with type 2 diabetes (20 - 70 years old, low-density lipoprotein cholesterol (LDL-C) level over 120 mg/dl, and no history of treatment with antidiabetic or antihyperlipidemic drugs) were enrolled." | ( Aoki, K; Ijima, T; Kamiko, K; Kamiyama, H; Terauchi, Y, 2015) |
| "Intensified multifactorial treatment in type 2 diabetes results in an enhanced decrease in hs-CRP." | ( Berends, J; Beulens, JW; den Ouden, H; Rutten, GE; Stellato, RK, 2015) |
| "Elderly patients with type 2 diabetes on SU monotherapy were more likely to use ER than those on other monotherapies." | ( Brodovicz, K; Engel, SS; Fu, C; Heaton, PC; Rajpathak, SN, 2015) |
| "Most persons with type 2 diabetes are treated with oral anti diabetic drugs (OADs)." | ( Gupta, Y; Kalra, S, 2015) |
| "In people with type 2 diabetes treated with Gla-300 or Gla-100, and non-sulphonylurea OADs, glycaemic control was sustained over 12 months, with less nocturnal hypoglycaemia in the Gla-300 group." | ( Bergenstal, RM; Bolli, GB; Maroccia, M; Muehlen-Bartmer, I; Riddle, MC; Wardecki, M; Yki-Järvinen, H; Ziemen, M, 2015) |
| "Cases had type 2 diabetes and used metformin + insulin or metformin + sulphonylureas at the time of a first MI or first stroke between 1995 and 2010; controls used the same treatment combinations and were randomly sampled from the same population." | ( Dublin, S; Flory, JH; Floyd, JS; Heckbert, SR; Psaty, BM; Sitlani, CM; Smith, NL; Wiggins, KL, 2015) |
| "In addition, a group of type 2 diabetes patients who underwent treatment with metformin during a 12-week period was incorporated into the study." | ( Alvarez, A; Bañuls, C; Diaz-Morales, N; Escribano-López, I; Gomez, M; Hernandez-Mijares, A; Lopez-Domenech, S; Rios-Navarro, C; Rocha, M; Rovira-Llopis, S; Victor, VM, 2015) |
| "Treatment naïve subjects with type 2 diabetes mellitus were assigned to either sitagliptin 25-50 mg/day (n = 69) or alogliptin 12." | ( Hirate, M; Kutoh, E; Wada, A, 2015) |
| "Hypogonadal men with type 2 diabetes mellitus and metabolic syndrome were examined in several trials, demonstrating the beneficial effects of therapy on sexual function and insulin sensitivity." | ( Kathrins, M; Niederberger, C; Seftel, AD, 2015) |
| "We studied 30 consecutive patients with type 2 diabetes who had poor glycemic control despite treatment with metformin and/or sulfonylurea." | ( Aso, Y; Fukushima, M; Hara, K; Iijima, T; Inukai, T; Jojima, T; Kasai, K; Momobayashi, A; Suzuki, K; Takebayashi, K; Terasawa, T, 2015) |
| "Patients with type 2 diabetes mellitus (T2DM) using sulphonylurea and metformin received dapagliflozin 10 mg/day or placebo added to therapy for 52 weeks (24-week randomized, double-blind period plus 28-week double-blind extension)." | ( Bowering, K; Johnsson, E; Matthaei, S; Parikh, S; Rohwedder, K; Sugg, J, 2015) |
| "To observe the clinical effect on type 2 diabetes mellitus (T2DM) complicated with pulmonary tuberculosis (TB) of insulin, isoniazid, rifampicin, pyrazinamide and ethambutol (conventional medication) administered together with Qi-boosting and Yin-nourishing decoction derived from Traditional Chinese Medicine (TCM)." | ( Shi, G; Zhang, L, 2015) |
| "Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)." | ( Bekker, P; de Zeeuw, D; Gouni-Berthold, I; Hasslacher, C; Heerspink, HJ; Henkel, E; Mehling, H; Potarca, A; Schall, TJ; Tesar, V, 2015) |
| "We enrolled patients with type 2 diabetes aged 18-75 years with proteinuria (first morning void urinary albumin to creatinine ratio [UACR] 100-3000 mg/g), estimated glomerular filtration rate of 25 mL/min per 1·73 m(2) or higher, and taking stable antidiabetic treatment and ACE inhibitors or ARBs, for at least 8 weeks before study entry." | ( Bekker, P; de Zeeuw, D; Gouni-Berthold, I; Hasslacher, C; Heerspink, HJ; Henkel, E; Mehling, H; Potarca, A; Schall, TJ; Tesar, V, 2015) |
| "Among early type 2 diabetes patients receiving their first metformin add-on treatment, HbA(1c) reduction with different non-insulin drugs is similar to, and comparable with, that observed in randomised trials, yet 41% do not achieve HbA(1c) <7% (<53 mmol/mol) within 6 months." | ( Baggesen, LM; Buhl, ES; Haase, CL; Johnsen, SP; Nørrelund, H; Pedersen, L; Søgaard, M; Thomsen, RW, 2015) |
| "TREAT enrolled 4,038 patients with type 2 diabetes, chronic kidney disease (estimated glomerular filtration rate 20-60 mL/min per 1." | ( Burdmann, EA; Claggett, B; Eckardt, KU; Ivanovich, P; Kewalramani, R; Levey, AS; Lewis, EF; McMurray, JJ; Parfrey, PS; Pfeffer, MA; Solomon, SD; Toto, R, 2015) |
| "Less than 10% of type 2 diabetes patients switched back to oral antidiabetic drugs within 90 days after start of basal insulin therapy." | ( Dippel, FW; Kostev, K; Rathmann, W, 2016) |
| "Patients with type 2 diabetes failing metformin were randomized to add-on exenatide twice daily (n = 515) or glimepiride (n = 514) until treatment failure defined by hemoglobin A1C." | ( Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Kiljański, J; Rosas-Guzmàn, J; Schernthaner, G; Simó, R; Zhou, M, 2015) |
| "We present a patient with Type 2 diabetes who attended clinic with a limb threatening foot infection complicated by osteomyelitis and requiring emergency surgery and antibiotic administration." | ( Lopez, F; Morley, R; Webb, F, 2016) |
| "A 66-year-old man with type 2 diabetes on hemodialysis treatment was admitted due to poor glycemic control." | ( Nagao, M; Nakajima, Y; Oikawa, S; Sugihara, H; Takaya, M; Takemitsu, S; Uchigata, Y, 2015) |
| "Only about half of patients with type 2 diabetes treated with antihyperglycemic drugs achieve glycemic control (HbA1c <7%), most commonly due to poor treatment adherence." | ( Guo, XH, 2016) |
| "The management of type 2 diabetes mellitus (T2DM) by primary care physicians (PCPs) has become increasingly complex due to limitations on consultation time, an increasing array of drug treatment options, and issues of comorbidities and polypharmacy." | ( Adkins, SE; Lavernia, F; Shubrook, JH, 2015) |
| "Seventeen obese subjects with type 2 diabetes were treated with the DJBL for 24 weeks." | ( Bloom, SR; Bouvy, ND; Buurman, WA; de Jonge, C; Greve, JW; le Roux, CW; Rensen, SS; Verdam, FJ; Vincent, RP, 2016) |
| "Since antiplatelet therapy in type 2 diabetes mellitus (T2DM) patients is very important after intracoronary stenting, and because the most commonly used therapies have been the dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel and the triple antiplatelet therapy (TAPT) consisting of aspirin, clopidogrel and cilostazol, we aim to compare the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in T2DM patients." | ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group." | ( Han, LN; Huang, H; Jing, XC; Wang, B; Wang, C; Wang, XH; Wen, XR; Yu, YR, 2015) |
| "In statin-treated men with type 2 diabetes mellitus, ERN decreased plasma Lp(a) concentrations by decreasing the production of apo(a) and Lp(a)-apoB-100." | ( Barrett, PH; Chan, DC; Hamilton, SJ; Marcovina, SM; McCormick, SP; Ooi, EM; Pang, J; Tenneti, VS; Watts, GF, 2015) |
| "The progressive nature of Type 2 diabetes necessitates treatment intensification over time in order to maintain glycaemic control, with many patients ultimately requiring insulin therapy." | ( Bain, SC; Wilding, JP, 2016) |
| "Identifying youth with type 2 diabetes at risk for rapid loss of glycemic control would allow more targeted therapy." | ( Copeland, KC; El Ghormli, L; Hirst, K; Levitsky, LL; Levitt Katz, L; Linder, B; McGuigan, P; White, NH; Wilfley, D; Zeitler, P, 2015) |
| "A 47-year-old man with type 2 diabetes treated with insulin had very poor glycemic control characterized by postprandial hyperglycemia unresponsive to insulin therapy and repetitive hypoglycemia due to insulin antibodies." | ( Hayashi, A; Kawai, S; Shichiri, M; Takano, K, 2016) |
| "The included 3810 patients with type 2 diabetes had their treatment intensified at baseline." | ( Bramlage, P; Gitt, AK; Schneider, S; Tschöpe, D, 2016) |
| "Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy is not sufficiently potent to reduce the A1c to the 6." | ( Abdul-Ghani, M; Cersosimo, E; Defronzo, RA; Solis-Herrera, C; Triplitt, C, 2015) |
| "It is widely used for the treatment of type 2 diabetes mellitus, and administered by subcutaneous injection once daily." | ( Flint, A; Ingwersen, SH; Jacobsen, LV; Olsen, AK, 2016) |
| "Due to the progressive nature of type 2 diabetes mellitus (T2DM), antidiabetic treatment needs to be continuously intensified to avoid long-term complications." | ( Pegelow, K; Pfohl, M; Pscherer, S; Seufert, J; Siegmund, T, 2015) |
| "Testosterone treatment in men with type 2 diabetes and HH increases insulin sensitivity, increases lean mass, and decreases subcutaneous fat." | ( Abuaysheh, S; Batra, M; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Green, K; Hejna, J; Kuhadiya, ND; Makdissi, A; Punyanitya, M; Sandhu, S, 2016) |
| "In the treatment of type 2 diabetes mellitus, it is very important to develop therapeutics with prolonged circulation half-life." | ( Chen, X; Gao, S; Jacobson, O; Kiesewetter, DO; Lang, L; Liu, Y; Ma, Q; Ma, Y; Wang, G; Zhang, H; Zhu, L, 2016) |
| "Renal impairment in type 2 diabetes limits available glucose-lowering treatment options." | ( Atkin, SL; Bain, SC; Bosch-Traberg, H; Davies, MJ; Rossing, P; Scott, D; Shamkhalova, MS; Syrén, A; Umpierrez, GE, 2016) |
| "In patients with type 2 diabetes, glucagon receptor antagonist treatment significantly lowered HbA1c and glucose levels with good overall tolerability and a low risk for hypoglycemia." | ( Deeg, MA; Ding, Y; Fu, H; Garhyan, P; Hardy, TA; Kazda, CM; Kelly, RP; Landschulz, WH; Lewin, AJ; Lim, CN; Moller, DE; Shi, C; Watson, DE, 2016) |
| "Patients with type 2 diabetes mellitus at an onset age of 25-74 years during 1999-2005 and newly treated with either metformin (n = 288198, "ever users of metformin") or other antidiabetic drugs (n = 16263, "never users of metformin") were followed for at least 6 months for oral cancer until December 31, 2011." | ( Tseng, CH, 2016) |
| "Ninety-eight patients with type 2 diabetes and albuminuria who were treated with RAAS inhibitors (angiotensin-converting enzyme inhibitor (ACE-i) or angiotensin receptor blocker (ARB)) have participated in this study." | ( Sayiner, ZA; Tiryaki, Ö; Usalan, C, 2016) |
| "A total of 657 type 2 diabetes patients who were randomly assigned to 48 weeks of therapy with either acarbose or metformin in the MARCH trial were divided into two groups based upon their hemoglobin A1c (HbA1c) levels at the end of follow-up: HbA1c <7% (<53 mmol/mol) and ≥7% (≥53 mmol/mol)." | ( Wang, N; Wang, X; Xing, X; Yang, W; Yang, Z; Zhang, J, 2016) |
| "Newly diagnosed type 2 diabetes patients with lower baseline 2hPPG and HOMA-IR values are more likely to achieve glucose control with acarbose or metformin treatment." | ( Wang, N; Wang, X; Xing, X; Yang, W; Yang, Z; Zhang, J, 2016) |
| "The study included 253 patients with type 2 diabetes and 170 age-matched controls treated between October and December 2013." | ( Kucukkaya, B; Oren, M; Turhan, M; Yetkin, DO, 2015) |
| "This study included 51 men with type 2 diabetes, 26 of whom had already been treated with metformin and 25 with glimepiride for at least 6 months." | ( Gilowski, W; Krysiak, R; Okopień, B, 2016) |
| "TECOS recruited patients with type 2 diabetes and a history of cardiovascular disease who received, as add-on to their usual therapy, either sitagliptin (n = 7." | ( Paquot, N; Scheen, AJ, 2015) |
| "Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i." | ( De Souza, A; Khawaja, KI; Masud, F; Saif, MW, 2016) |
| "To examine, among patients with type 2 diabetes, the association between hospitalization for heart failure (hHF) and treatment with dipeptidyl peptidase 4 inhibitors (DPP-4is) versus sulfonylureas (SUs), and treatment with saxagliptin versus sitagliptin." | ( Cappell, K; Cole, AL; Fowler, R; Fu, AZ; Ghannam, A; Johnston, SS; Kalsekar, I; Riehle, E; Sheehan, J; Tsai, K, 2016) |
| "In patients with type 2 diabetes, there was no association between hHF, or other selected cardiovascular outcomes, and treatment with a DPP-4i relative to SU or treatment with saxagliptin relative to sitagliptin." | ( Cappell, K; Cole, AL; Fowler, R; Fu, AZ; Ghannam, A; Johnston, SS; Kalsekar, I; Riehle, E; Sheehan, J; Tsai, K, 2016) |
| "Data on 25,386 patients with type 2 diabetes, newly treated with a DPP4 inhibitor (2007-2013), were sourced from a United Kingdom general practice database via the Health Improvement Network database." | ( Donnelly, R; Idris, I; Mamza, J; Mehta, R, 2016) |
| "Twenty-two patients with type 2 diabetes treated with metformin were studied on four occasions, receiving either 50 mg vildagliptin (VILD) or placebo (PLBO) on both the evening before and the morning of each study day." | ( Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X, 2016) |
| "In metformin-treated type 2 diabetes, a protein preload has the capacity to enhance the efficacy of vildagliptin to slow gastric emptying, increase plasma intact incretins, and reduce postprandial glycemia." | ( Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X, 2016) |
| "Modern treatment of type 2 diabetes should aim for near-normal glucose control." | ( Meier, JJ, 2016) |
| "The majority of patients with type 2 diabetes mellitus (T2DM) have hypertension requiring combination therapy." | ( Chilton, R; Johansen, OE; Tikkanen, I, 2016) |
| "Patients with Type 2 Diabetes Mellitus continuously used "experimentation" in their treatment strategies and help-seeking process." | ( Low, LL; Low, WY; Tong, SF, 2016) |
| "Participants were eligible if they had type 2 diabetes and were currently being treated with lifestyle changes or metformin." | ( Bowers, J; Dincer, F; Farr, OM; Filippaios, A; Gavrieli, A; Kanyuch, N; Ko, BJ; Liakou, C; Mantzoros, CS; Sahin-Efe, A; Sofopoulos, M; Srnka, A; Thakkar, B; Tseleni-Balafouta, S; Tsoukas, MA, 2016) |
| "We studied patients with type 2 diabetes, treated with metformin, insulin combined with metformin and conventional insulin." | ( Borowska, M; Dworacka, M; Dworacki, G; Krzyżagórska, E; Wesołowska, A; Winiarska, H, 2016) |
| "The safety of agents used to treat type 2 diabetes (T2D), a chronic disease requiring life-long intervention, is of particular interest." | ( Cahn, A; Cernea, S; Raz, I, 2016) |
| "The pathophysiology of type 2 diabetes mellitus is complex and involves multiple organs and hormones, suggesting that successful treatment may require therapies that target multiple mechanisms." | ( Brunton, S; Davidson, JA, 2016) |
| "However, different treatments for type 2 diabetes can affect fracture risk differently, with metaanalyses showing some agents increase risk (eg, thiazolidinediones) and some reduce risk (eg, sitagliptin)." | ( Eurich, DT; Josse, RG; Lin, M; Majumdar, SR, 2016) |
| "We present a series of 12 patients with type 2 diabetes (4 men and 8 women; age 53-87 years; diabetes duration 8-25 years) having chronic resistance to therapy for foot and lower extremity ulcerations." | ( Demetzos, C; Maltezos, E; Papanas, N; Pippa, N; Tentolouris, N, 2016) |
| "Among patients with uncontrolled type 2 diabetes taking glargine and metformin, treatment with degludec/liraglutide compared with up-titration of glargine resulted in noninferior HbA1c levels, with secondary analyses indicating greater HbA1c level reduction after 26 weeks of treatment." | ( Buse, JB; García-Hernández, P; Lehmann, L; Lingvay, I; Norwood, P; Pérez Manghi, F; Tarp-Johansen, MJ, 2016) |
| "Fourteen female patients with type 2 diabetes mellitus being treated with metformin and exenatide were enrolled." | ( Cavun, S; Guclu, M; Gul, Z; Kisakol, G; Kiyici, S; Sigirli, D; Topyildiz, F, 2016) |
| "Subjects with type 2 diabetes and with metabolic syndrome were treated with acarbose (12 weeks, 300mg/d) in a double-blind, placebo-controlled, cross-over intervention." | ( Bergmann, A; Bernigau, W; Birkenfeld, AL; Mertes, G; Murahovshi, V; Pfeiffer, AF; Pivovarova, O; Rudovich, N; Sparwasser, A; Tacke, C; Weickert, MO, 2016) |
| "Finally, when compared to untreated type 2 diabetes patients, the metformin-treated diabetic patients showed increased IGFBP-2 levels with diminished serum IGF-1 levels." | ( Cho, HC; Choi, HS; Im, SS; Kang, HS; Koo, SH; Lee, IK; Lee, JH; Oh, GT; Park, BH; Song, DK, 2016) |
| "Insulin therapy in type 2 diabetes may increase mortality and cancer incidence, but the impact of different types of basal insulins on these endpoints is unclear." | ( Christopher, S; Haukka, J; Hoti, FJ; Korhonen, P; Strandberg, AY; Strandberg, TE, 2016) |
| "23 751 individuals aged ≥40 with type 2 diabetes, who initiated basal insulin therapy in 2006-2009 were identified from national registers, with comprehensive data for mortality, causes of death, and background variables." | ( Christopher, S; Haukka, J; Hoti, FJ; Korhonen, P; Strandberg, AY; Strandberg, TE, 2016) |
| "GK rats, a validated model of type II diabetes mellitus, and age matched Wistar rats were treated with low intensity extracorporeal shock wave therapy twice weekly for 3 weeks." | ( Alexandre, L; Assaly-Kaddoum, R; Behr-Roussel, D; Bernabé, J; Giuliano, F; Gorny, D; Kergoat, M; Laurin, M; Vardi, Y, 2016) |
| "At week 4 and week 8, type 2 diabetes mellitus patients treated with sesame oil blend or glibenclamide or combination of glibenclamide and sesame oil blend showed significant reduction of fasting and postprandial blood glucose (P <." | ( Ali, A; Chatterjee, B; Devarajan, S; Ganapathy, S; Singh, R; Urata, H; Zhang, B, 2016) |
| "In conclusion, in patients with type 2 diabetes very similar reductions in HbA1c after 6 months of second-line therapy were achieved regardless of the type of therapy." | ( Bongaerts, B; Kostev, K; Rathmann, W, 2016) |
| "In treatment of type 2 diabetes mellitus it is important to reach glycaemic targets." | ( Ferenci, T; Simonyi, G, 2016) |
| "Differentiating between type 1 and type 2 diabetes is fundamental to ensuring appropriate management of patients, but can be challenging, especially when treating with insulin." | ( Fox, C; Hattersley, AT; Hope, SV; Jones, AG; Khunti, K; King, SM; Knight, BA; Oram, RA; Shepherd, M; Shields, BM; Wienand-Barnett, S, 2016) |
| "In patients with hypertension and type 2 diabetes, aliskiren was beneficial in lowering BP, with no observed increases in major adverse effects compared with RAS-blocking therapy alone." | ( Bramlage, P; Dechend, R; Hagedorn, I; Kistner, I; Pittrow, D; Riemer, T; Schmieder, RE; Senges, J; Zeymer, U, 2016) |
| "A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines." | ( Abdesselam, I; Ancel, P; Bernard, M; Darmon, P; Dutour, A; Gaborit, B; Jacquier, A; Kober, F; Lefur, Y; Lesavre, N; Martin, JC; Mrad, G; Pradel, V; Ronsin, O, 2016) |
| "Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013." | ( Balakrishnan, S; Brown, NJ; Fireman, BH; Graham, DJ; Griffin, MR; Hamilton, J; Hampp, C; Iyer, A; Lendle, S; Nathwani, N; Pimentel, M; Pucino, F; Reichman, ME; Rucker, M; Toh, S, 2016) |
| "The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) clinical trial documented that metformin plus rosiglitazone, but not metformin plus lifestyle intervention, provided superior durability of glycemic control relative to metformin monotherapy." | ( El Ghormli, L; Hirst, K; Ievers-Landis, CE; Linder, B; Marcus, MD; van Buren, DJ; Walders-Abramson, N; Wilfley, DE; Zeitler, P, 2017) |
| "Japanese patients with type 2 diabetes and inadequate glycaemic control despite diet and/or exercise (n = 282), or despite diet and/or exercise plus one oral antidiabetic agent [sulphonylurea (n = 262), rapid-acting insulin secretagogue (n = 124), α-glucosidase inhibitor (n = 141), biguanide (n = 136), thiazolidinedione (n = 139) or dipeptidyl peptidase-4 inhibitor (n = 138)] were randomized to treatment with fasiglifam 25 or 50 mg once daily for 52 weeks." | ( Enya, K; Kaku, K; Matsuno, R; Nakaya, R; Ohira, T, 2016) |
| "Most patients with type 2 diabetes does not achieve target glycemic control when treated with single antidiabetics and need for proper control of diabetes combination of several different drugs." | ( Edelsberger, T, 2016) |
| "Agents introduced into therapy of type 2 diabetes in the last few years are still the subject of numerous clinical and experimental studies." | ( Gumieniczek, A, 2016) |
| "Medical records of 340 patients with type 2 diabetes treated with pitavastatin or atorvastatin between 1 August 2013 and 31 May 2014 were reviewed." | ( Hsu, BR; Huang, CH; Huang, YY, 2016) |
| "In Chinese patients with type 2 diabetes, initial combination therapy with sitagliptin and metformin was generally well-tolerated, and provided improvement in glycemic control." | ( Engel, SS; Golm, GT; Han, P; Ji, L; Jou, YM; Kaufman, KD; Liu, J; O'Neill, EA; Shankar, RR; Wang, X; Zheng, S, 2016) |
| "Although intensive therapy for type 2 diabetes (T2D) prevents microvascular complications, 10% of well-controlled T2D patients develop microangiopathy." | ( Atsumi, T; Ishizu, A; Kusunoki, Y; Miyoshi, A; Miyoshi, H; Nakamura, A; Nakazawa, D; Shida, H; Tomaru, U; Yamada, M, 2016) |
| "To compare the remission of type 2 diabetes mellitus (T2DM) through treatment with laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LRYGB), and to analyze the cost-effectiveness of medical treatment, LSG, and LRYGB in T2DM patients (BMI ≥ 28)." | ( Song, P; Sun, Z; Tang, Q; Tang, W; Xu, G; Xu, L; Zhang, N, 2016) |
| "The study included patients with type 2 diabetes without a history of myocardial infarction and patients after myocardial infarction treated with primary angioplasty, with preserved left ventricular systolic function (LV EF ≥ 40%)." | ( Stępień-Wałek, A; Wożakowska-Kapłon, B, 2016) |
| "A 77-year-old female diagnosed with type 2 diabetes mellitus previously treated with insulin and gliclazide MR was started on metformin." | ( Ellen, R; Omar, A; Sorisky, A, 2016) |
| "Thirty-two patients with type 2 diabetes and 29 age- and weight-matched healthy control subjects were treated in randomized order with 100 mg once daily vildagliptin or placebo for 10 days." | ( Broschag, M; Deacon, CF; Foley, J; He, YL; Holst, JJ; Kind, J; Kjems, L; Köthe, LD; Nauck, MA, 2016) |
| "Obesity and its major co-morbidity, type 2 diabetes, have reached an alarming epidemic prevalence without an effective treatment available." | ( Ding, L; Huang, W; Li, J; Qi, M; Song, B; Wang, Z; Xiao, X; Yang, L; Zhang, B, 2016) |
| "Metformin is the first-line oral type 2 diabetes treatment." | ( Boyle, JA; Dengler-Crish, CM; Moorman, JM; Soric, MM, 2016) |
| "In this investigation, a model of type 2 diabetes mellitus (T2DM) was used on Sprague-Dawley (SD) rats to clarify more details of the mechanism in the therapy of T2DM." | ( Ai, RD; Gao, YF; Wang, TX; Wu, TC; Zhang, MN; Zhang, ZS, 2016) |
| "Patients with type 2 diabetes who have intermediate coronary artery stenosis (diameter stenosis <70%) as evaluated by CCTA will be treated with 25mg/day of alogliptin." | ( Fukui, K; Hibi, K; Kishi, S; Michishita, I; Nozue, T; Sozu, T; Takamura, T, 2017) |
| "The prevalence of early-onset type 2 diabetes mellitus (T2DM), which responds poorly to medical treatment, is increasing." | ( Aung, L; Chen, JC; Chen, SC; Chong, K; Lee, WJ; Lee, YC; Ser, KH; Wu, CC, 2016) |
| "To describe common type 2 diabetes treatment intensification regimens, patients' characteristics and changes in glycated hemoglobin (HbA1c) and body mass index (BMI)." | ( Greevy, RA; Griffin, MR; Grijalva, CG; Hung, AM; Liu, X; Roumie, CL, 2016) |
| "Patients aged ≥18 years with type 2 diabetes who were included in the ZODIAC cohort between 1998 and 2012 and who received metformin monotherapy at inclusion (n = 29 195), and had used metformin as monotherapy for at least 1 year before receiving dual therapy through the addition of an SU for at least 1 year were eligible for inclusion." | ( Bilo, HJ; de Bock, GH; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; Schrijnders, D; van Hateren, KJ; Wever, R, 2016) |
| "In patients with type 2 diabetes treated in primary care, strict glycaemic control can be maintained with SUs used as add-on therapy to metformin, without the offset of relevant weight changes." | ( Bilo, HJ; de Bock, GH; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; Schrijnders, D; van Hateren, KJ; Wever, R, 2016) |
| "We genotyped 833 Scottish patients with type 2 diabetes treated with pioglitazone or rosiglitazone and jointly investigated association of variants in these two genes with therapeutic outcome." | ( Carr, F; Dawed, AY; Donnelly, L; Leese, G; Palmer, CN; Pearson, ER; Tavendale, R; Zhou, K, 2016) |
| "An increasing number of patients with type 2 diabetes are treated with high doses of insulin." | ( Adams-Huet, B; Harrison, L; Li, X; Lingvay, I; Vanderheiden, A; Warshauer, J, 2016) |
| "Patients with type 2 diabetes who had been on metformin monotherapy and started another agent in addition to metformin were eligible for inclusion." | ( Ekström, N; Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Miftaraj, M; Svensson, AM; Zethelius, B, 2016) |
| "Patients with type 2 diabetes mellitus (±background glucose-lowering therapy) received: dapagliflozin 10 mg (n = 2026) vs." | ( Fioretto, P; Johnsson, E; Mansfield, TA; Parikh, S; Ptaszynska, A; Yavin, Y, 2016) |
| "Patients with type 2 diabetes mellitus (T2DM) treated with PCI <24h in 2 coronary care units were included." | ( Cottin, Y; Feldman, LJ; Juliard, JM; Labalette-Bart, M; Potier, L; Roussel, R; Steg, PG; Zeller, M, 2016) |
| "Data from patients with type 2 diabetes and microalbuminuria (n = 49) treated with irbesartan 300 mg/day were used for discovery." | ( Andersen, S; Dallmann, G; Heerspink, HJ; Heinzel, A; Mayer, B; Parving, HH; Pena, MJ; Rossing, K; Rossing, P, 2016) |
| "Treatment guidelines for type 2 diabetes mellitus (T2DM) suggest weight loss as a means to maintain glycemic control." | ( Fain, R; Garvey, WT; Ma, T; Pi-Sunyer, X; Shanahan, W, 2016) |
| "Sulfonylureas are widely used to treat type 2 diabetes (T2DM)." | ( Cai, X; Edwards, SL; Han, X; Ji, L; Li, X; Liu, Z; Paul, SK; Ren, Q; Tang, Y; Wang, H; Xiao, D; Zhang, S; Zhang, X, 2016) |
| "However, the metabolic effects in type 2 diabetes treated with a thiazide diuretic have not been fully elucidated." | ( Chang, HC; Chen, HY; Ku, CT; Lin, JJ, 2016) |
| "Sixty-nine metformin-treated type 2 diabetes patients were randomised to the GLP1 receptor agonist, exenatide (EXE) twice daily (BID) or to insulin glargine (GLAR)." | ( Bunck, MC; Cornér, A; Diamant, M; Eliasson, B; Heine, RJ; Hoekstra, T; Mari, A; Smith, U; Smits, MM; van Raalte, DH, 2016) |
| "Combined treatment for type 2 diabetes with degludec and liraglutide therapy provides complementary therapeutic efficacy in the treatment of individuals with type 2 diabetes." | ( Davis, SN; Lamos, EM, 2016) |
| "The treatment of patients with type 2 diabetes mellitus remains challenging, as it goes beyond adequate glycemic control, in particular addressing weight, blood pressure and other contributors to cardiovascular disease." | ( Mathieu, C; Peene, B; Stinkens, K, 2016) |
| "Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study." | ( Adda, G; Arosio, M; Lombardo, M; Montefusco, L; Rossi, A; Saponaro, F; Sonaglioni, A, 2016) |
| "In patients with type 2 diabetes, 6months liraglutide treatment was associated with a significant improvement in diastolic function." | ( Adda, G; Arosio, M; Lombardo, M; Montefusco, L; Rossi, A; Saponaro, F; Sonaglioni, A, 2016) |
| "Female patients with type 2 diabetes at an onset age of 25-74 years during 1999-2005 and newly treated with metformin (n=132971, "ever users of metformin") or other antidiabetic drugs (n=6940, "never users of metformin") were followed for at least 6 months until December 31, 2011." | ( Tseng, CH, 2016) |
| " Patients with type 2 diabetes who initiated pioglitazone (n=56 337) matched with patients with type 2 diabetes in the same country exposed to diabetes drug treatments other than pioglitazone (n=317 109)." | ( Bahmanyar, S; Christopher, S; Dolin, P; Heintjes, EM; Hoti, F; Kool-Houweling, L; Korhonen, P; Linder, M; Majak, M; Strongman, H; Williams, R, 2016) |
| "In patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin monotherapy, the addition of alogliptin contributed to clinically significant increases in pulmonary function through regulating glycemia and improving the imbalance of the oxidative-related substances in the serum, without increasing the incidence of hypoglycemia, dyslipidemia, dysarteriotony, and any notable increase in body weight." | ( Dong, QY; Kuang, JS; Li, LB; Liu, XG; Tai, H; Wang, MY; Zhao, YP, 2016) |
| "131 949 patients with type 2 diabetes who initiated pharmacotherapy with a GLD between 2005 and 2012." | ( Mor, A; Petersen, I; Sørensen, HT; Thomsen, RW, 2016) |
| "In treatment algorithms of type 2 diabetes mellitus in Western countries, biguanides are recommended as first-line agents." | ( Motonaga, R; Nomiyama, T; Tanabe, M; Terawaki, Y; Yanase, T, 2017) |
| "We conducted a cohort study including type 2 diabetes patients who received their first metformin prescription between 2007 and 2013 in the Groningen Initiative to Analyze Type 2 Diabetes Treatment (GIANTT) database." | ( Denig, P; Hak, E; Lambers Heerspink, H; Martono, DP; Wilffert, B, 2016) |
| "Treatment of individuals with type 2 diabetes mellitus (T2DM) with sodium-glucose transporter 2 inhibitors (SGLT2i) improves insulin sensitivity." | ( Abdul-Ghani, M; Daniele, G; DeFronzo, RA; Eldor, R; Merovci, A; Norton, L; Solis-Herrera, C; Tripathy, D; Xiong, J, 2016) |
| "Forty participants with type 2 diabetes were included in a 12-wk treatment of either linagliptin 5mg/d or placebo." | ( Baltzis, D; Dushay, JR; Greenman, RL; Loader, J; Roustit, M; Veves, A; Wu, J, 2016) |
| "Patients with type 2 diabetes diagnosed during 1999-2005 and newly treated with metformin (n=287971, "ever users of metformin") or other antidiabetic drugs (n=16217, "never users of metformin") were followed until December 31, 2011." | ( Tseng, CH, 2016) |
| "A total of 480 participants with type 2 diabetes mellitus with a HbA1c between 6 and 10 % despite receiving diet/exercise therapy and/or standard anti-diabetic agents for at least 3 months, will be randomized systematically (1:1) into either ipragliflozin or control (continuation of conventional therapy) groups." | ( Eguchi, K; Higashi, Y; Inoue, T; Ishizu, T; Kadokami, T; Kario, K; Kitakaze, M; Kodera, S; Maemura, K; Matsuhisa, M; Murohara, T; Nanasato, M; Nishio, Y; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Shimabukuro, M; Suzuki, M; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H, 2016) |
| "The treatment of type 2 diabetes with full peroxisome proliferator-activated receptor gamma (PPARγ) agonists improves insulin sensitivity, but is associated with weight gain, heart failure, peripheral oedema and bone loss." | ( Byrjalsen, I; Christiansen, C; Genovese, F; Henriksen, K; Karsdal, MA; Leeming, DJ; Nielsen, MJ; Riis, BJ; Schuppan, D, 2017) |
| "Sixteen obese mice with type 2 diabetes (db/db) and eight age-matched control mice (db/+) were divided into three groups: diabetic group treated with phlorizin (DMT group), vehicle-treated diabetic group (DM group), and normal control group (CC group)." | ( Gao, Z; Hu, H; Li, X; Liu, G; Mei, X; Wang, Z; Zhang, X; Zou, L, 2016) |
| "Sulfonylureas are widely used to treat type 2 diabetes, with considerable inter-individual variation in the hypoglycaemic response to sulfonylureas." | ( Dhawan, D; Padh, H, 2016) |
| "A total of 16 patients with type 2 diabetes treated with metformin and liraglutide (1." | ( Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA, 2017) |
| "A total of 58 patients with type 2 diabetes, admitted for glycemic control, were randomized to basal-bolus insulin therapy (BBT) alone or BBT plus 50 mg ipragliflozin and/or 20 mg teneligliptin." | ( Emoto, N; Hattori, N; Nagamine, T; Nakamura, Y; Okajima, F; Sugihara, H, 2017) |
| "The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study demonstrated that glycemic failure rates in the three treatments combined-metformin plus rosiglitazone, metformin alone, and metformin plus lifestyle-were higher in non-Hispanic blacks (NHB; 52." | ( Arslanian, S; Bacha, F; Caprio, S; El Ghormli, L; Goland, R; Haymond, MW; Levitsky, L; Nadeau, KJ; White, NH; Willi, SM, 2017) |
| "Metformin, a first-line therapy for type 2 diabetes, is the only drug demonstrated to reduce cardiovascular complications in diabetic patients." | ( Cao, Y; Gu, J; Huang, W; Ji, C; Lee, KH; Li, K; Lu, Y; Ma, L; Morris-Natschke, SL; Niu, H; Qin, C; Wei, Z; Wen, L; Xia, Q; Xin, G; Xing, Z; Yeh, JL; Zhang, R; Zheng, H, 2016) |
| "Twenty-one type 2 diabetes mellitus patients on hemodialysis treated with insulin were enrolled." | ( Hayashi, M; Takahashi, H; Yajima, K; Yajima, T; Yasuda, K, 2016) |
| "Most patients with type 2 diabetes, who receive monotherapy, are unable to maintain glucose levels with the progress of disease." | ( Hu, J; Tan, X; Zhang, S; Zhou, M; Zou, P, 2016) |
| "It is also used to delay the onset of type 2 diabetes mellitus, in treating gestational diabetes, and in women with polycystic ovary syndrome." | ( Alquraini, H; MacEachern, M; Mizokami-Stout, K; Tan, MH, 2016) |
| "Recent studies in type 2 diabetes have reported an association between hypoglycemia and severe cardiovascular adverse events, which are relatively increased in standard versus intensively treated individuals." | ( Davis, SN; Joy, NG; Mikeladze, M; Tate, DB; Younk, LM, 2016) |
| "Seventeen subjects with well-controlled type 2 diabetes (T2D) were treated with placebo and 150 mg/day resveratrol (resVida) in a randomized double-blind crossover study for 30 days." | ( de Ligt, M; Hansen, J; Hesselink, MK; Kunz, I; Moonen-Kornips, E; Phielix, E; Schaart, G; Schrauwen, P; Schrauwen-Hinderling, VB; Timmers, S; van de Weijer, T, 2016) |
| "Incretin hormone-based therapy in type 2 diabetes has been widely used, and dipepdityl peptidase-4 (DPP-4) inhibitors, which prevent incretin degradation, have become popular oral hypoglycemic agents." | ( Choe, EY; Han, E; Kang, ES; Kim, CH; Kim, CS; Kim, LK; Kwak, SH; Kwon, O; Lee, SH; Lee, YH; Park, HS; Park, KS; Wang, HJ, 2016) |
| "Eight participants with type 2 diabetes and obesity, aged 7-16 years, non-medicated (n = 1) or treated with metformin (n = 7) and in some cases insulin (n = 3), followed a VLED (<3360 kJ/day) for 8 weeks, then transitioned to a hypocaloric diet (∼6300 kJ/day) that they followed to 34 weeks." | ( Baur, LA; Cowell, CT; Garnett, SP; Gow, ML; Johnson, NA, 2017) |
| "A total of 73 patients with type 2 diabetes treated with insulin were randomly assigned to receive either add-on therapy of vildagliptin (n=37) or conventional therapy without DPP-4 inhibitors (n=36) for glucose control." | ( Kanazawa, I; Kiyohara, N; Koike, S; Notsu, M; Sasaki, M; Sugimoto, T; Tada, Y; Tanaka, KI; Tanaka, S; Yamane, Y; Yamauchi, M, 2017) |
| "For patients with type 2 diabetes at high CV risk but no CKD, fenofibrate therapy added to statin reduced the CV mortality and the rate of fatal and non-fatal CHF." | ( Applegate, WB; Cushman, W; Doumas, M; Lovato, L; Mottle, A; Nylen, E; Papademetriou, V; Punthakee, Z; Tsioufis, C, 2017) |
| "Patients with uncontrolled type 2 diabetes mellitus (T2DM) are a priority group for intensified therapy without weight gain and with low risk of hypoglycaemia." | ( Ericsson, Å; Lundqvist, A, 2017) |
| "Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity." | ( Clar, C; Clegg, A; Colquitt, J; Court, R; Cummins, E; Holt, T; Johnston, R; McGrane, D; O'Hare, JP; Royle, P; Shantikumar, S; Tan, BK; Uthman, O; Waugh, N, 2017) |
| "The study included all type 2 diabetes patients aged ≥65 years who started treatment with tofogliflozin during the first 3 months after its launch on 23 May 2014." | ( Fujii, S; Fujiwara, H; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Kurihara, Y; Senda, M; Shimmoto, N; Tamura, M; Utsunomiya, K, 2017) |
| "Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study." | ( Anholm, C; Fabricius-Bjerre, A; Haugaard, SB; Kristiansen, O; Kumarathurai, P; Madsbad, S; Nielsen, OW; Sajadieh, A, 2017) |
| "We recruited 38 patients with type 2 diabetes on stable background metformin therapy for a randomized, double-blind, placebo-controlled crossover trial of DPP-4 inhibition with sitagliptin (100 mg/day)." | ( Branum, A; Malik, M; Puppala, VK; Signorelli, K; Suboc, TM; Tanner, MJ; Tyagi, S; Wang, J; Widlansky, ME; Ying, R, 2017) |
| "Patients of advanced age with type 2 diabetes were often treated with antidiabetic and cardiovascular drugs even when approaching death." | ( Gulliford, MC; Hamada, S, 2017) |
| "Veterans 50 years or older with either type 2 diabetes and long-term metformin therapy (n = 3,687) or without diabetes and no prescription for metformin (n = 13,258)." | ( Elliott, JL; Holland, NW; Johnson, TM; Kancherla, V; Khakharia, A; Oakley, GP; Patel, BB; Phillips, LS; Vaughan, CP, 2017) |
| "Among patients with type 2 diabetes treated with insulin, perioperative hyperglycemia and hypoglycemia may cause undesirable symptoms, surgery delay or cancellation, or unexpected hospitalization." | ( Carlson, KT; Demma, LJ; Duggan, EW; Morrow, JG; Umpierrez, G, 2017) |
| "Patients with moderate CKD and Type 2 diabetes or previous kidney transplantation showed stable renal function that was unaffected by administration of low-dose ESA." | ( Dellanna, F; Fliser, D; Koch, M; Wiggenhauser, A, 2017) |
| "In patients with type 2 diabetes, both supervised exercise and treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) liraglutide may improve cardiac function." | ( Jensen, JS; Jensen, MT; Jørgensen, PG; Knop, FK; Mensberg, P; Nyby, S; Storgaard, H; Vilsbøll, T, 2017) |
| "Patients with type 2 diabetes who received exenatide or BI between 2009 and 2014 as their first recorded exposure to injectable therapy were selected." | ( Berni, ER; Currie, CJ; Holden, SE; Jenkins-Jones, S; Morgan, CL; Qiao, Q, 2017) |
| "MATERIAL AND METHODS Five patients with type 2 diabetes were enrolled and treated with insulin degludec and metformin as a basal therapy." | ( Ihana-Sugiyama, N; Kakei, M; Noda, M; Sugiyama, T; Tsujimoto, T; Yamamoto-Honda, R, 2017) |
| "Treatment-naïve subjects with type 2 diabetes mellitus received canagliflozin 50-100 mg/day monotherapy." | ( Kutoh, E; Murayama, T; Takizawa, Y; Wada, A, 2017) |
| "A total of 50 outpatients with type 2 diabetes mellitus (T2DM) treated with Alo and 47 outpatients with T2DM treated with Pio were switched to Alo-Pio FDCT, and its efficacy and usefulness were evaluated." | ( Aoki, C; Aso, Y; Kasai, K; Kuroda, H; Sagara, M; Shimizu, M; Suzuki, K, 2017) |
| "While earlier type 2 diabetes trials demonstrated that intensive glucose lowering reduces microvascular complications, it is only recently that treatment with some of the newer antihyperglycemic agents has been associated with macrovascular benefits." | ( Leong-Poi, H; Pan, Y; Polemidiotis, J; Quan, A; Singh, KK; Teoh, H; Verma, S, 2017) |
| "BACKGROUND In clinics, patients with type 2 diabetes complicated with non-alcoholic fatty liver disease (NAFLD) have been shown to receive significant improvements in blood glucose levels, lipid levels, and liver function after sitagliptin treatment, although the mechanism of drug action remains poorly understood." | ( Chen, L; Lei, T; Shen, T; Wang, H; Xia, J; Xu, B; Yu, M; Zhang, C, 2017) |
| "Treatment of patients with type 2 diabetes mellitus (T2DM) and a history of cardiovascular (CV) disease or CV risk factors may present clinical challenges due to the presence of comorbid conditions and the use of concomitant medications." | ( Davies, MJ; Merton, K; Qiu, R; Vijapurkar, U; Yee, J, 2017) |
| "Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled." | ( Chu, C; de Vries, F; Kothny, W; Lopez-Leon, S; Schlienger, R; Serban, C; Williams, R, 2017) |
| "Thirty type 2 diabetes patients with ischemic foot ulcerations were randomly assigned to receive either low-intensity CDC at sensory threshold (ES group, n=15) or placebo treatment (control group, n=15) for 1h/day, 3days/week, for 4weeks (12 sessions)." | ( Ahmadi, M; Asadi, MR; Gohardani, RF; Hedayati, M; Mohajeri-Tehrani, MR; Torkaman, G, 2017) |
| "Fifty patients with type 2 diabetes, treated with statins, were selected and divided into two groups." | ( Arimura, A; Arimura, H; Deguchi, T; Hashiguchi, H; Kikuti, A; Kurano, M; Nishio, Y; Shinnakasu, A; Yamamoto, K, 2017) |
| "In a population with type 2 diabetes at high cardiovascular risk, there were numerically fewer events of acute pancreatitis among liraglutide-treated patients (regardless of previous history of pancreatitis) compared with the placebo group." | ( Buse, JB; Ghorbani, MLM; Nauck, MA; Steinberg, WM; Ørsted, DD, 2017) |
| "We enrolled 176 individuals with type 2 diabetes, which were divided into four treatment groups according to different oral drugs: metformin alone, sitagliptin alone, pioglitazone alone, or combination of metformin and sitagliptin." | ( Chen, W; Liu, X; Mei, T; Ye, S, 2017) |
| "In patients with type 2 diabetes previously on insulin and treated with BIL, large VLDL concentration increased from baseline." | ( Antalis, CJ; Cariou, B; Connelly, MA; Hoogwerf, BJ; Ivanyi, T; Orchard, TJ; Otvos, JD; Zhang, S, 2017) |
| "Patients with type 2 diabetes from the Fremantle Diabetes Study Phase II and on stable renin-angiotensin system blocking therapy were divided into those remaining untreated with a PPI (group 1, n = 686), on PPI therapy throughout (group 2, n = 174), and commencing (group 3, n = 109) or discontinuing regular PPI therapy (group 4, n = 67) during the 2 years between assessments." | ( Davis, TME; Davis, WA; Drinkwater, J, 2017) |
| "We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-to-target, event-driven cardiovascular outcomes trial." | ( Brown-Frandsen, K; Buse, JB; Emerson, SS; Haahr, PM; Kvist, K; Lange, M; Marso, SP; McGuire, DK; Moses, A; Pieber, TR; Poulter, NR; Pratley, RE; Skibsted, S; Zinman, B, 2017) |
| "Choices for the treatment of type 2 diabetes mellitus (T2DM) have multiplied as our understanding of the underlying pathophysiologic defects has evolved." | ( Thrasher, J, 2017) |
| "Bringing patients with type 2 diabetes to recommended glycated hemoglobin (HbA1c) treatment targets can reduce the risk of developing diabetes-related complications." | ( Dang-Tan, T; Gamble, C; Hunt, B; McConnachie, CC, 2017) |
| "Treatment of type 2 diabetes with sodium-glucose cotransporter 2 (SGLT2) inhibitors may result in genital fungal infections." | ( Adamson, KA; Bain, SC; Barnes, DJ; Chowdhury, TA; Chuah, LL; Morris, DS; Robinson, AM; Ryder, REJ; Thong, KY; Yadagiri, M, 2018) |
| "Among patients with type 2 diabetes treated with insulin and with at least 1 hypoglycemia risk factor, 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of overall symptomatic hypoglycemia." | ( Bhargava, A; Chaykin, L; de la Rosa, R; Handelsman, Y; Kvist, K; Norwood, P; Troelsen, LN; Wysham, C, 2017) |
| "Many people with type 2 diabetes mellitus (T2DM) fail to achieve glycaemic control promptly after diagnosis and do not receive timely treatment intensification." | ( Ceriello, A; Corcos, A; Gentilella, R; Pechtner, V; Reach, G, 2017) |
| "The therapy of Type 2 Diabetes Mellitus (T2DM) stays a challenging issue." | ( Abdel Azeem, MN; Abdel-Twab, SM; Ahmed, OM; Hassan, MA, 2017) |
| "The main aim of the treatment of type 2 diabetes is overall control of cardiovascular risk factors." | ( Cuatrecasas, G; Goñi-Goicoechea, F, 2016) |
| "Originally used for the treatment of type 2 diabetes, metformin, now proven to prevent or delay diabetes, may serve as an important tool in battling the growing diabetes epidemic." | ( Aroda, VR; Crandall, JP; Darwin, C; Edelstein, SL; Heckman-Stoddard, BM; Jeffries, SL; Kahn, SE; Knowler, WC; Molitch, ME; Nathan, DM; Perreault, L; Pi-Sunyer, X; Temprosa, M, 2017) |
| "In a patient with type 2 diabetes not well controlled with a basal insulin - metformin combination, several therapeutic options may be considered: intensifying insulin therapy with different schemes (appropriate titration using a more favourable basal insulin analogue, adding one, two or three rapid-acting insulin analogues, shift to two or three premix insulin injections), adding a dipeptidyl peptidase-4 inhibitor (gliptin) or an inhibitor of sodium-glucose cotransporters type 2 (gliflozin), or combining a glucagon-like peptide-1 receptor agonist with basal insulin." | ( Paquot, N; Scheen, AJ, 2017) |
| "The study participants were 87 type 2 diabetes mellitus patients who had been treated with dipeptidyl peptidase-4 inhibitors for ≥8 weeks and had a low-density lipoprotein cholesterol (LDL-C) level of ≥120 mg/dL." | ( Arao, T; Kobayashi, T; Kurozumi, A; Masuda, D; Okada, Y; Tanaka, Y; Yamashita, S, 2018) |
| "A total of 451 patients with type 2 diabetes naïve to insulin treatment were recruited." | ( Ahn, CW; Kang, S; Kim, KR; Kim, M; Lee, M; Lee, S; Park, JS; You, J, 2019) |
| "We randomized 240 patients with type 2 diabetes mellitus on insulin monotherapy to 5-mg saxagliptin or placebo as add-on therapy for a 16-week, double-blind period." | ( Kadowaki, T; Muto, S; Ouchi, Y; Seino, Y; Shimazaki, R, 2017) |
| "In DEVOTE, patients with type 2 diabetes were randomised to receive either insulin degludec or insulin glargine U100 (100 units/ml) once daily (between dinner and bedtime) in an event-driven, double-blind, treat-to-target cardiovascular outcomes trial." | ( Barner Lekdorf, J; Brown-Frandsen, K; Buse, JB; Emerson, SS; Heller, S; Kvist, K; Lange, M; Lehmann, L; Marso, SP; McGuire, DK; Moses, A; Pieber, TR; Poulter, NR; Pratley, RE; Woo, V; Zinman, B, 2018) |
| "Fifteen metformin-treated patients with type 2 diabetes; all participants completed the study." | ( Albér, A; Brønden, A; Holst, JJ; Knop, FK; Rehfeld, JF; Rohde, U; Vilsbøll, T, 2017) |
| "Treatment strategies for type 2 diabetes mellitus (T2DM) targeted towards reducing the systemic metabolic burden, rather than demanding greater insulin production from an already beleaguered β-cell, should be emphasized to maintain endogenous insulin secretory function and delay the progression of T2DM." | ( Boland, BB; Grimsby, JS; Rhodes, CJ, 2017) |
| "However, statin therapy predisposes to type 2 diabetes, particularly in patients with predisposition to this condition." | ( Beyaz, Ş; Ükinç, K, 2017) |
| "Many patients with type 2 diabetes mellitus have heart failure and it is important to know about the safety of new treatments for diabetes in these individuals." | ( Bolli, GB; Kothny, W; Kozlovski, P; Krum, H; Lewsey, JD; Lukashevich, V; McMurray, JJV; Ponikowski, P, 2018) |
| "Patients with advanced type 2 diabetes (T2D) and high glycated haemoglobin (HbA1c) values can be difficult to treat because of their severe metabolic disease." | ( Busch, RS; Han, J; Hardy, E; Ruggles, J, 2017) |
| "Since type 2 diabetes (T2D) is associated with oxidative stress and metformin has been shown to exert a protective role against the said stress, we wondered whether metformin treatment might also modulate endoplasmic reticulum (ER) stress and autophagy in leukocytes of T2D patients." | ( Bañuls, C; Diaz-Morales, N; Escribano-Lopez, I; Hernandez-Mijares, A; Iannantuoni, F; Rocha, M; Rovira-Llopis, S; Sola, E; Victor, VM, 2018) |
| "Management of Type 2 diabetes mellitus by diet is achievable at the early stage of the disease; patients usually underestimate this approach and an appropriate drug therapy is required." | ( Aiello, F; Badolato, M; Brizzi, A; Caroleo, MC; Carullo, G; Cione, E; Di Gioia, ML; Manetti, F; Perri, M, 2017) |
| "In a type 2 diabetes mellitus mouse model (db/db), oral administration of geraniol improved glucose homeostasis by increasing plasma GLP-1 and insulin levels." | ( Choi, JH; Choi, JS; Jang, HJ; Kim, KH; Kim, KS; Kim, Y; Lee, IS; Park, J, 2017) |
| "We analyzed 9002 patients with type 2 diabetes (T2D) inadequately controlled with oral hypoglycemic agents from 8 geographic regions and 2 hospital tiers in China who initiated and maintained BI treatment." | ( Gao, Y; Guo, X; Ji, J; Ji, L; Li, X; Zhang, H; Zhang, P; Zhang, T; Zhao, F; Zhu, D, 2017) |
| "Several novel treatment strategies for type 2 diabetes (T2D) mimic GLP-1 actions or inhibit incretin degradation (DPP4 inhibitors), but none is thus far aimed at increasing the secretion of endogenous incretins." | ( Ahlqvist, E; Almgren, P; Asplund, O; Groop, L; Hakaste, L; Holst, JJ; Krus, U; Laurila, E; Lindqvist, A; Melander, O; Nilsson, PM; Orho-Melander, M; Ottosson-Laakso, E; Prasad, RB; Sonestedt, E; Tuomi, T; Wierup, N, 2017) |
| "Evaluate the incidence of type 2 diabetes mellitus (T2DM) and hyperlipidemia (HLD) in CML patients initiating therapy with dasatinib or nilotinib." | ( Burns, L; Franklin, M; Makenbaeva, D; Perez, S; Yerragolam, D, 2018) |
| "Many adolescents with type 2 diabetes (T2D) have rapid deterioration of glycemic control on metformin monotherapy within 2 years of diagnosis." | ( Bacha, F; Beck, RW; Cheng, P; Gal, RL; Klingensmith, GJ; Kollman, C; Manseau, K; Tamborlane, WV; Wood, J, 2018) |
| "In Japanese patients with type 2 diabetes treated with vildagliptin and low-dose metformin, metformin up-titration significantly but modestly improved glycemic control without hypoglycemia and weight gain." | ( Azuma, K; Goto, H; Ikeda, F; Kanazawa, A; Komiya, K; Masuyama, A; Mita, T; Ogihara, T; Ohmura, C; Osonoi, T; Osonoi, Y; Saito, M; Sato, J; Shimizu, T; Someya, Y; Suzuki, L; Takayanagi, N; Takeno, K; Uzawa, H; Watada, H, 2017) |
| "Sixteen patients with type 2 diabetes were newly administered dapagliflozin 5 mg daily as the experimental SGLT2i group." | ( Abiru, N; Ando, T; Haraguchi, A; Hongo, R; Horie, I; Ito, A; Kawakami, A; Nakamura, T; Natsuda, S; Sagara, I, 2018) |
| "Because of concomitant type 2 diabetes, all participants were treated with metformin (3 g daily)." | ( Krysiak, R; Okopień, B; Szkróbka, W, 2018) |
| "A 64-year-old woman with Type 2 diabetes receiving insulin therapy was taken to an emergency department because of disturbed consciousness 21 h after self-injection of 300 units of insulin degludec (4." | ( Katsuki, T; Kawai, T; Oikawa, Y; Shimada, A; Takeda, H; Uchida, J, 2018) |
| "Patients with type 2 diabetes, non-insulin treated, with painful osteoarthritis of the knee were requested to participate in our study." | ( Artul, S; Chernin, M; Habib, G; Jabaly-Habib, H; Jabbour, A; Sakas, F, 2018) |
| "Metformin treatment for type 2 diabetes mellitus (T2DM) can be limited by gastrointestinal (GI) adverse events (AEs), resulting in treatment discontinuation." | ( Feng, B; Ji, L; Li, Q; Li, W; Li, X; Li, Y; Liang, L; Liang, Z; Lin, M; Lin, S; Liu, J; Liu, Y; Luo, Y; Ma, L; Ma, T; Qu, S; Song, W; Wang, J; Xi, S; Xu, H; Yang, J; Yang, Y; Zeng, J; Zhu, D, 2018) |
| "Adult patients with type 2 diabetes mellitus (T2DM) who initiated a DPP4-i (linagliptin, sitagliptin, saxagliptin) between 1 January 2011 and 30 June 2014 were identified using electronic medical records and administrative claims, with index date being the date of first observed DPP4-i treatment." | ( Bauer, E; Huang, H; Lang, K; Shetty, S, 2018) |
| "TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) was a multicenter randomized trial of 3 treatments including 521 participants with type 2 diabetes, aged 10-17 years, and with 2-6 years of follow-up." | ( Bacha, F; Bjornstad, P; El Ghormli, L; Gidding, SS; Levitsky, LL; Levitt Katz, LE; Lima, JAC; Lynch, J; Tryggestad, JB; Weinstock, RS, 2018) |
| "Because of coexistent type 2 diabetes, these women were treated with metformin (2." | ( Krysiak, R; Okopień, B; Szkróbka, W, 2018) |
| "In patients with uncontrolled type 2 diabetes while using metformin, co-administration of ertugliflozin and sitagliptin provided more effective glycaemic control through 52 weeks compared with the individual agents." | ( Eldor, R; Engel, SS; Golm, G; Huyck, SB; Johnson, J; Lauring, B; Mancuso, JP; Pratley, RE; Qiu, Y; Raji, A; Sunga, S; Terra, SG, 2018) |
| "Twenty-four patients with obesity and type 2 diabetes receiving combined oral and insulin therapy were randomly assigned to receive either exenatide 10 μg or placebo twice a day for 12 weeks." | ( Abuaysheh, S; Batra, M; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Green, K; Kuhadiya, ND; Makdissi, A, 2018) |
| "Challenges facing the treatment of type 2 diabetes necessitate the search for agents which act via alternative pathways to provide better therapeutic outcomes." | ( Corcoran, O; Mohamed, D; Ofosu, WA; Ojo, OO, 2019) |
| "Patients with type 2 diabetes (T2D) typically use several drug treatments during their lifetime." | ( Kwon, CS; Rodriguez-Monguio, R; Seoane-Vazquez, E, 2018) |
| "She was diagnosed with type 2 diabetes mellitus at this visit and treated with insulin injection." | ( Chitasombat, MN; Jinawath, A; Lertvikool, S; Nernsai, P; Sophonsritsuk, A, 2018) |
| "New classes of drugs to treat type 2 diabetes are continually being developed and marketed." | ( Covino, J; Hoffman, J, 2018) |
| "Many individuals with type 2 diabetes (T2D) will eventually require insulin therapy to help achieve and maintain adequate glycemic control." | ( Blumer, I; Pettus, JH; Santos Cavaiola, T, 2018) |
| "We enrolled 14 patients with type 2 diabetes and hypertriglyceridemia treated with statins and dipeptidyl peptidase-4 inhibitors with glycated hemoglobin (HbA1c) < 8." | ( Ide, K; Ishikawa, T; Koshizaka, M; Maezawa, Y; Takemoto, M; Tokuyama, H; Tokuyama, T; Yokote, K, 2018) |
| "Young and middle-aged men with type 2 diabetes should undergo regular screening for androgen deficiency with the purpose of its early diagnosis and timely treatment." | ( Proshchai, GA; Vorokhobina, NV; Zagarskikh, EY, 2018) |
| "Elderly subjects with metformin-treated type 2 diabetes have lower glucagon levels at 3." | ( Ahrén, B; Farngren, J; Persson, M, 2018) |
| "Moderately obese Japanese type 2 diabetes patients, treated with luseogliflozin for a year, were observed prospectively and evaluated for body composition changes." | ( Fukuda, M; Sasaki, T; Sugawara, M, 2019) |
| "Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US." | ( Boye, KS; Currie, BM; Jordan, J; Lando, LF; Matza, LS; Mody, R; Paczkowski, R, 2018) |
| "As more and more studies suggest that type 2 diabetes mellitus (T2DM) is closely related to male hypogonadism, people begin to pay more attention to the role of testosterone in the development of T2DM and the effect and safety of testosterone supplementary therapy." | ( Cai, K; Chen, GM; Cheng, Z; He, W; Liao, ZH; Zhang, LY, 2017) |
| "A total of 168 patients with type 2 diabetes treated with >4 mg of glimepiride and 1000 mg of metformin by using free or fixed-dose combination therapy for at least 2 weeks were enrolled." | ( Ahn, KJ; Cha, BY; Chung, MY; Kang, JG; Kim, IJ; Kim, JD; Kim, JT; Lee, HW; Min, KW; Park, CY; Park, KS; Park, SW; Won, JC, 2018) |
| "Subjects with inadequately controlled type 2 diabetes (drug-naïve or on background treatment) were randomized to subcutaneous semaglutide 0." | ( Ahrén, B; Atkin, SL; Birch, S; Charpentier, G; Holst, AG; Leiter, LA; Warren, ML; Wilding, JPH, 2018) |
| "In participants with type 2 diabetes and a self-reported history of CABG surgery, treatment with empagliflozin was associated with profound reductions in cardiovascular and all-cause mortality, hospitalisation for heart failure, and incident or worsening nephropathy." | ( Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Pfarr, E; Verma, S; Zinman, B, 2018) |
| "We recruited 126 adults with type 2 diabetes who completed the FFQ and three 24-HDRs administered by a registered dietitian." | ( Chang, CI; Chen, HJ; Hsu, CC; Huang, MC; Huang, YF; Hung, HC; Lee, CH; Lin, KD; Shin, SJ; Wu, YJ, 2018) |
| "Adults with Type 2 diabetes were safely transitioned from insulin injections to the PAQ and had significantly improved glycaemic control and treatment satisfaction with insulin therapy." | ( Aberer, F; Bai, J; Bechara, CF; Bismuth, J; Busch, MA; Buttery, AK; Chen, T; Chen, WH; DeBusk, K; Donelson, SM; Fitzgerald, K; Gaber, AO; Globe, G; Han, M; Harding, G; Heidemann, C; Higgins, PDR; Jia, X; Jiang, X; Johns, D; Knight, RJ; Leidy, NK; Lilly, LC; Lin, L; Liu, Y; Lu, T; Luo, X; Mader, JK; Maske, UE; Ning, Q; Ortmeier, BG; Paprott, R; Patrick, DL; Pieber, TR; Poettler, T; Revicki, DA; Rieckmann, N; Scheidt-Nave, C; Shi, A; Tian, H; Trautmann, M; Viswanathan, H; Warner, JL; Weikert, B; Xiao, F; Yan, W; Yi, SG; Zhang, X; Zhen, W; Zhu, L, 2017) |
| "Fifty patients with type 2 diabetes and NAFLD were randomly assigned to either the empagliflozin group (standard treatment for type 2 diabetes plus empagliflozin 10 mg daily) or the control group (standard treatment without empagliflozin) for 20 weeks." | ( Bansal, B; Choudhary, NS; Farooqui, KJ; Gill, HK; Jevalikar, G; Kaur, P; Krishan, S; Kuchay, MS; Mishra, SK; Mithal, A; Singh, MK; Wasir, JS, 2018) |
| "Patients with type 2 diabetes who initiated a long-acting insulin analog or NPH insulin were included and censored at death, loss of health plan coverage, change in insulin treatment, or study end on September 30, 2015." | ( Huang, ES; Karter, AJ; Lipska, KJ; Moffet, HH; Parker, MM, 2018) |
| "There were 25 489 patients with type 2 diabetes who initiated basal insulin therapy (mean age, 60." | ( Huang, ES; Karter, AJ; Lipska, KJ; Moffet, HH; Parker, MM, 2018) |
| "Studies on patients with type 2 diabetes treated with metformin analyzed data on total of 146 496 patients." | ( Dobrzycka, M; Jędrusik, P; Kobiela, J; Kobiela, P; Śledziński, Z; Spychalski, P; Zdrojewski, T, 2019) |
| "In patients with type 2 diabetes, empagliflozin 25 mg as add-on to metformin for 208 weeks reduced HbA1c with a significantly lower risk of hypoglycaemia and a significantly smaller proportion of patients receiving rescue therapy compared with glimepiride." | ( Andersen, KR; Ridderstråle, M; Rosenstock, J; Salsali, A; Woerle, HJ, 2018) |
| "84 participants with type 2 diabetes and NAFLD were randomly assigned 1:1:1:1 to four treatments by a centralised randomisation system, and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments." | ( Eriksson, JW; Forsberg, GB; Jansson, PA; Johansson, L; Kvarnström, M; Lind, L; Lundkvist, P; Miliotis, T; Moris, L; Oscarsson, J; Risérus, U, 2018) |
| "In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin ± sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated." | ( Engel, SS; Kaufman, KD; Lam, RLH; Morgan, J; O'Neill, EA; Raji, A; Scott, R; Zimmer, Z, 2018) |
| "After induction of type 2 diabetes, diabetic rats were orally treated with 20 mg/kg body mass gallic acid and 40 mg/kg body mass p-coumaric acid for six weeks." | ( Abdel-Moneim, A; Ashour, MB; El-Twab, SMA; Reheim, ESA; Yousef, AI, 2018) |
| "The progressive nature of type 2 diabetes (T2D) requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic targets are not attained." | ( IJzerman, RG; Muskiet, MHA; van Baar, MJB; van Bloemendaal, L; van Raalte, DH; van Ruiten, CC, 2018) |
| "Treatment of type 2 diabetes (T2D) in children and adolescents is particularly challenging." | ( Guandalini, C; Patel, A; Steffen, A; Tamborlane, W; Van Name, MA, 2018) |
| "The choice of therapy for type 2 diabetes after metformin is guided by overall estimates of glycemic response and side effects seen in large cohorts." | ( Dennis, JM; Hamilton, WT; Hattersley, AT; Henley, WE; Holman, RR; Janmohamed, S; Jones, AG; Lonergan, M; Pearson, ER; Rodgers, LR; Sattar, N; Shields, BM; Weedon, MN, 2018) |
| "We compared treatment satisfaction in type 2 diabetes patients taking daily and weekly glucagon-like peptide-1 receptor agonists." | ( Aoki, S; Atsumi, T; Cho, KY; Dannoura, M; Kurihara, Y; Manda, N; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Takase, T; Yamamoto, C, 2019) |
| "To evaluate, in patients with type 2 diabetes and hypertension, the effects of 6 months treatment with canagliflozin, or perindopril, an angiotensin converting enzyme inhibitor, on central BP and carotid-femoral pulse wave velocity (cfPWV)." | ( Ramirez, AJ; Sanchez, MJ; Sanchez, RA, 2019) |
| "The recruited 140 type 2 diabetes were randomly divided into the treatment group and control group which were both received basic diabetic management including anti-hyperglycemia, anti-hypertension, life style adjustment and health education etc." | ( An, X; Liu, J; Liu, S; Xu, W; Yu, J; Yu, X; Zhao, Y, 2018) |
| "For patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control, addition of basal insulin is recommended, but titration and optimization of basal insulin therapy in primary care is not well understood." | ( Anderten, H; Borck, A; Bramlage, P; Fritsche, A; Pegelow, K; Pfohl, M; Pscherer, S; Seufert, J, 2019) |
| "Induction of type 2 diabetes mellitus in experimental animals was carried out by manipulation of diet using high fat diet for fourteen days and then administration of streptozotocin at low dose of 35 mg/kg, i." | ( Kulkarni, YA; Oza, MJ, 2018) |
| "Pharmacologically, type 2 diabetes can be treated with 9 different approved classes of drugs, but metformin is suggested as the first line of therapy, followed by sulfonylureas." | ( Arif, MA; Kanwal, N; Khalid, S; Masood, N; Moeez, S; Niazi, R; Riaz, S, 2019) |
| "Pharmacotherapy used to treat type 2 diabetes mellitus (T2DM) is facing a paradigm shift in clinical practice with recent cardiovascular (CV) outcome trials having a substantial impact on drug prescription with treatment having a more tailored approach." | ( De Ponti, F; Marchesini, G; Mazzotti, A; Poluzzi, E; Raschi, E, 2018) |
| "Metformin, the first-line drug to treat type 2 diabetes (T2D), inhibits mitochondrial glycerolphosphate dehydrogenase in the liver to suppress gluconeogenesis." | ( Berg, M; Dash, SN; Dumont, V; Groop, PH; Hautala, LC; Lehtonen, S; Lindfors, S; Mirtti, T; Naams, JB; Nisen, H; Polianskyte-Prause, Z; Tienari, J; Tolvanen, TA; Van, M; Wähälä, K; Wang, H, 2019) |
| "A total of 79 subjects with type 2 diabetes mellitus and dyslipidaemia were included; 46 subjects were treated with atorvastatin 10 mg daily plus diet and 33 were managed by diet alone for 12 months." | ( Eleftheriadou, I; Grigoropoulou, P; Sykara, M; Tentolouris, A; Tentolouris, N; Tsilingiris, D; Vlachopoulos, C, 2019) |
| "A total of 75 patients with type 2 diabetes and CKD and inadequate glycemic control receiving any pharmacological antidiabetic treatment were randomly assigned to 2 groups." | ( Satirapoj, B; Supasyndh, O; Watanakijthavonkul, K, 2018) |
| "In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure." | ( Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Kuder, JF; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA, 2019) |
| "Medical treatment of type 2 diabetes in pregnancy is generally restricted to insulin, as data on the safety and efficacy of oral hypoglycemic agents in pregnancy are limited." | ( Berry, DC; Boggess, K; de Los Angeles Abreu, M; Dorman, KF; Ivins, AR; Thomas, SD; Young, L, 2018) |
| "Patients with type 2 diabetes had higher rates of withdrawal because of adverse events when treated with detemir compared with glargine (relative risk 2." | ( Crabtree, E; Holmes, RS; McDonagh, MS, 2019) |
| "Older patients with type 2 diabetes are prone to developing adverse events with aggressive antihyperglycaemic therapy." | ( Hannallah, F; Hooda, A; Mehta, A, 2018) |
| "One patient with >20-year history of type 2 diabetes mellitus had irregular episodes of hypoglycemia 2 years of after treatment with insulin." | ( Chen, F; Liu, Y; Wang, W; Yang, J; You, W; Zhu, L, 2018) |
| "The progressive nature of type 2 diabetes (T2D) means that many patients will require basal insulin therapy at some point in the course of the disease due to β-cell failure." | ( Johnson, E; Perreault, L; Rodbard, H; Valentine, V, 2019) |
| "Patients with arterial hypertension and type 2 diabetes mellitus (n=94) were divided in two subgroups: persons from the first (n=54) were treated by telmisartan 40-80 mg/day; second (n=40) - by lisinopril 10-20 mg/day." | ( Chernatska, O; Demikhova, N, 2018) |
| "Among insured adult patients with type 2 diabetes initiating second-line ADM therapy, the short-term cardiovascular outcomes of GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors were similar." | ( Ackermann, RT; Cooper, AJ; Kang, RH; Karam, SL; Lancki, N; Liss, DT; Moran, MR; O'Brien, MJ; Prospect, TA; Wallia, A, 2018) |
| "Metformin, the mainstay of type 2 diabetes mellitus (T2DM)-treatment, reduces the risk of hepatocarcinogenesis." | ( Hinrichs, JB; Ivanyi, P; Kirstein, MM; Koch, S; Manns, MP; Marhenke, S; Pinter, M; Rodt, T; Scheiner, B; Schulte, L; Schweitzer, N; Vogel, A; Voigtländer, T; Weinmann, A, 2019) |
| "Patients with type 2 diabetes mellitus subjected to GLP-1 receptor agonist therapy with exenatide were examined before and shortly after initiation of treatment." | ( Beti, C; Bokman, G; Dreier, J; Fischer, M; Hauber, M; Knabbe, C; Lee-Barkey, YH; Stratmann, B; Tschoepe, D, 2019) |
| "Treatment of older adults with type 2 diabetes (T2D) is complex because they represent a heterogeneous group with a broad range of comorbidities, functional abilities, socioeconomic status, and life expectancy." | ( Freeman, J, 2019) |
| "for the treatment of type 2 diabetes (T2D)." | ( Brønden, A; Dejgaard, TF; Heimbürger, SM; Johansen, NJ; Knop, FK; Vilsbøll, T, 2019) |
| "Insulin-treated patients with type 2 diabetes (T2D) and obesity are challenged in achieving body weight stability or reduction, in addition to glycaemic control." | ( Aberle, J; Fuechtenbusch, M; Heitmann, E; Jung, H; Nicolay, C, 2019) |
| "Results could be an indicator of type 2 diabetes delayed development during irradiation exposure and support the importance of GLP-1R as a target gene in radiotherapy against T2DM and its chronic complications." | ( Al-Daoude, A; Khalil, A, 2019) |
| "So, prevention of type 2 diabetes mellitus by taking necessary steps like regular physical exercise, intake of healthy diet and behavior therapy may help in prevention of type 2 diabetes mellitus related complication." | ( Chowdhury, JA; Nessa, A, 2019) |
| "Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study." | ( Castellino, G; Chianetta, R; Citarrella, R; Corrado, E; Giglio, RV; Magan-Fernandez, A; Montalto, G; Nikolic, D; Patti, AM; Provenzano, F; Provenzano, V; Rizvi, AA; Rizzo, M, 2019) |
| "Among people with type 2 diabetes treated with diuretics, there was a significant increase in the risk of LLE, predominantly in the risk of LLA." | ( Bumbu, A; Hadjadj, S; Marre, M; Matar, O; Mohammedi, K; Potier, L; Ragot, S; Roussel, R; Saulnier, PJ; Schneider, F; Velho, G, 2019) |
| "Rats with type 2 diabetes were exposed to GYY4137, a slow release donor of hydrogen sulfide with or without administration of the Sirtuin3 short hairpin ribonucleic acid plasmid, and then subjected to a surgical model of ischemia-reperfusion injury of the lung (n = 8)." | ( Cui, X; Ding, W; Jiang, T; Liu, T; Liu, Y; Lv, X; Meng, Q; Yue, Z, 2019) |
| "Twenty-six type 2 diabetes patients with foot ulceration were randomly assigned to the two groups, thirteen treated with negative pressure wound therapy and the others treated with traditional debridement therapy." | ( Chen, B; Fan, L; Li, X; Liu, J; Tao, Y; Wang, T; Wang, X, 2019) |
| "Vildagliptin is indicated for type 2 diabetes mellitus (T2DM); however, the onset and exacerbation of diabetic complications in Japanese T2DM patients treated with vildagliptin is unknown." | ( Murayama, H; Oyama, N; Shinfuku, Y; Tanaka, Y; Taniguchi, T; Toda, M; Tsumiyama, I, 2019) |
| "In patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or those at high risk for CVD, subsequently to lifestyle changes and metformin therapy, the administration of an SGLT-2 inhibitor with established benefits for cardiovascular outcome (CVOT) should be considered." | ( Aharon-Hananel, G; Raz, I, 2019) |
| "We present a patient with PAD who has type 2 diabetes mellitus, who has previously been repeatedly treated for lower limb ischemia with multiple vascular surgeries performed." | ( Antova, E; Bosevska, G; Bosevski, M; Krstevski, G; Mitevska, I, 2018) |
| "Metformin is a first-line therapy for type 2 diabetes." | ( Soukas, AA; Yerevanian, A, 2019) |
| ": The prevalence of hypertension, type 2 diabetes mellitus (DM2) and the metabolic syndrome continues to increase in Latin America, while the rates of diagnosis, treatment and control of these disorders remain low." | ( Accini, JL; Alcocer, L; Barbosa, E; Camacho, PA; Cobos, L; Coca, A; Diaz, M; Lanas, F; López-Jaramillo, P; Molina, DI; Pasquel, M; Ponte-Negretti, CI; Sanchez, R; Sebba-Barroso, W; Wyss, F; Zanchetti, A, 2019) |
| "Strategies to prevent and treat type 2 diabetes through manipulation of the gut microbiota are being developed." | ( Caesar, R, 2019) |
| "Metformin is first-line treatment of type 2 diabetes mellitus and reduces cardiovascular events in patients with insulin resistance and type 2 diabetes." | ( Brøsen, K; Feddersen, S; Gormsen, LC; Grønbaek, H; Hamilton-Dutoit, SJ; Heebøll, S; Jakobsen, S; Jessen, N; Munk, OL; Pedersen, SB; Sundelin, EIO; Vendelbo, MH, 2019) |
| "Patients with type 2 diabetes with no or early DR were randomized 1:1:1 to topical treatment with placebo, brimonidine, or somatostatin in a 96-week prospective, phase II to III, European multicenter trial." | ( Cunha-Vaz, J; Fernández-Carneado, J; Frydkjaer-Olsen, U; Grauslund, J; Hernández, C; Peto, T; Ponsati, B; Simó, R, 2019) |
| "A rodent model of type 2 diabetes (30 mg/kg streptozotocin and high-fat feeding in male Sprague-Dawley rats) was used to assess 12 weeks of co-treatment with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and exercise (EX; treadmill running) on glycemic control and exercise capacity." | ( Beebe, DA; Braun, B; Esler, WP; Gorgoglione, MF; Hamilton, KL; Linden, MA; Miller, BF; Ross, TT, 2019) |
| "Forty hypertensive patients with type 2 diabetes were randomly assigned to 4-week treatment with dapagliflozin 10 mg or hydrochlorothiazide (HCT) 12." | ( Biancalana, E; Bruno, RM; Dardano, A; Ghiadoni, L; Giannini, L; Parolini, F; Rossi, C; Seghieri, M; Solini, A; Taddei, S, 2019) |
| "In the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study, metformin plus rosiglitazone (M + R) maintained glycemic control better than metformin alone (M) or metformin plus lifestyle (M + L) in youth with type 2 diabetes (T2D)." | ( Copeland, KC; Dhaliwal, R; El Ghormli, L; Geffner, ME; Higgins, J; Levitsky, LL; Nadeau, KJ; Shepherd, JA; Weinstock, RS; White, NH, 2019) |
| "As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach." | ( Chin, J; Choi, H; Choung, W; Hong, E; Hwang, H; Jang, SM; Jang, TH; Joo, J; Jung, K; Kim, H; Kim, KH; Kim, SH; Kim, WS; Lee, BR; Lee, G; Lim, JS; Myung, J; Park, M; Yang, D, 2019) |
| "Similar insulin resistance is found in type 2 diabetes and is currently treated with insulin sensitizers (IS)." | ( Craig, A; Issberner, J; Parvez, F, 2019) |
| "Initiating treatment of type 2 diabetes with a sulfonylurea rather than metformin is associated with higher rates of ischaemic stroke, cardiovascular death, and all-cause mortality." | ( Azoulay, L; Douros, A; Filion, KB; Suissa, S; Yin, H; Yu, OH, 2019) |
| "Nutrition is an integral part of type 2 diabetes (T2DM) treatment, but the optimal macronutrient composition is still debated and previous studies have not addressed the role of ethnicity in dietary response." | ( Blaychfeld-Magnazi, M; Knobler, H; Madar, Z; Reshef, N; Zornitzki, T, 2020) |
| "Early treatment intensification for type 2 diabetes mellitus (T2DM) is often required to achieve glycaemic control and avoid longer-term complications." | ( Blak, BT; Fenici, P; Medina, J; Nolan, ST; Rigney, U; Wilding, JPH, 2019) |
| "The provocative idea that type 2 diabetes (T2D) may be a surgically treated disorder is based on accumulating evidence suggesting impressive remission rates of obesity and diabetes following bariatric surgery interventions." | ( Karras, SN; Kotsa, K; Koufakis, T; Mustafa, OG, 2019) |
| "Metformin is first-line therapy for type 2 diabetes mellitus, although its effects on the cardiovascular system are unproved." | ( Bergmark, BA; Bhatt, DL; Braunwald, E; Cahn, A; Gurmu, Y; Im, K; Kanevsky, E; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG, 2019) |
| "Thus, among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl, changes in albuminuria are directly related to changes in eGFR, challenging the conventional construct that increases in albuminuria universally reflect kidney injury and denote harm." | ( Block, GA; Chertow, GM; Chin, MP; Goldsberry, A; Heerspink, HJL; McCullough, PA; Meyer, CJ; Packham, D; Pergola, PE; Rossing, P; Spinowitz, B; Sprague, SM; Warnock, DG, 2019) |
| "Because of concomitant type 2 diabetes, all men were treated with metformin (2550-3000 mg daily)." | ( Krysiak, R; Okopień, B; Szkróbka, W, 2020) |
| "Fifty-two years old patient with type II diabetes mellitus, who had spontaneous cutaneous and intra muscular bleeding after starting treatment with Exenatide." | ( Andrawus, E; Azzam, ZS; Bishop, BY; Khoury, J, 2018) |
| "Given the high prevalence of type 2 diabetes mellitus (T2DM) in HT patients, we investigated the association between metformin therapy and cardiovascular outcomes after HT." | ( Amunts, S; Fisman, EZ; Klempfner, R; Lavee, J; Maor, E; Ovdat, T; Peled, Y; Ram, E; Sternik, L; Tenenbaum, A, 2019) |
| "A total of 20 376 patients with type 2 diabetes mellitus (T2DM) receiving insulin therapy were enrolled during 2000 to 2012." | ( Hsu, CC; Hwu, CM; Pan, CW; Wang, HC; Wei, JC; Yen, FS, 2020) |
| "Novel biomarkers of type 2 diabetes (T2D) and response to preventative treatment in individuals with similar clinical risk may highlight metabolic pathways that are important in disease development." | ( Chen, ZZ; Clish, C; Dagogo-Jack, S; Ferguson, JF; Florez, JC; Gerszten, RE; Hamman, RF; Heckman-Stoddard, BM; Knowler, WC; Lee, CG; Liu, J; Mather, KJ; Morningstar, J; Perreault, L; Temprosa, M; Wang, TJ, 2019) |
| "Drug-naïve subjects with type 2 diabetes (T2DM) received 50 - 100 mg/day canagliflozin monotherapy (n = 40) for 3 months." | ( Hayashi, J; Kuto, AN; Kutoh, E; Wada, A, 2019) |
| "So, prevention of type 2 diabetes mellitus by taking necessary steps like regular physical exercise, intake of healthy diet and behavior therapy may supplementation of magnesium help in prevention of type 2 diabetes mellitus related complication." | ( Chowdhury, JA; Nessa, A, 2019) |
| "Metformin, the first choice drug for type 2 diabetes treatment in all stages of therapy, and one of the most widely prescribed anti-hyperglycemic agents worldwide, represents a rare example of an old drug which continues to display new beneficial effects in various fields." | ( Adinolfi, LE; Imbriani, S; Marfella, R; Monaco, L; Nevola, R; Pafundi, PC; Ricozzi, C; Rinaldi, L; Salvatore, T; Sardu, C; Sasso, FC, 2019) |
| "One hundred and twenty patients with type 2 diabetes were examined and randomized into 4 groups: the computerized training group, the exercise therapy group, the akatinol memantine group and the control group." | ( Matveeva, MV; Ratkina, KR; Samoilova, YG; Yakimovich, IY; Zhukova, NG, 2019) |
| "In the treatment of type 2 diabetes, use of the sulfonylureas that act on the ATP sensitive potassium channel, damages the beta cells, which eventually fail; these drugs do not improve the cardiovascular outcomes." | ( Islam, MS, 2020) |
| "When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference." | ( Boye, KS; Coyne, KS; Currie, BM; Cutts, KN; García-Pérez, LE; Hietpas, RT; Ishak, KJ; Jordan, JB; Malley, KG; Matza, LS; Stewart, KD; Wang, Q; Wullenweber, PK; Yu, M, 2020) |
| "Subjects with type 1 (n = 73) and type 2 diabetes (n = 77) undergoing changes to improve glycemic control (n = 98) or with stable diabetes therapy (n = 52)." | ( Desouza, CV; Fonseca, VA; Frias, JP; Holcomb, RG; Hsia, SH; Klein, EJ; Kohzuma, T; Rosenstock, J; Zhou, R, 2020) |
| "Twenty-four patients with type 2 diabetes were enrolled in a prospective, single-center, randomized, open-label study and were randomly allocated to 4 weeks of treatment with metformin (1000 mg/day) or anagliptin (200 mg/day)." | ( Hamajima, H; Inoue, E; Mieno, E; Miyachi, A; Nagai, Y; Nakagawa, T; Takahashi, M; Tanaka, Y; Yamamoto, Y, 2019) |
| "Rats were induced with type 2 diabetes (T2D) by administration of 10% fructose solution (ad libitum) followed by streptozotocin injection (40 mg/kg BW) and treated with different doses of tofacitinib (10 and 20 mg/kg BW), aspirin (100 and 200 mg/kg BW) and combination of the two drugs at both doses for 9 weeks." | ( Bako, HY; Ibrahim, MA; Ibrahim, S; Isah, MS, 2019) |
| "This trial in patients with type 2 diabetes at a high risk of cardiovascular events and on statin therapy showed that anagliptin reduced LDL-C levels to a greater extent than sitagliptin." | ( Arasaki, O; Chihara, A; Morimoto, T; Node, K; Nomiyama, T; Sakuma, M; Shimabukuro, M; Tanaka, A; Ueda, S, 2019) |
| "As the prevalence of type 2 diabetes mellitus and obesity increases worldwide, scientifically rigorous research is needed in this field to determine effective interventions for the prevention and treatment of these chronic diseases." | ( Allison, DB; Hannon, BA; Siu, CO; Thomas, DM, 2019) |
| "In patients with type 2 diabetes mellitus (T2DM) and poor glycemic control receiving metformin (MET), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended as the adjunctive therapy." | ( An, P; Jin, X; Mu, Y; Wang, J; Yu, S, 2019) |
| "Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1." | ( Bizino, MB; Geelhoed-Duijvestijn, PH; Jazet, IM; Kharagjitsingh, AV; Lamb, HJ; Paiman, EHM; Rensen, PCN; Smit, JWA; van Aalst, MMA; van der Geest, RJ; van Eyk, HJ; Westenberg, JJM, 2020) |
| "Patients with type 2 diabetes (T2D) are usually treated with (combinations of) glucose-lowering medication." | ( Davids, M; Herrema, H; Kramer, MHH; Nieuwdorp, M; van Bommel, EJM; van Raalte, DH, 2020) |
| "Metformin is used to treat type 2 diabetes." | ( Konishi, A; Obinata, H; Tanaka, Y; Tsuneoka, M, 2019) |
| "Although patients with type 2 diabetes mellitus (T2DM) may fail to achieve adequate hemoglobin A1c (HbA1c) control despite metformin-sulfonylurea (Met-SU) dual therapy, a third-line glucose-lowering medication-including dipeptidyl peptidase-4 inhibitor (DPP4i), insulin, or thiazolidinedione (TZD)-can be added to achieve this." | ( Chan, EW; Ho, CW; Lam, CLK; Man, KKC; Shi, M; Tse, ETY; Wong, CKH; Wong, ICK, 2019) |
| "The prevalence of type 2 diabetes (T2D) continues to increase, and its association with cardiovascular (CV) disease has led to the inclusion of CV endpoints in clinical trials on the treatment of T2D." | ( Aguiar, C; Birne, R; Branco, P; Calado, J; Matos, P; Melo, M; Monteiro, P; Polónia, J; Silva-Nunes, J, 2019) |
| "Depression is a common complication in Type 2 diabetes mellitus (T2DM); however, it has long been underrecognized and undertreated." | ( Chen, H; Chen, Q; Fang, W; Gao, Y; Shi, X; Tang, X; Wang, H; Wang, S; Wang, X; Yao, J, 2020) |
| "Outcomes in type 2 diabetes mellitus (T2DM) could be optimized by identifying which treatments are likely to produce the greatest improvements in glycemic control for each patient." | ( Del Parigi, A; Lee, C; Liu, D; Pratley, R; Tang, W, 2019) |
| "In patients with type 2 diabetes, GIP infusion on top of treatment with metformin and a long-acting GLP-1R agonist did not affect energy intake, appetite, or energy expenditure but increased plasma glucose compared with placebo." | ( Bergmann, NC; Christensen, MB; Dela, F; Gasbjerg, LS; Hartmann, B; Heimbürger, SM; Holst, JJ; Jessen, L; Knop, FK; Krogh, LSL; Lund, A; Vilsbøll, T, 2020) |
| "Sixty-three Lebanese patients with type 2 diabetes who administered metformin, were followed up for six months and genotyped for rs622342A>C." | ( El Shamieh, S; Fakhoury, R; Naja, K, 2020) |
| "Insulin-naive adults with type 2 diabetes who initiate and continue treatment with human vs analogue insulins had similar observed rates of major cardiovascular events, CVD mortality, and overall mortality." | ( Anderson, JP; Desai, JR; Dyer, W; Ho, PM; Loes, L; Neugebauer, R; O'Connor, PJ; Pimentel, N; Reynolds, K; Schmittdiel, JA; Schroeder, EB; Vazquez-Benitez, G, 2020) |
| "Metformin is used for the treatment of type 2 diabetes mellitus and has shown therapeutic effects in preclinical models of other pathologies, such as cancer and autoimmune diseases." | ( Caserta, CA; Lefoulon, F; Marcucci, F; Romeo, E; Rumio, C, 2020) |
| "Patients with type 2 diabetes mellitus (T2DM) often experience hypoglycaemia and weight gain due to treatment side effects." | ( Benjasuratwong, Y; Nitiyanant, W; Ongphiphadhanakul, B; Pratipanawatr, T; Satirapoj, B; Suwanwalaikorn, S, 2020) |
| "In treatment options for type 2 diabetes in adolescents and youth (TODAY), 4." | ( Arslanian, S; Chan, CL; Chernausek, SD; El Ghormli, L; Gandica, RG; Gubitosi-Klug, R; Haymond, MH; Levitsky, LL; Siska, M; Willi, SM, 2020) |
| "Men and women with type 2 diabetes treated with lifestyle modification ± metformin were included." | ( Andrew, R; Olsson, T; Otten, J; Ryberg, M; Stomby, A; Walker, BR, 2020) |
| "Mild hyperbaric treatment prevents type 2 diabetes progression due to increased oxygen concentration and blood flow in skeletal muscle." | ( Fujita, N; Goto, N; Hisatsune, K; Nino, W; Nishijo, H; Ochi, R; Urakawa, S, 2020) |
| "He was diagnosed with type 2 diabetes mellitus, started treatment with empagliflozin, and his body weight decreased gradually." | ( Miyauchi, T, 2020) |
| "With the rising prevalence of type 2 diabetes (T2D), there is a substantial interest in novel, glucose-lowering drugs that may complement existing treatment options." | ( Brønden, A; Christensen, MB; Johansson, KS; Knop, FK, 2020) |
| "Most individuals with type 2 diabetes also have obesity, and treatment with some diabetes medications, including insulin, can cause further weight gain." | ( Birkenfeld, AL; Dicker, D; Garvey, WT; Jensen, C; Mingrone, G; Mosenzon, O; Pedersen, SD; Satylganova, A; Skovgaard, D; Sugimoto, D, 2020) |
| "The effects on central hemodynamics, pulse wave velocity (PWV) and endothelial function over the 12-week administration were analyzed." | ( Au-Yeung, F; Jenkins, AL; Josse, R; Jovanovski, E; Komishon, A; Sung, MK; Vuksan, V; Zurbau, A, 2020) |
| "A total of 66,807 people with type 2 diabetes were treated with metformin (MET) plus a combination of second- and third-line therapies." | ( Hejlesen, O; Jakobsen, PE; Jensen, MH; Kjolby, M; Vestergaard, P, 2020) |
| "Prompt identification of MODY allows patients to have effective and safe treatments and prevent the development of premature complications; in addition, its identification allows genetic counseling and can guide the management of other first-degree relatives who also suffer from it." | ( Chávez-García, T; Ferreira-Hermosillo, A; Mendoza-Zubieta, V; Rangel-Coronado, R, 2019) |
| "In patients with type 2 diabetes and coronary artery disease, treatment with sitagliptin resulted in a significantly lower rate of progression of coronary atherosclerosis compared with conventional treatment." | ( Chen, YD; Ding, Y; Li, B; Li, JW; Luo, YR; Shi, WM; Tian, F; Tian, JW; Zhang, YQ; Zhu, M, 2020) |
| "Chinese guidelines for the treatment of type 2 diabetes (T2D) recommend basal or premixed insulins as insulin starters after failed oral antihyperglycaemic medication (OAM)." | ( Chen, H; Chen, L; Ji, L; Lou, Y; Ma, Y; Zhang, X, 2020) |
| "Objective Type 2 diabetes mellitus (T2DM) is a worldwide health problem, and medical nutrition therapy is essential for improving the quality of life of patients with type 2 diabetes." | ( Karakaya, RE; Ozdemir, D; Saka, M, 2020) |
| "Adults with type 2 diabetes insufficiently controlled with sulphonylurea + BI ± another oral anti-hyperglycemic drug were randomized 1:1 to receive lixisenatide + BI or to continue sulphonylurea + BI treatment." | ( Azar, S; Coudert, M; Djaballah, K; Hafidh, K; Hanif, W; Hassanein, M; Sahay, R; Shehadeh, N, 2020) |
| "Since type 2 diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 90-95%) and often the mono-target therapy fails in managing blood glucose levels and the other comorbidities, this review focuses on the potential drugs acting on multi-targets involved in the treatment of this type of diabetes." | ( Artasensi, A; Fumagalli, L; Pedretti, A; Vistoli, G, 2020) |
| "In patients with type 2 diabetes, standard plus empagliflozin attenuated neointimal progression as compared with intensive standard therapy after DES implantation." | ( Hashikata, T; Ikutomi, M; Jimba, T; Kakuda, N; Katsushika, S; Kishi, M; Matsushita, M; Ohnishi, S; Sato, T; Shindo, A; Yamasaki, M; Yokoyama, M, 2020) |
| "Treatment of type 2 diabetes (T2D) should aim at preventing or delaying complications through the control of glycaemia and cardiovascular risk factors." | ( Avogaro, A; Consoli, A; Fadini, GP; Morieri, ML; Purrello, F; Sesti, G, 2021) |
| "The Treatment Options for type 2 Diabetes in Adolescent and Youth study, a randomized clinical trial of three treatments for type 2 diabetes (T2DM) in youth, demonstrated treatment failure (defined as sustained HbA1c ≥8%, or inability to wean insulin after 3 months after acute metabolic decomposition) in over half of the participants." | ( Bacha, F; Braffett, BH; Gidding, SS; Gubitosi-Klug, RA; Levitt Katz, LE; Shah, AS; Shah, RD; Tryggestad, JB; Urbina, EM, 2020) |
| "Forty-four people with type 2 diabetes were randomized to 12 weeks of dapagliflozin 10 mg/day or gliclazide 30 mg/day treatment." | ( Heerspink, HJL; Joles, JA; Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Ruiter, D; Smits, MM; Touw, DJ; van Bommel, EJM; van Raalte, DH, 2020) |
| "In patients with type 2 diabetes, we investigated the effect of treatment with teneligliptin (a DPP-4 inhibitor) for 24 weeks on plasma levels of CCL11/Eotaxin, CCL22/MDC and CXCL10/IP-10 during a meal test." | ( Aso, Y; Iijima, T; Jojima, T; Kase, M; Sagara, M; Sakurai, S; Tomaru, T; Usui, I, 2020) |
| "We enrolled 38 patients with type 2 diabetes mellitus who were not treated with a GLP-1 RA (≥20 years of age, HbA1c ≥6." | ( Aoki, K; Kamiyama, H; Nakajima, S; Shibata, E; Shinoda, K; Taguri, M; Takihata, M; Terauchi, Y; Yoshii, T, 2020) |
| "60 newly-diagnosed type 2 diabetes patients were randomly divided into three treatment groups: sitagliptin (n = 20), metformin (n = 20), and combination sitagliptin and metformin (n = 20)." | ( Chen, M; Deng, D; Fang, Z; Wang, Y; Xu, M; Zhang, S; Zhao, X; Zheng, M, 2020) |
| "Given that it has been reported that type 2 diabetes mellitus may affect the pharmacokinetics of a large number of drugs and that there are still no published population pharmacokinetic (PopPK) analyses in routinely treated patients with hypertension and type 2 diabetes mellitus as comorbid condition, the aim of this study was to determine PK variability of bisoprolol in 70 Serbian patients using the PopPK approach." | ( Janković, SM; Jovanović, A; Milovanović, JR; Momčilović, S; Nikolić, VN; Pešić, M; Radojković, D, 2020) |
| "60 patients with DPN and type 2 diabetes mellitus with a disease duration of 6 to 25 years were examined and treated." | ( Kolbakhova, SN; Konchugova, TV; Kulchitskaya, DB; Tsoi, AV; Turova, EA, 2020) |
| "A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide." | ( Kapitza, C; Meier, JJ; Menge, BA; Nauck, MA; Quast, DR; Schenker, N, 2020) |
| "paliurus), has the ability to treat type 2 diabetes mellitus (T2DM), but cannot be digested by our digestive system." | ( Chen, H; Wang, D; Wang, W; Wu, N; Yan, L; Yao, Y, 2020) |
| "Patients with type 2 diabetes who initiated treatment with DPP-4 inhibitors or second-generation sulfonylurea were included." | ( Chung, HJ; Kim, DH; Lee, H; Patorno, E; Pawar, A, 2020) |
| "Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) often occur concurrently, and untreated OSA may potentially amplify the high risk of cardiovascular disease in T2DM." | ( Adams, V; Burgess, M; Craig, SE; Cuthbertson, DJ; Emegbo, S; Kemp, GJ; Manuel, A; Murphy, K; Needham, AJ; Schwab, RJ; Sprung, VS; Thomas, M; Weimken, A; Wilding, JP, 2020) |
| "Human stem cell therapy for type 2 diabetes/obesity (T2D/O) complications is performedwith stem cell autografts, exposed to the noxious T2D/O milieu, often with suboptimal results." | ( Cooper, C; DeCastro, WB; Gelfand, R; Gonzalez-Cadavid, NF; Kovanecz, I; Lin, G; Lue, T; Ohanian, A; Sharifzad, S, 2020) |
| "Metformin, the first-line drug to treat type 2 diabetes, inhibits mitochondrial glycerolphosphate dehydrogenase in the liver to suppress gluconeogenesis." | ( Diao, J; Ding, L; Du, A; Wen, S; Xu, C; Yuan, X; Zhou, L, 2021) |
| "A total of 60 elderly patients with type 2 diabetes will be randomly divided into treatment group and control group, 30 cases in each group." | ( Chen, Q; Gao, Y; Han, X; Sun, L; Yu, W; Zeng, M; Zhang, L; Zhou, D, 2020) |
| "Although the link between gout and type 2 diabetes mellitus (T2DM) has been documented, our understanding of the association between urate-lowering therapy (ULT) among gout patients and T2DM development remains poor." | ( Chung, YL; Fang, YJ; Lim, YP; Lin, CL, 2020) |
| "Metformin is the first-line therapy for type 2 diabetes, but there are large inter-individual variations in responses to this drug." | ( Bäckhed, F; Koh, A; Mannerås-Holm, L; Molinaro, A; Nilsson, PM; Perkins, R; Ryu, SH; Smith, JG; Yunn, NO, 2020) |
| "In a STZ-induced type 2 diabetes mellitus (T2DM), body weight of rats in CSQ treated and control groups were unaltered." | ( Jaishree, V; Narsimha, S, 2020) |
| "This study evaluated the influence of type 2 diabetes mellitus on bone loss, bone repair and cytokine production in hyperglycemic rats, treated or not with metformin." | ( Azarias, JS; Bastos, MF; Garcia, RP; Malta, FS; Miranda, TS; Ribeiro, GKDR; Shibli, JA, 2020) |
| "Despite the known heterogeneity of type 2 diabetes and variable response to glucose lowering medications, current evidence on optimal treatment is predominantly based on average effects in clinical trials rather than individual-level characteristics." | ( Dennis, JM, 2020) |
| "In patients with type 2 diabetes, 24-week treatment with exenatide improved liver fat content in patients carrying PNPLA3 148I/I better than in patients with 148M/M." | ( Chen, Y; Liang, H; Xu, F; Xu, X; Yan, X; Yuan, S, 2020) |
| "A total of 15 992 patients with type 2 diabetes initiating second-line glucose-lowering therapy." | ( Chen, H; Cid-Ruzafa, J; Fenici, P; Gomes, MB; Hammar, N; Ji, L; Khunti, K; Kosiborod, M; Nicolucci, A; Pocock, S; Rathmann, W; Shestakova, MV; Shimomura, I; Tang, F; Watada, H, 2020) |
| "To date, no cases of MODY 5 treated with glucagon-like peptide-1 receptor agonist (GLP-1RA) have been reported." | ( Chujo, D; Hamano, S; Kajio, H; Nakamura, T; Ohsugi, M; Tanabe, A; Terakawa, A; Ueki, K; Ueno, K; Yasuda, K, 2020) |
| "These subgroups were based on type 2 diabetes status, age, sex, angiotensin receptor neprilysin inhibitor (ARNI) treatment, New York Heart Association (NYHA) functional class, race, history of hospitalisation for heart failure, estimated glomerular filtration rate (eGFR), body-mass index, and region (post-hoc)." | ( Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Ofstad, AP; Packer, M; Pfarr, E; Pocock, SJ; Zannad, F, 2020) |
| "Rat models of type 2 diabetes mellitus (T2DM) were established and were treated with berberine." | ( Chen, M; Gu, L; Si, Y; Wu, Z; Yin, W; Zhang, T; Zhao, M, 2021) |
| "Despite being the frontline therapy for type 2 diabetes, the mechanisms of action of the biguanide drug metformin are still being discovered." | ( Dayn, A; Dayn, Y; Hellberg, K; Luo, EC; Shaw, RJ; Shokhirev, MN; Van Nostrand, EL; Van Nostrand, JL; Yeo, GW; Yu, J, 2020) |
| "A diagnosis of type 2 diabetes and treatment for hyperkalaemia within the previous 24 h were negatively associated." | ( Devine, K; Javaid, U; Leech, NJ; Potts, A; Quinton, R; Razvi, S; Roberts, G; Tee, SA, 2021) |
| "Approximately 50% of patients with type 2 diabetes mellitus (T2DM) do not achieve glycemic targets and require treatment intensification." | ( Caruso, I; Giorgino, F; Napoli, R, 2020) |
| "Therapies for treatment of type 2 diabetes (T2D) involve a variety of medications, depending on the stage of T2D progression." | ( Man, CD; Schiavon, M; Visentin, R, 2020) |
| "Thirty patients with type 2 diabetes and hypertension received a four week-treatment with Dapagliflozin 10 mg or Hydrochlorothiazide 12." | ( Biancalana, E; Carli, F; Gastaldelli, A; Guiducci, L; Mengozzi, A; Parolini, F; Solini, A, 2021) |
| "To investigate the impact of type 2 diabetes mellitus (T2DM) and metformin treatment on the prognosis of oral squamous cell carcinoma (OSCC) patients received radical surgical treatment." | ( Chen, W; Hu, X; Huang, D; Huang, L; Mao, T; Shu, Y; Su, T; Wang, C; Wang, Z; Xia, K; Xiong, H; Yang, L; Yu, J, 2020) |
| "Patients with type 2 diabetes (T2D) have a lower risk of Mycobacterium tuberculosis infection, progression from infection to tuberculosis (TB) disease, TB morality and TB recurrence, when being treated with metformin." | ( Ackart, D; Basaraba, R; Böhme, J; Frenkel, JH; Kornfeld, H; Lachmandas, E; Larbi, A; Lee, A; Lee, B; Li, S; Lum, J; Martinez, N; Marzuki, M; Netea, MG; Newell, E; Ng, TP; Shihui, F; Singhal, A; Tizazu, AM; Todd, A; van Crevel, R, 2020) |
| "first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short intervals between injections (twice daily for exenatide b." | ( Meier, JJ; Nauck, MA; Quast, DR; Wefers, J, 2021) |
| "Despite its widespread use in type 2 diabetes treatment, little information has been published concerning the physical-chemical aspects and exenatide stability in this product." | ( Ackermann, R; Beig, A; Benet, A; Chandrashekar, A; Hong, JKY; Kang, J; Li, T; Qin, B; Schwendeman, AS; Schwendeman, SP; Walker, J; Wang, Y, 2021) |
| "In subjects with type 2 diabetes treated with PIO for 6 months we found a restored SKLM protein abundance of ATP5A, ETFA, CX6B1, and mitofilin." | ( Abdul-Ghani, M; Cas, MD; Chavez, AO; Daniele, G; DeFronzo, RA; Fiorentino, TV; Folli, F; Hribal, ML; Kamath, S; Monroy, A; Sesti, G; Sotero, R; Tripathy, D, 2021) |
| "A 77-year-old man with type 2 diabetes was admitted to the Jichi Medical University Hospital for the treatment of major depression." | ( Kobayashi, T; Okada, T; Suda, S; Takano, M, 2021) |
| "Patients with type 2 diabetes mellitus (T2DM) have many treatment options." | ( Alsumali, A; Briggs, A; Davies, G; Kowal, S; Lautsch, D; Li, Q; Rajpathak, S; Wehler, E, 2021) |
| "An improvement of type 2 diabetes treatment is represented by the recent availability of a fixed-ratio combination of slow insulin degludec and GLP-1 RA liraglutide (IDegLira), which shows encouraging clinical trial results." | ( Celleno, R; Del Sindaco, P; Di Loreto, C; Piastrella, L, 2020) |
| "These effects were studied in type 2 diabetes mellitus rats which were administrated ADMSCs, exenatide or their combination four weeks post-induction." | ( Habib, HA; Heeba, GH; Khalifa, MMA, 2021) |
| "The progressive nature of type 2 diabetes mellitus (T2DM) renders the shifting of patients from oral drugs to insulin therapy an inevitability in most patients especially in those with long duration of diabetes." | ( Ahmad, A; Biswas, K; Chakravorty, S; Makkar, BM; Mohan, V; Roy, A; Sidduri, SR; Sinha, AK; Suryanarayana, KM, 2020) |
| "Individuals with type 1 and advanced type 2 diabetes require daily insulin therapy to maintain blood glucose levels in normoglycemic ranges to prevent associated morbidity and mortality." | ( Buse, JB; Gu, Z; Kahkoska, AR; Wang, J; Wang, Z, 2021) |
| "In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo." | ( Agarwal, R; Anker, SD; Bakris, GL; Filippatos, G; Joseph, A; Kolkhof, P; Nowack, C; Pitt, B; Rossing, P; Ruilope, LM; Schloemer, P, 2020) |
| "The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that glycemic failure rates were significantly lower in youth randomized to metformin plus rosiglitazone treatment than in youth randomized to metformin alone or metformin plus intensive lifestyle intervention." | ( , 2021) |
| "The primary outcomes at 2 years were type 2 diabetes (2-h OGTT glucose ≥11·1 mmol/L) and mean change from baseline in 2-h OGTT glucose, assessed by intention to treat." | ( Allan, C; Bracken, K; Conway, A; Daniel, M; Fui, MNT; Gebski, V; Grossmann, M; Hague, W; Handelsman, DJ; Inder, W; Jenkins, A; Jesudason, D; Keech, A; McLachlan, R; Robledo, KP; Stuckey, B; Wittert, G; Yeap, BB, 2021) |
| "We investigated PCSK9 concentration in type 2 diabetes mellitus (T2DM) and the impact of treatment with anagliptin or sitagliptin on PCSK9 level as a sub-analysis of the REASON trial." | ( Arasaki, O; Furuhashi, M; Higashiura, Y; Matsumoto, M; Morimoto, T; Node, K; Nomiyama, T; Sakai, A; Sakuma, I; Sakuma, M; Shimabukuro, M; Ueda, S, 2022) |
| "The proposed novel type 2 diabetes subgroups provide an interesting concept that could lead to a better understanding of the pathophysiology of the broad group of type 2 diabetes, paving the way for personalised treatment choices based on understanding the root cause of the disease." | ( Erazo-Tapia, E; Oscarsson, J; Schrauwen, P; Veelen, A, 2021) |
| "Metformin as first-line treatment in type 2 diabetes mellitus (T2 D) shows benefits in terms of reducing cardiovascular events, but the risk of a lactic acidosis as a serious adverse event especially in patients with decreased renal function is still relevant." | ( Eisert, A; Freitag, M; Masur, S, 2021) |
| "Using GLP-1RAs versus insulin for type 2 diabetes patients requiring intensified injection therapy in clinical practice is cost-effective." | ( Chen, YR; Kuo, S; Ou, HT; Yang, CY, 2021) |
| "Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains unclear." | ( Gongol, B; He, M; Hepokoski, M; Jiang, W; Li, J; Li, WX; Liu, J; Malhotra, A; Marin, T; McCowen, KC; Shyy, JY; Thomas, RL; Wei, Q; Xiong, N; Xiong, W; Yuan, JX, 2020) |
| "Patients with type 2 diabetes treated with DPP-4i or SGLT2i during a 3-year period were identified in the database of the National Institute of Health Insurance Fund in Hungary." | ( Fábián, I; Jermendy, G; Kempler, P; Kiss, Z; Molnár, GA; Poór, G; Rokszin, G; Sütő, G; Szekanecz, Z; Wittmann, I, 2021) |
| "Metformin remains the cornerstone of type 2 diabetes treatment after lifestyle modifications, which should always be encouraged before medications." | ( Gariani, K; Jornayvaz, FR, 2021) |
| "Metformin is a first-line drug in type 2 diabetes mellitus (T2DM) treatment, yet whether metformin may increase all-cause or cardiovascular mortality of T2DM patients remains inconclusive." | ( Chen, M; Gu, C; Li, T; Liu, M; Ma, H; Mu, N; Providencia, R; Wang, Y; Yin, Y; Yu, L, 2021) |
| "In recent years, the efficacy of type 2 diabetes mellitus (T2DM) drugs in the treatment of Alzheimer's disease (AD) has attracted extensive interest owing to the close associations between the two diseases." | ( Meng, L; Shen, L; Wang, YZ; Zhuang, QS, 2021) |
| "Veterans with new onset type 2 diabetes were identified using National Veterans Health Administration Data." | ( Egge, JA; Meyer, MM; Waterbury, NV; Zenti, KJ, 2021) |
| "Pemafibrate was administered to type 2 diabetes patients with hypertriglyceridemia." | ( Komiya, I; Sunakawa, S; Wakugami, T; Yamamoto, A, 2021) |
| "The target populations of patients with type 2 diabetes (n = 279,763), those prescribed liraglutide (n = 14,421), and those eligible to receive liraglutide based on the treatment stage (n = 85,610) differed substantially in terms of hemoglobin A1c, body mass index, prevalence of heart failure, and chronic kidney disease." | ( Abrahami, D; Azoulay, L; Baumfeld Andre, E; Pradhan, R; Sahasrabudhe, V; Yin, H; Yu, OHY, 2021) |
| "Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets." | ( Blonde, L; Del Prato, S; Galstyan, G; Rosenstock, J; Skolnik, N, 2021) |
| "A 43-year-old male with type 2 diabetes, under treatment with 5 mg/day of dapagliflozin, was referred to our hospital with upper left abdominal pain and marked hypertriglyceridemia (triglycerides [TGs], 5,960 mg/dl)." | ( Imai, Y; Kaneto, M; Nakatou, T; Senoo, M; Shimomura, Y; Teshigawara, S; Tone, A; Watanabe, S, 2021) |
| "In this study, 24 patients with type 2 diabetes mellitus (T2DM) treated with insulin were selected to receive three intravenous infusions of stem cells from human exfoliated deciduous teeth (SHED) over the course of 6 weeks and were followed up for 12 months." | ( Guo, Z; Huang, Q; Jiao, X; Li, J; Li, W; Shi, S; Song, J; Sui, B; Zhao, Y, 2021) |
| "Individuals with type 2 diabetes mellitus and established atherosclerotic CVD were randomised to receive ertugliflozin 5 mg or 15 mg (observations from both doses were pooled), or matching placebo, added on to existing treatment." | ( Cannon, CP; Charbonnel, B; Cherney, DZI; Cosentino, F; Dagogo-Jack, S; Frederich, R; Maldonado, M; McGuire, DK; Pong, A; Pratley, R; Shih, WJ, 2021) |
| "A revolution in the Type II diabetes mellitus treatment has occurred with the arrival of new antidiabetic drugs, which are thought to compromise metformin place." | ( Barrios, V; Rajjoub Al-Mahdi, EA; Zamorano, JL, 2021) |
| "Individuals with type 2 diabetes mellitus and asymptomatic impaired left ventricular systolic function were randomly allocated in a 1:1 ratio to receive for 48 weeks either linagliptin 5 mg daily or placebo, in addition to their diabetes therapy." | ( Cioffi, G; Giorda, CB; Latini, R; Lucci, D; Maggioni, AP; Mancusi, C; Nada, E; Ognibeni, F, 2021) |
| "Data from 157 participants with type 2 diabetes receiving tofogliflozin monotherapy in a phase 3 study were analysed." | ( Fujihara, K; Kaku, K; Matsubayashi, Y; Oe, M; Sato, T; Sone, H; Suganami, H; Tanaka, S; Yaguchi, Y; Yamada, T; Yoshida, A, 2021) |
| "Metformin is used to treat type 2 diabetes but also exhibits regulation of the autophagy pathway." | ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021) |
| "Metformin is the primary drug for type 2 diabetes treatment and a promising candidate for other disease treatment." | ( Klovins, J; Komasilovs, V; Kurlovics, J; Stalidzans, E; Zaharenko, L; Zake, DM, 2021) |
| "Many patients with type 2 diabetes treated with premixed insulin gradually have inadequate glycemic control and switch to a basal-bolus regimen, which raises some concerns for weight gain and increased hypoglycemic risk." | ( Chen, X; Duan, Y; He, W; Hu, J; Hu, S; Li, W; Liao, Y; Lin, M; Liu, L; Liu, P; Liu, Z; Ma, J; Shao, S; Shen, L; Xu, Y; Xue, Y; Yin, P; Yu, X; Zeng, J; Zeng, Z; Zhang, J; Zhao, S; Zhao, T, 2021) |
| "Outcomes from the type 2 diabetes treatment paralleling of CLD were presented." | ( Fu, BY; Wang, XJ, 2022) |
| "The main outcome was type 2 diabetes visits where a prescription drug was used ("treatment visit")." | ( Alexander, GC; Christopher, J; Heyward, J; Kalyani, RR; Sarkar, S; Shin, JI, 2021) |
| "Treatments for type 2 diabetes targeting baseline glucose levels but not postprandial glucose can result in normalized fasting blood glucose but suboptimal overall glycemic control (high glycated hemoglobin): residual hyperglycemia." | ( Baxter, M; Iizuka, K; Kaneto, H; Watanabe, D; Yabe, D, 2021) |
| "Patients with type 2 diabetes (T2DM) who require injectable therapy have been conventionally treated with insulin." | ( Jung, CH; Kim, HS; Lee, J; Lee, WJ; Park, JY, 2021) |
| "Metformin is a major treatment for type 2 diabetes." | ( Cho, JY; Chung, JY; Ji, SC; Kim, AH; Kim, E; Lee, Y; Yu, KS, 2021) |
| "As a novel treatment drug for type 2 diabetes, exenatide possesses protective properties against retinal neurodegeneration." | ( Yang, Y; Zhao, Q, 2021) |
| "Youth-onset type 2 diabetes is characterised by pathophysiological heterogeneity and inadequate glycaemic control, highlighting the need for new treatment approaches and innovative study designs in populations of varied genetic and cultural backgrounds." | ( Kelsey, MM; Pyle, L, 2021) |
| "Insulin-treated patients with type 2 diabetes (n = 21, age (mean ± s." | ( Abelin, KU; Andersen, A; Bagger, JI; Baldassarre, MPA; Christensen, MB; Faber, J; Gislason, G; Holst, JJ; Knop, FK; Lindhardt, TB; Pedersen-Bjergaard, U; Vilsbøll, T, 2021) |
| "In insulin-treated patients with type 2 diabetes and controls without diabetes, hypoglycemia causes clinically significant and similar increases in cardiac repolarization that might increase vulnerability for serious cardiac arrhythmias and sudden cardiac death." | ( Abelin, KU; Andersen, A; Bagger, JI; Baldassarre, MPA; Christensen, MB; Faber, J; Gislason, G; Holst, JJ; Knop, FK; Lindhardt, TB; Pedersen-Bjergaard, U; Vilsbøll, T, 2021) |
| "Severely insulin-resistant type 2 diabetes (T2D) patients face unique treatment challenges." | ( Borra, S; Chen, J; Fan, L; Hood, RC; Huang, A; Pollom, RD, 2021) |
| "To explore the views of people with type 2 diabetes who had initiated metformin monotherapy about what influences adherence and persistence." | ( Inder, M; Maclennan, K; Moata'ane, L; Parkin, L; Te Morenga, L, 2021) |
| "In stable patients with type 2 diabetes (T2D), insulin treatment is associated with elevated risk for major adverse cardiovascular events (MACE)." | ( Ginsberg, HN; Halliday, C; Johansson, JO; Kalantar-Zadeh, K; Kulikowski, E; Nicholls, SJ; Ray, KK; Schwartz, GG; Sweeney, M; Toth, PP; Wong, NCW, 2021) |
| "Many patients with type 2 diabetes will ultimately require the inclusion of basal insulin in their treatment regimen." | ( Goldenberg, R; Katselnik, D; Kuritzky, L; Mehta, R, 2021) |
| "In INSTRIDE 2, patients with type 2 diabetes treated with oral antidiabetic drugs, insulin naive or not, received MYL-1501D or reference insulin glargine over a 24-week period." | ( Aubonnet, P; Barve, A; Bowsher, RR; Donnelly, C; Pathak, D; Raiter, Y; Ramaswamy, S; Rao, A; Roy, AS; Sengupta, N; Sun, B; Waichale, V, 2021) |
| "In the treatment of type 2 diabetes, evidence of the comparative effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas-the second most widely used antihyperglycemic class after metformin-is lacking." | ( Al-Aly, Z; Bowe, B; Gibson, AK; Maddukuri, G; McGill, JB; Xie, Y, 2021) |
| "With the increasing incidence of type 2 diabetes, it is imperative to identify how to effectively prevent or treat this disease." | ( He, Q; Park, KY; Shang, GS; Tan, Q; Tan, X; Zhao, X; Zhou, X, 2021) |
| "A 55-year-old female was diagnosed with type 2 diabetes mellitus (T2DM) one month after the end of a nine-month isotretinoin treatment period." | ( Bozkuş, Y, 2021) |
| "People with type 2 diabetes and hospitalization more often received insulin (55%) than comparisons (45%), and 45% discontinued insulin or stopped all glucose-lowering therapy after first hospitalization." | ( Bengtsen, MB; Knudsen, JS; Møller, N; Thomsen, RW, 2021) |
| "Understanding role of microbiota in type 2 diabetes and the mechanisms connecting T2DM and alterations in gut microbiota could be the key to improved treatment of T2DM." | ( Bohatyrewicz, A; Dzieżyc, A; Stachowska, E; Wiśniewska, M, 2021) |
| "A promising approach for treating type 2 diabetes mellitus (T2DM) is to target the Peroxisome Proliferator-Activated Receptor γ (PPARγ) transcription factor, which regulates the expression of proteins critical for T2DM." | ( Bruning, JB; Frkic, RL; Richter, K, 2021) |
| "With the increasing prevalence of type 2 diabetes and fatty liver disease, there is still an unmet need to better treat hyperglycemia and hyperlipidemia." | ( Aikio, MA; Appel, EA; Camporez, JP; Carcamo-Orive, I; Dou, FY; Gardner, CD; Jiang, Z; Jung, Y; Knowles, JW; Maikawa, CL; Roche, AM; Rosen, ED; Sahai, T; Shulman, GI; Spiegelman, BM; Svensson, KJ; Tsai, L; Voilquin, L; Wabitsch, M; Zhao, M, 2021) |
| "The present analysis of the EMPA haemodynamic study examined the early and delayed effects of empagliflozin treatment on haemoglobin and haematocrit levels, in addition to measures of erythropoiesis and iron metabolism, to better understand the underlying mechanisms." | ( Böhm, M; Hartmann, NK; Jankowski, J; Keszei, AP; Lehrke, M; Marx, N; Möllmann, J; Rau, M; Thiele, K, 2021) |
| "Among adult patients with type 2 diabetes, metformin was by far the most frequent first-line treatment." | ( Glynn, RJ; Patorno, E; Schneeweiss, S; Shin, H, 2021) |
| "Participants with type 2 diabetes were randomized to treatment with liraglutide 1." | ( Curovic, VR; Hansen, TW; Jensen, JK; Kjaer, A; Rasmussen, IKB; Ripa, RS; Rossing, P; von Scholten, BJ; Zobel, EH, 2021) |
| "Thirty-six patients with type 2 diabetes mellitus (T2DM) treated with once-daily DPP-4 inhibitors for at least 12 weeks were randomized to either continue once-daily DPP-4 inhibitors or receive omarigliptin, a once-weekly DPP-4 inhibitor, for 24 weeks." | ( Ara, T; Chiba, H; Fujikawa, T; Fukui, T; Hirano, T; Hiromura, M; Kohata, Y; Mori, Y; Nagaike, H; Ogawa, M; Ohara, M; Omachi, T; Sasajima, R; Sugawara, A; Terasaki, M; Yamagishi, SI; Yokoyama, H, 2021) |
| "People with type 2 diabetes mellitus who initiated metformin monotherapy between 1 January 2006 and 30 September 2014 (n=93 874)." | ( Barson, D; Guo, J; Horsburgh, S; Parkin, L; Zeng, J, 2021) |
| "Real-world type 2 diabetes treatment patterns in New Zealand are complex and not always consistent with guidelines." | ( Barson, D; Guo, J; Horsburgh, S; Parkin, L; Zeng, J, 2021) |
| "Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, finerenone therapy improved cardiovascular outcomes as compared with placebo." | ( Agarwal, R; Anker, SD; Bakris, GL; Filippatos, G; Joseph, A; Kolkhof, P; Nowack, C; Pitt, B; Rossing, P; Ruilope, LM; Schloemer, P, 2021) |
| "Parallelly, type 2 diabetes (T2D) was developed in C57BL/6 mice by HFD feeding and administered PST inhibitor (PSTi8)." | ( Gayen, JR; Husain, A; Reza, MI; Singh, P; Syed, AA, 2021) |
| "Current drugs for treating type 2 diabetes mellitus (T2DM) are based on the use of gastrointestinal hormones." | ( Kaneko, S, 2021) |
| "Current drugs for treating type 2 diabetes mellitus (T2DM) are based on the use of gastrointestinal hormones." | ( Kaneko, S, 2021) |
| "In patients with type 2 diabetes, higher risk was associated with sodium-glucose cotransporter 2 inhibitor therapy (IRR, 1." | ( Galindo, RJ; McCoy, RG; O'Connor, PJ; Shah, ND; Swarna, KS; Umpierrez, GE; Van Houten, HK, 2021) |
| "In patients with type 2 diabetes and preserved renal function treatment with M+I resulted in reduction of renal perfusion and increase in vascular resistance, in contrast to treatment with E+I that preserved renal perfusion and reduced vascular resistance." | ( Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Korn, M; Ott, C; Schiffer, M; Schmieder, RE; Striepe, K, 2021) |
| "The number of adults treated for type 2 diabetes mellitus increased from 1,867 (2." | ( Im, YJ; Jin, HY; Kim, EY; Kim, YJ; Lee, KA; Park, TS, 2021) |
| "For patients with type 1 and advanced type 2 diabetes mellitus, insulin therapy is essential." | ( Lyu, B; Pei, S; Wen, P; Xu, G; Yao, X; Zhao, J; Zhou, H, 2022) |
| "Historically, treatment of type 2 diabetes has focused on decreasing hyperglycemia and glycated hemoglobin levels." | ( Ecelbarger, CM; Shepard, BD, 2021) |
| "Pharmacological therapy for type 2 diabetes mellitus features various combinations of treatments, with different therapies providing different levels of effectiveness." | ( Sauriasari, R; Septini, R; Wafa, W, 2022) |
| "Metformin, a drug prescribed to treat type 2 diabetes, has been reported to possess antitumor activity via immunity activation." | ( Fan, X; Li, J; Li, M; Qi, X; Sun, L; Wu, Y; Xia, W; Yuan, Y, 2021) |
| "GLP-1can be used for treatment of type 2 diabetes." | ( Cao, B; Chen, J; Dong, Y; Wang, Y; Wu, P; Zhang, Y, 2022) |
| "Sulfonylurea drugs, commonly used in type 2 diabetes mellitus treatment, bind to the octamer KATP channels composed of four pore-forming Kir6." | ( Nowak, W; Walczewska-Szewc, K, 2021) |
| "We enrolled 35 patients with type 2 diabetes not receiving treatment with metformin due to suspected gastrointestinal intolerance." | ( Álvarez-Bermúdez, MD; Díaz-Perdigones, CM; Moreno-Indias, I; Muñoz-Garach, A; Tinahones, FJ, 2022) |
| "The therapeutic arsenal for treating type 2 diabetes mellitus (T2DM) has been enriched recently with the inclusion of type 1 glucagon-like peptide (GLP-1)." | ( Mandarim-de-Lacerda, CA; Spezani, R, 2022) |
| "105 type 1 or type 2 diabetes patients regularly took a daily dose of the dietary supplement Flebotrofine® for three consecutive months, and haematological and biochemical parameters were checked at baseline, after three months of treatment, and one month after its suspension." | ( Bagnati, M; Basile, M; Bauce, G; Bellomo, G; Dianzani, U; Grigollo, B; Prodam, F; Puricelli, C; Rolla, R, 2021) |
| "In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potentially represent a treatment for fatty liver disease." | ( Hyötyläinen, T; Jendle, J; Nyström, T; Orešič, M, 2021) |
| "Lifestyle intervention studies to treat type 2 diabetes (T2D) are on the rise." | ( Battjes-Fries, MCE; de Jong, HBT; Patijn, ON; Pijl, H; Pot, GK; Voshol, PJ, 2022) |
| "In patients with type 2 diabetes, combined SGLT-2i and ACEi significantly upregulated plasma renin activity [pre-treatment median and interquartile range 298." | ( Antlanger, M; Domenig, O; Hecking, M; Kaltenecker, CC; Kopecky, C; Kovarik, JJ; Müller, MM; Poglitsch, M; Rathkolb, V; Säemann, MD; Schwaiger, E, 2022) |
| "We assessed 624 Japanese patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease who received SGLT2i treatment for greater than 1 year." | ( Furuki, T; Hatori, N; Hatori, Y; Kanamori, A; Kobayashi, K; Miyakawa, M; Sakai, H; Sato, K; Tamura, K; Toyoda, M, 2022) |
| "At EOS, subjects with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis versus conventional therapy; the severity of hepatic steatosis and fibrosis were both strongly and inversely correlated with insulin resistance; and changes in liver fibrosis scores (APRI, NFS, Fibrosis-4, and AST/ALT ratio) have limited value in predicting response to therapy." | ( Abdelgani, S; Abdul-Ghani, M; Adams, J; Alatrach, M; Alkhouri, N; Cersosimo, E; Clarke, GD; DeFronzo, RA; Gastaldelli, A; Lavynenko, O; Li, J; Puckett, C; Triplitt, C; Vasquez, JA, 2022) |
| "Twenty-nine patients with type 2 diabetes treated with exenatide BID were included in this study and switched to exenatide QW for 24 weeks." | ( Inaishi, J; Itoh, H; Masaoka, T; Saisho, Y; Sasaki, H; Tsuchiya, T; Watanabe, Y, 2022) |
| "Patients with type 2 diabetes mellitus who initiated BI treatment due to uncontrolled hyperglycemia (HbA1c≥7 %) by oral antidiabetic drugs (OADs) were recruited in Chinese real-world settings between 2011 and 2013." | ( Chen, M; Duolikun, N; Ji, J; Ji, L; Li, X; Luo, Y; Wang, D; Zhang, H; Zhang, P; Zhu, D, 2022) |
| "Metformin remains the cornerstone of type 2 diabetes treatment after lifestyle modifications, which should always be encouraged before medications." | ( Gariani, K; Jornayvaz, FR, 2022) |
| "Eighty-four percent of the patients had type 2 diabetes mellitus, 75% were receiving treatment with hypoglycemic medications, and 61% were receiving treatment with insulin." | ( Eisenberg, Y; Gimbar, RP; Lin, J; Maheswaran, AB, 2022) |
| "Early clinical trials in adults with type 2 diabetes mellitus (T2DM) suggested a significant improvement in kidney and cardiovascular outcomes with SGLT2i therapy." | ( Kula, AJ, 2022) |
| "Adults with type 2 diabetes mellitus without foot ulcers were administered 400 mg oral 11β-HSD1 inhibitor AZD4017 (n = 14) or placebo (n = 14) bi-daily for 35 days." | ( Abbas, A; Ajjan, RA; Arlt, W; Del Galdo, F; Fairclough, RJ; Freeman, A; Hensor, EMA; Morgan, AW; Pegg, L; Russell, DA; Shams, K; Stewart, PM; Tahrani, AA; Taylor, AE; Tiganescu, A; Webber, L, 2022) |
| "Participants had type 2 diabetes on metformin monotherapy, and started a second-line ADM during the study period." | ( Ackermann, RT; Aikman, C; Cherupally, M; Cooper, A; DeCarlo, K; Harris, SA; Kang, RH; Liss, DT; O'Brien, MJ; Wallia, A, 2022) |
| "Among patients with type 2 diabetes and inadequate glycemic control despite treatment with insulin glargine, the addition of subcutaneous tirzepatide, compared with placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 weeks." | ( Bray, R; Dahl, D; Huh, R; Norwood, P; Onishi, Y; Patel, H; Rodríguez, Á, 2022) |
| "In people with type 2 diabetes on metformin, 26-week treatment with iGlarLixi resulted in a marked improvement in β-cell function concomitant with sparing of endogenous insulin release and a reduction in meal absorption." | ( Dex, T; Ferrannini, E; Mari, A; Niemoeller, E; Servera, S, 2022) |
| "Thirty-six patients with type 2 diabetes inadequately controlled with metformin monotherapy were randomized to receive liraglutide, dapagliflozin, or acarbose treatment for 16 weeks." | ( Bi, Y; Cheng, H; Liu, J; Miao, Y; Ni, W; Wang, J; Zhang, B; Zhang, W; Zhang, Z, 2022) |
| "Data from adult patients with type 2 diabetes newly initiating treatment with dulaglutide or semaglutide between January 2018 and January 2020 (index date was defined as the earliest fill date), without evidence of glucagon-like peptide 1 receptor agonist use in the 6M baseline period, and with continuous enrollment in the 6M baseline and 6M or 12M follow-up period were included." | ( Irwin, DE; Malik, RE; Manjelievskaia, J; Marchlewicz, EH; Mody, R; Yu, M; Zimmerman, NM, 2022) |
| "In total, 63 patients with type 2 diabetes and hypercholesterolemia were treated using either rosuvastatin monotherapy or rosuvastatin/ezetimibe combination therapy for 12 weeks." | ( Joung, KH; Kang, SM; Kim, HJ; Kim, JM; Ku, BJ; Lee, JC, 2022) |
| "The relationship between type 2 diabetes and Alzheimer's disease (AD) provides evidence that insulin and insulin sensitizers may be beneficial for the treatment of AD." | ( Kazkayasi, I; Nemutlu, E; Telli, G; Uma, S, 2022) |
| "His medical history was significant for type II diabetes mellitus and chronic lymphocytic leukemia, stable on no therapy since diagnosis 8 years prior." | ( Chwalisz, BK; Fischbein, NJ; Gaier, ED; Kane, JE; Lefebvre, DR; Liebman, DL; Lithgow, MY; Tam, EK, 2022) |
| "Rat models of type 2 diabetes were treated with verapamil at doses of 4, 12, 24 and 48 mg/kg/day by gavage respectively, twice a day." | ( Cen, H; Gong, H; Hu, X; Li, C; Shi, P; Wu, X, 2022) |
| "Aside being the first-line therapy for Type 2 Diabetes (T2D), many pleiotropic effects have been discovered in recent years, such as its capacity to reduce cancer risk and tumorigenesis." | ( Ferreira-Hermosillo, A; García-Sáenz, M; Lobaton-Ginsberg, M, 2022) |
| "Adults with insulin-treated type 1 and type 2 diabetes, inadequate glycemic control, and no severe diabetes-related complications and/or comorbidities were eligible for this study." | ( Cignarelli, A; Cormio, S; De Cosmo, S; Di Molfetta, S; Giorgino, F; Lamacchia, O; Laviola, L; Massa, M; Mosca, A; Natalicchio, A; Paleari, R; Patruno, P; Perrini, S, 2022) |
| "Sixty-six people with type 2 diabetes were randomized to 16 weeks of dapagliflozin 10 mg/day, exenatide 10 µg twice daily, dapagliflozin-exenatide, or placebo treatment." | ( IJzerman, RG; Kok, MD; Kramer, MHH; Nieuwdorp, M; Serné, EH; Smits, MM; van Raalte, DH; van Ruiten, CC, 2022) |
| "Patients with type 2 diabetes who attended clinics belonging to the study group between 2002 and 2018 were included to examine trends in glycated hemoglobin A1c (HbA1c) by treatment group using multivariable non-linear regression model." | ( Araki, SI; Kabata, D; Kanatsuka, A; Kawai, K; Maegawa, H; Oishi, M; Shintani, A; Shirabe, SI; Yagi, N; Yamazaki, K; Yokoyama, H, 2022) |
| "393 patients with type 2 diabetes mellitus (T2DM) treated with basal or premixed insulin for more than 3 months were enrolled." | ( Cai, T; Ding, B; Hu, Y; Jing, T; Li, H; Ma, J; Su, X; Wang, H; Wang, Y; Zhou, Y, 2022) |
| "Db/db mice, an animal model of type 2 diabetes, were treated with dapagliflozin orally, and the electroretinogram (ERG) response and acellular capillary numbers were assessed." | ( Bello, E; Bhatwadekar, AD; Dhami, H; Leley, SP; Luo, Q; Mathew, D, 2022) |
| "Specific pathogen-free KK-Ay/TaJcl (type 2 diabetes model) mice were orally administered with SGLT-2 inhibitor (dapagliflozin) daily for 4 weeks at a dose of 1 mg/kg/d." | ( Hiramoto, K; Horikawa, T; Ooi, K; Tanaka, S, 2022) |
| "Due to the overlap in the mechanisms of type 2 diabetes and brain disorders, common effective pharmacological interventions to treat both T2D and AD is under extensive research." | ( Khan, RH; Majid, N; Malik, S; Masroor, A; Salam, S; Siddiqi, MK; Zaidi, N, 2022) |
| "The gold standard for the treatment of type 2 diabetes is metformin, which has a beneficial impact on the mitochondrial metabolism." | ( Abad-Jiménez, Z; Apostolova, N; Canet, F; de Marañón, AM; Díaz-Morales, N; Díaz-Pozo, P; López-Domènech, S; Morillas, C; Rocha, M; Vezza, T; Víctor, VM, 2022) |
| "Seventeen male participants with type 2 diabetes completed (1) 3 months of daily melatonin treatment (10 mg) 1 h before bedtime (M) and (2) 3 months of placebo treatment 1 h before bedtime (P)." | ( Christensen, LL; Jessen, N; Kampmann, U; Lauritzen, ES; Møller, N; Pedersen, MGB; Støy, J, 2022) |
| "Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the first-choice drug used daily by approximately 150 million people." | ( Bshesh, K; Ding, H; Hill, MA; Hollenberg, MD; MacDonald, R; Marei, I; Mohammed, I; Triggle, CR; Ye, K, 2022) |
| "Metformin (MtF) is a treatment used for type 2 diabetes." | ( Bodeau, S; Dulaurent, S; El Balkhi, S; Griffeuille, P; Lamoureux, F; Marquet, P; Saint-Marcoux, F, 2023) |
| "As monotherapy in patients with type 2 diabetes, once-weekly efpeglenatide significantly improved glycemic control and body weight with a safety and tolerability profile similar to that of other GLP-1 RAs." | ( Baek, S; Choi, J; Frias, JP; Muehlen-Bartmer, I; Niemoeller, E; Popescu, L; Rosenstock, J, 2022) |
| "Patients with type 2 diabetes with admission blood glucose (BG) 140-400 mg/dL treated with basal-bolus insulin were randomized to intensive (correction for BG >140 mg/dL, n = 108) or to nonintensive (correction for BG >260 mg/dL, n = 107) administration of rapid-acting sliding scale insulin before meals and bedtime." | ( Cardona, S; Davis, GM; Fayfman, M; Galindo, RJ; Migdal, A; Pasquel, FJ; Peng, L; Umpierrez, GE; Urrutia, MA; Vellanki, P, 2022) |
| "Among non-ICU patients with type 2 diabetes on optimal basal-bolus insulin regimen with moderate hyperglycemia (BG <260 mg/dL), a less intensive sliding scale insulin treatment did not significantly affect glycemic control." | ( Cardona, S; Davis, GM; Fayfman, M; Galindo, RJ; Migdal, A; Pasquel, FJ; Peng, L; Umpierrez, GE; Urrutia, MA; Vellanki, P, 2022) |
| "Approved treatments for type 2 diabetes in pediatric patients include metformin, liraglutide, and insulin." | ( Al-Abdulrazzaq, D; Bishai, R; Carter, D; Doehring, O; Geller, D; Karoly, E; Monyak, J; Shehadeh, N; Sjöström, CD; Tamborlane, WV; Troja, T; Vazquez, EM, 2022) |
| "In youth with type 2 diabetes suboptimally controlled with current treatments, once-weekly exenatide reduced glycated hemoglobin at 24 weeks and was well tolerated." | ( Al-Abdulrazzaq, D; Bishai, R; Carter, D; Doehring, O; Geller, D; Karoly, E; Monyak, J; Shehadeh, N; Sjöström, CD; Tamborlane, WV; Troja, T; Vazquez, EM, 2022) |
| "However, a risk of type 2 diabetes mellitus (T2DM) is evoked under PCSK9i therapy." | ( Agbangla, C; Akpovi, CD; Burtea, C; Coppée, F; Declèves, AE; Laurent, S; Tchéoubi, SER, 2022) |
| "Patients with type 2 diabetes who initiated basal insulin treatment between 2002 and 2018 were included in the study." | ( Brunetti, VC; Filion, KB; Platt, RW; Yu, OHY, 2022) |
| "In our study, ≈85% of patients with type 2 diabetes and dyslipidemia could achieve the combined lipid goal with statin monotherapy." | ( Ho, LT; Hwu, CM; Lee, IT; Sheu, WH; Wu, TH, 2022) |
| "Both hypertension and type 2 diabetes, if treated inappropriately, lead to serious complications, increasing the mortality of patients and generating much higher costs of health systems." | ( Bielka, W; Pawlik, A; Przezak, A, 2022) |
| "In patients with type 2 diabetes and CKD, baseline BNP and early changes in BNP in response to atrasentan were associated with HF hospitalization, highlighting the importance of natriuretic peptide monitoring upon initiation of atrasentan treatment." | ( Bakris, GL; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Januzzi, JL; Kitzman, DW; Kohan, DE; Kolansky, DM; Koomen, J; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Smeijer, JD; Tobe, S, 2022) |
| "We recently presented a type 2 diabetes (T2D) simulator as tool for in silico testing of new molecules and guiding treatment optimization." | ( Cobelli, C; Dalla Man, C; Visentin, R, 2022) |
| "Among patients in this age group with type 2 diabetes treated with medication, an A1C level of less than 7% is associated with increased risk of hospitalization for hypoglycemia, especially when using a sulfonylurea or insulin." | ( Ebell, MH; Grad, R, 2022) |
| "In this study, 27 patients with type 2 diabetes were randomized into exenatide and insulin glargine treatment groups." | ( Akyay, OZ; Cakmak, Y; Canturk, Z; Cetinarslan, B; Karakaya, D; Sahin, T; Selek, A; Tarkun, I, 2022) |
| "Heart failure coexists with type 2 diabetes mellitus, which seriously affects the clinical treatment and prognosis." | ( Gu, N; Liang, B, 2022) |
| "For this purpose 49 patients with type 2 diabetes who started treatment with liraglutide were included." | ( Abreu, C; García-Ramírez, M; Gómez-Peralta, F; Gómez-Rodríguez, S; Hernández, C; Simó, R; Simó-Servat, O, 2022) |
| "Among statin-treated patients with type 2 diabetes mellitus (T2DM), there is still a great residual cardiovascular risk." | ( Ding, Y; Ge, H; Han, H; Liu, X; Shen, H; Sun, Y; Wang, K; Wang, R; Yang, J; Zhou, Y, 2023) |
| "DPP-4Is are well recognized therapy for type 2 diabetes." | ( Afifi, H; Atya, HB; Awad, SM; El-Hameed, RHA; El-Shehry, MF; Fatahala, SS; Mahgoub, S; Sayed, AI; Taha, H, 2022) |
| "The top 10 treatments of type 2 diabetes in children and adolescents aged 10-17 years were saxagliptin+metformin, liraglutide+metformin, liraglutide, dapagliflozin, exenatide-2 mcg, sitagliptin+metformin, linagliptin-5 mg, linagliptin-1 mg, metformin, and exenatide-5/10 mcg." | ( Feng, Y; Ge, Y; He, Y; Hou, L; Huo, M; Ji, Y; Li, H; Liu, X; Liu, Y; Luo, Q; Qian, F; Wang, J; Wei, Y; Wu, S; Wu, Y; Xue, F; Yu, Y, 2022) |
| "In addition, the signature type 2 diabetes microflora was established by analyzing the microflora structure of healthy mice, type 2 diabetes mice, and mice treated with myricetin." | ( Chen, Y; Han, X; Li, J; Li, L; Li, X; Sun, H; Wang, X; Zhao, Z; Zhu, L, 2022) |
| "Patients with type II diabetes mellitus and chronic kidney disease, controlled from glycaemic status, were treated or not with pulsed electrostatic field (PESF) cycles to evaluate effect on the perfusion of peripheral tissues." | ( Coli, M; D'Ettorre, D; Di Luzio, R; La Torre, S; Lattanzio, S; Liani, R; Liani, V; Melchiorre, A; Tripaldi, R; Velussi, C, 2022) |
| "In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups." | ( Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N, 2022) |
| "Over the past decade, the type 2 diabetes (T2D) treatment landscape has evolved, allowing for more therapeutic options and the opportunity to tailor treatments to achieve patient treatment goals." | ( Blonde, L; LaSalle, J; Novak, LM, 2022) |
| "Ninety-three patients with type 2 diabetes mellitus combined with acute myocardial infarction who were hospitalized and treated in our hospital from January 2021 to June 2021 were recruited for prospective analysis and equally divided into group A (HbA1c < 6." | ( An, H; Fang, D; Li, W; Sun, M; Zeng, G; Zheng, Q, 2022) |
| "Semaglutide was used to treat type 2 diabetes mellitus (T2DM) combined with NAFLD mice for 12 weeks." | ( Fang, P; Hu, K; Kong, D; Li, L; Li, R; She, D; Xu, W; Xue, Y; Ye, Z; Zhang, K; Zhou, Y; Zong, G, 2022) |
| "Metformin as a first-line drug for type 2 diabetes mellitus(T2DM) treatment is widely studied." | ( Cao, G; Du, Y; Ge, T; Gong, T; Liu, J; Wang, Y, 2022) |
| "Specific pharmacotherapy for type 2 diabetes between 2007 and 2018 was examined." | ( Alexander, GC; Carrero, JJ; Chang, AR; Chodick, G; Cohen, CM; Coresh, J; Fu, EL; Grams, ME; Karasik, A; Lyu, B; Sang, Y; Selvin, E; Shalev, V; Shin, JI; Xu, Y, 2022) |
| "Celastrol can prevent and treat type 2 diabetes by reversing insulin resistance in a number of ways." | ( Wu, M; Zhang, Y, 2022) |
| "Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort." | ( Bezin, J; Faillie, JL; Garrel, R; Gouverneur, A; Hillaire-Buys, D; Mathieu, C; Pariente, A; Pénichon, M, 2023) |
| "This study aimed to evaluate the FGV in type 2 diabetes mellitus (T2DM) patients administered basal insulin using a needle-free insulin injector (NFII)." | ( Gao, B; Heng, C; Ji, Q; Li, S; Liu, H; Ma, K; Ren, L; Sun, F; Tian, L; Xing, Y; Yang, A; Zhou, J, 2022) |
| "This study aimed to evaluate the FGV in type 2 diabetes mellitus (T2DM) patients administered basal insulin using a needle-free insulin injector (NFII)." | ( Gao, B; Heng, C; Ji, Q; Li, S; Liu, H; Ma, K; Ren, L; Sun, F; Tian, L; Xing, Y; Yang, A; Zhou, J, 2022) |
| "This study aimed to evaluate the FGV in type 2 diabetes mellitus (T2DM) patients administered basal insulin using a needle-free insulin injector (NFII)." | ( Gao, B; Heng, C; Ji, Q; Li, S; Liu, H; Ma, K; Ren, L; Sun, F; Tian, L; Xing, Y; Yang, A; Zhou, J, 2022) |
| "A total of 217 patients with type 2 diabetes treated with IDegAsp and having follow-up data were included." | ( Altay, FP; Bozkuş, Y; Farzaliyeva, A; İyidir, ÖT; Kırnap, NG; Kut, A; Nar, A; Tütüncü, NB, 2023) |
| "A total of 217 patients with type 2 diabetes treated with IDegAsp and having follow-up data were included." | ( Altay, FP; Bozkuş, Y; Farzaliyeva, A; İyidir, ÖT; Kırnap, NG; Kut, A; Nar, A; Tütüncü, NB, 2023) |
| "A total of 217 patients with type 2 diabetes treated with IDegAsp and having follow-up data were included." | ( Altay, FP; Bozkuş, Y; Farzaliyeva, A; İyidir, ÖT; Kırnap, NG; Kut, A; Nar, A; Tütüncü, NB, 2023) |
| "AIS patients with type 2 diabetes mellitus who receive continuous metformin treatment before stroke onset and after admission have improved functional outcome at 90 days." | ( Dang, M; Feng, Y; Jian, Y; Li, T; Li, Y; Lu, J; Lu, Z; Wang, H; Wang, X; Yang, Y; Zhang, G; Zhang, L; Zhang, Y; Zhao, L, 2023) |
| "AIS patients with type 2 diabetes mellitus who receive continuous metformin treatment before stroke onset and after admission have improved functional outcome at 90 days." | ( Dang, M; Feng, Y; Jian, Y; Li, T; Li, Y; Lu, J; Lu, Z; Wang, H; Wang, X; Yang, Y; Zhang, G; Zhang, L; Zhang, Y; Zhao, L, 2023) |
| "Patients with type 2 diabetes underwent CGM before and after switching from a twice-daily pre-mixed insulin treatment regimen to a GLP-1 RA (liraglutide) plus basal insulin regimen." | ( Chen, HY; Chen, ST; Fu, SC; Hsieh, SH; Huang, YY; Lin, CH; Lin, SH; Lin, YH; Sun, JH; Tai, AS, 2022) |
| "Patients with type 2 diabetes underwent CGM before and after switching from a twice-daily pre-mixed insulin treatment regimen to a GLP-1 RA (liraglutide) plus basal insulin regimen." | ( Chen, HY; Chen, ST; Fu, SC; Hsieh, SH; Huang, YY; Lin, CH; Lin, SH; Lin, YH; Sun, JH; Tai, AS, 2022) |
| "Two-thirds of patients with type 2 diabetes mellitus have hypertension, and thus the combination of two or more drugs to treat these diseases is common." | ( Gou, XY; Ma, YR; Ran, FL; Wu, XA; Wu, YF, 2022) |
| "Two-thirds of patients with type 2 diabetes mellitus have hypertension, and thus the combination of two or more drugs to treat these diseases is common." | ( Gou, XY; Ma, YR; Ran, FL; Wu, XA; Wu, YF, 2022) |
| "Metformin is widely used to treat type 2 diabetes mellitus (T2DM) individuals." | ( Jayaram, P; Mallya, S; Nagri, SK; Prabhu, NB; Rai, PS; Sharma, AR; Umakanth, S; Vohra, M, 2023) |
| "Metformin is widely used to treat type 2 diabetes mellitus (T2DM) individuals." | ( Jayaram, P; Mallya, S; Nagri, SK; Prabhu, NB; Rai, PS; Sharma, AR; Umakanth, S; Vohra, M, 2023) |
| "Metformin is a drug for treating type 2 diabetes mellitus (T2DM)." | ( Feng, H; Fu, D; He, L; Huang, Y; Li, A; Li, J; Liu, Y; Zhao, H, 2023) |
| "The pharmacotherapy of type 2 diabetes mellitus (T2DM) has markedly evolved in the last two decades." | ( Scheen, AJ, 2023) |
| "Individuals with type 2 diabetes mellitus (T2DM) have an increased risk of bone metabolic disorders and bone fracture due to disease progression and clinical treatment." | ( Armstrong, DG; Chen, T; Deng, B; Deng, W; Duan, X; Ma, Y; Rui, S; Song, P, 2022) |
| "Large numbers of patients with type 2 diabetes receive treatment with a sodium-glucose co-transporter-2 inhibitor (SGLT2i)." | ( Garcia Rodriguez, LA; Gonzalez Perez, A; Lind, M; Sáez, ME; Vizcaya, D, 2023) |
| "Exenatide is a peptide used to treat type 2 diabetes mellitus." | ( Bryniarski, MA; Campos-Bilderback, SB; Chaves, LD; Fraser-McArthur, J; Molitoris, BA; Morris, ME; Ruszaj, DM; Sandoval, RM; Yacoub, R; Yee, BM, 2023) |
| "The diagnosis of Type 2 Diabetes Mellitus (T2DM) is made by demonstrating the hypoglycemic condition, which involves the determination of plasma glucose, and the follow-up of hypoglycemic treatment is performed by assessing the glycated hemoglobin (HbA1c) concentration." | ( Castelo, PM; da Costa Aguiar Alves, B; da Veiga, GL; de Faria Baltazar, H; Fonseca, FLA; Gascón, T; Pereira, EC, 2023) |
| "To compare outcomes in adults with type 2 diabetes (T2D) suboptimally controlled with basal insulin who initiated treatment with iGlarLixi or premixed insulin." | ( Dex, T; Heller, C; Kilpatrick, CR; Lajara, R; Lew, E; Li, X; Pantalone, KM, 2023) |
| "In the AWARD-7 study in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, once-weekly dulaglutide slowed the decline in estimated glomerular filtration rate (eGFR) and decreased the urine albumin/creatinine ratio compared to insulin glargine at the end of 52 weeks of treatment." | ( Botros, FT; Duffin, KL; Genovese, F; Karsdal, MA; Lin, Y; Qian, HR; Tuttle, KR; Wilson, JM, 2023) |
| "In participants with type 2 diabetes and albuminuria, treatment with dapagliflozin, exenatide and dapagliflozin-exenatide reduced albuminuria, with a numerically larger reduction in the combined dapagliflozin-exenatide treatment group." | ( Apperloo, E; Friedli, I; Heerspink, HJL; Hoogenberg, K; Johansson, L; Jongs, N; Rouw, DB; Sjöström, CD; van der Aart-van der Beek, AB; van Raalte, DH, 2023) |
| "Newly diagnosed type 2 diabetes participants without glucose-lowering treatment were randomized to consume a Mediterranean or a low-fat diet." | ( Alcalá-Diaz, JF; Arenas-Larriva, AP; Cardelo, MP; de la Cruz-Ares, S; Delgado-Lista, J; Gutierrez-Mariscal, FM; Lopez-Miranda, J; Malagón, MM; Ordovás, JM; Pérez-Martínez, P; Quintana-Navarro, GM; Romero-Cabrera, JL; Torres-Peña, JD; Yubero-Serrano, EM, 2023) |
| "Patients with type 2 diabetes treated with liraglutide (0." | ( Iijima, T; Ito, Y; Shibuya, M; Terauchi, Y, 2023) |
| "Most of our type 2 diabetes patients, treated with low-premixed insulin, did not meet the recommended TBR target for older/high-risk patients while meeting the TIR and TAR targets." | ( Krajnc, M; Kravos Tramšek, NA, 2023) |
| "Patients with type 2 diabetes (T2D) treated with glucagon-like peptide-1 receptor agonists may experience reductions in weight and blood pressure." | ( Blue, EK; Dunn, J; Ferdinand, KC; Nicolay, C; Sam, F; Wang, H, 2023) |
| "Overall, compared with control group in type 2 diabetes, liraglutide treatment shows no obvious effect on GFR (SMD=0." | ( He, D; Hu, Z; Luo, C; Yang, H; Zhu, C; Zhu, J, 2022) |
| "She had type 2 diabetes mellitus and was on oral antidiabetic therapy of vildagliptin metformin hydrochloride daily." | ( Fujimaru, T; Hifumi, T; Ito, Y; Kadota, N; Konishi, K; Kuno, H; Nagahama, M; Nakayama, M; Otani, N; Sekiguchi, M; Taki, F; Watanabe, K, 2023) |
| "In the treatment of type 2 diabetes mellitus (T2DM), comprehensive management of multiple risk factors, such as blood glucose, body weight, and lipids, is important to prevent disease progression." | ( Goto, T; Iijima, H; Inoue, K; Kawada, T; Kawarasaki, S; Nomura, W; Sawazaki, H; Takahashi, H, 2023) |
| "In this real-world type 2 diabetes population, discontinuation of GLP-1 RA treatment was associated to a higher risk of major cardiovascular events, in both subjects with and without a history of CV events." | ( Favacchio, G; Folli, F; Lania, AG; Mazziotti, G; Mirani, M; Morenghi, E; Panico, C; Piccini, S, 2023) |
| "Participants (aged ≥40 years) with type 2 diabetes and atherosclerotic cardiovascular disease were randomly assigned (1:1:1) to once-daily ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo in addition to background standard-of-care treatment." | ( Adamsons, I; Cannon, CP; Cherney, DZI; Cosentino, F; Dagogo-Jack, S; Essex, MN; Jones, PLS; Lawrence, D; Liu, J; McGuire, DK; Pratley, RE, 2023) |
| "A patient with type 2 diabetes mellitus treated with empagliflozin underwent an elective hip replacement surgery." | ( Lukes, M; Sitina, M; Sramek, V, 2023) |
| "Treatment of people with type 2 diabetes mellitus (T2D) and obesity should include glycemic control and sustained weight loss." | ( Ambery, P; Iqbal, N; Logue, J; Mallappa, A; Sjöström, CD, 2023) |
| "While type 2 diabetes mellitus (T2DM) increases the risk of cardiac complications, diabetes treatment choices may increase or decrease the rates of cardiac events." | ( Aktas, G; Atak Tel, BM; Balci, B; Tel, R, 2023) |
| "KK-Ay mice, a type 2 diabetes mellitus (T2DM) model, were administered CycloZ either as a preventive intervention, or as a therapy." | ( Auwerx, J; Baek, S; Fang, S; Jeon, J; Jeon, JH; Jung, HY; Kim, B; Kim, KT; Kim, MJ; Lee, D; Lee, IK; Lim, CW; Oh, CJ; Park, BY; Park, O; Ryu, D, 2023) |
| "Veterans with type 2 diabetes on metformin monotherapy between 2004 and 2006 were identified." | ( Axon, RN; Chandler, O; Gebregziabher, M; Strychalski, ML; Taber, DJ; Ward, R; Weeda, ER, 2023) |
| "Compared with homogenous type 2 diabetes, treatment for individuals in the high-risk subgroups could cost 22." | ( 't Hart, LM; Altunkaya, J; Beulens, JWJ; Elders, PJM; Feenstra, TL; Leal, J; Li, X; Pearson, ER; Slieker, RC; van Giessen, A, 2023) |
| "Our study aimed to explore whether type 2 diabetes (T2DM) can affect arsenic metabolism in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide." | ( Hai, X; Hostetter, TH; Lu, S; Pang, C; Wu, M, 2023) |
| "We included 18 ICU patients with type 2 diabetes receiving empagliflozin (10 mg daily) and insulin to target glucose range of 10-14 mmol/l according to our liberal glucose control protocol for patients with diabetes (treatment group)." | ( Bellomo, R; Cioccari, L; Cutuli, SL; Luethi, N; Maeda, A; Mårtensson, J; Osawa, EA; Toh, L; Yanase, F, 2023) |
| "In our pilot study of ICU patients with type 2 diabetes, empagliflozin therapy was associated with increases in sodium and chloride levels but was not significantly associated with acid-base changes, hypoglycemia, ketoacidosis, worsening kidney function, bacteriuria, or mortality." | ( Bellomo, R; Cioccari, L; Cutuli, SL; Luethi, N; Maeda, A; Mårtensson, J; Osawa, EA; Toh, L; Yanase, F, 2023) |
| "Exercise is a first-line treatment for type 2 diabetes and preserves β-cell function by hitherto unknown mechanisms." | ( Axelrod, CL; Bozadjieva-Kramer, N; Collier, JJ; Heintz, EC; Kirwan, JP; McDowell, R; Mulya, A; Nieuwoudt, S; Seeley, RJ; Vandanmagsar, B; Zhang, H; Zunica, ERM, 2023) |
| "Based on 294 patients with type 2 diabetes and elevated low-density lipoprotein (LDL) cholesterol, this study looked at how much patients’ lipid-lowering medication would need to be intensified for them to be able to reach the old and the new, lower treatment target for LDL-cholesterol that was introduced in 2019, along with the cost and feasibility, and estimated cardiovascular benefits of doing so." | ( Bilz, S; Brändle, M; Laimer, M; Lehmann, R; Renström, F; Singeisen, H, 2023) |
| "A total of 36 Japanese patients with type 2 diabetes mellitus received a SGLT2 inhibitor (luseogliflozin or dapagliflozin) for 3 months, and the prevalences of balance-regulating bacteria and balance-disturbing bacteria in the feces of the patients before and after SGLT2 inhibitor treatment were determined." | ( Hisano, F; Kusunoki, A; Kusunoki, M; Matsuda, SI; Miyata, T; Tsutsumi, K; Wakazono, N, 2023) |
| "Metformin, a type 2 diabetes treatment, improves the cognitive function of aged mice; however, whether the protective effects of metformin on cognitive function in aged mice are associated with the gut microbiome is poorly understood." | ( Feng, S; Huang, C; Huo, F; Liu, H; Shen, J; Wang, H; Zhu, X, 2023) |
| "Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide." | ( Alexandersen, C; Borch, J; Dela, F; Graungaard, B; Helge, JW; Holst, JJ; Ingersen, A; Schmücker, M; Thorngreen, T, 2023) |
| "Metformin, used to treat Type 2 diabetes, is the active ingredient of one of the most prescribed drugs in the world, with over 120 million yearly prescriptions globally." | ( Hughes, D; Lapen, DR; Littlejohn, C; Pappas, JJ; Renaud, JB; Sabourin, L; Sumarah, MW; Tuteja, B; Ussery, E; Yeung, KK, 2023) |
| "Metformin, a frontline therapy for type 2 diabetes and related metabolic diseases, results in variable outcomes." | ( Bernier, A; de Lartigue, G; Rourk, K; Singh, A, 2023) |
| "An important target in the treatment of type 2 diabetes is α-glucosidase." | ( Emadi, M; Faramarzi, MA; Ghadimi, R; Halimi, M; Hosseini, S; Mahdavi, M; Moazzam, A; Moghadamnia, AA; Mohammadi-Khanaposhtani, M; Mojtabavi, S; Nasli-Esfahani, E, 2023) |
| "Among people with insulin-naive type 2 diabetes, once-weekly icodec demonstrated superior HbA1c reduction to once-daily degludec after 26 weeks of treatment, with no difference in weight change and a higher rate of combined level 2 or 3 hypoglycemic events in the context of less than 1 event per patient-year exposure in both groups." | ( Asong, M; Desouza, C; Gourdy, P; Kar, S; Lingvay, I; Mu, Y; Vianna, A; Vilsbøll, T; Vinther, S, 2023) |
| "In people with type 2 diabetes, treatment with CagriSema resulted in clinically relevant improvements in glycaemic control (including CGM parameters)." | ( Davies, M; Deenadayalan, S; Erichsen, L; Frias, JP; Knop, FK; Lingvay, I; Macura, S; Mathieu, C; Pedersen, SD, 2023) |
| "Fifty-two patients with type 2 diabetes complicated by NAFLD who started SGLT2i treatment between 2014 and 2020 at our hospital were selected from the database." | ( Ando, Y; Fujii, Y; Fujino, H; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ogawa, Y; Oka, S; Ono, A; Tsuge, M; Uchikawa, S; Yamaoka, K; Yamauchi, M, 2023) |
| "Basal insulin treatment for type 2 diabetes is usually initiated on a background of oral glucose-lowering medications (OGLM)." | ( Abd El Aziz, M; Nauck, MA; Wollenhaupt, D; Wolters, J, 2023) |
| "Originally developed for type 2 diabetes (T2D), these drugs cause dramatic weight loss in people with overweight or obesity, but how do they work, and are these therapeutics the long-sought-after solution to obesity? Here we explain the mechanisms of action of GLP-1R agonists in the context of weight loss and discuss their importance as therapeutics for obesity treatment." | ( Dowsett, GKC; Yeo, GSH, 2023) |
| "Drugs currently used to treat type 2 diabetes mellitus may have mechanisms of action that are relevant to the prevention and treatment of sarcopenia, for those with type 2 diabetes and those without diabetes." | ( Granic, A; Pearson, E; Robinson, SM; Sayer, AA; Witham, MD, 2023) |
| "In early type 2 diabetes, the strategy of "induction" with short-term intensive insulin therapy followed by "maintenance" with metformin can stabilize pancreatic beta-cell function in some patients but not others." | ( Emery, A; Gerstein, HC; Harris, SB; Kramer, CK; McInnes, N; Pu, J; Reichert, SM; Retnakaran, R; Zinman, B, 2023) |
| "Among patients with type 2 diabetes, initiating SGLT2i treatment after an episode of acute heart failure was significantly associated with a reduced combined risk of heart failure readmission and cardiovascular mortality in a nationwide cohort reflecting routine clinical practice." | ( Jeong, HE; Lee, H; Park, S; Shin, JY; You, SC, 2023) |
| "Obesity and type 2 diabetes (T2D) are growing health challenges with unmet treatment needs." | ( Ali, MS; Andersen, NR; Ditzel, N; Dollet, L; Fritzen, AM; Gerhart-Hines, Z; Havula, E; Jafari, A; Kiens, B; Kieser, A; Møller, LLV; Nieminen, AI; Pham, TCP; Raun, SH; Richter, EA; Salling Olsen, M; Schjerling, P; Simpson, SJ; Suomalainen, A; Sylow, L, 2023) |
| "Twelve newly diagnosed patients with type 2 diabetes were examined for changes in the abundance of L delbrueckii and F prausnitzii by Fluorescence in Situ Hybridization 1 week after administration of GLP-1 RAs." | ( Chen, L; Liang, L; Nian, X; Nie, R; Rao, E; Su, X; Wu, B; Zhang, X, 2023) |
| "PYY is a potential treatment for type 2 diabetes mellitus (T2DM) because of its ability to delay gastric emptying, reduce appetite, decrease weight, and lower blood glucose." | ( Binbin, G; Chen, W; Jing, H; Lidan, S; Qiang, Z, 2023) |
| "In total, 446 patients with type 2 diabetes on metformin monotherapy were randomized to receive the addition of once-daily cetagliptin 100 mg, cetagliptin 50 mg and placebo in a 2:2:1 ratio for 24-week double-blind treatment." | ( Bai, J; Cheng, Z; Ding, J; Gao, L; Ji, L; Li, J; Li, P; Lu, J; Tian, J; Wang, T; Xie, D; Yan, X; Yu, Q; Zhang, L; Zhao, J, 2023) |
| "In this study, in type 2 diabetes or insulin-treated GDM, the glucose increased area under the curve above limit was associated with increased LGA." | ( de Valk, HW; DeVries, JH; Evers, IM; Franx, A; Mol, BW; Painter, RC; Rademaker, D; Siegelaar, SE; van der Wel, AWT; van Eekelen, R; van Rijn, BB; Voormolen, DN, 2023) |
| "Many people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral glucose-lowering medications rather than intensifying treatment with a glucagon-like peptide-1 receptor agonist, despite an efficacious, orally administered option, oral semaglutide, being available." | ( Bain, S; Berry, S; Hunt, B; Malkin, SJP; Ren, H, 2023) |
| "Metformin is a medication used to treat type 2 diabetes by inhibiting hepatic glucose production through adenosine monophosphate-activated protein kinase (AMPK) activation." | ( Baek, HS; Kang, HM; Kim, IR; Kim, YS; Oh, JM; Park, BS, 2023) |
| "In people with inadequately controlled type 2 diabetes treated with basal insulin, weekly tirzepatide compared with prandial insulin as an additional treatment with insulin glargine demonstrated reductions in HbA1c and body weight with less hypoglycemia." | ( Fernández Landó, L; Frías, JP; Huh, R; Patel, H; Rodbard, HW; Rosenstock, J; Sears, E; Tofé, S, 2023) |
| "Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity commonly co-occur but clinical treatment options do not effectively target all disorders." | ( Alexopoulos, SJ; Beretta, M; Byrne, FL; Cantley, J; Chen, SY; Garcia, CJ; Hoehn, KL; Larance, M; Olzomer, EM; Philp, A; Salamoun, JM; Santos, WL; Shah, DP; Smith, GC; Turner, N, 2024) |
| "Thirty patients with type 2 diabetes with peripheral neuropathy as assessed by a visual analog scale (VAS) and divided into two groups of 15 patients, treated for up to three months." | ( Ahmadi, SA; Bagheri, S; Dolatkhah, H; Hassanzadeh, S; Majid Ahmadi, S; Moradishibany, I; Reisi, S, 2023) |